var images_info;if (!images_info) images_info =[]; images_info["96"]={"96008":{"type":"graphic_table","displayName":"Vulvar edema","title":"Differential diagnosis of skin-colored or erythematous edema of the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of skin-colored or erythematous edema of the vulva</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\"> <p>Postsurgical and postradiation edema</p> <p>Crohn disease</p> <p>Hidradenitis suppurativa</p> <p>Pregnancy</p> Edema due to infection</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\"> <p>Postinfectious edema</p> <p>Bartholin duct abscess</p> <p>Allergic contact dermatitis</p> Trauma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\"> <p>Acute allergic angioedema</p> <p>Lymphangioma edema</p> <p>Milroy's congenital edema</p> Melkersson-Rosenthal syndrome</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96008 Version 2.0</div></div></div>"},"96017":{"type":"graphic_table","displayName":"Ulcerative lesions vulva","title":"Differential diagnosis of ulcerative lesions on the vulva","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of ulcerative lesions on the vulva</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">More common</td> <td class=\"subtitle1_single\">Less common</td> <td class=\"subtitle1_single\">Uncommon</td> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Infectious <ul> <li>Herpes simplex virus (HSV) in immunosuppressed host </li> <li>Human immunodeficiency virus (HIV) </li> </ul> </li> <li>Non-infectious <ul> <li>Aphthous ulcers </li> <li>Contact dermatitis </li> <li>Crohn disease&nbsp;&nbsp; </li> </ul> </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>Primary syphilis </li> <li>Drug-induced </li> <li>Malignancy <ul> <li>Squamous cell carcinoma </li> <li>Melanoma </li> </ul> </li> <li>Pyoderma gangrenosum </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>Primary syphilis (chancre) </li> <li>Trauma, accidental and self-induced </li> <li>Ulcerated malignancy </li> <li>Pyoderma gangrenosum </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>Granuloma inguinale </li> <li>Chancroid </li> <li>Beh&#231;et's disease </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96017 Version 3.0</div></div></div>"},"96035":{"type":"graphic_diagnosticimage","displayName":"Imaging bone islands (enostoses)","title":"Radiographic appearance of a bone island (enostosis)","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Radiographic appearance of a bone island (enostosis)</div><div class=\"cntnt\"><img style=\"width:626px; height:487px;\" src=\"images/RADIOL/96035_Img_bne_islnd_enostoses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal reformatted CT scan (A) shows a 2 mm bone island as a well-circumscribed sclerotic focus within the left proximal femur compatible with a benign bone island (arrow). Image B is an axial view of the lesion (arrow). Image C is a radiograph of a larger bone island in the right sacrum (arrow) shown on a CT in axial projection (D, arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joseph Konrad, MD.</div><div id=\"graphicVersion\">Graphic 96035 Version 1.0</div></div></div>"},"96045":{"type":"graphic_table","displayName":"Differential diagnosis of intrahepatic cholestasis of pregnancy","title":"Diagnosis of intrahepatic cholestasis of pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis of intrahepatic cholestasis of pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Differential diagnosis</td> <td class=\"subtitle1\">Typical clinical presentation</td> <td class=\"subtitle1\">Distinguishing features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pregnancy-specific causes of pruritus</td> </tr> <tr> <td class=\"indent1\">Pruritus gravidarum</td> <td>Pruritus, usually in the third trimester</td> <td>Similar presentation to intrahepatic cholestasis of pregnancy, but normal liver function tests and bile acids</td> </tr> <tr> <td class=\"indent1\">Atopic eruption of pregnancy</td> <td>Pruritus, usually in the first trimester</td> <td> <p>Dry, red rash with or without small blisters</p> Typically affects trunk and limb flexures</td> </tr> <tr> <td class=\"indent1\">Polymorphic eruption of pregnancy</td> <td>Pruritus, usually in the third trimester</td> <td> <p>Typically affects lower abdominal striae with umbilical-sparing</p> Urticarial papules or plaques, vesicles, and target lesions</td> </tr> <tr> <td class=\"indent1\">Pemphigoid gestationis</td> <td>Itchy rash, usually in the second or third trimester</td> <td> <p>Rare autoimmune condition characterized by complement-fixing immunoglobulin G antibodies</p> <p>Rash develops into large, tense blisters</p> <p>Associated with increased risk of preterm delivery and SGA</p> Recurs in subsequent pregnancies and with combined oral contraceptive</td> </tr> <tr> <td class=\"indent1\">Prurigo of pregnancy</td> <td>Pruritus, usually in the third trimester</td> <td> <p>Groups of red-brown papules on the abdomen and extensor surfaces of the limbs</p> Papules may persist postpartum</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pruritic folliculitis of pregnancy</td> <td>Pruritus, usually in the third trimester</td> <td> <p>Acneiform eruption on the shoulders, upper back, thighs, and arms</p> Follicular papules and pustules, which may be filled with pus, but culture is typically sterile; rash usually improves with advancing gestation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preexisting causes of pruritus</td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis</td> <td>Pruritus, any gestation</td> <td>History of atopy</td> </tr> <tr> <td class=\"indent1\">Allergic or drug reaction</td> <td>Pruritus, any gestation</td> <td> <p>History of exposure to allergen or drug</p> Maculopapular rash</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systemic disease</td> <td>History of liver, renal, or thyroid disease</td> <td> <p>Signs and symptoms of systemic disease</p> History of pruritus before conception</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pregnancy-specific causes of hepatic impairment</td> </tr> <tr> <td class=\"indent1\">Acute fatty liver of pregnancy</td> <td>Nausea, vomiting, headache, abdominal pain, polyuria, polydipsia in the third trimester</td> <td> <p>New nausea and vomiting in the third trimester are not caused by hyperemesis gravidarum</p> Women with AFLP are more unwell and often have associated renal impairment, coagulopathy, hypoglycemia, and preeclampsia</td> </tr> <tr> <td class=\"indent1\">Hemolysis, elevated liver enzymes and low platelets syndrome</td> <td>Hypertension, proteinuria, headache, epigastric pain, visual disturbance in the second or third trimester</td> <td>Hypertension and proteinuria are predominant features</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hyperemesis gravidarum</td> <td>Nausea and vomiting in the first trimester</td> <td>Presentation in early pregnancy, abnormal liver function test resolves with successful treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preexisting causes of hepatic impairment</td> </tr> <tr> <td class=\"indent1\">Viral hepatitis</td> <td>Jaundice, nausea, vomiting, abdominal pain</td> <td>Systemic symptoms, generally unwell, contacts</td> </tr> <tr> <td class=\"indent1\">Primary biliary cirrhosis or primary sclerosing cholangitis</td> <td>Pruritus, jaundice, lethargy, other autoimmune disorders</td> <td>Symptoms before pregnancy; associated autoantibodies</td> </tr> <tr> <td class=\"indent1\">Autoimmune hepatitis</td> <td>Nausea, lethargy, jaundice, other autoimmune disorders</td> <td>Symptoms before pregnancy; associated autoantibodies</td> </tr> <tr> <td class=\"indent1\">Drug-induced liver injury</td> <td>Pruritus, jaundice</td> <td>Ingestion of drugs before onset of symptoms or biochemical abnormalities</td> </tr> <tr> <td class=\"indent1\">Biliary obstruction</td> <td>Abdominal pain, pale stools, dark urine</td> <td>Liver ultrasound scan abnormalities</td> </tr> <tr> <td class=\"indent1\">Venoocclusive disease</td> <td>Abdominal pain, distension (ascites), jaundice, gastrointestinal bleeding</td> <td>Thrombosis demonstrated on imaging, thrombophilia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SGA: small for gestational age; AFLP: acute fatty liver of pregnancy.</div><div class=\"graphic_reference\">From: Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014; 124:120. DOI: <A spellcheck=true href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=07000&amp;article=00017&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000000346</A>. Copyright Â© 2014 American College of Obstetricians and Gynecologists. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96045 Version 4.0</div></div></div>"},"96049":{"type":"graphic_table","displayName":"Intrauterine adhesions procedures symptoms","title":"Occurrence of intrauterine adhesions following surgery for various conditions and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Occurrence of intrauterine adhesions following surgery for various conditions and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition/procedure</td> <td class=\"subtitle1\">%</td> <td class=\"subtitle1\">Reference</td> </tr> <tr class=\"divider_bottom\"> <td>Secondary amenorrhea</td> <td class=\"centered\">1.7</td> <td>Jones<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Infertility</td> <td class=\"centered\">6.9</td> <td>Nawroth et al<sup>[2]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Postcesarean delivery</td> <td class=\"centered\">2.8</td> <td>Rochet et al<sup>[3]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Postpartum D&#38;C (any time)</td> <td class=\"centered\">3.7</td> <td>Bergman<sup>[4]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Postpartum D&#38;C (second to fourth week)</td> <td class=\"centered\">23.4</td> <td>Eriksen and Kaestel<sup>[5]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Early spontaneous abortion D&#38;C</td> <td class=\"centered\">6.4</td> <td>Adoni et al<sup>[6]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Late spontaneous abortion D&#38;C</td> <td class=\"centered\">30.9</td> <td>Adoni et al<sup>[6]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Missed abortion</td> <td class=\"centered\">35</td> <td>Schenker and Margalioth<sup>[7]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Elective abortion D&#38;C</td> <td class=\"centered\">13</td> <td>Kralj and Lavric<sup>[8]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Recurrent abortion</td> <td class=\"centered\">39</td> <td>Toaff and Ballas<sup>[9]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Retained products of conception</td> <td class=\"centered\">40</td> <td>Westendorp et al<sup>[10]</sup></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Spontaneous abortion</td> </tr> <tr> <td class=\"indent1\">One</td> <td class=\"centered\">16.3</td> <td class=\"divider_bottom\" rowspan=\"3\">Friedler et al<sup>[11]</sup></td> </tr> <tr> <td class=\"indent1\">Two</td> <td class=\"centered\">14</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Three or more</td> <td class=\"centered\">32</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"3\">Hysteroscopic myomectomy</td> </tr> <tr> <td class=\"indent1\">Single</td> <td class=\"centered\">31.3</td> <td rowspan=\"3\">Taskin et al<sup>[12]</sup></td> </tr> <tr> <td class=\"indent1\">Multiple</td> <td class=\"centered\">45.5</td> </tr> <tr> <td class=\"indent1\">Hysteroscopic metroplasty</td> <td class=\"centered\">6.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">D&amp;C: dilation and curettage.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jones WE. Traumatic intrauterine adhesions. A report of 8 cases with emphasis on therapy. Am J Obstet Gynecol 1964; 89:304.</LI>&#xD;&#xA;<LI>Nawroth F, Foth D, Schmidt T. Minihysteroscopy as routine diagnostic procedure in women with primary infertility. J Am Assoc Gynecol Laparosc 2003; 10:396.</LI>&#xD;&#xA;<LI>Rochet Y, Dargent D, Bremond A, et al. The obstetrical future of women who have been operated on for uterine synechiae. 107 cases operated on [author's translation]. J Gynecol Obstet Biol Reprod (Paris) 1979; 8:723.</LI>&#xD;&#xA;<LI>Bergman P. Traumatic intra-uterine lesions. Acta Obstet Gynecol Scand 1961; 40(Suppl 4):1.</LI>&#xD;&#xA;<LI>Eriksen J, Kaestel C. The incidence of uterine atresia after post-partum curettage. A follow-up examination of 141 patients. Dan Med Bull 1960; 7:50.</LI>&#xD;&#xA;<LI>Adoni A, Palti Z, Milwidsky A, Dolberg M. The incidence of intrauterine adhesions following spontaneous abortion. Int J Fertil 1982; 27:117.</LI>&#xD;&#xA;<LI>Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertil Steril 1982; 37:593.</LI>&#xD;&#xA;<LI>Kralj B, Lavric V. Cervico isthmic incompetence. In: The Ljubljana Abortion Study 1971â1973, Andolsek L (Ed), Bethesda, MD: National Institutes of Health; 1974: 28.</LI>&#xD;&#xA;<LI>Toaff R, Ballas S. Traumatic hypomenorrhea-amenorrhea (Asherman's syndrome). Fertil Steril 1978; 30:379.</LI>&#xD;&#xA;<LI>Westendorp ICD, Ankum WM, Mol BWJ, Vonk J. Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. Hum Reprod 1998; 13:3347.</LI>&#xD;&#xA;<LI>Friedler S, Margalioth EJ, Kafka I, Yaffe H. Incidence of post-abortion intra-uterine adhesions evaluated by hysteroscopyâa prospective study. Hum Reprod 1993; 8:442.</LI>&#xD;&#xA;<LI>Taskin O, Sadik S, Onoglu A, et al. Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. J Am Assoc Gynecol Laparosc 2000; 7:351.</LI></OL>Reproduced with permission from: March CM. Asherman's syndrome. Semin Reprod Med 2011; 29:83. Copyright Â© 2011 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 96049 Version 1.0</div></div></div>"},"96050":{"type":"graphic_picture","displayName":"Pigmentary demarcation lines B","title":"Pigmentary demarcation lines type B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigmentary demarcation lines type B</div><div class=\"cntnt\"><img style=\"width:338px; height:501px;\" src=\"images/DERM/96050_PigmentarydemarcatlineB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical pigmentary demarcation line type B over the posterior aspect of the thigh and leg.</div><div class=\"graphic_reference\">From: Gupta LK, Kuldeep CM, Mittal A, et al. Pigmentary demarcation lines in pregnancy. Indian J Dermatol Venereol Leprol 2005; 71:292. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2005 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96050 Version 2.0</div></div></div>"},"96054":{"type":"graphic_figure","displayName":"ASRM classification intrauterine adhesions","title":"American Fertility Society/American Society for Reproductive Medicine classification of intrauterine adhesions","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">American Fertility Society/American Society for Reproductive Medicine classification of intrauterine adhesions</div><div class=\"cntnt\"><img style=\"width:610px; height:812px;\" src=\"images/OBGYN/96054_ASRM_class_intraut_adhesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">G: gravida; P: para; Sp Ab: spontaneous abortion; VTB: induced abortion; HSG: hysterosalpingogram.</div><div class=\"graphic_reference\">Reproduced from: The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, M&uuml;llerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96054 Version 1.0</div></div></div>"},"96055":{"type":"graphic_table","displayName":"ESH classification intrauterine adhesions","title":"European Society for Hysteroscopy classification of intrauterine adhesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society for Hysteroscopy classification of intrauterine adhesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Extent of intrauterine adhesions</td> </tr> <tr> <td class=\"centered\">I</td> <td>Thin or filmy adhesions easily ruptured by hysteroscope sheath alone. Cornual areas normal.</td> </tr> <tr> <td class=\"centered\">II</td> <td>Singular filmy adhesions connecting separate parts of the uterine cavity. Visualization of both tubal ostea possible. Cannot be ruptured by hysteroscope sheath.</td> </tr> <tr> <td class=\"centered\">IIa</td> <td>Occluding adhesions only in the region of the internal cervical os. Upper uterine cavity normal.</td> </tr> <tr> <td class=\"centered\">III</td> <td>Multiple firm adhesions connecting separate parts of the uterine cavity. Unilateral obliteration of ostial areas of the tubes.</td> </tr> <tr> <td class=\"centered\">IIIa</td> <td>Extensive scarring of the uterine cavity wall with amenorrhea or hypomenorrhea.</td> </tr> <tr> <td class=\"centered\">IIIb</td> <td>Combination of III and IIIa.</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Extensive firm adhesions with agglutination of uterine walls. Both tubal ostial areas occluded.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Deans R, Abbott J. Review of intrauterine adhesions. J Minim Invasive Gynecol 2010; 17:555. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96055 Version 1.0</div></div></div>"},"96056":{"type":"graphic_algorithm","displayName":"Rx algorithm vertebral bone metastases","title":"Suggested algorithmic approach to management for vertebral bone metastases","html":"<div class=\"graphic\"><div style=\"width: 1073px\" class=\"figure\"><div class=\"ttl\">Suggested algorithmic approach to management for vertebral bone metastases</div><div class=\"cntnt\"><img style=\"width:1053px; height:857px;\" src=\"images/ONC/96056_Algvertebralbonemetastas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assumes optimization of systemic therapy. First-line therapies for bone pain include adequate analgesia with nonsteroidal antiinflammatory drugs with or without opioids. Osteoclast inhibitors recommended for most patients with bone metastases to enhance analgesia and prevent skeletal-related events.</div><div class=\"graphic_footnotes\">VCF: vertebral compression fracture; LE: life expectancy; PS: performance status; EBRT: external beam radiation therapy; VA: vertebral augmentation; SBRT: stereotactic body radiotherapy; CRPC: castration-resistant prostate cancer.<br />* Assess spine stability using a validated classification system such as the Spine Instability Neoplastic Score (SINS). Refer to UpToDate text.<br />Â¶ VA is generally reserved for symptomatic osteolytic spinal metastases with an intact bone cortex and without epidural disease, spinal cord compression, or retropulsion of bone fragments into the spinal cord.<br />Î If observation is chosen, consider periodic repeat imaging and treat with EBRT if lesion progresses or there is an impending fracture.<br /><FONT class=lozenge>â</FONT> EBRT is the preferred option for most patients. SBRT could be considered for reirradiation or radioresistant malignancy (eg, renal cell sarcoma, melanoma). Refer to UpToDate text.<br />Â§ Most of the data on radiopharmaceuticals are in patients with metastatic prostate cancer; they could also be considered for others with diffuse osteoblastic painful metastases versus large-field/hemibody irradiation.</div><div id=\"graphicVersion\">Graphic 96056 Version 5.0</div></div></div>"},"96057":{"type":"graphic_figure","displayName":"Intraperitoneal mesh repair of parastomal hernia","title":"Intraperitoneal mesh repair of parastomal hernia","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Intraperitoneal mesh repair of parastomal hernia</div><div class=\"cntnt\"><img style=\"width:524px; height:635px;\" src=\"images/SURG/96057_Intraperitoneal_mesh_repair_of_parastomal_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A:&nbsp;An intraperitoneal Sugarbaker mesh repair<br />B: An intraperitoneal key-hole mesh repair</div><div id=\"graphicVersion\">Graphic 96057 Version 1.0</div></div></div>"},"96061":{"type":"graphic_table","displayName":"Examples of ABCDs of dignity conserving care","title":"Examples of the ABCDs of dignity-conserving care in the intensive care unit (ICU)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of the ABCDs of dignity-conserving care in the intensive care unit (ICU)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Attitudes</td> </tr> <tr> <td class=\"indent1\">Attitudes and assumptions can affect practice; make a conscious effort to reflect on how your own attitudes, assumptions, and life experiences affect the way you deliver care to each patient.</td> </tr> <tr> <td class=\"indent1\">Create a culture within the ICU setting in which acknowledgement and discussion of attitudes and assumptions as they apply to the entire healthcare team becomes a standard part of delivering care.</td> </tr> <tr> <td class=\"subtitle1_single\">Behaviors</td> </tr> <tr> <td class=\"indent1\">Behaviors should always enhance patient dignity; a lack of curative options should never rationalize or justify a lack of ongoing patient contact.</td> </tr> <tr> <td class=\"indent1\">Always invite the patient to have someone from his or her support network present, particularly if the planned discussion includes complex or difficult information.</td> </tr> <tr> <td class=\"indent1\">Do not rush; try to be seated at a comfortable distance for conversation, at the patient's eye level, when possible; make eye contact when talking with patients and their families.</td> </tr> <tr> <td class=\"indent1\">As much as possible, turn off digital devices and avoid jargon when talking with patients and their families.</td> </tr> <tr> <td class=\"subtitle1_single\">Compassion</td> </tr> <tr> <td class=\"indent1\">Recognize and relieve suffering. Compassion is sensitivity to the suffering of others and the desire to relieve it.</td> </tr> <tr> <td class=\"indent1\">Show compassion with an understanding look, or a gentle touch on the shoulder, arm or hand, or some form of communication (spoken or unspoken) that acknowledges the person beyond the illness.</td> </tr> <tr> <td class=\"indent1\">Acknowledge the effect of the illness on the patient's broader life experience.</td> </tr> <tr> <td class=\"subtitle1_single\">Dialog</td> </tr> <tr> <td class=\"indent1\">Acknowledge personhood and recognize the emotional impact that accompanies illness by making statements such as, \"This must be frightening for you\" or \"It's natural to feel pretty overwhelmed at times like these.\"</td> </tr> <tr> <td class=\"indent1\">Ask who else should be involved to help the patient and family through a difficult time (eg, psychosocial services, close friends, clergy).</td> </tr> <tr> <td class=\"indent1\">Explore the issues and values that are most important to patients and their families as they face the end of life.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Cook D, Rocker G. Dying with Dignity in the Intensive Care Unit. N Engl J Med 2014; 370:2506.</LI>&#xD;&#xA;<LI>Chochinov HM. Dignity and the essence of medicine: the A, B, C, and D of dignity conserving care. BMJ 2007; 335:184.</LI></OL></div><div id=\"graphicVersion\">Graphic 96061 Version 1.0</div></div></div>"},"96064":{"type":"graphic_table","displayName":"AAGL classification of laparoscopic hysterectomy","title":"AAGL classification of laparoscopic hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AAGL classification of laparoscopic hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Type 0</strong></td> <td colspan=\"2\">Laparoscopic-directed preparation for vaginal hysterectomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\" colspan=\"2\"><strong>Type I*</strong></td> <td colspan=\"2\">Dissection up to but not including uterine arteries</td> </tr> <tr> <td><em>Type I&#913;</em></td> <td>Ovarian artery pedicle(s) only</td> </tr> <tr> <td><em>Type I&#914;<sup>&#182;</sup></em></td> <td>I &#913; + anterior structures</td> </tr> <tr> <td><em>Type IC</em></td> <td>I &#913; + posterior culdotomy</td> </tr> <tr class=\"divider_bottom\"> <td><em>Type ID<sup>&#182;</sup></em></td> <td>I &#913; + anterior structures and posterior culdotomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\" colspan=\"2\"><strong>Type II*</strong></td> <td colspan=\"2\">Type I + uterine artery occlusion and division, unilateral or bilateral</td> </tr> <tr> <td><em>Type II&#913;</em></td> <td>Ovarian artery(ies) and uterine artery(ies) occlusion and division only</td> </tr> <tr> <td><em>Type II&#914;<sup>&#182;</sup></em></td> <td>II &#913; + anterior structures</td> </tr> <tr> <td><em>Type IIC</em></td> <td>II &#913; + posterior culdotomy</td> </tr> <tr class=\"divider_bottom\"> <td><em>Type IID<sup>&#182;</sup></em></td> <td>II &#913; + anterior structures and posterior culdotomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\" colspan=\"2\"><strong>Type III*</strong></td> <td colspan=\"2\">Type II + portion of cardinal-uterosacral ligament complex only, unilateral or bilateral</td> </tr> <tr> <td><em>Type III&#913;</em></td> <td>Uterine and ovarian artery pedicles with portion of the cardinal-uterosacral complex only, unilateral or bilateral</td> </tr> <tr> <td><em>Type III&#914;<sup>&#182;</sup></em></td> <td>III &#913; + anterior structures</td> </tr> <tr> <td><em>Type IIIC</em></td> <td>III &#913; + posterior culdotomy</td> </tr> <tr class=\"divider_bottom\"> <td><em>Type IIID<sup>&#182;</sup></em></td> <td>III &#913; + anterior structures and posterior culdotomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\" colspan=\"2\"><strong>Type IV*</strong></td> <td colspan=\"2\">Type II + total cardinal-uterosacral ligament complex, unilateral or bilateral</td> </tr> <tr> <td><em>Type IV&#913;</em></td> <td>Uterine and ovarian artery pedicles with complete detachment of the total cardinal-uterosacral ligament complex only, unilateral or bilateral</td> </tr> <tr> <td><em>Type IV&#914;<sup>&#182;</sup></em></td> <td>IV &#913; + anterior structures</td> </tr> <tr> <td><em>Type IVC</em></td> <td>IV &#913; + posterior culdotomy</td> </tr> <tr> <td><em>Type IVD<sup>&#182;</sup></em></td> <td>IV &#913; + anterior structures and posterior culdotomy</td> </tr> <tr> <td><em>Type IVE</em></td> <td>Laparoscopically directed removal of entire uterus</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The system describes the portion of the procedure completed laparoscopically.</div><div class=\"graphic_footnotes\">* A suffix \"o\" may be added if unilateral or bilateral oophorectomy is performed concomitantly (eg, type IoA).<br />Â¶ The B and D subgroups may be further subclassified according to the degree of dissection involving the bladder and whether an anterior culdotomy is created: (1) incision of vesicouterine peritoneum only, (2) dissection of any portion of bladder from cervix, (3) creation of an anterior culdotomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Munro MG, Parker WH. A classification system for laparoscopic hysterectomy. Obstet Gynecol 1993; 82:624. Copyright &copy; 1993 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96064 Version 4.0</div></div></div>"},"96067":{"type":"graphic_waveform","displayName":"Crochetage ECG","title":"Crochetage ECG","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Crochetage ECG</div><div class=\"cntnt\"><img style=\"width:800px; height:462px;\" src=\"images/CARD/96067_Crochetage_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crochetage (a notch near the apex of the R wave in inferior limb leads) in a female patient who is status post-closure of a secundum atrial septal defect. Crochetage has been described as an independent electrocardiographic sign of atrial septal defect.</div><div class=\"graphic_reference\">Courtesy of Martin A. St. John Sutton, MD.</div><div id=\"graphicVersion\">Graphic 96067 Version 1.0</div></div></div>"},"96111":{"type":"graphic_algorithm","displayName":"Treatment of aluminum toxicity in symptomatic patients","title":"Treatment of aluminum toxicity in symptomatic patients","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Treatment of aluminum toxicity in symptomatic patients</div><div class=\"cntnt\"><img style=\"width:692px; height:585px;\" src=\"images/NEPH/96111_Tx_aluminum_tox_symptomatic.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Serum aluminum measured before deferoxamine infusion and two days later.</div><div class=\"graphic_reference\">Courtesy of Dr. Wajeh Y Qunibi, MD.</div><div id=\"graphicVersion\">Graphic 96111 Version 1.0</div></div></div>"},"96112":{"type":"graphic_algorithm","displayName":"Treatment of aluminum toxicity in asymptomatic patients","title":"Treatment of aluminum toxicity in asymptomatic patients","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Treatment of aluminum toxicity in asymptomatic patients</div><div class=\"cntnt\"><img style=\"width:744px; height:585px;\" src=\"images/NEPH/96112_Tx_alumin_tox_asymptomatic.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Serum aluminum measured before deferoxamine infusion and two days later.<br />&Delta; Eg, diabetes mellitus, secondary hyperparathyroidism, vitamin D status, high citrate intake.</div><div class=\"graphic_reference\">Courtesy of Dr. Wajeh Y Qunibi, MD.</div><div id=\"graphicVersion\">Graphic 96112 Version 1.0</div></div></div>"},"96117":{"type":"graphic_table","displayName":"CAPOX small intestinal adenocarcinoma","title":"Capecitabine plus oxaliplatin (CAPOX, XELOX) for small bowel adenocarcinoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine plus oxaliplatin (CAPOX, XELOX) for small bowel adenocarcinoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>130 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL of 5% dextrose in water (D5W)* and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#182;</sup></td> <td>750 mg/m<sup>2</sup> orally</td> <td>Twice daily (total daily dose 1500 mg/m<sup>2</sup>). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#916;</sup></td> <td>Evening of day 1 to morning of day 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin: MODERATE. </li> <li>Oral capecitabine: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for oxaliplatin. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT (QTc) interval and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function every three weeks prior to treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment. </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The treatment cycle should be delayed one week if the absolute neutrophil count is &#60;1500/microL, or the platelet count is &#60;75,000/microL on day 1.<sup>[1]</sup> If treatment is delayed beyond one week, reduce doses of capecitabine and oxaliplatin by 25%. Interrupt capecitabine for grade 3 or 4 hematologic toxicity during treatment (except anemia). Reduce dose of oxaliplatin by 25% for grade 3 or 4 hematologic toxicity (excluding anemia) during treatment. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original trial, for paresthesias with pain or functional impairment lasting longer than seven days, the oxaliplatin dose was decreased by 25%, and oxaliplatin was discontinued for persistence throughout a cycle.<sup>[1]</sup> The United States Prescribing Information suggests dose reduction for persistent NCI-CTC grade 2 neurosensory events (sensory alteration or paresthesias including tingling but not interfering with activities of daily living [ADLs]) and discontinuation of oxaliplatin for persistent grade 3 (objective sensory loss or paresthesias including tingling interfering with function but not ADLs) or grade 4 neurosensory events.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hand-foot syndrome</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine during a cycle for grade &#8805;2 hand-foot syndrome until recovered to grade &#8804;1.<sup>[1]</sup> Reduce subsequent capecitabine dose by 25% for grade 2 hand-foot syndrome and by 50% for grade 3 hand-foot syndrome. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[3]</sup> After recovery, reduce the dose of oxaliplatin by 25% after the first episode of grade 3 or worse diarrhea or mucositis. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of grade 2 or 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[3]</sup> Reduce the dose of oxaliplatin by 25% for drug-related grade 3 or 4 nonhematologic toxicity (except hand-foot syndrome).<sup>[1]</sup> Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of a grade 2 or grade 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine omitted for toxicity are not replaced or restored; instead, the patient should resume with the next planned treatment cycle.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio; NCI-CTC: National Cancer Institute Common Toxicity Criteria.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Â¶ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />Î Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Overman MJ, et al. J Clin Oncol 2009; 27:2598.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Nehls O, et al. Br J Cancer 2008; 98:309.</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 96117 Version 12.0</div></div></div>"},"96118":{"type":"graphic_diagnosticimage","displayName":"Primary ciliary dysfunction EM","title":"Electron micrographs showing defects associated with primary ciliary dysfunction","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Electron micrographs showing defects associated with primary ciliary dysfunction</div><div class=\"cntnt\"><img style=\"width:664px; height:196px;\" src=\"images/PULM/96118_Prim_ciliary_dysfunction_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrographs of nasal cilia from patients with primary ciliary dyskinesia (PCD) illustrating dynein defects. Panel A&nbsp;illustrates ultrastructure of a normal cilium from nasal epithelium of a healthy, clinically unaffected subject. The adjacent panels are&nbsp;from three different PCD patients. Panel B&nbsp;illustrates&nbsp;absence of&nbsp;the&nbsp;inner and outer dynein arms; Panel C shows&nbsp;absence&nbsp;of the&nbsp;outer dynein arms only; and Panel D shows absence of the&nbsp;inner dynein arms only.</div><div class=\"graphic_footnotes\">ODA: outer dynein arms; IDA: inner dynein arms.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Genetics in Medicine. Leigh MW, Pittman JE, Carson JL, et al. Clinical and Genetic Aspects of Primary Ciliary Dyskinesia/Kartagener Syndrome. Genet Med 2009; 11:473. Copyright &copy; 2009. <a href=\"http://www.nature.com/gim\" spellcheck=\"true\" target=\"_blank\">www.nature.com/gim</a>.</div><div id=\"graphicVersion\">Graphic 96118 Version 1.0</div></div></div>"},"96123":{"type":"graphic_picture","displayName":"Plexiform neurofibroma with tissue hypertrophy in NF1","title":"Plexiform neurofibroma with tissue hypertrophy in a patient with neurofibromatosis 1","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Plexiform neurofibroma with tissue hypertrophy in a patient with neurofibromatosis 1</div><div class=\"cntnt\"><img style=\"width:540px; height:590px;\" src=\"images/ALLRG/96123_Plexi_neuro_tissue_hypertro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesion involves the side of the face, neck, upper chest, and shoulder.</div><div id=\"graphicVersion\">Graphic 96123 Version 1.0</div></div></div>"},"96124":{"type":"graphic_picture","displayName":"Axillary freckling in a patient with NF1","title":"Axillary freckling in a patient with neurofibromatosis 1","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Axillary freckling in a patient with neurofibromatosis 1</div><div class=\"cntnt\"><img style=\"width:590px; height:393px;\" src=\"images/ALLRG/96124_Axillary_freckling_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96124 Version 1.0</div></div></div>"},"96125":{"type":"graphic_picture","displayName":"Multiple cafe-au-lait spots in a patient with NF1","title":"Multiple cafe-au-lait spots in a patient with neurofibromatosis 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple cafe-au-lait spots in a patient with neurofibromatosis 1</div><div class=\"cntnt\"><img style=\"width:400px; height:590px;\" src=\"images/ALLRG/96125_Multiple_cafe-au-lait_spots.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96125 Version 1.0</div></div></div>"},"96127":{"type":"graphic_picture","displayName":"Multiple cutaneous neurofibromas in a patient with NF1","title":"Multiple cutaneous neurofibromas in a patient with neurofibromatosis 1","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Multiple cutaneous neurofibromas in a patient with neurofibromatosis 1</div><div class=\"cntnt\"><img style=\"width:590px; height:393px;\" src=\"images/ALLRG/96127_Multi_dermal_neurofibromas.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96127 Version 1.0</div></div></div>"},"96128":{"type":"graphic_figure","displayName":"Elliptical rhombic excision","title":"Elliptical or rhombic excision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elliptical or rhombic excision</div><div class=\"cntnt\"><img style=\"width:391px; height:400px;\" src=\"images/DERM/96128_Ellipticalrhombicincision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Classic ellipse with a 3:1 length-to-width ratio.<br />(B) Tangent-to-circle or rhombic excision with a 3:1 length-to-width ratio.</div><div class=\"graphic_reference\">Redrawn from: Goldberg LH, Alam M. Elliptical excisions: variations and the eccentric parallelogram. Arch Dermatol 2004; 140:176.</div><div id=\"graphicVersion\">Graphic 96128 Version 4.0</div></div></div>"},"96131":{"type":"graphic_figure","displayName":"Buried vertical mattress suture","title":"Buried vertical mattress suture","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Buried vertical mattress suture</div><div class=\"cntnt\"><img style=\"width:521px; height:238px;\" src=\"images/DERM/96131_Buried_vertical_mattress_suture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The purpose of the vertical mattress suture is to optimize wound margin eversion while burying the surgical knot in the deep dermis or superficial adipose tissue.</div><div class=\"graphic_reference\">Modified from: Surgery of the Skin: Procedural Dermatology, 2nd ed, Robinson JK, Hanke CW, Siegel DM, Fratila A (Eds), St. Louis: Mosby, 2010.</div><div id=\"graphicVersion\">Graphic 96131 Version 2.0</div></div></div>"},"96151":{"type":"graphic_movie","displayName":"FEES showing aspiration","title":"Fiberoptic endoscopic evaluation of swallowing (FEES) showing aspiration","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Fiberoptic endoscopic evaluation of swallowing (FEES) showing aspiration</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/96151_FEESshowingaspirationvid.mp4\" style=\"width:528px;height:368px\"></div><img style=\"width:375px; height:302px;\" src=\"images/PEDS/96151_FEESshowingaspirationimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fiberoptic endoscopic evaluation of swallowing (FEES) of a teenager who aspirates. The green-stained noodle is present in the larynx after the swallow is complete.</div><div class=\"graphic_reference\">Video courtesy or Jeremy Prager, MD.</div><div id=\"graphicVersion\">Graphic 96151 Version 1.0</div></div></div>"},"96162":{"type":"graphic_diagnosticimage","displayName":"Aspiration on a videofluoroscopic swallow study","title":"Aspiration on a videofluoroscopic swallow study","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration on a videofluoroscopic swallow study</div><div class=\"cntnt\"><img style=\"width:391px; height:346px;\" src=\"images/PEDS/96162_Aspir_videofluoroscopic_bar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Videofluoroscopic swallow study (modified barium swallow) of a 12 month old male with chronic cough, demonstrating aspiration of thin liquid into the trachea (arrow).</div><div class=\"graphic_reference\">Courtesy of Emily DeBoer, MD.</div><div id=\"graphicVersion\">Graphic 96162 Version 2.0</div></div></div>"},"96163":{"type":"graphic_picture","displayName":"Nummular eczema","title":"Nummular eczema","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nummular eczema</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96163_Nummulareczema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly, and crusted round-shaped&nbsp;plaque in the ankle area.</div><div id=\"graphicVersion\">Graphic 96163 Version 3.0</div></div></div>"},"96164":{"type":"graphic_picture","displayName":"Nummular eczema 2","title":"Nummular eczema","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nummular eczema</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96164_Nummulareczema2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plaque of nummular eczema with erythema, vesiculation, and crusting.</div><div id=\"graphicVersion\">Graphic 96164 Version 3.0</div></div></div>"},"96165":{"type":"graphic_picture","displayName":"Nummular eczema coin","title":"Nummular eczema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nummular eczema</div><div class=\"cntnt\"><img style=\"width:399px; height:597px;\" src=\"images/DERM/96165_NummularEczemacoindemo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nummular eczema on the arm, characterized by the presence of multiple coin-shaped lesions.</div><div id=\"graphicVersion\">Graphic 96165 Version 3.0</div></div></div>"},"96166":{"type":"graphic_movie","displayName":"Surgical unroofing for hidradenitis","title":"Surgical unroofing for hidradenitis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Surgical unroofing for hidradenitis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/DERM/96166_Surgunroofhidradenitvid.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:540px; height:350px;\" src=\"images/DERM/96166_Surgunroofhidradenitimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96166 Version 1.0</div></div></div>"},"96170":{"type":"graphic_table","displayName":"Rx anthrax meningitis","title":"Intravenous antimicrobial regimens for the treatment of systemic anthrax with possible or confirmed meningitis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous antimicrobial regimens for the treatment of systemic anthrax with possible or confirmed meningitis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nonpregnant adults</td> <td class=\"subtitle1\">Pregnant, postpartum, and lactating&nbsp;women</td> <td class=\"subtitle1\">Children and adolescent<br /> (age &#8805;1 month through 17 years)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">First bactericidal agent:</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Preferred:</td> </tr> <tr> <td class=\"indent2\">Ciprofloxacin 400 mg every 8 hours</td> <td> <p>Ciprofloxacin 400 mg every 8 hours</p> <p>NOTE: The treatment of pregnant, postpartum, and lactating&nbsp;women is similar to that for nonpregnant adults, except that <strong>ciprofloxacin is strongly preferred as the first bactericidal agent</strong></p> At least one agent with transplacental passage is recommended; agents with transplacental passage include ciprofloxacin, levofloxacin, meropenem, ampicillin, penicillin, clindamycin, rifampin</td> <td>Ciprofloxacin 30 mg/kg per day divided every 8 hours, not to exceed 400 mg per dose</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives if ciprofloxacin is unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class=\"indent2\">Levofloxacin 750 mg every 24 hours <strong>OR</strong></td> <td>Levofloxacin 750 mg every 24 hours <strong>OR</strong></td> <td>Levofloxacin <ul class=\"decimal_heading\"> <li>&#60;50 kg: 16 mg/kg per day divided every 12 hours, not to exceed 250 mg per dose </li> <li>&#8805;50 kg: 500 mg every 24 hours <strong>OR</strong> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Moxifloxacin 400 mg every 24 hours</td> <td>Moxifloxacin 400 mg every 24 hours</td> <td>Moxifloxacin <ul class=\"decimal_heading\"> <li>3 months to &#60;2 years: 12 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose </li> <li>2 to 5 years: 10 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose </li> <li>6 to 11 years: 8 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose </li> <li>12 to 17 years, &#60;45 kg: 8 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose </li> <li>12 to 17 years, &#8805;45 kg: 400 mg every 24 hours </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\" colspan=\"3\">PLUS</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Second bactericidal agent:</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Preferred for all strains, regardless of penicillin susceptibility or if susceptibility is unknown:</td> </tr> <tr> <td class=\"indent2\">Meropenem 2 g every 8 hours</td> <td>Meropenem 2 g every 8 hours<sup>&#916;</sup></td> <td>Meropenem 120 mg/kg per day divided every 8 hours, not to exceed 2 g per dose</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives if meropenem is unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class=\"indent2\">Imipenem 1 g every 6 hours<sup>&#9674;</sup> <strong>OR</strong></td> <td>Imipenem 1 g every 6 hours<sup>&#916;</sup><sup>&#9674;</sup> <strong>OR</strong></td> <td>Imipenem 100 mg/kg per day divided every 6 hours, not to exceed 1 g per dose<sup>&#9674;</sup> <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Doripenem 500 mg every 8 hours</td> <td>Doripenem 500 mg every 8 hours<sup>&#916;</sup></td> <td>Doripenem 120 mg/kg per day divided every 8 hours, not to exceed 1 g per dose <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">&nbsp;</td> <td>&nbsp;</td> <td>Vancomycin 60 mg/kg per day divided every 8 hours, not to exceed 2 grams per dose; maintain serum trough concentration of 15 to 20 mcg/mL</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives for penicillin-susceptible strains (MIC &#60;0.125 mcg/mL):<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent2\">Penicillin G 4 million units every 4 hours <strong>OR</strong></td> <td>Penicillin G 4 million units every 4 hours<sup>&#916;</sup> <strong>OR</strong></td> <td>Penicillin G 400,000 units/kg per day divided every 4 hours, not to exceed 4 million units per dose <strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ampicillin 3 g every 6 hours</td> <td>Ampicillin 3 g every 6 hours<sup>&#916;</sup></td> <td>Ampicillin 400 mg/kg per day divided every 6 hours, not to exceed 3 g per dose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\" colspan=\"3\">PLUS</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Protein synthesis inhibitor (preferred):</td> </tr> <tr> <td class=\"indent2\">Linezolid 600 mg every 12 hours<sup>&#165;</sup></td> <td>Linezolid 600 mg every 12 hours<sup>&#165;</sup></td> <td>Linezolid<sup>&#165;</sup> <ul class=\"decimal_heading\"> <li>&#60;12 years old: 30 mg/kg per day divided every 8 hours, not to exceed 600 mg per dose </li> <li>&#8805;12 years old: 30 mg/kg per day divided every 12 hours, not to exceed 600 mg per dose </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternatives if linezolid unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class=\"indent2\">Clindamycin 900 mg every 8 hours <strong>OR</strong></td> <td>Clindamycin 900 mg every 8 hours <strong>OR</strong></td> <td>Clindamycin 40 mg/kg per day divided every 8 hours, not to exceed 900 mg per dose <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Rifampin 600 mg every 12 hours<sup>&#135;</sup> <strong>OR</strong></td> <td>Rifampin 600 mg every 12 hours<sup>&#135;</sup></td> <td>Rifampin 20 mg/kg per day divided every 12 hours, not to exceed 300 mg per dose<sup>&#135;</sup> <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Chloramphenicol 1 g every 6 to 8 hours<sup>&#134;</sup></td> <td>Chloramphenicol 1 g every 6 to 8 hours<sup>&#134;</sup></td> <td>Chloramphenicol 100 mg/kg per day divided every 6 hours, not to exceed 1 g per dose<sup>&#134;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In addition to antimicrobial therapy, antitoxin therapy (raxibacumab, obiltoxaximab,&nbsp;or anthrax immunoglobulin) should also be given. Patients should be treated with IV antimicrobial therapy for at least two to three weeks and until clinically stable, whichever is longer. These recommendations are based on the susceptibilities of <EM>B. anthracis</EM> isolated during the 2001 bioterrorism event in the United States. In the event of another bioterrorism event, susceptibilities must be rechecked and antimicrobial therapy modified accordingly. Following completion of IV antimicrobial therapy, patients exposed to aerosolized spores will require PEP to complete 60 days of therapy from onset of illness. Refer to the related topic reviews and table on anthrax PEP for additional details.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; IV: intravenous; PEP: postexposure prophylaxis.<br />* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.<br />Î Pharmacokinetic data indicate that penicillin, ampicillin, and carbapenems may require higher doses in pregnant and postpartum&nbsp;women than those recommended for nonpregnant adults.<br /><FONT class=lozenge>â</FONT> Imipenem is associated with an increased risk of seizures.<br />Â§ Penicillin-based antimicrobial drug use requires a high index of suspicion for emergence of resistance.<br />Â¥ Linezolid should be used with caution in patients with thrombocytopenia because it might exacerbate it. Linezolid use for &gt;14 days has additional bone marrow toxicity.<br />â¡ Rifampin is not a protein synthesis inhibitor. However, it may be used as an alternative agent based on its in vitro synergy for staphylococci in place of a protein synthesis inhibitor if they (linezolid, clindamycin) cannot be given. It has not been evaluated for <EM>B. anthracis</EM>.<br />â  Because of toxicity concerns, chloramphenicol should only be used if other options are not available.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014; 20.</LI>&#xD;&#xA;<LI>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 2014; 20.</LI>&#xD;&#xA;<LI>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014; 133:e1411.</LI></OL></div><div id=\"graphicVersion\">Graphic 96170 Version 4.0</div></div></div>"},"96171":{"type":"graphic_table","displayName":"Selected patient-reported outcome instruments","title":"Selected patient-reported outcome instruments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected patient-reported outcome instruments</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name of tool</td> <td class=\"subtitle1\">Total question number</td> <td class=\"subtitle1\">Domains assessed (number of questions)</td> <td class=\"subtitle1\">Time frame</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">General health scales</td> </tr> <tr> <td class=\"indent1\">EQ-5D (formally EuroQol)</td> <td>6</td> <td> <ul> <li>Physical function (2): mobility, self-care </li> <li>Social functioning (1): usual activities </li> <li>Symptom (1): pain/discomfort </li> <li>Mental functioning (1): anxiety/depression </li> <li>Health state thermometer </li> </ul> </td> <td>Current</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Medical Outcomes Study 36 (MOS SF-36) version 2.0</td> <td>36</td> <td> <ul> <li>General health </li> <li>Comparison to 1 year ago </li> <li>8 scales/domains: physical functioning, role limitations due to physical issues, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health </li> <li>2 summary measures that aggregate scales </li> </ul> </td> <td>Past 4 weeks</td> <td> <p>Healthy and ill individuals</p> Available in standard (4-week) and acute (1-week) recall versions</td> </tr> <tr> <td class=\"indent1\">Sickness Impact Profile (SIP)</td> <td>136</td> <td> <ul> <li>2 domains: physical, psychosocial </li> <li>12 categories: sleep/rest, eating, work, home management, recreation, ambulation, mobility, body care and movement, social interaction, alertness, emotional functioning, communication </li> </ul> </td> <td>Current</td> <td> <p>For individuals with chronic illness</p> Shorter version (68 items) also available</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Disease-specific QOL scales (for patients with cancer)</td> </tr> <tr> <td class=\"indent1\">European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30) version 3.0</td> <td>30</td> <td> <ul> <li>Global health (2) </li> <li>Functional Scales <ul> <li>Physical functioning (5) </li> <li>Role functioning (2) </li> <li>Emotional functioning (4) </li> <li>Cognitive functioning (2) </li> <li>Social functioning (2) </li> </ul> </li> <li>Symptoms scales/items <ul> <li>Fatigue (3) </li> <li>Nausea/vomiting (2) </li> <li>Pain (2) </li> <li>Global QOL (1 each: dyspnea, insomnia, appetite, constipation, diarrhea, financial) </li> </ul> </li> </ul> </td> <td>Past week</td> <td>Any cancer</td> </tr> <tr> <td class=\"indent1\">Functional Assessment of Cancer Therapy-General (FACT-G) version 4</td> <td>27</td> <td> <ul> <li>4 domains/scales: functional wellbeing, emotional wellbeing, social/family wellbeing, physical wellbeing </li> </ul> </td> <td>Past week</td> <td>Any cancer</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Site-specific symptom and functional assessment tools</td> </tr> <tr> <td class=\"indent1\">EORTC QLQ-H&#38;N35 </td> <td>35</td> <td> <ul> <li>7 domains/scales: pain (4), swallowing (4), senses (2), speech (3), social eating (4), social contact (5), sexuality (2) </li> <li>Single items specific to HNC: teeth, trismus, dry mouth, sticky saliva, cough, felt ill, pain killers, nutritional supplements, feeding tube, weight loss, weight gain </li> </ul> </td> <td>Past week</td> <td> <p>HNC</p> Designed to be used with EORTC-C30</td> </tr> <tr> <td class=\"indent1\">FACT-H&#38;N (version 4)</td> <td>39</td> <td> <ul> <li>Physical wellbeing (7) </li> <li>Social/family wellbeing (7) </li> <li>Emotional wellbeing (6) </li> <li>Functional wellbeing (7) </li> <li>H&#38;N&nbsp;specific (12) </li> </ul> </td> <td>Past week</td> <td> <p>HNC</p> Not tested as thoroughly as FACT-G</td> </tr> <tr> <td class=\"indent1\">University of Washington UW-QOL</td> <td>16</td> <td> <ul> <li>Global health (3) </li> <li>Symptoms (pain, appearance, swallowing, chewing, speech, shoulder, taste, saliva) </li> <li>Function (activity, recreation, mood, anxiety) </li> </ul> </td> <td>Past week</td> <td>HNC</td> </tr> <tr> <td class=\"indent1\">VHNSS version 2.0</td> <td>50</td> <td> <ul> <li>Nutrition (4) </li> <li>Swallowing/eating foods (9) </li> <li>Xerostomia (4) </li> <li>Mucositis (3) </li> <li>Pain (4) </li> <li>Excess mucus (4) </li> <li>Speech/communication (3) </li> <li>Hearing (1) </li> <li>Taste Change (4) </li> <li>Smell (2) </li> <li>Dental health (5) </li> <li>Mucosal sensitivity (5) </li> <li>Range of motion (2) </li> </ul> </td> <td>Past week</td> <td>HNC</td> </tr> <tr> <td class=\"indent1\">MD Anderson Symptom Inventory (MDASI)-HN</td> <td>28</td> <td> <ul> <li>13 general symptom severity items: pain, fatigue, nausea, sleep, distress, shortness of breath, appetite, drowsiness, dry mouth, sadness, vomiting, memory, numbness or tingling </li> <li>6 general symptom interference items: general activity, mood, walking ability, normal work, relationships, enjoyment of life </li> <li>9 HNC treatment related: mucus, swallowing/chewing, choking/coughing, voice/speech, skin, constipation, taste, oral sores, dental health </li> </ul> </td> <td>Current</td> <td>HNC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EQ-5D: EuroQol five dimensions questionnaire; QLQ: quality of life questionnaire; QOL: quality of life; H&amp;N: head and neck; HNC: head and neck cancer; VHNSS: Vanderbilt Head and Neck Symptom Survey.</div><div id=\"graphicVersion\">Graphic 96171 Version 2.0</div></div></div>"},"96172":{"type":"graphic_picture","displayName":"Recluse spider bite with vesiculation","title":"Recluse spider bite with vesiculation","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Recluse spider bite with vesiculation</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/EM/96172_Reclu_spider_bite__vesicula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This verified recluse spider bite shows central and surrounding vesiculation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96172 Version 1.0</div></div></div>"},"96173":{"type":"graphic_picture","displayName":"Recluse spider bite bulls eye lesion","title":"Recluse spider bite with bull's eye appearance","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Recluse spider bite with bull's eye appearance</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/EM/96173_Rec_spid_bite_bulls_eye_les.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This recluse spider bite wound displays a central vesicle&nbsp;with an&nbsp;area of ecchymosis and eschar surrounded by a ring of pallor and then an outer ring of redness.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc. </div><div id=\"graphicVersion\">Graphic 96173 Version 1.0</div></div></div>"},"96174":{"type":"graphic_picture","displayName":"Recluse spider bite with skin necrosis","title":"Recluse spider bite with skin necrosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Recluse spider bite with skin necrosis</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/EM/96174_Rec_spider_bite_skin_necros.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96174 Version 1.0</div></div></div>"},"96175":{"type":"graphic_picture","displayName":"Healing recluse spider bite","title":"Healing recluse spider bite","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Healing recluse spider bite</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/EM/96175_Healing_recluse_spider_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows sloughing of eschar and healing by secondary intention several weeks after a recluse spider bite.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc. </div><div id=\"graphicVersion\">Graphic 96175 Version 1.0</div></div></div>"},"96185":{"type":"graphic_table","displayName":"iwCLL criteria for active disease","title":"iwCLL criteria for \"active disease\"","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">iwCLL criteria for \"active disease\"</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The iwCLL defines \"active disease\" by the presence of one or more of the following criteria:</td> </tr> <tr> <td class=\"indent1\">Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia.</td> </tr> <tr> <td class=\"indent1\">Massive (ie, at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly.</td> </tr> <tr> <td class=\"indent1\">Massive nodes (ie, at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.</td> </tr> <tr> <td class=\"indent1\">Progressive lymphocytosis with an increase of more than 50 percent over a two-month period or LDT of less than six months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of two weeks over an observation period of two to three months. In patients with initial blood lymphocyte counts of less than 30 x 10<sup>9</sup>/L (30,000/L), LDT should not be used as a single parameter to define a treatment indication. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infection) should be excluded.</td> </tr> <tr> <td class=\"indent1\">Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy.</td> </tr> <tr> <td class=\"indent1\">Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs: <p class=\"indent2\">a. Unintentional weight loss of 10 percent or more within the previous six months</p> <p class=\"indent2\">b. Significant fatigue (ie, ECOG PS 2 or worse; inability to work or perform usual activities)</p> <p class=\"indent2\">c. Fevers higher than 100.5&#176;F or 38.0&#176;C for two or more weeks without other evidence of infection</p> <p class=\"indent2\">d. Night sweats for more than one month without evidence of infection</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table provides the iwCLL criteria for \"active disease\", which identify patients for whom therapy is indicated. Lymphocytosis itself, even if extreme, is not an indication for treatment if patients have no symptoms and adequate bone marrow function. Likewise, hypogammaglobulinemia or monoclonal or oligoclonal paraproteinemia does not by itself constitute a basis for initiating therapy.</div><div class=\"graphic_footnotes\">iwCLL: International Workshop on Chronic Lymphocytic Leukemia; LDT: lymphocyte doubling time; ECOG: Eastern Cooperative Oncology Group; PS: performance status.</div><div class=\"graphic_reference\">Data from: Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.</div><div id=\"graphicVersion\">Graphic 96185 Version 2.0</div></div></div>"},"96192":{"type":"graphic_table","displayName":"Peripartum or intrapartum hypoxic-ischemic event","title":"Markers of an acute peripartum or intrapartum hypoxic-ischemic event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Markers of an acute peripartum or intrapartum hypoxic-ischemic event</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neonatal signs consistent with an acute peripartum or intrapartum event:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Apgar score of &#60;5 at 5 minutes and 10 minutes </li> <li>Fetal umbilical artery acidemia: fetal umbilical artery pH &#60;7.0, or base deficit &#8805;12 mmol/L, or both </li> <li>Neuroimaging evidence of acute brain injury seen on brain MRI or MRS consistent with hypoxia-ischemia </li> <li>Presence of multisystem organ failure consistent with hypoxic-ischemic encephalopathy </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Type and timing of contributing factors that are consistent with an acute peripartum or intrapartum event:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A sentinel hypoxic or ischemic event occurring immediately before or during labor and delivery: <ul> <li>Ruptured uterus </li> <li>Severe abruptio placentae </li> <li>Umbilical cord prolapse </li> <li>Amniotic fluid embolus with coincident severe and prolonged maternal hypotension and hypoxemia </li> <li>Maternal cardiovascular collapse </li> <li>Fetal exsanguination from either vasa previa or massive fetomaternal hemorrhage </li> </ul> </li> <li>Fetal heart rate monitor patterns consistent with an acute peripartum or intrapartum event, particularly a category I fetal heart rate pattern on presentation that converts to one of the following patterns: <ul> <li>Category III pattern </li> <li>Tachycardia with recurrent decelerations </li> <li>Persistent minimal variability with recurrent decelerations </li> </ul> </li> <li>Timing and type of brain injury patterns based on imaging studies consistent with an etiology of an acute peripartum or intrapartum event. Well-defined patterns on brain MRI typical of hypoxic-ischemic cerebral injury in the newborn are: <ul> <li>Deep nuclear gray matter (ie, basal ganglia or thalamus) injury </li> <li>Watershed (borderzone) cortical injury </li> </ul> </li> <li>No evidence of other proximal or distal factors that could be contributing </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Developmental outcome is spastic quadriplegia or dyskinetic cerebral palsy:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Other subtypes of cerebral palsy are less likely to be associated with acute intrapartum hypoxic-ischemic events </li> <li>Other developmental abnormalities may occur, but they are not specific to acute intrapartum hypoxic-ischemic encephalopathy and may arise from a variety of other causes </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">MRI: magnetic resonance imaging; MRS: magnetic resonance spectroscopy</div><div class=\"graphic_reference\">Source: Neonatal encephalopathy and neurologic outcome, second edition. Report of the American College of Obstetricians and Gynecologists' Task Force on Neonatal Encephalopathy. Obstet Gynecol 2014; 123:896.</div><div id=\"graphicVersion\">Graphic 96192 Version 1.0</div></div></div>"},"96193":{"type":"graphic_figure","displayName":"B cell flow cytometry for CVID","title":"B cell flow cytometry for common variable immunodeficiency","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">B cell flow cytometry for common variable immunodeficiency</div><div class=\"cntnt\"><img style=\"width:765px; height:502px;\" src=\"images/ALLRG/96193_B_cell_flow_cytometry_CVID.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top) Left: Patterns of normal B cell differentiation in peripheral blood based on IgD and CD27. Right: Similar staining in a patient with CVID demonstrating reduced-switched memory B cells.<br />(Bottom) Left: Normal expression of CD21 and CD27 on B cells (cells gated on CD19). Right: Elevated CD21 low expressing CD19+ B cells in patient with CVID and splenomegaly.</div><div class=\"graphic_footnotes\">IgD: immunoglobulin D; CD: cluster of differentiation; CVID: common variable immunodeficiency; %: percent.</div><div id=\"graphicVersion\">Graphic 96193 Version 1.0</div></div></div>"},"96194":{"type":"graphic_figure","displayName":"Flow cytometry of Tfh","title":"Flow cytometry of follicular helper T cells (Tfh)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow cytometry of follicular helper T cells (Tfh)</div><div class=\"cntnt\"><img style=\"width:381px; height:252px;\" src=\"images/ALLRG/96194_Flow_cytometry_of_Tfh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular helper T cells provide essential help to antigen-specific B cells in the germinal centers of the follicle. These cells express CXCR5, which also marks B cells.</div><div class=\"graphic_footnotes\">Tfh: follicular helper T cell; CD: cluster of differentiation; CXCR5: C-X-C&nbsp;motif chemokine receptor 5, where C = cysteine and X = any amino acid.</div><div id=\"graphicVersion\">Graphic 96194 Version 1.0</div></div></div>"},"96198":{"type":"graphic_table","displayName":"Malignancies in PIDs","title":"Most prevalent cancer types and known mechanisms for malignancy formation among patients with primary immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most prevalent cancer types and known mechanisms for malignancy formation among patients with primary immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"22%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Genetic defect or probable pathogenesis</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Mechanism of malignancy formation</td> <td class=\"subtitle1\">Type of malignancy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Combined immunodeficiencies</td> </tr> <tr> <td class=\"indent1\">Severe combined immunodeficiency (SCID)</td> <td>Mutations in IL2RG, <em>JAK3</em>, <em>IL7RA</em>, <em>RAG1</em>, <em>RAG2</em>, <em>DCLRE1C</em>, CORO1A, CD3D, CD3E, CD3Z, PTPRC, PRKDC, <em>ADA</em>, and AK2</td> <td>AR in most cases, also XL</td> <td>Probably impaired function of immune system and decreased viral clearance (EBV)</td> <td> <p>NHL, Hodgkin lymphoma, leukemia</p> <p>Multiple renal and pulmonary leiomyomata</p> <p>EBV-associated lymphoma (Artemis)</p> Burkitt lymphoma (ADA deficiency treated with PEG-ADA)</td> </tr> <tr> <td class=\"indent1\">ITK deficiency (an EBV-associated lymphoproliferative disease)</td> <td>Mutations in <em>ITK</em> (IL-2 inducible T cell kinase)</td> <td>AR</td> <td>Impaired function of immune system, decreased viral clearance (EBV)</td> <td>Lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MAGT1 deficiency (ie, XMEN)&nbsp;</td> <td>Mutations in <em>MAGT1</em> (magnesium transporter 1)</td> <td>&nbsp;XL</td> <td>&nbsp;</td> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Well-defined syndromes with immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Wiskott-Aldrich syndrome</td> <td>Mutations in <em>WAS</em></td> <td>XL</td> <td>Impaired function of immune system, decreased viral clearance (EBV), probably impaired genetic stability</td> <td>Diffuse large B cell lymphomas,&nbsp;NHL of larynx, leukemia, cerebellar astrocytoma, Kaposi sarcoma, smooth muscle tumors</td> </tr> <tr> <td class=\"indent1\">Ataxia-telangiectasia</td> <td>Mutations in <em>ATM</em></td> <td>AR</td> <td>Impaired genetic stability</td> <td>Lymphoid leukemias, lymphomas (both B and T cell, NHL), epithelial tumors</td> </tr> <tr> <td class=\"indent1\">Nijmegen breakage syndrome</td> <td>Mutations in <em>NBS1</em></td> <td>AR</td> <td>Impaired genetic stability</td> <td>Brain tumors, lymphomas (both B and T, NHL, DLBCL and T-LBL), leukemia</td> </tr> <tr> <td class=\"indent1\">Cartilage-hair hypoplasia</td> <td>Mutations in <em>RMRP</em></td> <td>AR</td> <td>&nbsp;</td> <td>NHL basal cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant hyperimmunoglobulin E&nbsp;syndrome (AD-HIES)</td> <td>Mutations in <em>STAT3</em></td> <td>AD</td> <td>&nbsp;</td> <td>NHL, squamous cell carcinoma of the vulva, pulmonary adenocarcinoma with liver, bone, and spinal cord metastases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">AR-HIES (DOCK8 deficiency)</td> <td>Mutations in <em>DOCK8</em></td> <td>AR</td> <td>Probably defective tumor suppression genes in DOCK8 deficiency</td> <td>Squamous cell carcinoma, cutaneous T cell lymphoma/leukemia, Burkitt lymphoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Predominantly antibody deficiencies</td> </tr> <tr> <td class=\"indent1\">X-linked agammaglobulinemia</td> <td>Mutations in <em>BTK</em></td> <td>XL</td> <td>&nbsp;</td> <td>Lymphoproliferative disorders, gastric adenocarcinoma, colorectal cancer</td> </tr> <tr> <td class=\"indent1\">Common variable immunodeficiency (CVID)</td> <td>Unknown in most cases, mutations in <em>TNFRSF13B </em>(encodes TACI), <em>TNFRSF13C </em>(encodes BAFF-R), CD19, CD20, CD81, and ICOS</td> <td>Variable</td> <td>Probably defective tumor suppression genes</td> <td>NHL, epithelial tumors (carcinomas of stomach, breast, bladder, cervix), carcinoma of the vulva (ICOS deficiency), tonsillar carcinoma of epithelial origin (TNFRSF13B)</td> </tr> <tr> <td class=\"indent1\">X-linked hyperimmunoglobulin M syndrome</td> <td>Mutations in <em>CD40LG</em></td> <td>XL</td> <td>Probably defective clearance of Cryptosporidium</td> <td>Carcinomas of the liver, pancreas, biliary tract and associated <span style=\"color: black;\">neuroectodermal </span><span style=\"color: black;\">endocrine </span>cells</td> </tr> <tr> <td class=\"indent1\">IgG subclass deficiency</td> <td>Unknown</td> <td>Variable</td> <td>&nbsp;</td> <td>Lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Selective IgA deficiency</td> <td>Unknown</td> <td>Variable</td> <td>&nbsp;</td> <td>Lymphoma,&nbsp;gastrointestinal carcinoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Diseases of immune dysregulation</td> </tr> <tr> <td class=\"indent1\">Chediak-Higashi syndrome</td> <td>Mutations in CHS1 (LYST) gene</td> <td>AR</td> <td>&nbsp;</td> <td>Lymphoma</td> </tr> <tr> <td class=\"indent1\">Hermansky-Pudlak syndrome, type 2</td> <td>Mutations in AP3B1 gene</td> <td>AR</td> <td>&nbsp;</td> <td>Lymphoma</td> </tr> <tr> <td class=\"indent1\">Perforin deficiency, Familial hemophagocytic lymphohistiocytosis, type 2 (FHL2)</td> <td>Mutation in PRF1</td> <td>AR</td> <td>&nbsp;</td> <td>Lymphoma</td> </tr> <tr> <td class=\"indent1\">STXBP2 (Munc 18-2) deficiency, FHL5</td> <td>Mutation in STXBP2</td> <td>AR</td> <td>&nbsp;</td> <td>Lymphoma</td> </tr> <tr> <td class=\"indent1\">SH2DA1 deficiency, X-linked lymphoproliferative disease (XLP1)</td> <td>Mutations in <em>SH2D1A</em></td> <td>XL</td> <td>Impaired function of immune system, decreased viral clearance (EBV)</td> <td>Hodgkin B cell lymphoma,&nbsp;NHL in the intestinal region</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Autoimmune lymphoproliferative syndrome (ALPS)</td> <td>Mutations in <em>TNFRSF6</em></td> <td>AD (mostly)</td> <td>Probably defective tumor suppression genes</td> <td>Hodgkin lymphoma&nbsp;and NHL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Phagocytic defects</td> </tr> <tr> <td class=\"indent1\">Severe congenital neutropenia</td> <td>Mutations in <em>ELANE</em>, <em>HAX 1</em>, and <em>WASP</em></td> <td>AD, AR, or XL</td> <td>Genetic predisposition, iatrogenic (G-CSF treatment)</td> <td>Leukemia</td> </tr> <tr> <td class=\"indent1\">Shwachman-Diamond syndrome</td> <td>SBDS: Defective ribosome synthesis</td> <td>AR</td> <td>Probably iatrogenic (G-CSF treatment)</td> <td>Leukemia</td> </tr> <tr> <td class=\"indent1\">Chronic granulomatous disease</td> <td>Mutations in <em>gp91phox</em>, <em>p22phox</em>, <em>p47phox</em>, <em>p67phox</em>, and <em>p40phox</em></td> <td>XL or AR</td> <td>&nbsp;</td> <td>Lymphoma, leukemia, retinoblastoma, melanoma, rhabdomyosarcoma of the liver, glioblastoma multiforme</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MonoMAC syndrome</td> <td><em>GATA2</em>: Loss of stem cells</td> <td>AD</td> <td>&nbsp;</td> <td>AML, CML, vulvar carcinoma, metastatic melanoma, cervical carcinoma, Bowen disease of the vulva, leiomyosarcoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Defects in innate immunity</td> </tr> <tr> <td class=\"indent1\">WHIM syndrome</td> <td>Mutations in CXCR4</td> <td>AD</td> <td>Decreased viral clearance</td> <td>HPV-related cancers, lymphoma</td> </tr> <tr> <td class=\"indent1\">Epidermodysplasia verruciformis</td> <td>Mutations in <em>EVER1</em> and <em>EVER2</em></td> <td>AR</td> <td>Impaired function of immune system, decreased viral clearance (HPV), probably impaired genetic stability</td> <td>Squamous cell carcinoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=red><EM><FONT color=black>IL2RG</FONT></EM><FONT color=black>: gene for interleukin receptor common gamma chain;<EM> JAK</EM>3:&nbsp;gene for Janus&nbsp;kinase 3; <EM innerHtml>IL7RA:</EM> gene for interleukin-7 receptor alpha chain<EM innerHtml>; RAG1: </EM>recombination-activating gene 1;<EM innerHtml> RAG2: </EM>recombination-activating gene 2<EM innerHtml>; DCLRE1C:</EM> gene for DNA cross-link repair protein 1<EM innerHtml>C; </EM>CORO1A<EM innerHtml>: </EM>Coronin 1<EM innerHtml>; </EM>CD3D: CD3 delta; CD3E: CD3 epsilon; CD3Z: CD3 zeta; PTPRC: protein tyrosine phosphatase, receptor&nbsp;type C; PRKDC: protein kinase, DNA-activated, catalytic polypeptide<EM innerHtml>;</EM></FONT></FONT><FONT color=black> ADA: adenosine deaminase; AK2:&nbsp;mitochondrial adenylate kinase 2; </FONT>AR: autosomal <FONT color=black>recessive; XL: X-linked; EBV: Epstein-Barr virus; NHL: non-Hodgkin lymphoma; PEG-ADA: polyethylene glycol-modified bovine ADA; ITK: gene for IL-2 inducible T cell kinase;</FONT> IL-2: interleukin-2; XMEN: X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasm;<FONT color=black> <EM>WAS</EM>: gene for Wiskott-Aldrich syndrome protein; <EM>ATM</EM>: ataxia-telangiectasia, mutated; <EM>NBS1</EM>: NBS gene 1; DLBCL: </FONT>diffuse large B cell lymphoma; <FONT color=black>T-LBL: T cell lymphoblastic leukemia/lymphoma; <EM>RMRP</EM>: ribonuclease mitochondrial RNA processing gene;</FONT> AD: autosomal dominant; HIES: hyperimmunoglobulin E syndrome; <FONT color=red><EM><FONT color=black>STAT3</FONT></EM><FONT color=black>: gene for signal transducer and activator of transcription 3; <EM>DOCK8</EM>: dedicator of cytokinesis 8; <EM>BTK</EM>: gene for Bruton tyrosine kinase;</FONT></FONT><FONT color=black> </FONT><FONT color=red><FONT color=black>TACI: transmembrane activator and calcium-modulator and cyclophilin ligand; BAFF-R: B cell activating factor of the tumor necrosis factor family receptor; ICOS: inducible co-stimulator of activated T cells;</FONT> <EM><FONT color=black>CD40LG</FONT></EM><FONT color=black>: gene for CD40 ligand;</FONT></FONT> IgG: immunoglobulin G; IgA: immunoglobulin A; <FONT color=red><EM><FONT color=black>CHS1</FONT></EM><FONT color=black>: Chediak-Higashi syndrome gene (aka <EM>LYST</EM>); <EM>AP3B1</EM>: gene for adaptor-related protein complex 3, beta 1 subunit; <EM>PRF1</EM>: gene for perforin 1; <EM>STXBP2</EM>: gene for syntaxin binding protein 2; FHL5: familial hemophagocytic lymphohistiocytosis, type 5; <EM>SH2DA1</EM> (aka <EM>SAP</EM>): gene for slam-associated protein;</FONT> <EM><FONT color=black>TNFRSF6</FONT></EM><FONT color=black>: tumor necrosis factor receptor superfamily, member 6 gene&nbsp;(codes for FAS receptor); <EM>ELANE</EM>: gene for neutrophil elastase; <EM>HAX 1</EM>: gene for XCLSI associated protein X-1; WASP: Wiskott-Aldrich syndrome protein; G-CSF: granulocyte colony-stimulating factor; SBDS: Shwachman-Bodian Diamond syndrome; </FONT><EM><FONT color=black>GATA2</FONT></EM><FONT color=black>: gene for&nbsp;GATA-binding protein 2;</FONT></FONT> AML: acute myelogenous leukemia; CML: chronic myelogenous leukemia; <FONT color=red><FONT color=black>WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis;</FONT> <FONT color=black>CXCR4: chemokine receptor 4;</FONT></FONT> HPV: human papillomavirus.</div><div id=\"graphicVersion\">Graphic 96198 Version 3.0</div></div></div>"},"96204":{"type":"graphic_picture","displayName":"Conjunctival suffusion in leptospirosis","title":"Conjunctival suffusion with subconjunctival hemorrhage in a patient with leptospirosis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Conjunctival suffusion with subconjunctival hemorrhage in a patient with leptospirosis</div><div class=\"cntnt\"><img style=\"width:598px; height:398px;\" src=\"images/ID/96204_Conjunct_suffus_leptospiro.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission of American Society of Tropical Medicine and Hygiene, from: Lin CY, Chiu NC, Lee CM. Leptospirosis after typhoon. Am J Trop Med Hyg 2012; 86:187. Copyright Â© 2012; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 96204 Version 3.0</div></div></div>"},"96206":{"type":"graphic_diagnosticimage","displayName":"Apical four-chamber view of PPCM","title":"ApicalÂ four-chamber view of peripartum cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Apical&nbsp;four-chamber view of peripartum cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:605px; height:403px;\" src=\"images/CARD/96206_Apical4chamberviewPPCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Apical&nbsp;four-chamber view obtained in a patient with peripartum cardiomyopathy. Please note dilatation of all four cardiac chambers. Overall LV performance was reduced with a left ventricular ejection fraction of 38 percent. Panel B: Note, in the same patient, a color Doppler&nbsp;jet of moderate mitral regurgitation.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; RA: right atrium; LA: left atrium.</div><div class=\"graphic_reference\">Courtesy of Roberto M. Lang, MD.</div><div id=\"graphicVersion\">Graphic 96206 Version 2.0</div></div></div>"},"96207":{"type":"graphic_picture","displayName":"Systemic JIA rash with Koebner phenomenon","title":"Systemic juvenile idiopathic arthritis rash with Koebner phenomenon","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Systemic juvenile idiopathic arthritis rash with Koebner phenomenon</div><div class=\"cntnt\"><img style=\"width:571px; height:397px;\" src=\"images/ALLRG/96207_Syst_JIA_rsh_Koeb_phenom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systemic&nbsp;juvenile idiopathic arthritis&nbsp;rash on a patient's back is shown in Panel A, with a close-up view in Panel B. The rash usually consists of multiple round to oval, salmon-pink macules that are slightly raised and are of differing sizes.&nbsp;The rash&nbsp;can appear following stroking of the skin or other minor trauma (Koebner phenomenon).</div><div class=\"graphic_reference\">Courtesy of Yukiko Kimura, MD.</div><div id=\"graphicVersion\">Graphic 96207 Version 3.0</div></div></div>"},"96210":{"type":"graphic_table","displayName":"Aspiration precautions","title":"Aspiration precautions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aspiration precautions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Provide comprehensive oral care before eating or drinking, clearing secretions from the oral cavity and moistening the mouth </li> </ul> </td> </tr> <tr> <td> <ul> <li>Upright positioning as close as possible to a 90 degree angle </li> </ul> </td> </tr> <tr> <td> <ul> <li>Flex the head to a neutral or slightly downward position </li> </ul> </td> </tr> <tr> <td> <ul> <li>Supervised hand feeding at a slow pace ensuring completed swallow before proceeding to the next </li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid rushed or forced feeding </li> </ul> </td> </tr> <tr> <td> <ul> <li>Inspection of the oral cavity for residual food or liquid after a swallow </li> </ul> </td> </tr> <tr> <td> <ul> <li>Elevate the head of bed to at least a 30 degree angle after eating for at least an hour </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96210 Version 2.0</div></div></div>"},"96218":{"type":"graphic_diagnosticimage","displayName":"Radiograph of trapezium fracture","title":"Fracture of the trapezium on radiograph","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Fracture of the trapezium on radiograph</div><div class=\"cntnt\"><img style=\"width:604px; height:476px;\" src=\"images/RADIOL/96218_Xray_trapezium_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is an oblique&nbsp;radiograph of the left hand following blunt trauma, and shows a fracture through the trapezium (arrow). Image B is a magnified view of the fracture (arrow).</div><div class=\"graphic_reference\">Courtesy of Greg Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 96218 Version 1.0</div></div></div>"},"96220":{"type":"graphic_figure","displayName":"Skin anatomy trunk face","title":"Anatomic differences between the truncal and facial skin","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Anatomic differences between the truncal and facial skin</div><div class=\"cntnt\"><img style=\"width:597px; height:230px;\" src=\"images/DERM/96220_Skin_anatomy_trunk_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pigmentation along an undulated dermo-epidermal junction characterized by elongated rete ridges.<br />(B) Pigmentation along a flattened dermo-epidermal junction characterized by a high density of hair follicles.</div><div id=\"graphicVersion\">Graphic 96220 Version 1.0</div></div></div>"},"96221":{"type":"graphic_picture","displayName":"Pigment network and pseudonetwork","title":"Dermoscopic images of pigment network and pseudonetwork","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Dermoscopic images of pigment network and pseudonetwork</div><div class=\"cntnt\"><img style=\"width:599px; height:238px;\" src=\"images/DERM/96221_Pigment_network_pseudon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) True pigment network due to melanin along elongated rete ridges: pigmented lines that form a network pattern.<br />(B) Facial pseudonetwork due to melanin along a flat dermo-epidermal junction: structureless pigmentation intermingled by hypopigmented follicular openings.</div><div id=\"graphicVersion\">Graphic 96221 Version 1.0</div></div></div>"},"96222":{"type":"graphic_figure","displayName":"Lentigo maligna versus pigmented actinic keratosis","title":"Difference in pigment distribution in lentigo maligna and pigmented actinic keratosis of the face","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Difference in pigment distribution in lentigo maligna and pigmented actinic keratosis of the face</div><div class=\"cntnt\"><img style=\"width:597px; height:231px;\" src=\"images/DERM/96222_Lenti_malig_pigm_act_kerat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pigmented melanocytes that invade the hair follicles and melanophages in the upper dermis.<br />(B) Keratotic plugs within the follicular openings, pigmented keratinocytes, and melanophages in the upper dermis.</div><div id=\"graphicVersion\">Graphic 96222 Version 1.0</div></div></div>"},"96223":{"type":"graphic_picture","displayName":"Dermoscopic patterns of gray circles and yellow clods","title":"Dermoscopic patterns seen in lentigo maligna and pigmented actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Dermoscopic patterns seen in lentigo maligna and pigmented actinic keratosis</div><div class=\"cntnt\"><img style=\"width:596px; height:248px;\" src=\"images/DERM/96223_Lentig_malig_v_pigm_AK_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lentigo maligna: Melanocytes invading the follicular structures appear as gray circles (B) Pigmented actinic keratosis: Keratotic plugs appear as enlarged white to yellow clods.</div><div id=\"graphicVersion\">Graphic 96223 Version 3.0</div></div></div>"},"96224":{"type":"graphic_picture","displayName":"Lobomycosis on ear","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:393px; height:590px;\" src=\"images/DERM/96224_Lobomycosis_on_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular lesion on the helix. This is a common location for lobomycosis.</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96224 Version 3.0</div></div></div>"},"96225":{"type":"graphic_picture","displayName":"Lobomycosis on knee","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:395px; height:590px;\" src=\"images/DERM/96225_Lobomycosis_on_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reddish, keloid-like nodules on the knee.</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96225 Version 2.0</div></div></div>"},"96226":{"type":"graphic_picture","displayName":"Lobomycosis plaques","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96226_Lobomycosis_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keloid-like plaques on the extremity, consistent with lobomycosis.</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96226 Version 2.0</div></div></div>"},"96227":{"type":"graphic_picture","displayName":"Lobomycosis infiltrative","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:590px; height:395px;\" src=\"images/DERM/96227_Lobomycosis_infiltrative.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infiltrative form of lobomycosis in a patient with longstanding disease.</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96227 Version 2.0</div></div></div>"},"96228":{"type":"graphic_picture","displayName":"Lobomycosis histopathology","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96228_Lobomycosis_histopathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grocott-Gomori silver stain of tissue from lobomycosis demonstrating regular, round, yeast-like structures that are isolated or in chains.</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96228 Version 2.0</div></div></div>"},"96229":{"type":"graphic_picture","displayName":"Lobomycosis epidermal changes","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/96229_Lobomycosis_epidermal_chang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stain showing epidermal acanthosis and hyperkeratosis in a skin biopsy specimen from lobomycosis. Small, round vacuolated areas consistent with fungal cells are present in the dermis.</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96229 Version 2.0</div></div></div>"},"96230":{"type":"graphic_table","displayName":"Reversal strategies DOAC bleeding","title":"Direct oral anticoagulant-associated bleeding reversal strategies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Direct oral anticoagulant-associated bleeding reversal strategies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of bleeding</td> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Possible interventions</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Major bleeding (eg, intracranial, retroperitoneal, compartment syndrome, massive gastrointestinal)</td> <td>Dabigatran (Pradaxa)</td> <td> <ul> <li>Idarucizumab&nbsp; </li> <li>Activated PCC* (eg, FEIBA) </li> <li>Antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid) </li> <li>Anticoagulant discontinuation&nbsp;</li> <li>Oral activated charcoal (if last dose within prior two hours) </li> <li>Hemodialysis </li> <li>RBC transfusions if needed for anemia </li> <li>Platelet transfusions if needed for thrombocytopenia or impaired platelet function (eg, due to aspirin) </li> <li>Surgical/endoscopic intervention if appropriate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), betrixaban (Bevyxxa)</td> <td> <ul> <li>4-factor unactivated PCC* (eg, Kcentra) </li> <li>Antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid) </li> <li>Anticoagulant discontinuation&nbsp;</li> <li>Oral activated charcoal (if last dose recent enough) </li> <li>RBC transfusions if needed for anemia </li> <li>Platelet transfusions if needed for thrombocytopenia or impaired platelet function (eg, due to aspirin) </li> <li>Surgical/endoscopic intervention if appropriate </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">Minor bleeding (eg, epistaxis, uncomplicated soft tissue bleeding, minor [slow] gastrointestinal bleeding)</td> <td>Dabigatran (Pradaxa)</td> <td> <ul> <li>Local hemostatic measures </li> <li>Possible anticoagulant discontinuation <ul> <li>Half-life (normal renal function<sup>&#182;</sup>): 12 to 17 hours </li> </ul> </li> <li>Possible antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid) </li> </ul> </td> </tr> <tr> <td>Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), betrixaban (Bevyxxa)</td> <td> <ul> <li>Local hemostatic measures </li> <li>Possible anticoagulant discontinuation <ul> <li>Half-lives (normal renal function<sup>&#182;</sup>): <ul> <li>Rivaroxaban&nbsp;5 to&nbsp;9 hours </li> <li>Apixaban&nbsp;8 to&nbsp;15 hours </li> <li>Edoxaban 6 to 11 hours </li> </ul> </li> </ul> </li> <li>Possible antifibrinolytic agent (eg, tranexamic acid, epsilon-aminocaproic acid) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table describes measures that may be used to manage bleeding associated with DOACs. Clinical judgment is essential in all cases of DOAC-associated bleeding in order to assess the risks of bleeding and weigh these against the risks of thrombosis if anticoagulation is discontinued or reversed. Refer to UpToDate topics on the use of direct thrombin inhibitors and direct factor Xa inhibitors and management of DOAC-associated bleeding for further details and dosing. The onset of all of the agents discussed herein is approximately 2 to 4 hours.</div><div class=\"graphic_footnotes\">PCC: prothrombin complex concentrate; FEIBA: factor eight inhibitor bypassing activity; RBC: red blood cell; DOAC: direct oral anticoagulant.<br />* Use PCC product only if continued bleeding is reasonably likely to be fatal within hours.<br />Â¶ The anticoagulant effect of these agents (especially dabigatran) will dissipate more slowly as renal function declines. Severe hepatic failure may also prolong the half-life for rivaroxaban, apixaban, edoxaban, and betrixaban.</div><div id=\"graphicVersion\">Graphic 96230 Version 13.0</div></div></div>"},"96231":{"type":"graphic_picture","displayName":"Lobomycosis histopathology dermis","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96231_Aspiration_precautions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stain of a biopsy specimen from lobomycosis demonstrating a dense and diffuse histiocytic infiltrate and numerous round fungal cells (arrow).</div><div class=\"graphic_reference\">Courtesy of Fabio Francesconi, MD.</div><div id=\"graphicVersion\">Graphic 96231 Version 2.0</div></div></div>"},"96233":{"type":"graphic_picture","displayName":"Blue nevus face","title":"Blue nevus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Blue nevus</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96233_Blue_nevus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A blue nevus of the face presenting as a small bluish macule.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96233 Version 1.0</div></div></div>"},"96236":{"type":"graphic_algorithm","displayName":"Diagnostic approach to pediatric appendicitis","title":"Diagnostic approach to pediatric appendicitis","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to pediatric appendicitis</div><div class=\"cntnt\"><img style=\"width:656px; height:726px;\" src=\"images/EM/96236_Diag_ap_pediatric_appendic.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PAS: Pediatric Appendicitis Score; WBC: white blood cell count; ANC: absolute neutrophil count; CRP: C-reative protein; RLQ: right lower quadrant.<br />* Classic signs of early appendicitis consist of abdominal pain for less than two days that begins periumbilically and then begins to radiate and localize to the right lower quadrant. The pain is associated with anorexia, vomiting, and low grade fever. RLQ tenderness is present on physical examination and the white blood cell count, absolute neutrophil count, and/or c-reactive protein are elevated.<br />Â¶ For components of the pediatric appendicitis score refer to UpToDate graphics on pediatric appendicitis score and to the UpToDate topic on clinical manifestations and diagnosis of appendicitis in children.<br />Î Diagnostic imaging prior to surgical consultation is typically performed for these patients. For specific discussion of which imaging tests to order, refer to UpToDate topics on diagnostic imaging in pediatric appendicitis. If local resources are insufficient to adequately perform or interpret pediatric diagnostic imaging or if surgeons with pediatric expertise are not available, the patient should be transferred to a facility with pediatric radiologic and surgical capability and no imaging should be performed at the local institution.</div><div id=\"graphicVersion\">Graphic 96236 Version 3.0</div></div></div>"},"96242":{"type":"graphic_picture","displayName":"Oral mucosa examination","title":"Examination of the oral mucosa","html":"<div class=\"graphic\"><div style=\"width: 869px\" class=\"figure\"><div class=\"ttl\">Examination of the oral mucosa</div><div class=\"cntnt\"><img style=\"width:849px; height:494px;\" src=\"images/DERM/96242_Oralmucosaexamination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The examination of the oral mucosa during a total body skin examination in a 72-year-old male patient revealed a reddish tumor underneath the tip of the tongue.<br />(B) Dermoscopic examination shows structureless red and whitish areas, suggesting hematoma.<br />(C) Complete spontaneous regression of the lesion after six weeks.</div><div class=\"graphic_reference\">Reproduced by permission from: Springer. Der Hautarzt. Blum A. [Who examines the oral mucosa during the total body skin examination?] Hautarzt 2012; 63:899. <A spellcheck=true href=\"https://link.springer.com/journal/105\" target=_blank>https://link.springer.com/journal/105</A>.</div><div id=\"graphicVersion\">Graphic 96242 Version 3.0</div></div></div>"},"96245":{"type":"graphic_picture","displayName":"Penile adhesions after circumcision","title":"Penile adhesions after neonatal circumcision","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Penile adhesions after neonatal circumcision</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/PEDS/96245_Penile_adhesion_aftr_circum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Penile adhesions occurred due to inadequate separation of the glans from the inner prepuce during circumcision with excess skin left after circumcision or from inadequate postoperative care.</div><div class=\"graphic_reference\">Courtesy of Jenny H Yiee, MD.</div><div id=\"graphicVersion\">Graphic 96245 Version 2.0</div></div></div>"},"96246":{"type":"graphic_picture","displayName":"Congenital buried penis","title":"Congenital buried penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital buried penis</div><div class=\"cntnt\"><img style=\"width:438px; height:586px;\" src=\"images/PEDS/96246_Congenital_buried_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This typical \"volcano-like\" appearance should lead one to suspect a congenital buried penis. The tight phimosis, megaprepuce, and abnormal tissue attachments associated with this condition make neonatal circumcision difficult with conventional methods.</div><div class=\"graphic_reference\">Courtesy of Jenny H Yiee, MD.</div><div id=\"graphicVersion\">Graphic 96246 Version 2.0</div></div></div>"},"96247":{"type":"graphic_picture","displayName":"Penoscrotal webbing","title":"Penoscrotal webbing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penoscrotal webbing</div><div class=\"cntnt\"><img style=\"width:381px; height:714px;\" src=\"images/PEDS/96247_Penoscrotal_webbing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to the penoscrotal webbing, showing the abnormal transition from penile shaft skin to scrotal skin. Neonatal circumcision using conventional methods is difficult in this setting.</div><div class=\"graphic_reference\">Courtesy of Laurence S Baskin, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 96247 Version 2.0</div></div></div>"},"96249":{"type":"graphic_table","displayName":"Cranial nerves involved in swallowing","title":"Cranial nerves involved in swallowing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cranial nerves involved in swallowing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cranial nerve</td> <td class=\"subtitle1\">Sensory innervation</td> <td class=\"subtitle1\">Motor innervation</td> </tr> <tr class=\"divider_bottom\"> <td>CN V trigeminal mandibular branch (V<sub>3</sub>)</td> <td> <ul> <li>Sensation to the lining of the buccal cavity, tongue, teeth. </li> </ul> </td> <td> <ul> <li>Muscles of mastication. </li> <li>Mylohyoid and anterior belly of the digastric muscles for hyolaryngeal elevation, tensor veli palatini. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>CN VII facial</td> <td> <ul> <li>Taste to the anterior two-thirds of the oral tongue. </li> <li>Sensation to the facial muscles. </li> </ul> </td> <td> <ul> <li>Muscles of facial expression. </li> <li>Lip closure, protrusion, and retraction. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>CN IX glossopharyngeal</td> <td> <ul> <li>Receives input from tonsils, pharynx, posterior tongue. </li> <li>Supplies taste to the posterior one-third of the tongue. </li> </ul> </td> <td> <ul> <li>Stylopharyngeus elevates pharynx and larynx. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>CN X vagus</td> <td> <ul> <li>Sensation to the pharynx, larynx, trachea. </li> </ul> </td> <td> <ul> <li>Muscles of the velopharyngeal mechanism. </li> <li>Pharyngeal constrictors including cricopharyngeus. </li> <li>Intrinsic muscles of the larynx including vocal folds. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>CN&nbsp;XI accessory</td> <td> <ul> <li>No sensory component. </li> </ul> </td> <td> <ul> <li>Sternocleidomastoid and trapezius muscles. </li> </ul> </td> </tr> <tr> <td>CN XII hypoglossal</td> <td> <ul> <li>No sensory component. </li> </ul> </td> <td> <ul> <li>Extrinsic tongue muscles. </li> <li>Intrinsic muscles of the tongue for speech articulation and bolus manipulation. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96249 Version 3.0</div></div></div>"},"96253":{"type":"graphic_table","displayName":"Herbs intended uses toxicities and interactions with chemo","title":"Herbs and herbal mixtures and their intended uses toxicities and interactions with chemotherapy agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Herbs and herbal mixtures and their intended uses toxicities and interactions with chemotherapy agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name of herb</td> <td class=\"subtitle1\">Intended use</td> <td class=\"subtitle1\">Toxicity</td> <td class=\"subtitle1\">Interaction with chemotherapeutics</td> </tr> <tr class=\"divider_bottom\"> <td>Nettle</td> <td>To strengthen immune system, prostate diseases, urinary system diseases, allergy, arthritis, and anti-inflammatory</td> <td>Abdominal pain, diarrhea, fever, bleeding problems, gynecomastia, galactorrhea, and hypoglycemia</td> <td>It may interact with cancer drugs, which metabolize where it affects cytochrome P450 enzyme system.</td> </tr> <tr class=\"divider_bottom\"> <td>Garlic</td> <td>Hypertension, hyperlipidemia, antineoplastic, antimicrobial</td> <td>Bleeding problems</td> <td>Its usage with dacarbazine should be avoided (CYP2E1 inhibition).</td> </tr> <tr class=\"divider_bottom\"> <td>Green tea</td> <td>In cancer prevention, prostate cancer, cardiac diseases, gastrointestinal diseases, for losing weight</td> <td>Nausea, insomnia, diarrhea, confusion</td> <td>While increasing the effect of drugs such as anthracycline, <span style=\"color: black;\">taxanes, and tamoxifen&nbsp;(CYP3A4 inhibition), </span>it may decrease the effect of bortezomib by different interaction routes.</td> </tr> <tr class=\"divider_bottom\"> <td><em>Ginkgo biloba</em> (Ginkgo tree)</td> <td>Antiemetic, antioxidant, pro-circulatory, dementia, tinnitus</td> <td>Bleeding, allergy/hypersensitivity, stroke, headache</td> <td>It interacts with numerous chemotherapy agents, including EGFR-TKI (CYP3A4 and CYP2C19 inhibition). </td> </tr> <tr class=\"divider_bottom\"> <td>Echinacea (purple cone flower) </td> <td>To strengthen immune system, common cold</td> <td>Hypersensitivity (including anaphylaxis)</td> <td>It interacts with numerous chemotherapy agents,&nbsp;<span style=\"color: black;\"> including<strong> etoposide</strong> and&nbsp;EGF</span>R-TKI&nbsp;(CYP3A4,<span style=\"color: black;\"> CYP2C19, </span><span style=\"color: black;\">and CYP2D6&nbsp;inhibition). </span></td> </tr> <tr class=\"divider_bottom\"> <td>Soya products</td> <td>Menopause symptoms, osteoporosis, cancer prevention</td> <td>Meteorism, allergic reactions</td> <td>It should not be used with tamoxifen in ER-positive breast cancer and in endometrial cancer.</td> </tr> <tr class=\"divider_bottom\"> <td>Saw palmetto (<em>Serenoa repens</em>)</td> <td>Benign prostate hypertrophy</td> <td>Abdominal pain, nausea, vomiting, constipation or diarrhea, bleeding problems, emboli</td> <td>No significant interaction has been reported.</td> </tr> <tr class=\"divider_bottom\"> <td>Ginseng</td> <td>Sedative, aphrodisiac, antidepressant, and diuretic</td> <td>Nausea, diarrhea, euphoria, insomnia, headache, hypertension, hypotension, hypoglycemia, mastalgia, vaginal bleeding, and cerebral arteritis</td> <td>It interacts with numerous chemotherapy agents, including EGFR-TKI&nbsp;<span style=\"color: #ff0000;\"> </span>(<span style=\"color: black;\">CYP3A4, CYP2C9&nbsp;inhibitio</span><span style=\"color: black;\">n) and imatinib (could increase risk of hepatotoxicity); </span>it should not be used in ER-positive breast cancer or in endometrial cancer.</td> </tr> <tr class=\"divider_bottom\"> <td>St. John's wort (Tipton's weed, <em>Hypericum perforatum</em>)</td> <td>Depression</td> <td>Allergic dermal reactions, constipation, dry mouth, gastrointestinal disorder, dizziness, asthenia, and sleep disorder</td> <td>It interacts with almost all <span style=\"color: black;\">chemotherapy agents, including&nbsp;BCR-ABL TKI, VEGF-TKI, EGFR-TKI, ALK inhibitors, the mTOR inhibitor everolimus, antiestrogens, aromatase inhibitors, the phosphatidylinositol 3-kinase inhibitor idelalisib, and the BRAF kinase inhibitor vemurafenib </span>(CYP2B6, CYP2C9, CYP2C19, CYP2E1, CYP3A4, and P-glycoprotein induction). It also decreases level of active metabolite of irinotecan and cyclophosphamide plasma concentration. </td> </tr> <tr class=\"divider_bottom\"> <td>Black cohosh (horseradish root)</td> <td>Menopause symptoms, sedation</td> <td>Dizziness, headache, nausea, vomiting</td> <td>It affects CYP3A4 enzyme system. It increases the toxicity of doxorubicin and docetaxel. It increases the effect of tamoxifen.</td> </tr> <tr class=\"divider_bottom\"> <td>Cranberry (blueberry, huckleberry)</td> <td>Urinary tract infection</td> <td>Bleeding problems</td> <td>No significant interaction has been reported.</td> </tr> <tr class=\"divider_bottom\"> <td>Valerian (<em>Polemonium</em>)</td> <td>Sleep irregularities, stress</td> <td>It may cause headache, restlessness, cardiac problems</td> <td>It interacts with numerous chemotherapy agents (CYP2C9 inhibition, CYP2C19 induction). The ones using tamoxifen, cyclophosphamide, etoposide, and teniposide should be careful.</td> </tr> <tr class=\"divider_bottom\"> <td>Milk thistle (<em>Eryngium</em>)</td> <td>Hepatosteatosis, cirrhosis, cancer prevention</td> <td>Laxative effect and menstrual stimulation</td> <td>It causes doxorubicin metabolism to decrease by interacting with cytochrome P450 system.</td> </tr> <tr class=\"divider_bottom\"> <td>Evening primrose (<em>Oenothera biennis</em>)</td> <td>Menopausal symptoms, pain, neuropathy </td> <td>Headache, nausea, and increasing risk of pregnancy complication</td> <td>Since it binds to serum proteins and it may modify chemotherapy efficacy, its usage is not recommended.</td> </tr> <tr class=\"divider_bottom\"> <td>Kava (stonecrop)</td> <td>Anxiety, insomnia, stress</td> <td>Stupor, vision disorders, dizziness, yellowing at skin and nail, fatal liver toxicity</td> <td>It interacts with numerous chemotherapy agents and EGFR-TKI (CYP3A4 induction).</td> </tr> <tr class=\"divider_bottom\"> <td>Bilberry (blueberry)<br /> Red grape seed</td> <td> <p>Diabetes retinopathy</p> Allergic rhinitis, cancer prevention, hyperlipidemia</td> <td> <p>Bleeding problems</p> No significant toxicity has been reported.</td> <td> <p>No significant interaction has been reported.</p> It interacts with numerous chemotherapy agents and EGFR-TKI (CYP3A4 induction).</td> </tr> <tr class=\"divider_bottom\"> <td>PC-SPES</td> <td>Prostate cancer</td> <td>Gynecomastia, loss of libido, gastric disorders, cramps, thrombus, diarrhea, cardiac problems, hot flush</td> <td>Since it affects enzyme system in the liver, it may interact with many chemotherapeutics. It should not be used together with these.</td> </tr> <tr class=\"divider_bottom\"> <td>Reishi mushroom (red reishi)</td> <td>Allergy, arthritis, bronchitis, gastric ulcer, diabetes, hypertension, chronic hepatitis, nephritis, insomnia, scleroderma, and cancer</td> <td>Nausea, vomiting, liver toxicity, and bleeding problems</td> <td>Since it affects enzyme system in the liver (CYP2E1, CYP1A2, and CYP3A inhibition), it may interact with many chemotherapeutics. It should not be used together with these.</td> </tr> <tr class=\"divider_bottom\"> <td>Oleander (rosebay)</td> <td>Cancer treatment, cardiac failure, HIV, AIDS, rheumatoid arthritis, psoriasis</td> <td>Abdominal pain, hypothermia, dizziness, respiratory paralysis, death</td> <td>No significant interaction has been reported.</td> </tr> <tr class=\"divider_bottom\"> <td>Essiac</td> <td>Cancer treatment, health maintenance, support for immunity, HIV and AIDS</td> <td>No significant toxicity has been reported</td> <td>It interacts with chemotherapy drugs by inhibiting CYP3A.</td> </tr> <tr class=\"divider_bottom\"> <td>Mistletoe (<em>Iscum album</em>)</td> <td>Cancer treatment, immune stimulation, arthritis, sedation</td> <td>Hepatotoxicity, anaphylactic shock</td> <td>It interacts with chemotherapy drugs by CYP3A4 inhibition.</td> </tr> <tr class=\"divider_bottom\"> <td>Licorice</td> <td>Cancer treatment, gastroprotective, antiinflammatory, antiallergic</td> <td>Hypokalemia (myopathy), hypertension, pulmonary edema, digoxin toxicity</td> <td>It interacts with chemotherapy drugs by causing CYP3A induction.</td> </tr> <tr class=\"divider_bottom\"> <td><em>Astragalus</em> (wild licorice)</td> <td>To strengthen immune system, diabetes, and cardiac diseases</td> <td>No significant toxicity has been reported</td> <td>It interacts with cyclophosphamide.</td> </tr> <tr class=\"divider_bottom\"> <td>Ginger</td> <td>In treatment of acute and delayed nausea developing due to chemotherapy</td> <td>No significant toxicity has been reported</td> <td>No significant interaction has been reported.</td> </tr> <tr> <td>Curcuma</td> <td>In colorectal cancer and leukemia</td> <td>Nausea, gastric irritation, diarrhea, bleeding problems</td> <td>It interacts with many drugs, mainly doxorubicin and cyclophosphamide.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EGFR: anti-epidermal growth factor receptor; TKI:&nbsp;tyrosine kinase inhibitor; ER: estrogen receptor; VEGF: vascular endothelial growth factor; mTOR:&nbsp;mammalian target of rapamycin.</div><div class=\"graphic_reference\">Modified&nbsp;with permission from: Arslan D, Tural D, Akar E. Herbal administration and interaction of cancer treatment. J Palliat Med 2013; 16:1466. Copyright Â© 2013 Mary Ann Liebert, Inc. Publishers. All rights reserved.<br />Additional data from:<br /><OL>&#xD;&#xA;<LI>Collado-Borrell R, Escudero-Vilaplana V, Romero-Jimenez R, et al. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.&nbsp;&nbsp;J Cancer Res Clin Oncol 2016; 142:2319.</LI></OL></div><div id=\"graphicVersion\">Graphic 96253 Version 2.0</div></div></div>"},"96254":{"type":"graphic_picture","displayName":"Dermatoscope covered with plastic wrap","title":"Dermatoscope covered with plastic warp","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermatoscope covered with plastic warp</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96254_Dermatoscope_cvrd_plstc_wrp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To examine mucosal lesions or lesions located on the skin/mucosa transition zone, the contact dermatoscopes can be conveniently covered with plastic food wrap.</div><div id=\"graphicVersion\">Graphic 96254 Version 2.0</div></div></div>"},"96260":{"type":"graphic_diagnosticimage","displayName":"CTA grade III internal carotid artery injury","title":"Grade III internal carotid artery injury on CTA","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Grade III internal carotid artery injury on CTA</div><div class=\"cntnt\"><img style=\"width:718px; height:317px;\" src=\"images/RADIOL/96260_CTA_grIII_int_carot_art_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four months after sustaining blunt trauma related to a motor vehicle collision, this 30-year-old male presented with headache and left-sided weakness. Coronal (A, B) and axial (C) contrast enhanced CT angiographic images demonstrate multiple pseudoaneurysms (arrows) involving both internal carotid arteries.</div><div class=\"graphic_footnotes\">CTA: computed tomographic angiography.</div><div class=\"graphic_reference\">Courtesy of Joe Farnam, MD.</div><div id=\"graphicVersion\">Graphic 96260 Version 1.0</div></div></div>"},"96261":{"type":"graphic_diagnosticimage","displayName":"MRA grade III internal carotid artery injury","title":"Grade III internal carotid artery injury on MRA","html":"<div class=\"graphic\"><div style=\"width: 737px\" class=\"figure\"><div class=\"ttl\">Grade III internal carotid artery injury on MRA</div><div class=\"cntnt\"><img style=\"width:717px; height:476px;\" src=\"images/RADIOL/96261_MRA_grade_III_int_carot_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR imaging six months following initial diagnosis. Contrast-enhanced coronal MR angiography (A) redemonstrates multiple bilateral internal carotid pseudoaneurysms (arrows). Fat-saturated axial T1 images (B, C) demonstrate T1 hyperintensity (arrowheads) consistent with hematoma at the location of these pseudoaneurysms.</div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiography; MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 96261 Version 2.0</div></div></div>"},"96262":{"type":"graphic_diagnosticimage","displayName":"Two-year follow-up MRA grade III carotid injury","title":"Grade III carotid injury two-year follow-up on MRA","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Grade III carotid injury two-year follow-up on MRA</div><div class=\"cntnt\"><img style=\"width:524px; height:485px;\" src=\"images/RADIOL/96262_Two_year_MRA_III_carot_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow-up imaging performed at 18 months following initial diagnosis. Contrast-enhanced coronal MR angiography demonstrates persistent right-sided internal carotid pseudoaneurysms (arrows) with interval resolution of the left internal carotid pseudoaneurysm.</div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiography.</div><div class=\"graphic_reference\">Courtesy of Joe Farnam, MD.</div><div id=\"graphicVersion\">Graphic 96262 Version 1.0</div></div></div>"},"96263":{"type":"graphic_diagnosticimage","displayName":"Imaging Grade II vertebral artery injury dissection","title":"Grade II vertebral artery injury dissection on imaging","html":"<div class=\"graphic\"><div style=\"width: 863px\" class=\"figure\"><div class=\"ttl\">Grade II vertebral artery injury dissection on imaging</div><div class=\"cntnt\"><img style=\"width:843px; height:519px;\" src=\"images/RADIOL/96263_Img_gr_II_vert_art_inj_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 21-year-old male presented to the emergency department following blunt trauma while riding an all-terrain vehicle. CT angiography of the neck in the axial view (A), and reconstructed in the coronal plane (B), shows a sub-total occlusion of the right vertebral artery (arrows). The left vertebral artery (arrowhead) is normal. Digital subtraction arteriography (C) demonstrates a linear filling defect (arrow), consistent with dissection.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 96263 Version 1.0</div></div></div>"},"96264":{"type":"graphic_table","displayName":"Goal BP by age and comorbid conditions in guideline statements","title":"Goal blood pressure (BP) by age and comorbid conditions according to consensus guideline statements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Goal blood pressure (BP) by age and comorbid conditions according to consensus guideline statements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Guideline</td> <td class=\"subtitle1\">&#60;60 years</td> <td class=\"subtitle1\">60-79 years</td> <td class=\"subtitle1\">&#8805;80 years</td> <td class=\"subtitle1\">Diabetes</td> <td class=\"subtitle1\">CKD</td> </tr> <tr> <td><strong>AHA/ACC</strong></td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">140-145/&#60;90*</td> <td class=\"centered\">&#60;140/&#60;90*</td> <td class=\"centered\">&#60;140/&#60;90*</td> </tr> <tr> <td><strong>ASH/ISH</strong></td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;150/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> </tr> <tr> <td><strong>BHS/NICE</strong></td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;150/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> </tr> <tr> <td><strong>CHEP</strong></td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;150/&#60;90</td> <td class=\"centered\">&#60;130/&#60;80</td> <td class=\"centered\">&#60;140/&#60;90</td> </tr> <tr> <td><strong>ESH/ESC</strong></td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\"> <p>&#60;150/&#60;90<sup>&#182;</sup></p> &#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;85</td> <td class=\"centered\">&#60;140/&#60;90</td> </tr> <tr> <td><strong>2014 Expert Panel \"JNC 8\"</strong></td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\"> <p>&#60;150/&#60;90<sup>&#916;</sup></p> &#60;140/&#60;90</td> <td class=\"centered\"> <p>&#60;150/&#60;90<sup>&#916;</sup></p> &#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> <td class=\"centered\">&#60;140/&#60;90</td> </tr> <tr> <td><strong>ISHIB</strong><sup>&#9674;</sup></td> <td class=\"centered\">&#60;135/&#60;85</td> <td class=\"centered\">&#60;135/&#60;85</td> <td class=\"centered\">&#60;135/&#60;85</td> <td class=\"centered\">&#60;130/&#60;80</td> <td class=\"centered\">&#60;130/&#60;80</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AHA/ACC: American Heart Association/American College of Cardiology; ASH/ISH: American Society of Hypertension/International Society of Hypertension; BHS/NICE: British Hypertension Society/National Institute for Health and Clinical Excellence; CHEP: Canadian Hypertension Education Program; ESH/ESC: European Society of Hypertension/European Society of Cardiology; 2014 Expert Panel report \"JNC 8\": Recommendations from panel members formerly appointed to the Eighth Joint National Committee; ISHIB: International Society of Hypertension in Blacks.<br />* AHA/ACC blood pressure goal for patients â¥80 years of age&nbsp;qualified this recommendation with \"if tolerated\"; lower goals may be appropriate for patients with heart disease, diabetes, and chronic kidney disease.<br />Â¶ Blood pressure &lt;150/&lt;90 is the general blood pressure goal for individuals â¥80 years of age. For individuals â¥80 years of age who are judged to be fit, the blood pressure goal is &lt;140/&lt;90.<br />Î Goal blood pressure for individuals â¥60 years of age is &lt;150/&lt;90. If treatment leads to a blood pressure &lt;140/&lt;90 and is well tolerated, then treatment does not need to be adjusted.<br /><FONT class=lozenge>â</FONT> In blacks.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation task force on clinical expert consensus documents. Circulation 2011; 123:2434.</li>&#xD;&#xA;    <li>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3.</li>&#xD;&#xA;    <li>Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: Summary of NICE guidance. BMJ 2011; 343:d4891.</li>&#xD;&#xA;    <li>Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014; 30:485.</li>&#xD;&#xA;    <li>Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.</li>&#xD;&#xA;    <li>James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507.</li>&#xD;&#xA;    <li>Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56:780.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96264 Version 4.0</div></div></div>"},"96265":{"type":"graphic_figure","displayName":"Physiologic responses to HD involved in IDH pathogenesis","title":"Physiologic response to hemodialysis that might be involved in the pathogenesis of intradialytic hypotension","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Physiologic response to hemodialysis that might be involved in the pathogenesis of intradialytic hypotension</div><div class=\"cntnt\"><img style=\"width:616px; height:328px;\" src=\"images/NEPH/96265_Phys_respon_HD_IDH_pathogen.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CAD: coronary artery disease; TPR: total peripheral resistance.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Kidney International. McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int 2009; 76:371. Copyright &copy; 2009. <a href=\"http://www.nature.com/ki\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 96265 Version 2.0</div></div></div>"},"96267":{"type":"graphic_picture","displayName":"Non-bullous impetigo on chin","title":"Non-bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Non-bullous impetigo</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96267_Non_bullous_impetigo_chin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gold-colored crusts on the chin of a patient with non-bullous impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96267 Version 1.0</div></div></div>"},"96268":{"type":"graphic_picture","displayName":"Nonbullous impetigo: Perinasal","title":"Nonbullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nonbullous impetigo</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96268_Non_bullous_impet_perinasal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perinasal erythema, erosions, and crusts in a child with nonbullous impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96268 Version 5.0</div></div></div>"},"96269":{"type":"graphic_picture","displayName":"Bullous impetigo on neck","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96269_Bullous_impetigo_on_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullae, erosions, and crusts in a patient with bullous impetigo on the neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96269 Version 1.0</div></div></div>"},"96270":{"type":"graphic_algorithm","displayName":"Urgent-start PD flow from patient presentation to discharge","title":"Urgent-start peritoneal dialysis flow demonstrating steps from patient presentation until discharge home","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Urgent-start peritoneal dialysis flow demonstrating steps from patient presentation until discharge home</div><div class=\"cntnt\"><img style=\"width:455px; height:449px;\" src=\"images/NEPH/96270_Urgnt_strt_PD_flw_ptnt_prsntt_dschrg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; NPO: no intake by mouth; IPD: intermittent peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; CCPD: continuous cycling peritoneal dialysis.</div><div class=\"graphic_reference\">Modified with permission from: Ghaffari A, Kumar V, Guest S. Infrastructure requirements for an urgent start peritoneal dialysis program. Peritoneal Dialysis International 2013; 33:611. Published in Peritoneal Dialysis International. Copyright &copy; 2013 Peritoneal Dialysis International.</div><div id=\"graphicVersion\">Graphic 96270 Version 1.0</div></div></div>"},"96271":{"type":"graphic_diagnosticimage","displayName":"Fluoroscopy of ulnar collateral ligament incompetence","title":"Ulnar collateral ligament incompetence on fluoroscopy","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ulnar collateral ligament incompetence on fluoroscopy</div><div class=\"cntnt\"><img style=\"width:598px; height:291px;\" src=\"images/RADIOL/96271_Fluorosc_ulnr_col_lig_incom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A shows a fluoroscopic image of the left thumb of a 35-year-old person complaining of pain after a blunt injury. Image B shows displacement of the joint (arrow) following stress, reflecting mild incompetence of the ulnar collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 96271 Version 1.0</div></div></div>"},"96272":{"type":"graphic_picture","displayName":"Bullous impetigo with crusting","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96272_Bullous_impetigo_crusting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crusts at the sites of ruptured bullae in bullous impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96272 Version 1.0</div></div></div>"},"96273":{"type":"graphic_picture","displayName":"Ecthyma on extremity","title":"Ecthyma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ecthyma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96273_Ecthyma_on_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple ulcers with adherent crusts.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96273 Version 1.0</div></div></div>"},"96274":{"type":"graphic_picture","displayName":"Ecthyma ulcer","title":"Ecthyma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ecthyma</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/96274_Ecthyma_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcer with adherent crust.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright &copy; 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96274 Version 1.0</div></div></div>"},"96275":{"type":"graphic_picture","displayName":"Secondary impetigo","title":"Secondary impetigo (impetiginization)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Secondary impetigo (impetiginization)</div><div class=\"cntnt\"><img style=\"width:590px; height:521px;\" src=\"images/DERM/96275_Secondary_impetigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Non-bullous impetigo at sites of skin injury in a patient with a skin picking disorder.</div><div class=\"graphic_reference\">Courtesy of Ted Rosen, MD.</div><div id=\"graphicVersion\">Graphic 96275 Version 1.0</div></div></div>"},"96277":{"type":"graphic_table","displayName":"Follow-up of fetuses with selected arrhythmias","title":"A regional practice protocol for follow-up of fetuses with selected arrhythmias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A regional practice protocol for follow-up of fetuses with selected arrhythmias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Fetal arrhythmia</td> <td class=\"subtitle1\">Range of recommendations for prenatal follow-up with a cardiologist after initial consultation</td> <td class=\"subtitle1\">Range of recommendations for post-natal follow-up</td> </tr> <tr> <td>Frequent PACs with normal heart structure/function</td> <td>None to one follow-up visit with a cardiologist; weekly follow-up with obstetrician to screen for SVT until resolution of frequent PACs</td> <td>None or EKG after birth</td> </tr> <tr> <td>Occasional PACs with normal heart structure/function</td> <td>No follow-up needed</td> <td>None</td> </tr> <tr> <td>Occasional PACs with abnormal heart structure</td> <td>Follow-up based on structural heart disease, not PACs</td> <td>Depends on the structural heart disease</td> </tr> <tr> <td>Nonsustained SVT with normal heart structure/function</td> <td>None to one follow-up visit with a cardiologist</td> <td>None or EKG after birth</td> </tr> <tr> <td>Sustained fetal SVT controlled with medication</td> <td>One to two visits/week to one visit every two weeks with a cardiologist; follow-up with obstetrician between visits to a cardiologist</td> <td>Depends on cardiac anatomy/function and course during pregnancy</td> </tr> <tr> <td>Sinus tachycardia, normal heart structure/function</td> <td>No follow-up to every two weeks with a cardiologist</td> <td>None or EKG after birth</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These recommendations reflect the practice pattern of a group of pediatric cardiologists in the northeastern United States.</div><div class=\"graphic_footnotes\">PAC: premature atrial contractions; SVT: supraventricular tachycardia; EKG: surface electrocardiogram.</div><div id=\"graphicVersion\">Graphic 96277 Version 4.0</div></div></div>"},"96279":{"type":"graphic_figure","displayName":"Causes of intradialytic hypotension","title":"Causes of intradialytic hypotension","html":"<div class=\"graphic\"><div style=\"width: 910px\" class=\"figure\"><div class=\"ttl\">Causes of intradialytic hypotension</div><div class=\"cntnt\"><img style=\"width:890px; height:304px;\" src=\"images/NEPH/96279_Caus_intradialytic_hypoten.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Seabra VF, Jaber BL. Acute complications during hemodialysis. In: Comprehensive Clinical Nephrology, 4th ed, Floege J, Johnson RJ, Feehally J (Eds), Elsevier, Philadelphia, 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96279 Version 1.0</div></div></div>"},"96281":{"type":"graphic_table","displayName":"Urticaria control test","title":"Urticaria control test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urticaria control test</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\"><br /> <strong>Patient name:</strong></td> <td colspan=\"2\"><br /> <strong>Date</strong> (dd/mmm/yyyy)<strong>:</strong> _____ /_____ /_____</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><br /> <strong>Date of birth</strong> (dd/mmm/yyyy)<strong>:</strong> _____ /_____ /_____</td> </tr> <tr> <td colspan=\"5\"><strong>Instructions:</strong> You have urticaria. The following questions should help us understand your current health situation. Please read through each question carefully and choose an answer from the five options that <em>best fits</em> your situation. Please limit yourself to <em>the last four weeks</em>. <em>Please do not think about the questions for a long time,</em> and do remember to answer <em>all questions</em> and to provide <em>only one answer to each question</em>.</td> </tr> <tr> <td colspan=\"5\"> <ol> <li>How much have you suffered from the <strong>physical symptoms of the urticaria (itch, hives [welts], and/or swelling)</strong> in the last four weeks? </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> Very much</td> <td><span class=\"primarybox_left\">&nbsp;</span> Much</td> <td><span class=\"primarybox_left\">&nbsp;</span> Somewhat</td> <td><span class=\"primarybox_left\">&nbsp;</span> A little</td> <td><span class=\"primarybox_left\">&nbsp;</span> Not at all</td> </tr> <tr> <td colspan=\"5\"> <ol start=\"2\"> <li>How much was your <strong>quality of life</strong> affected by the urticaria in the last four weeks? </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> Very much</td> <td><span class=\"primarybox_left\">&nbsp;</span> Much</td> <td><span class=\"primarybox_left\">&nbsp;</span> Somewhat</td> <td><span class=\"primarybox_left\">&nbsp;</span> A little</td> <td><span class=\"primarybox_left\">&nbsp;</span> Not at all</td> </tr> <tr> <td colspan=\"5\"> <ol start=\"3\"> <li>How often was the <strong>treatment</strong> for your urticaria in the last four weeks <strong>not enough</strong> to control your urticaria symptoms? </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> Very often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Seldom</td> <td><span class=\"primarybox_left\">&nbsp;</span> Not at all</td> </tr> <tr> <td colspan=\"5\"> <ol start=\"4\"> <li><strong>Overall,</strong> how well have you had your urticaria <strong>under control</strong> in the last four weeks? </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><span class=\"primarybox_left\">&nbsp;</span> Not at all</td> <td><span class=\"primarybox_left\">&nbsp;</span> A little</td> <td><span class=\"primarybox_left\">&nbsp;</span> Somewhat</td> <td><span class=\"primarybox_left\">&nbsp;</span> Well</td> <td><span class=\"primarybox_left\">&nbsp;</span> Very well</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133:1365. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96281 Version 2.0</div></div></div>"},"96282":{"type":"graphic_figure","displayName":"Estimated graft survival rates by KDPI","title":"Estimated graft survival rates by Kidney Donor Profile Index","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Estimated graft survival rates by Kidney Donor Profile Index</div><div class=\"cntnt\"><img style=\"width:586px; height:458px;\" src=\"images/NEPH/96282_Estim_graft_surv_rates_KDPI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">KDPI: Kidney Donor Profile Index.</div><div class=\"graphic_reference\">Reproduced from: United Network for Organ Sharing (UNOS). Available at: <a href=\"http://optn.transplant.hrsa.gov/\" target=\"_blank\">http://optn.transplant.hrsa.gov/</a> (Accessed on July 21, 2014).</div><div id=\"graphicVersion\">Graphic 96282 Version 1.0</div></div></div>"},"96283":{"type":"graphic_picture","displayName":"Dermoscopy intradermal nevus face","title":"Dermoscopic image of a facial intradermal nevus (Miescher nevus)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a facial intradermal nevus (Miescher nevus)</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96283_Dermo_intradermal_nevus_fac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Structureless light brown pigmentation and comma-shaped vessels are characteristic dermoscopic features of facial intradermal nevi of the Miescher type. Residual brown globules and circles are also visible in this lesion.</div><div id=\"graphicVersion\">Graphic 96283 Version 1.0</div></div></div>"},"96284":{"type":"graphic_picture","displayName":"Dermoscopy blue nevus face","title":"Dermoscopic image of a facial blue nevus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a facial blue nevus</div><div class=\"cntnt\"><img style=\"width:590px; height:390px;\" src=\"images/DERM/96284_Dermoscopy_blue_nevus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dermoscopic hallmark of blue nevi is a structureless blue pigmentation.</div><div id=\"graphicVersion\">Graphic 96284 Version 1.0</div></div></div>"},"96285":{"type":"graphic_picture","displayName":"Dermoscopy facial Spitz nevus","title":"Dermoscopic image of nonpigmented facial Spitz nevus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nonpigmented facial Spitz nevus</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96285_Dermo_facial_spitz_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coiled vessels and a white network (also called reticular depigmentation or negative network) over a pink to reddish background are characteristic dermoscopic features of nonpigmented Spitz nevus.</div><div id=\"graphicVersion\">Graphic 96285 Version 1.0</div></div></div>"},"96286":{"type":"graphic_picture","displayName":"Dermoscopy Reed nevus","title":"Dermoscopic image of a facial pigmented Spitz nevus (Reed nevus)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a facial pigmented Spitz nevus (Reed nevus)</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96286_Dermoscopy_reed_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopy, the Reed nevus is characterized by a structureless dark brown to black center with hypopigmented follicular openings and peripheral streaks, pseudopods, or globules.</div><div id=\"graphicVersion\">Graphic 96286 Version 1.0</div></div></div>"},"96287":{"type":"graphic_table","displayName":"Common cancer related physical impairments","title":"Common cancer related physical impairments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common cancer related physical impairments</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"24%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neurological</td> <td class=\"subtitle1\">Musculoskeletal</td> <td class=\"subtitle1\">Pain syndromes</td> <td class=\"subtitle1\">General</td> </tr> <tr> <td> <p>Brain injury</p> <p>Spinal cord injury</p> <p>Peripheral nerve injury</p> <p>Cervical dystonia</p> <p>Ataxia</p> Autonomic dysfunction</td> <td> <p>Bone metastasis</p> <p>Myopathy</p> <p>Graft versus host disease</p> <p>Radiation fibrosis</p> <p>Trismus</p> <p>Repetitive strain injury</p> Lymphedema</td> <td> <p>CRPS</p> <p>Axillary web syndrome</p> Diffuse arthralgias</td> <td> <p>Fatigue</p> <p>Deconditioning</p> <p>Bowel/bladder/sexual dysfunction</p> Cognitive dysfunction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRPS: complex regional pain syndrome.</div><div id=\"graphicVersion\">Graphic 96287 Version 1.0</div></div></div>"},"96288":{"type":"graphic_picture","displayName":"Dermoscopy sebaceous hyperplasia","title":"Dermoscopic image of sebaceous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of sebaceous hyperplasia</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96288_Dermo_sebaceous_hyperplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopic examination, sebaceous hyperplasia shows a structureless yellow to whitish center surrounded by short linear vessels (\"crown vessels\") that do not cross the center.</div><div id=\"graphicVersion\">Graphic 96288 Version 1.0</div></div></div>"},"96289":{"type":"graphic_picture","displayName":"Dermoscopy solar lentigo","title":"Dermoscopic image of a facial solar lentigo","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a facial solar lentigo</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96289_Dermoscopy_solar_lentigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial solar lentigines may show on dermoscopy a faint, light brown pseudonetwork with well-defined borders and a so-called \"moth-eaten\" edge.</div><div id=\"graphicVersion\">Graphic 96289 Version 3.0</div></div></div>"},"96290":{"type":"graphic_table","displayName":"Initial prescription for urgent-start peritoneal dialysis","title":"Initial prescription for urgent-start peritoneal dialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial prescription for urgent-start peritoneal dialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Volume per exchange and number of exchanges:</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">BSA &#8804;1.7/m<sup>2</sup></td> <td class=\"subtitle2\">BSA &#62;1.7/m<sup>2</sup></td> </tr> <tr> <td><strong>If eGFR &#62;7 mL/min/1.73 m<sup>2</sup></strong></td> <td>750 mL four cycles</td> <td>1000 mL five cycles</td> </tr> <tr class=\"divider_bottom\"> <td><strong>If eGFR &#8804;7 mL/min/1.73 m<sup>2</sup></strong></td> <td>1000 mL six cycles</td> <td>1250 mL six cycles</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Total cycler time:</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Four cycles - Minimum of 5 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Five cycles - Minimum of 6 hours, 40 minutes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Six cycles - Minimum of 8 hours (staffing and time permitting)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Solution:</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">1.5% dextrose dialysate, if no peripheral edema or shortness of breath</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">2.5% dextrose dialysate, if edema or shortness of breath</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">4.25% dextrose dialysate, if prescribed by treating physician</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Special instructions:</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">All exchanges are to be performed with the use of a cycler in supine position</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Have patient use bathroom before being connected to cycler</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">The patient should remain supine while dwelling any fluid</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">If the patient needs to sit up or stand, he/she will have to be fully drained</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">If patient has a cough, call clinician for a cough suppressant</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Tell patients to avoid straining; if constipated, call clinician for laxative</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Instruct patient to wear loose clothing </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Eating during dialysis should be limited to the drain phase of exchange</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">If patient has severe volume overload, call clinician for high-dose oral diuretic and 4.25% dextrose dialysate</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">eGFR as per MDRD equation.</div><div class=\"graphic_footnotes\">IPD: intermittent peritoneal dialysis; eGFR: estimated glomerular filtration rate; BSA: body surface area.</div><div class=\"graphic_reference\">Original figure modified for this publication. Ghaffari A. Urgent-start peritoneal dialysis: A quality improvement report. Am J Kidney Dis 2012; 59:400. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96290 Version 2.0</div></div></div>"},"96291":{"type":"graphic_picture","displayName":"Dermoscopy facial seborrheic keratosis","title":"Dermoscopic image of a facial seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a facial seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96291_Dermo_fac_seborrheic_kerato.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic keratosis arising on a solar lentigo. Parallel, curvy lines (fingerprint stuctures) are visible at the periphery of the lesion; multiple milia-like cysts and comedo-like openings are present in the center.</div><div id=\"graphicVersion\">Graphic 96291 Version 1.0</div></div></div>"},"96294":{"type":"graphic_picture","displayName":"Dermoscopy grade 1 actinic keratosis","title":"Dermoscopic image of grade 1 actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of grade 1 actinic keratosis</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96294_Dermo_grd1_actinic_keratosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grade 1 actinic keratoses are characterized by a red pseudonetwork pattern and discrete, white scales.</div><div id=\"graphicVersion\">Graphic 96294 Version 2.0</div></div></div>"},"96295":{"type":"graphic_picture","displayName":"Dermoscopy grade 2 actinic keratosis","title":"Dermoscopic image of grade 2 actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of grade 2 actinic keratosis</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96295_Dermo_grd2_actinic_keratosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grade 2 actinic keratosis shows on dermoscopy the so-called strawberry pattern, characterized by an erythematous background intermingled by white-to-yellow, keratotic, and enlarged follicular openings similar to the surface of a strawberry.</div><div id=\"graphicVersion\">Graphic 96295 Version 2.0</div></div></div>"},"96296":{"type":"graphic_picture","displayName":"Dermoscopy grade 3 actinic keratosis","title":"Dermoscopic image of grade 3 actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of grade 3 actinic keratosis</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96296_Dermo_grd3_actinic_keratosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopy, grade 3 actinic keratoses show enlarged follicular openings filled with keratotic plugs over a scaly and white-yellow appearing background.</div><div id=\"graphicVersion\">Graphic 96296 Version 1.0</div></div></div>"},"96297":{"type":"graphic_picture","displayName":"Dermoscopy pigmented actinic keratosis","title":"Dermoscopic image of a facial pigmented actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a facial pigmented actinic keratosis</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96297_Derm_pigment_actinic_kerato.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pigmented actinic keratosis shows an annular-granular pattern that closely resembles&nbsp;the pattern typically seen in lentigo maligna.</div><div id=\"graphicVersion\">Graphic 96297 Version 2.0</div></div></div>"},"96298":{"type":"graphic_picture","displayName":"Dermoscopy Bowen nonpigmented","title":"Dermoscopic image of nonpigmentes squamous cell carcinoma in situ (Bowen disease).","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nonpigmentes squamous cell carcinoma in situ (Bowen disease).</div><div class=\"cntnt\"><img style=\"width:590px; height:391px;\" src=\"images/DERM/96298_Dermoscopy Bowen nonpigmented.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, coiled (glomerular) vessels in a grouped arrangement and yellow surface scales are the dermoscopic hallmarks of nonpigmented Bowen disease.</div><div id=\"graphicVersion\">Graphic 96298 Version 1.0</div></div></div>"},"96300":{"type":"graphic_picture","displayName":"Dermoscopy squamous cell carcinoma","title":"Dermoscopic image of facial invasive squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of facial invasive squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96300_Dermo_squam_cell_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopy, white circles surrounding a yellow clod over a white background are a clue for invasive squamous cell carcinoma.</div><div id=\"graphicVersion\">Graphic 96300 Version 1.0</div></div></div>"},"96302":{"type":"graphic_picture","displayName":"Dermoscopy nodular nonpigmented BCC","title":"Dermoscopic image of nonpigmented nodular basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nonpigmented nodular basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96302_Derm_nodular_nonpigment_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bright red and branching arborizing vessels are the main dermoscopic feature of nodular nonpigmented basal cell carcinoma.</div><div id=\"graphicVersion\">Graphic 96302 Version 1.0</div></div></div>"},"96303":{"type":"graphic_picture","displayName":"Dermoscopy nodular pigmented BCC","title":"Dermoscopic image of pigmented nodular basal cell carcinoma of the face","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of pigmented nodular basal cell carcinoma of the face</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96303_Dermo_nodular_pigmented_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arborizing vessels and blue-gray globules or dots are visible in this pigmented nodular basal cell carcinoma.</div><div id=\"graphicVersion\">Graphic 96303 Version 1.0</div></div></div>"},"96305":{"type":"graphic_picture","displayName":"Dermoscopy superficial pigmented BCC","title":"Dermoscopic image of pigmented superficial basal cell carcinoma of the face","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of pigmented superficial basal cell carcinoma of the face</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96305_Dermo_superfic_pigment_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light brown to grayish globules are visible in this pigmented superficial basal cell carcinoma.</div><div id=\"graphicVersion\">Graphic 96305 Version 1.0</div></div></div>"},"96306":{"type":"graphic_table","displayName":"Serious causes of pediatric chest pain and key findings","title":"Serious causes of pediatric chest pain and key findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serious causes of pediatric chest pain and key findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Physical exam findings</td> <td class=\"subtitle1\">ECG findings</td> </tr> <tr class=\"divider_bottom\"> <td>Hypertrophic cardiomyopathy</td> <td> <p>Positive family history</p> <p>Exercise intolerance</p> <p>Exertional chest pain</p> Syncope and/or arrythmia</td> <td>Dynamic systolic murmur</td> <td> <p>Left ventricular hypertrophy or left axis deviation</p> <p>ST segment or T wave changes</p> <p>Q waves</p> <p>Arrhythmias, ventricular premature beats</p> Ventricular preexcitation (Wolff-Parkinson-White)</td> </tr> <tr class=\"divider_bottom\"> <td>Dilated cardiomyopathy</td> <td> <p>Family history</p> <p>Decreased exercise tolerance, syncope</p> Heart failure symptoms</td> <td> <p>Gallop</p> Mitral regurgitation murmur</td> <td> <p>Intraventricular conduction delay</p> <p>High or low QRS voltages</p> Arrhythmia, premature beats</td> </tr> <tr class=\"divider_bottom\"> <td>Anomalous coronary artery origin</td> <td> <p>Exertional chest pain</p> Exertional syncope</td> <td>Usually normal</td> <td>Usually normal</td> </tr> <tr class=\"divider_bottom\"> <td>Coronary ischemia</td> <td>Predisposing conditions:<br /> <ul class=\"decimal_heading\"> <li>History of Kawasaki disease </li> <li>Cardiac sugery or heart transplant </li> <li>Systemic arteriopathy (Williams syndrome) </li> <li>Severe familial hypercholesterolemia </li> <li>Drug use: cocaine, sympathomimetics </li> <li>Anginal chest pain </li> </ul> </td> <td> <p>Tachycardia</p> <p>Tachypnea</p> New murmur or gallop</td> <td> <p>ST segment depressions or elevation</p> <p>T wave changes</p> Q waves</td> </tr> <tr class=\"divider_bottom\"> <td>Severe left ventricular outflow tract obstruction</td> <td> <p>Exertional symptoms</p> Exertional syncope</td> <td>Loud systolic murmur</td> <td> <p>Left ventricular hypertrophy</p> Left ventricular strain pattern</td> </tr> <tr class=\"divider_bottom\"> <td>Arrhythmia</td> <td> <p>Palpitations</p> <p>Syncope</p> Positive family history</td> <td>Irregular rhythm</td> <td> <p>Atrial arrhythmia</p> <p>Ventricular arrhythmia</p> <p>Premature contractions</p> Ventricular preexcitation (Wolff-Parkinson-White)</td> </tr> <tr class=\"divider_bottom\"> <td>Pericarditis</td> <td> <p>Positional chest pain</p> Predisposing factors:<br /> <ul class=\"decimal_heading\"> <li>Rheumatologic conditions </li> <li>Malignancy </li> <li>Mediastinal radiation </li> <li>Infection (HIV, tuberculosis, viral) </li> <li>Renal failure </li> <li>Recent cardiac surgery </li> </ul> </td> <td> <p>Cardiac rub</p> <p>Tachycardia/tachypna</p> Distant heart sounds, JVD</td> <td> <p>Diffuse ST segment changes</p> T wave inversions</td> </tr> <tr class=\"divider_bottom\"> <td>Myocarditis</td> <td> <p>Fever</p> <p>Viral prodrome</p> <p>Short duration of symptoms</p> New onset heart failure symptoms</td> <td> <p>Tachycardia</p> <p>Tachypnea</p> <p>With or without gallop rhythm, ventricular ectopy</p> Cardiovascular collapse</td> <td> <p>Diffuse ST segment changes</p> <p>T wave inversions</p> <p>PR depression</p> <p>Ventricular ectopy</p> Low QRS voltages</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic dissection</td> <td> <p>Personal or family history of bicuspid aortic valve or connective tissue disorders (Marfan, Loey-Dietz, Ehlers-Danlos type IV, others)</p> Acute onset sharp or tearing type of pain</td> <td>Marfanoid body habitus</td> <td>See coronary ischemia above</td> </tr> <tr> <td>Pulmonary embolus</td> <td> <p>Pain description: acute onset, pleuritic, associated dyspnea</p> Personal or family risk factors (inherited thrombophilia, hypercoaguable states, immobilization, medications)</td> <td> <p>Right ventricular heave (elevated right ventricular pressure)</p> Loud and/or unsplit S2 (if right ventricular pressure elevated)</td> <td> <p>Right ventricular hypertrophy</p> Right ventricular strain pattern</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JVD: jugular venous distension.</div><div class=\"graphic_reference\">Reproduced from: Friedman KG, Alexander ME. Chest pain and syncope in children: A practical approach to the diagnosis of cardiac disease. J Pediatr 2013; 163: 896. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96306 Version 1.0</div></div></div>"},"96309":{"type":"graphic_diagnosticimage","displayName":"Radiograph capitate fracture","title":"Capitate fracture on plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">Capitate fracture on plain radiograph</div><div class=\"cntnt\"><img style=\"width:682px; height:508px;\" src=\"images/RADIOL/96309_Radiograph_capitate_fractur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;A magnified AP view of the right wrist, showing an impaction injury of the capitate (arrow) and a possible scaphoid fracture (arrowhead). <br />(B)&nbsp;A radiograph of a normal wrist, showing the normal shape and position of the capitate (arrow).<br />(C)&nbsp;A lateral projection of the wrist, showing a comminuted fracture of the capitate (arrow) and overlying soft tissue swelling (arrowhead).<br />(D)&nbsp;A lateral projection of a normal wrist.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 96309 Version 2.0</div></div></div>"},"96310":{"type":"graphic_diagnosticimage","displayName":"CT scan capitate fracture","title":"Capitate fracture on CT scan","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Capitate fracture on CT scan</div><div class=\"cntnt\"><img style=\"width:655px; height:231px;\" src=\"images/RADIOL/96310_CT_scan_capitate_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial projection of a CT scan through the capitate shows a comminuted fracture (arrows) confirmed on the sagittal reconstruction (B, arrow). Additional fractures of the trapezium and hamate were noted (not shown).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 96310 Version 1.0</div></div></div>"},"96311":{"type":"graphic_algorithm","displayName":"Algorithm for PFT interpretation","title":"Algorithm for pulmonary function test interpretation","html":"<div class=\"graphic\"><div style=\"width: 687px\" class=\"figure\"><div class=\"ttl\">Algorithm for pulmonary function test interpretation</div><div class=\"cntnt\"><img style=\"width:667px; height:415px;\" src=\"images/PULM/96311_Algo_PFT_interpretation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; DLCO: diffusing capacity for carbon monoxide; FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity; VC: vital capacity;&nbsp; ILD: interstitial lung disease.</div><div id=\"graphicVersion\">Graphic 96311 Version 2.0</div></div></div>"},"96312":{"type":"graphic_picture","displayName":"Dermoscopy gray circles","title":"Dermoscopic image of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96312_Dermoscopy_gray_circles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetric pigmented follicular openings appearing as small gray circles in an early lentigo maligna.</div><div id=\"graphicVersion\">Graphic 96312 Version 1.0</div></div></div>"},"96313":{"type":"graphic_picture","displayName":"Dermoscopy circles within a circle","title":"Dermoscopic image of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96313_Dermo_circles_within_circle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopic pattern of \"circles within a circle\" in an early lentigo maligna melanoma (Breslow thickness 0.3 mm): an inner small gray circle is surrounded by a larger gray to brown circle.</div><div id=\"graphicVersion\">Graphic 96313 Version 1.0</div></div></div>"},"96314":{"type":"graphic_picture","displayName":"Dermoscopy target-like pattern","title":"Dermoscopic image of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96314_Dermo_target_like_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Target-like pattern in a lentigo maligna. A gray dot surrounded by a gray circle is visible within the hair follicle.</div><div id=\"graphicVersion\">Graphic 96314 Version 1.0</div></div></div>"},"96315":{"type":"graphic_picture","displayName":"Dermoscopy obliterated hair follicles","title":"Dermoscopic image of lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96315_Dermo_obliterated_hair_foll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obliterated hair follicles in an invasive lentigo maligna melanoma (depth of invasion = 0.5 mm) appearing as structureless gray-black blotches.</div><div id=\"graphicVersion\">Graphic 96315 Version 1.0</div></div></div>"},"96316":{"type":"graphic_picture","displayName":"Dermoscopy annular-granular pattern","title":"Dermoscopic image of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/DERM/96316_Dermo_annular_granular_pat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular-granular pattern in a lentigo maligna. Multiple gray dots are seen.</div><div id=\"graphicVersion\">Graphic 96316 Version 1.0</div></div></div>"},"96317":{"type":"graphic_picture","displayName":"Dermoscopy pigmented rhomboidal structures","title":"Dermoscopic image of lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96317_Derm_pigmen_rhomboid_struct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented rhomboidal structures in a lentigo maligna melanoma (Breslow thickness 0.2 mm) appearing as angulated gray to brown lines in the interfollicular space.</div><div id=\"graphicVersion\">Graphic 96317 Version 1.0</div></div></div>"},"96318":{"type":"graphic_picture","displayName":"Dermoscopy red rhomboidal structures","title":"Dermoscopic image of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:590px; height:391px;\" src=\"images/DERM/96318_Dermo_red_rhomboidal_struct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red rhomboidal structures in a lentigo maligna. Red lines are seen in the interfollicular spaces.</div><div id=\"graphicVersion\">Graphic 96318 Version 1.0</div></div></div>"},"96319":{"type":"graphic_picture","displayName":"Dermoscopy increased density vascular network","title":"Dermoscopic image of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96319_Derm_increa_dens_vascu_netw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased density of the vascular network is visible in the right and lower part of the lesion.</div><div id=\"graphicVersion\">Graphic 96319 Version 1.0</div></div></div>"},"96321":{"type":"graphic_table","displayName":"MDS cytogenetic scoring system IPSS-R","title":"Myelodysplastic syndrome (MDS) cytogenetic scoring system: International Prognostic Scoring System, Revised","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Myelodysplastic syndrome (MDS) cytogenetic scoring system: International Prognostic Scoring System, Revised</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Prognostic subgroups</td> <td class=\"subtitle1\">Cytogenetic abnormalities</td> <td class=\"subtitle1\">Percent of patients</td> <td class=\"subtitle1\">Survival<br /> (years, median)</td> <td class=\"subtitle1\">AML evolution, 25 percent<br /> (years, median)</td> <td class=\"subtitle1\">Hazard ratio OS</td> <td class=\"subtitle1\">Hazard ratio AML</td> </tr> <tr> <td class=\"centered\">Very good</td> <td>&ndash;Y, del(11q)</td> <td class=\"centered\">4</td> <td class=\"centered\">5.4</td> <td class=\"centered\">NR</td> <td class=\"centered\">0.7</td> <td class=\"centered\">0.4</td> </tr> <tr> <td class=\"centered\">Good</td> <td>Normal, del(5q), del(12p), del(20q), double including del(5q)</td> <td class=\"centered\">72</td> <td class=\"centered\">4.8</td> <td class=\"centered\">9.4</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered\">Intermediate</td> <td>del(7q), +8, +19, i(17q), any other single or&nbsp;double independent clones</td> <td class=\"centered\">13</td> <td class=\"centered\">2.7</td> <td class=\"centered\">2.5</td> <td class=\"centered\">1.5</td> <td class=\"centered\">1.8</td> </tr> <tr> <td class=\"centered\">Poor</td> <td>&ndash;7, inv(3)/t(3q)/del(3q), double including &ndash;7/del(7q), complex: 3 abnormalities</td> <td class=\"centered\">4</td> <td class=\"centered\">1.5</td> <td class=\"centered\">1.7</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.3</td> </tr> <tr> <td class=\"centered\">Very poor</td> <td>Complex: &#62;3 abnormalities</td> <td class=\"centered\">7</td> <td class=\"centered\">0.7</td> <td class=\"centered\">0.7</td> <td class=\"centered\">3.8</td> <td class=\"centered\">3.6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; OS: overall survival.</div><div class=\"graphic_reference\">This research was originally published in Blood. Modified from: Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454-65. Copyright &copy; 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 96321 Version 4.0</div></div></div>"},"96322":{"type":"graphic_table","displayName":"Nonsurgical causes of ileus","title":"Nonsurgical causes of ileus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonsurgical causes of ileus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pharmacologic agents</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td>Antihypertensive agents: Non-dihydropyridine calcium channel blockers (verapamil&#62;diltiazem), clonidine</td> </tr> <tr> <td>Antineoplastic agents: Bortezomib, busulfan, pegylated liposomal doxorubicin, methotrexate,&nbsp;paclitaxel, thalidomide, vinblastine,&nbsp;vincristine</td> </tr> <tr> <td>Gastrointestinal agents:</td> </tr> <tr> <td> <ul> <li>Antidiarrheal/antispasmodic: Alosetron, loperamide, diphenoxylate-atropine, hyoscyamine </li> </ul> </td> </tr> <tr> <td> <ul> <li>Phenothiazine antiemetics: Prochlorperazine, promethazine </li> </ul> </td> </tr> <tr> <td>&nbsp;Other: Oral iron preparations, zoledronic acid</td> </tr> <tr> <td>&nbsp;Drugs with significant anticholinergic properties including: </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Selective serotonin reuptake inhibitor antidepressants (paroxetine&#62;fluoxetine) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Tricyclic antidepressants (eg, amitriptyline, imipramine, desipramine, nortriptyline) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Antipsychotics (eg, clozapine, haloperidol, olanzapine, quetiapine) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Parkinson disease medications (eg, benztropine, carbidopa-levodopa, entacapone) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>H<sub>1 </sub>antihistamines, first generation (eg, diphenhydramine, chlorpheniramine, cyproheptadine, meclizine) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Muscle relaxants (eg, baclofen, cyclobenzaprine, tizanidine) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Overactive bladder (OAB) medications (eg, oxybutynin, solifenacin, tolterodine) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Atropine products </li> </ul> </td> </tr> <tr> <td>&nbsp;A method for estimating additive anticholinergic effects of various drugs is provided in a separate table. This is not a complete list of all medications that can contribute to nonsurgical ileus.</td> </tr> <tr> <td class=\"subtitle1_single\">Medical conditions</td> </tr> <tr> <td>&nbsp;Pancreatitis</td> </tr> <tr> <td>&nbsp;Gastroenteritis</td> </tr> <tr> <td>&nbsp;Spinal cord injury</td> </tr> <tr> <td>&nbsp;Myocardial infarction</td> </tr> <tr> <td>&nbsp;Stroke</td> </tr> <tr> <td>&nbsp;Pneumonia</td> </tr> <tr> <td>&nbsp;Hypokalemia</td> </tr> <tr> <td>&nbsp;Diabetes (neuronal loss with progressive disease)</td> </tr> <tr> <td>&nbsp;Diabetic ketoacidosis</td> </tr> <tr> <td>&nbsp;Acute intermittent porphyria</td> </tr> <tr> <td>&nbsp;Botulism</td> </tr> <tr> <td>&nbsp;Severe burns</td> </tr> <tr> <td>&nbsp;Parkinson's disease</td> </tr> <tr> <td>&nbsp;Epilepsy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96322 Version 1.0</div></div></div>"},"96323":{"type":"graphic_algorithm","displayName":"Initial approach transfusion reaction","title":"Initial approach to a suspected acute transfusion reaction","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Initial approach to a suspected acute transfusion reaction</div><div class=\"cntnt\"><img style=\"width:770px; height:557px;\" src=\"images/HEME/96323_Init_appr_transfusion_react.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic includes some of the most common and life-threatening reactions; other reactions are also possible and should be pursued if the clinical picture seems inconsistent with one of these. The transfusion service should be notified of any severe transfusion reaction and may request samples of the transfused product and patient blood; the transfused product should not be discarded until discussion with the transfusion service has taken place. In cases of suspected AHTR, the transfusion service must be contacted immediately because another patient may be at risk of receiving the incorrect blood product. Refer to UpToDate topics on transfusion reactions for further details of the evaluation and management of these conditions.</div><div class=\"graphic_footnotes\">TACO: transfusion-associated circulatory overload; TRALI: transfusion-related acute lung injury; FNHTR: febrile nonhemolytic transfusion reaction; AHTR: acute hemolytic transfusion reaction; ALI/ARDS: acute lung injury/adult respiratory distress syndrome; DAT: direct antiglobulin test (Coombs test); CBC: complete blood count; CXR: chest x-ray; LDH: lactate dehydrogenase; DIC: disseminated intravascular coagulation.</div><div id=\"graphicVersion\">Graphic 96323 Version 1.0</div></div></div>"},"96324":{"type":"graphic_picture","displayName":"Dog ear","title":"Dog ear","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Dog ear</div><div class=\"cntnt\"><img style=\"width:754px; height:138px;\" src=\"images/DERM/96324_Dogear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dog ear is a standing cone of tissue that may form after a surgical defect has been linearized with sutures.</div><div class=\"graphic_reference\">From: Lee KS, Kim NG, Jang PY, et al. Statistical analysis of surgical dog-ear regression. Dermatol Surg 2008; 34:1070. DOI: <A href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2008&amp;issue=08000&amp;article=00014&amp;type=abstract\" target=_blank>10.1111/j.1524-4725.2008.34208.x</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright Â© 2008 American Society for Dermatologic Surgery. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96324 Version 3.0</div></div></div>"},"96325":{"type":"graphic_picture","displayName":"Three-point counter tension","title":"Elliptical excision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elliptical excision</div><div class=\"cntnt\"><img style=\"width:384px; height:582px;\" src=\"images/DERM/96325_Three_point_counter_tension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A three-point counter tension applied at the surgical site facilitates a smooth incision.</div><div id=\"graphicVersion\">Graphic 96325 Version 2.0</div></div></div>"},"96326":{"type":"graphic_table","displayName":"Medications associated with weight gain","title":"Medications associated with weight gain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with weight gain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Glucocorticoids (prednisone)</td> </tr> <tr> <td>Diabetes medications (insulin, sulfonylureas, thiazolidindiones, meglitinides)</td> </tr> <tr> <td>First-generation antipsychotics (thioridazine)</td> </tr> <tr> <td>Second-generation antipsychotics (risperidone, olanzapine, clozapine, quetiapine)</td> </tr> <tr> <td>Neurologic and mood stabilizing agents (carbamazepine, gabapentin, lithium, valproate)</td> </tr> <tr> <td>Antihistamines (especially cyproheptadine)</td> </tr> <tr> <td>Antidepressants (paroxetine, citalopram, amitriptyline, nortriptyline, imipramine, mirtazapine)</td> </tr> <tr> <td>Hormonal agents (especially progestins, eg, medroxyprogesterone)</td> </tr> <tr> <td>Beta-blockers (especially propranolol)</td> </tr> <tr> <td>Alpha-blockers (especially terazosin)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine</EM>, Tsai AG, Wadden TA, In the Clinic: Obesity, Vol 159, Pg ITCS-1. Copyright Â© 2013 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 96326 Version 5.0</div></div></div>"},"96327":{"type":"graphic_figure","displayName":"Rule of halves","title":"Elliptical excision: The rule of halves","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Elliptical excision: The rule of halves</div><div class=\"cntnt\"><img style=\"width:456px; height:383px;\" src=\"images/DERM/96327_Ruleofhalves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic illustrating the principle of halving sutures. Simple interrupted sutures are used to bisect the side of excess tissue. Additional sutures are used to equally divide the two remaining halves of the defect. The process is repeated until the excess tissue is gradually divided among progressive halving sutures.</div><div class=\"graphic_reference\">From: Kouba DJ, Miller SJ. \"Running pleated\" suture technique opposes wound edges of unequal lengths. Dermatol Surg 2006; 3:411. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 American Society for Dermatologic Surgery. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96327 Version 4.0</div></div></div>"},"96328":{"type":"graphic_figure","displayName":"M-plasty","title":"M-plasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-plasty</div><div class=\"cntnt\"><img style=\"width:399px; height:592px;\" src=\"images/DERM/96328_M-plasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the design of a standard M-plasty.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Krishnan RS, Donnelly HB. The nested M-plasty for scar length shortening. Dermatol Surg 2008; 34:1236.</LI>&#xD;&#xA;<LI>Hanke CW. The 2013/2014 Dermatology In-Review Study Guide. Educational Testing and Assessment Systems, 2013.</LI></OL></div><div id=\"graphicVersion\">Graphic 96328 Version 2.0</div></div></div>"},"96329":{"type":"graphic_picture","displayName":"Lichen planus-like keratosis","title":"Clinical and dermoscopic image of lichen planus-like keratosis","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic image of lichen planus-like keratosis</div><div class=\"cntnt\"><img style=\"width:599px; height:229px;\" src=\"images/DERM/96329_Lichen_planus_lik_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lichen planus-like keratosis, also called lichenoid keratosis, presenting as a solitary, gray to brown papule or plaque on the face.<br />(B) On dermoscopy, coarse, large, and partially confluent gray dots are seen.</div><div id=\"graphicVersion\">Graphic 96329 Version 1.0</div></div></div>"},"96330":{"type":"graphic_table","displayName":"Overview of comorbid condition levels","title":"Overview of comorbid condition levels, associated conditions, and life expectancies at ages 68, 74, and 79 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of comorbid condition levels, associated conditions, and life expectancies at ages 68, 74, and 79 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"18%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"18%\"></colgroup><colgroup span=\"7\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Comorbid condition group</td> <td class=\"subtitle1\" rowspan=\"2\">Population at age 74 years (%)</td> <td class=\"subtitle1\" rowspan=\"2\">Conditions included*</td> <td class=\"subtitle1\" rowspan=\"2\">HR<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"2\">Life expectancy at age 68 years (y)</td> <td class=\"subtitle1\" colspan=\"2\">Life expectancy at age 74 years (y)</td> <td class=\"subtitle1\" colspan=\"2\">Life expectancy at age 78 years (y)</td> </tr> <tr> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> </tr> <tr class=\"divider_bottom\"> <td>No comorbid conditions</td> <td class=\"centered\">69</td> <td>None</td> <td class=\"centered\">1.00</td> <td class=\"centered\">16.6</td> <td class=\"centered\">19.3</td> <td class=\"centered\">13.1</td> <td class=\"centered\">15.1</td> <td class=\"centered\">10.7</td> <td class=\"centered\">12.4</td> </tr> <tr class=\"divider_bottom\"> <td>Mild comorbid conditions</td> <td class=\"centered\">2</td> <td>History of MI, acute MI, ulcer, or rheumatologic disease</td> <td class=\"centered\">1.01-1.38</td> <td class=\"centered\">15.4</td> <td class=\"centered\">17.1</td> <td class=\"centered\">12.5</td> <td class=\"centered\">13.1</td> <td class=\"centered\">9.8</td> <td class=\"centered\">10.9</td> </tr> <tr class=\"divider_bottom\"> <td>Moderate comorbid conditions</td> <td class=\"centered\">12</td> <td>Cardiovascular disease; paralysis; diabetes; or combinations of diabetes with MI, ulcer, or rheumatologic disease</td> <td class=\"centered\">1.39-1.66</td> <td class=\"centered\">14.4</td> <td class=\"centered\">16.3</td> <td class=\"centered\">11.0</td> <td class=\"centered\">12.4</td> <td class=\"centered\">8.6</td> <td class=\"centered\">9.9</td> </tr> <tr class=\"divider_bottom\"> <td>Severe comorbid conditions</td> <td class=\"centered\">17</td> <td>AIDS, COPD, mild or severe liver disease, chronic renal failure, dementia, congestive heart failure, or combinations of aforementioned diseases not categorized under moderate comorbid conditions</td> <td class=\"centered\">&#8805;1.67</td> <td class=\"centered\">10.8</td> <td class=\"centered\">13.3</td> <td class=\"centered\">8.1</td> <td class=\"centered\">9.8</td> <td class=\"centered\">6.4</td> <td class=\"centered\">7.7</td> </tr> <tr> <td>Average health population</td> <td class=\"centered\">100</td> <td>All</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">15.7</td> <td class=\"centered\">18.3</td> <td class=\"centered\">11.9</td> <td class=\"centered\">13.9</td> <td class=\"centered\">9.6</td> <td class=\"centered\">11.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; HR: hazard ratio; MI: myocardial infarction.<br />* Any one of the conditions listed places a person in the associated comorbid condition level and its life expectancy at age 68, 74, or 78 years. Conditions included are those that affect life expectancy.<br />Â¶ HR for all-cause mortality compared with no comorbid conditions for the conditions included in each level.</div><div class=\"graphic_reference\">From<EM> Annals of Internal Medicine</EM>, Lansdorp-Vogelaar I, Gulati R, Mariotto AB, et al, Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, vol. 161, p. 104. Copyright Â© 2014 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 96330 Version 6.0</div></div></div>"},"96332":{"type":"graphic_figure","displayName":"Embryo and trophoblast","title":"Embryo and the trophoblast at the end of the third week of development","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Embryo and the trophoblast at the end of the third week of development</div><div class=\"cntnt\"><img style=\"width:638px; height:560px;\" src=\"images/OBGYN/96332_Embryoandtrophoblast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Presomite embryo and the trophoblast at the end of the third week. Tertiary and secondary stem villi give the trophoblast a characteristic radial appearance. Intervillous spaces, which are found throughout the trophoblast, are lined with syncytium. Cytotrophoblastic cells surround the trophoblast entirely and are in direct contact with the endometrium. The embryo is suspended in the chorionic cavity by means of the connecting stalk.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler TW. Langman's Medical Embryology, 13th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 96332 Version 3.0</div></div></div>"},"96333":{"type":"graphic_picture","displayName":"Cafe-au-lait spots - typical","title":"CafÃ©-au-lait spots in McCune-Albright syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CafÃ©-au-lait spots in McCune-Albright syndrome</div><div class=\"cntnt\"><img style=\"width:197px; height:286px;\" src=\"images/DERM/96333_Cafe-au-lait spots_typical.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical lesion on the face, chest, and arm of a five-year-old girl with McCune-Albright syndrome, which demonstrates jagged \"coast of Maine\" borders and the tendency for the lesions to both respect the midline and follow the developmental lines of Blaschko (a configuration of skin lesions characterized by arcs on the upper chest, S shapes on the abdomen, and V shapes over the posterior midline, caused by patterns of X-chromosome inactivation).</div><div class=\"graphic_reference\">Reproduced from: Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis 2008; 3:12. Copyright Â© 2008 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 96333 Version 2.0</div></div></div>"},"96336":{"type":"graphic_table","displayName":"Recommendations for prosthetic valve choice","title":"Recommendations for prosthetic valve choice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for prosthetic valve choice</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">COR</td> <td class=\"subtitle1\">LOE</td> </tr> <tr> <td>Choice of valve intervention and prosthetic valve type should be a shared decision process</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td>A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td>A mechanical prosthesis is reasonable for AVR or MVR in patients &#60;60 y of age who do not have a contraindication to anticoagulation</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>A bioprosthesis is reasonable in patients &#62;70 y of age</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>Either a bioprosthetic or mechanical valve is reasonable in patients between 60 y and 70 y of age</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td>Replacement of the aortic valve by a pulmonary autograft (the Ross procedure), when performed by an experienced surgeon, may be considered in young patients when VKA anticoagulation is contraindicated or undesirable</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AVR: aortic valve replacement; COR: class of recommendation; LOE: level of evidence; MVR: mitral valve replacement; N/A: not applicable; VKA: vitamin K antagonist.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96336 Version 1.0</div></div></div>"},"96339":{"type":"graphic_table","displayName":"Pharmacologic treatment of REM sleep behavior disorder","title":"Pharmacologic treatment of REM sleep behavior disorder in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic treatment of REM sleep behavior disorder in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Usual effective dose</td> <td class=\"subtitle1\">Metabolism</td> <td class=\"subtitle1\">Common side effects and precautions*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Melatonin</strong></td> <td> <p>3 mg orally at bedtime</p> (Note: Dose for treatment of adults with primary insomnia approved in some countries is 2 mg one to two hours before bedtime)</td> <td>6 to 15 mg orally at bedtime</td> <td> <p>Hepatic by CYP1A1 and 1A2; avoid or use with caution in patients with hepatic impairment</p> <p>Inhibitors of CYP1A (eg, ciprofloxacin, fluvoxamine, hormonal contraceptives, estrogen replacement therapy, methoxsalen) can increase melatonin concentrations</p> Inducers of CYP1A (eg carbamazepine, rifampin, cigarette smoke) can reduce melatonin concentrations</td> <td> <p>Similar to placebo in short-term use at physiologic doses<sup>&#182;</sup></p> <p>Daytime sleepiness and impairment of attention, memory, and coordination seen with higher doses and/or in combination with other sedating medicines</p> <p>Effects in long term use &#62;13 weeks are not established</p> Unlicensed, nonprescription products can vary widely in oral bioavailability due to differences in the type of preparation and additives used<sup>&#182;</sup></td> </tr> <tr> <td><strong>Clonazepam</strong></td> <td>0.25 mg orally at bedtime</td> <td>0.5 to 1 mg orally at bedtime</td> <td> <p>Hepatic by CYP3A4; use with caution in patients with hepatic impairment</p> Prolonged half-life (18 to 50 hours)</td> <td> <p>Morning sleepiness, confusion, dizziness, ataxia, amnesia</p> Avoid or use caution in patients with dementia, gait disorders, or obstructive sleep apnea</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Alternative choices in patients who do not respond to or cannot take melatonin and clonazepam may include cholinesterase inhibitors or other hypnotics. Refer to the topic discussion for additional information.</div><div class=\"graphic_footnotes\">REM: rapid eye movement.<br />* Avoid or use caution with alcohol or other central nervous system (CNS) depressants.<br />Â¶ For additional information refer to UpToDate topic review of physiology and clinical use of melatonin.</div><div class=\"graphic_reference\">Courtesy of authors with additional data from Aurora NR et al. J Clin Sleep Med 2010; 6:85; and Circadin (melatonin) 2 mg prolonged-release tablets; Summary of Product Characteristics (revised May 7, 2014) available at European Medicines Agency website.</div><div id=\"graphicVersion\">Graphic 96339 Version 2.0</div></div></div>"},"96342":{"type":"graphic_table","displayName":"Pertuzumab trastuzumab and docetaxel MBC","title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive* metastatic breast cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pertuzumab, trastuzumab, and docetaxel for HER2-positive* metastatic breast cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: Every 21 days.<br /> Duration of therapy: Until disease progression or unacceptable toxicity.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Pertuzumab</strong><sup>&#916;</sup><sup>&#9674;</sup></td> <td>840 mg IV (loading dose)</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#167;</sup> and administer over 60 minutes. <strong>DO NOT</strong> mix with 5 percent dextrose in water (D5W) and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 1)</td> </tr> <tr> <td><strong>Pertuzumab</strong><sup>&#916;</sup><sup>&#9674;</sup></td> <td>420 mg IV</td> <td>Dilute in 250 mL NS and administer over 30 to 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 2 and after)</td> </tr> <tr> <td><strong>Trastuzumab</strong>*<sup>&#165;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS and administer over 90 minutes for the loading dose. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 1)</td> </tr> <tr> <td><strong>Trastuzumab</strong>*<sup>&#165;</sup></td> <td>6 mg/kg</td> <td>Dilute in 250 mL NS and administer over 30 to 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 2 and after)</td> </tr> <tr> <td><strong>Docetaxel</strong></td> <td>75 mg/m<sup>2</sup> IV<sup>&#135;</sup></td> <td>Dilute in 250 mL NS to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW (10 to 30 percent). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with dexamethasone prior to docetaxel administration<sup>[2]</sup>. Premedication is not routinely indicated for pertuzumab. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> In the original study, the risk of febrile neutropenia was 14 percent<sup>[1]</sup>. The decision to use primary prophylaxis with hematopoietic growth factors should be individualized, and considered for patients who may be at risk for increased complications from prolonged neutropenia. Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations &#62;1.5 x ULN in conjunction with alkaline phosphatase &#62;2.5 x ULN. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiopulmonary issues:</strong> Trastuzumab and pertuzumab are associated with cardiotoxicity<sup>[3,4]</sup>; assess baseline left ventricular ejection fraction (LVEF) prior to therapy and then as clinically indicated. Patients with a baseline LVEF &#60;50 percent were excluded from the study<sup>[1]</sup>. Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for known drug interactions:</strong> Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided<sup>[2]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; It is recommended to observe the patient for one hour after the initial dose of pertuzumab and for 30 minutes after all subsequent doses for signs of infusion reactions<sup>[4]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess cardiac function at baseline and then as clinically indicated. In the clinical trial, LVEF was measured at screening and then every nine weeks<sup>[1]</sup>. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess changes in neurologic function prior to each cycle of docetaxel.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Reduce docetaxel dose by 25 percent for subsequent cycles in patients who develop severe prolonged neutropenia (less than 500 cells/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences)<sup>[1,2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatotoxicity:</strong> A 20 percent dose reduction in the dose of docetaxel may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy<sup>[2]</sup>. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> Hold both trastuzumab and pertuzumab if the LVEF drops to less than 45 percent or if the LVEF was 45 to 49 percent with a 10 percent or greater absolute decrease below baseline<sup>[4]</sup>. Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Discontinue trastuzumab for serious pulmonary toxicity. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infusion reactions:</strong> Respond as clinically indicated with supportive care and possible discontinuation of therapy for severe reactions. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous, mucosal, and neurologic toxicity:</strong> For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, reduce docetaxel dose by 25 percent<sup>[1]</sup>. Discontinue if toxicity persists<sup>[2]</sup>. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab and pertuzumab. Refer to UpToDate topic on \"HER2 and predicting response to therapy in breast cancer\".<br />&Delta; Administer pertuzumab, trastuzumab, and docetaxel sequentially, with either pertuzumab (followed by a 30-minute observation period for first dose then 60-minute observation period for subsequent cycles) or trastuzumab administered first; administer docetaxel after pertuzumab and trastuzumab<sup>[2]</sup>.<br /><span class=\"lozenge\">&loz;</span> If adverse reactions occur for which discontinuation of trastuzumab or pertuzumab is indicated, both drugs should be discontinued. Dose modifications of trastuzumab and pertuzumab were not allowed in the original protocol<sup>[1]</sup>. Docetaxel therapy may be discontinued without discontinuation of pertuzumab or trastuzumab.<br />&sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />&yen; For patients who miss a dose of trastuzumab by more than one week, a repeat loading dose should be administered.<br />&Dagger; Dose of docetaxel may be increased to 100 mg/m<sup>2</sup> based on tolerability<sup>[1]</sup>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Baselga J, et al. NEJM 2012; 366:109.</li>&#xD;&#xA;    <li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on November 18, 2013).</li>&#xD;&#xA;    <li>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 18, 2013).</li>&#xD;&#xA;    <li>Pertuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96342 Version 4.0</div></div></div>"},"96344":{"type":"graphic_picture","displayName":"Dermoscopic patterns mucosal lesions","title":"Dermoscopic patterns seen in mucosal lesions","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Dermoscopic patterns seen in mucosal lesions</div><div class=\"cntnt\"><img style=\"width:757px; height:386px;\" src=\"images/DERM/96344_Derm_pttrns_mucosal_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Dermoscopic patterns of lines, pseudopods, circles, clods, and dots can be seen in mucosal lesions. However, a single dot or a single line does not constitute a pattern.<br />(B) The term pattern is defined as a collection of multiple elements of the same type that cover a considerable part of the lesion: lines (1), pseudopods (1), circles (2), clods (3), dots (4), and structureless areas (5).</div><div class=\"graphic_reference\">(A) Reproduced with permission from: Kittler H. Dermatoscopy: Introduction of a new algorithmic method based on pattern analysis for diagnosis of pigmented skin lesions. Dermatopathology: Practical &amp; Conceptual 2007; 13:1-13. Copyright &copy; 2007 Derm101 LLC.<br />(B) Reproduced with permission from: Kittler H, Riedl E, Rosendahl C, Cameron A. Dermatoscopy of unpigmented lesions of the skin: a new classification of vessel morphology based on pattern analysis. Dermatopathology: Practical &amp; Conceptual 2008; 14:1-5. Copyright &copy; 2008 Derm101 LLC.</div><div id=\"graphicVersion\">Graphic 96344 Version 2.0</div></div></div>"},"96346":{"type":"graphic_picture","displayName":"Mucosal melanotic macules","title":"Clinical and dermoscopic image of mucosal melanotic macules","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic image of mucosal melanotic macules</div><div class=\"cntnt\"><img style=\"width:727px; height:275px;\" src=\"images/DERM/96346_Mucosalmelanoticmacules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clinical image of pigmented macules on the glans in a 37-year-old patient.<br />(B) Dermoscopic image showing structureless pattern and brown color.</div><div class=\"graphic_reference\">Reproduced with permission from: Blum A, Simionescu O, Argenziano G, et al. Dermoscopy of Pigmented Lesions of the Mucosa and the Mucocutaneous Junction. Results of a Multicenter Study by the International Dermoscopy Society (IDS). Arch Dermatol 2011; 147:1181. Copyright Â© 2011 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96346 Version 4.0</div></div></div>"},"96347":{"type":"graphic_picture","displayName":"Mucosal melanocytic nevus","title":"Clinical and dermoscopic image of a mucosal acquired melanocytic nevus","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic image of a mucosal acquired melanocytic nevus</div><div class=\"cntnt\"><img style=\"width:479px; height:179px;\" src=\"images/DERM/96347_Mucosal_melanocytic_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Acquired melanocytic nevus on the lower lip of a 26-year-old man.<br />(B) Dermoscopy shows a pattern of lines and structureless areas with brown colors.</div><div id=\"graphicVersion\">Graphic 96347 Version 1.0</div></div></div>"},"96348":{"type":"graphic_picture","displayName":"Congenital vulvar nevus","title":"Clinical and dermoscopic image of congenital vulvar nevus","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic image of congenital vulvar nevus</div><div class=\"cntnt\"><img style=\"width:595px; height:225px;\" src=\"images/DERM/96348_Congenital_vulvar_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Congenital melanocytic nevus on the vulva of an 11-year-old girl.<br />(B) On dermoscopic examination, the lesion shows a structureless pattern and brown color.</div><div id=\"graphicVersion\">Graphic 96348 Version 1.0</div></div></div>"},"96349":{"type":"graphic_picture","displayName":"Mucosal early invasive melanoma","title":"Mucosal early invasive melanoma: Clinical and dermoscopic image","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Mucosal early invasive melanoma: Clinical and dermoscopic image</div><div class=\"cntnt\"><img style=\"width:727px; height:276px;\" src=\"images/DERM/96349_Mcslearlyinvsvmlnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Early invasive melanoma (Breslow thickness 0.5 mm) of the vulva in a 61-year-old woman.<br />(B) Dermoscopy shows a structureless pattern, reticular lines, and brown, gray, and blue colors.</div><div class=\"graphic_reference\">Reproduced with permission from: Blum A, Simionescu O, Argenziano G, et al. Dermoscopy of Pigmented Lesions of the Mucosa and the Mucocutaneous Junction. Results of a Multicenter Study by the International Dermoscopy Society (IDS). Arch Dermatol 2011; 147:1181. Copyright &copy; 2011 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96349 Version 4.0</div></div></div>"},"96350":{"type":"graphic_picture","displayName":"Invasive mucosal melanoma","title":"Invasive mucosal melanoma: Clinical and dermoscopic images","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Invasive mucosal melanoma: Clinical and dermoscopic images</div><div class=\"cntnt\"><img style=\"width:595px; height:226px;\" src=\"images/DERM/96350_Invasive_mucosal_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Invasive melanoma on the glans of a 100-year-old patient.<br />(B) On dermoscopy, the lesion shows structureless areas, lines, circles, and brown, gray, and blue colors.</div><div id=\"graphicVersion\">Graphic 96350 Version 1.0</div></div></div>"},"96351":{"type":"graphic_diagnosticimage","displayName":"MRI of spine in patients with suspected axial SpA","title":"MRI of the spine in patients with suspected axial spondyloarthritis","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">MRI of the spine in patients with suspected axial spondyloarthritis</div><div class=\"cntnt\"><img style=\"width:600px; height:524px;\" src=\"images/RHEUM/96351_MRI_spine_pat_sus_axial_SpA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with ankylosing spondylitis demonstrates focal areas of inflammatory change as well as focal areas of fatty deposition. On the STIR sequence of the thoracic spine (A), the hyperintense inflammatory foci (arrows) are brighter on this sequence than on the T1 sequence (B, arrows). The areas of fatty deposition (arrowheads) are brighter on the T1 sequence (B) than on the STIR sequence (A).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; STIR: short tau inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-UniversitÃ¤t, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 96351 Version 3.0</div></div></div>"},"96353":{"type":"graphic_algorithm","displayName":"ASAS modification of the Berlin algorithm","title":"ASAS modification of the Berlin algorithm","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">ASAS modification of the Berlin algorithm</div><div class=\"cntnt\"><img style=\"width:518px; height:452px;\" src=\"images/RHEUM/96353_ASAS_mod_Berlin_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">IBP is deleted as obligatory entry criterion and implemented as an additional SpA feature.<br />Starting point is the presence of chronic back pain longer than three months with an onset of back pain before the age of 45.</div><div class=\"graphic_footnotes\">SpA: spondyloarthritis; AS: ankylosing spondylitis; x-rays: plain radiographs of the pelvis graded according to the modified New York criteria; IBP: inflammatory back pain; IBD: inflammatory bowel disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HLA: human leukocyte antigen; MRI: magnetic resonance imaging.<br />* &gt;3 months, onset &lt;45.</div><div class=\"graphic_reference\">Reproduced from Annals of the Rheumatic Diseases, van den Berg R, de Hooge M, Rudwaleit M, et al, Vol. 72, pages 1646-53, Copyright Â© 2013, with permission from BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 96353 Version 2.0</div></div></div>"},"96354":{"type":"graphic_picture","displayName":"Penile lichen planus","title":"Penile lichen planus: Clinical and dermoscopic image","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Penile lichen planus: Clinical and dermoscopic image</div><div class=\"cntnt\"><img style=\"width:596px; height:226px;\" src=\"images/DERM/96354_Penile_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lichen planus with typical Wickham's striae.<br />(B) Dermoscopy shows whitish lines and structureless areas.</div><div id=\"graphicVersion\">Graphic 96354 Version 1.0</div></div></div>"},"96356":{"type":"graphic_picture","displayName":"Genital lichen sclerosus","title":"Genital lichen sclerosus: Clinical and dermoscopic images","html":"<div class=\"graphic\"><div style=\"width: 890px\" class=\"figure\"><div class=\"ttl\">Genital lichen sclerosus: Clinical and dermoscopic images</div><div class=\"cntnt\"><img style=\"width:870px; height:249px;\" src=\"images/DERM/96356_Genitallichensclerosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Genital lichen sclerosus presenting with a violaceous and hemorrhagic lesion on the glans in a 65-year-old man.<br />(B) Dermoscopy shows asymmetric structureless areas with red and blue colors.</div><div class=\"graphic_reference\">Reproduced by permission from: Springer. Der Hautarzt. Blum A, Kittler H, Zalaudek I, et al. [Unclear clinical change on the glans penis leads to different dermoscopic diagnoses]. Hautarzt 2013; 64:768. Copyright Â© 2013. <A spellcheck=true href=\"https://link.springer.com/journal/105\" target=_blank>https://link.springer.com/journal/105</A>.</div><div id=\"graphicVersion\">Graphic 96356 Version 4.0</div></div></div>"},"96357":{"type":"graphic_picture","displayName":"Amalgam tattoo dermoscopy","title":"Amalgam tattoo","html":"<div class=\"graphic\"><div style=\"width: 850px\" class=\"figure\"><div class=\"ttl\">Amalgam tattoo</div><div class=\"cntnt\"><img style=\"width:830px; height:250px;\" src=\"images/DERM/96357_Amalgam_tattoo_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Amalgam tattoo presenting as a pigmented lesion on the ventral surface of the tongue in a 65-year-old woman.<br />(B) Dermoscopy shows an asymmetric whitish center with a blue-gray periphery.</div><div class=\"graphic_reference\">With kind permission from Springer Science+Business Media: Blum A. [Pigmented lesion at base of tongue: Mucosal melanoma or amalgam tattoo?] Hautarzt 2014; 65:349. Figure 3 and Figure 4. Copyright &copy; 2014 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 96357 Version 1.0</div></div></div>"},"96359":{"type":"graphic_picture","displayName":"Dermoscopy hemangioma lip","title":"Dermoscopic features of hemangioma","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of hemangioma</div><div class=\"cntnt\"><img style=\"width:596px; height:226px;\" src=\"images/DERM/96359_Dermoscopy_hemangioma_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hemangioma of the lip in an 80-year-old man presenting as a blue-colored papule.<br />(B) On dermoscopy, the lesion shows patterns of clods and lines with bluish, red, and whitish colors, corresponding to well-demarcated, blue-red lacunae separated by white septa.</div><div id=\"graphicVersion\">Graphic 96359 Version 1.0</div></div></div>"},"96360":{"type":"graphic_picture","displayName":"Papilloma tongue","title":"Papilloma of the tongue: Clinical and dermoscopic features","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Papilloma of the tongue: Clinical and dermoscopic features</div><div class=\"cntnt\"><img style=\"width:596px; height:207px;\" src=\"images/DERM/96360_Papilloma_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Papilloma of the tongue in a 32-year-old man.<br />(B) Dermoscopy shows a white structureless area.</div><div id=\"graphicVersion\">Graphic 96360 Version 1.0</div></div></div>"},"96361":{"type":"graphic_picture","displayName":"Bowenoid papulosis dermoscopy","title":"Clinical and dermoscopic images of bowenoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic images of bowenoid papulosis</div><div class=\"cntnt\"><img style=\"width:596px; height:222px;\" src=\"images/DERM/96361_Bowenoid_papulosis_dermos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bowenoid papulosis presenting as a pigmented lesion on the penis in a 54-year-old man.<br />(B) On dermoscopy, the lesion shows structureless areas, lines, and dots with different brown colors.</div><div class=\"graphic_reference\">Courtesy of W Stolz, MD,&nbsp;and&nbsp;U Weigert, MD, Munich, Germany.</div><div id=\"graphicVersion\">Graphic 96361 Version 2.0</div></div></div>"},"96362":{"type":"graphic_picture","displayName":"Papilloma tongue 2","title":"Papilloma of the tongue","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Papilloma of the tongue</div><div class=\"cntnt\"><img style=\"width:596px; height:235px;\" src=\"images/DERM/96362_Papilloma_tongue_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Papilloma on the left side of the tongue in a 71-year-old woman.<br />(B) Dermoscopy shows whitish structureless areas.</div><div id=\"graphicVersion\">Graphic 96362 Version 1.0</div></div></div>"},"96363":{"type":"graphic_picture","displayName":"Pigmented Bowen disease","title":"Pigmented Bowen disease: Clincal and dermoscopic image","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Pigmented Bowen disease: Clincal and dermoscopic image</div><div class=\"cntnt\"><img style=\"width:594px; height:227px;\" src=\"images/DERM/96363_Pigmented_Bowen_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bowen disease (squamous cell carcinoma in situ) presenting as a pigmented vulvar lesion in a 63-year-old woman.<br />(B) On dermoscopy, the lesion shows structureless areas and dots with brown, blue, and whitish colors.</div><div id=\"graphicVersion\">Graphic 96363 Version 1.0</div></div></div>"},"96364":{"type":"graphic_picture","displayName":"Mucosal melanoma dermoscopy 2","title":"Mucosal melanoma: Clinical and dermoscopic images","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Mucosal melanoma: Clinical and dermoscopic images</div><div class=\"cntnt\"><img style=\"width:727px; height:241px;\" src=\"images/DERM/96364_Mcslmlnmdrmscpy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Invasive vulvar melanoma in a 82-year-old patient.<br />(B) Dermoscopy shows structureless areas, parallel lines, gray, blue, and white colors.</div><div class=\"graphic_reference\">Reproduced with permission from: Blum A, Simionescu O, Argenziano G, et al. Dermoscopy of Pigmented Lesions of the Mucosa and the Mucocutaneous Junction. Results of a Multicenter Study by the International Dermoscopy Society (IDS). Arch Dermatol 2011; 147:1181. Copyright &copy; 2011 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96364 Version 4.0</div></div></div>"},"96365":{"type":"graphic_table","displayName":"Risk of celiac disease by HLA haplotype","title":"Cumulative risk of developing celiac autoimmunity or celiac disease by five years of age by HLA haplotype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cumulative risk of developing celiac autoimmunity or celiac disease by five years of age by HLA haplotype</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HLA DR-DQ genotype</td> <td class=\"subtitle1\">Celiac disease autoimmunity*</td> <td class=\"subtitle1\">Celiac disease<sup>&#182;</sup></td> <td class=\"subtitle1\">Adjusted hazard ratio for celiac disease autoimmunity<sup>&#916;</sup></td> <td class=\"subtitle1\">Adjusted hazard ratio for celiac disease<sup>&#916;</sup></td> </tr> <tr> <td> <p>DR3&ndash;DQ2/DR3-DQ2</p> (n = 1374, 21%)</td> <td>26%</td> <td>11%</td> <td> <p>5.70</p> (95% CI 4.66-6.97)</td> <td> <p>6.08</p> (95% CI 4.43-8.36)</td> </tr> <tr> <td> <p>DR3-DQ2/DR4-DQ8</p> (n = 2612, 41%)</td> <td>11%</td> <td>3%</td> <td> <p>2.09</p> (95% CI 1.7-2.56)</td> <td> <p>1.66</p> (95% CI 1.18-2.33) </td> </tr> <tr> <td> <p>DR4-DQ8/DR4-DQ8</p> (n = 1303, 20%)</td> <td>9%</td> <td>3%</td> <td>1.00</td> <td>1.00</td> </tr> <tr> <td> <p>DR4-DQ8/DR8-DQ4</p> (n = 1114, 17%)</td> <td>2%</td> <td>&#60;1%</td> <td>1.00</td> <td>1.00</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Results from a prospective study of 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8, living in the United States, Finland, Germany, or Sweden, which evaluated the risk of celiac disease by haplotype (TEDDY study).</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.<br />* Celiac disease autoimmunity was defined as the presence of tissue transglutaminase (tTG) antibodies on two consecutive tests at least three months apart.<br />Â¶ Celiac disease was defined as abnormal results of an intestinal biopsy (Marsh score â¥2) in 291 subjects. For patients with celiac autoimmunity who did not undergo biopsy, celiac disease was diagnosed if tTG was â¥100 units on two consecutive tests (21 subjects).<br />Î Adjusted for sex, family history of celiac disease, and country of origin, with the two lowest-risk haplotypes as the reference group.</div><div class=\"graphic_reference\">Based on data from: Liu E, Lee HS, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med 2014; 371:42.</div><div id=\"graphicVersion\">Graphic 96365 Version 2.0</div></div></div>"},"96366":{"type":"graphic_figure","displayName":"Height velocity by age for girls","title":"Height velocity in American girls","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Height velocity in American girls</div><div class=\"cntnt\"><img style=\"width:544px; height:700px;\" src=\"images/PEDS/96366_Height_velocity_age_girls.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Height velocity by age for American girls. The main set of curves (black lines) is centered on the population with average timing of peak growth velocity (around 11.5 years for girls), and show an approximate trajectory for individual children with this average pubertal timing. The two other curves outline a trajectory (50th percentile) for a child with 'early' (solid blue) or 'late' (solid orange) timing of peak growth velocity.</LI>&#xD;&#xA;<LI>Other height velocity curves (not shown here) have been developed that reflect population averages; those curves are substantially flatter than the trajectory followed by any individual patient<SUP innerHtml>[1]</SUP>. Those curves are based on data from a more recent and ethnically diverse population of children, and are valuable for understanding overall growth patterns in the population, but are less appropriate for evaluation of the growth of an individual patient.</LI></UL></div><div class=\"graphic_footnotes\">SD: standard deviations.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kelly A, Winer KK, Kalkwarf H, et al. Age-based reference ranges for annual height velocity in US children. J Clin Endocrinol Metab 2014; 99:2104.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Tanner JM, Davies S. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317. Copyright &copy; 1985 Elsevier.</div><div id=\"graphicVersion\">Graphic 96366 Version 3.0</div></div></div>"},"96367":{"type":"graphic_figure","displayName":"Height velocity by age for boys","title":"Height velocity in American boys","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Height velocity in American boys</div><div class=\"cntnt\"><img style=\"width:544px; height:700px;\" src=\"images/PEDS/96367_Height_velocity_age_boys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Height velocity by age for American boys. The main set of curves (black lines) is centered on the population with average timing of peak growth velocity (around 13.5 years for boys) and show an approximate trajectory for individual children with this average pubertal timing. The two other curves outline a trajectory (50th percentile) for a child with 'early' (solid blue) or 'late' (solid orange) timing of peak growth velocity.</LI>&#xD;&#xA;<LI>Other height velocity curves (not shown here) have been developed that reflect population averages; those curves are substantially flatter than the trajectory followed by any individual patient<SUP innerHtml>[1]</SUP>. Those curves are based on data from a more recent and ethnically diverse population of children, and are valuable for understanding overall growth patterns in the population, but are less appropriate for evaluation of the growth of an individual patient.</LI></UL></div><div class=\"graphic_footnotes\">SD: standard deviations.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kelly A, Winer KK, Kalkwarf H, et al. Age-based reference ranges for annual height velocity in US children. J Clin Endocrinol Metab 2014; 99:2104.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Tanner JM, Davies S. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317. Copyright &copy; 1985 Elsevier.</div><div id=\"graphicVersion\">Graphic 96367 Version 4.0</div></div></div>"},"96370":{"type":"graphic_table","displayName":"WAAARRRRMM weaning checklist","title":"\"WAAARRRRMM\" mnemonic for weaning from cardiopulmonary bypass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">\"WAAARRRRMM\" mnemonic for weaning from cardiopulmonary bypass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>W</strong>arm (nasopharyngeal temperature of 37&#176;C and core temperature of approximately 35.5&#176;C)</td> </tr> <tr> <td><strong>A</strong>nesthesia (most patients remain intubated and sedated with controlled postoperative mechanical ventilation)</td> </tr> <tr> <td><strong>A</strong>djuvant drugs (adequate supply of muscle relaxants, antiarrhythmic agents, inotropic agents, etc should be ready)</td> </tr> <tr> <td><strong>A</strong>ir (removed by ventilation and by massaging the heart, assisted by transesophageal echocardiography [TEE] visualization)</td> </tr> <tr> <td><strong>R</strong>hythm (normal sinus rhythm is ideal, but temporary epicardial pacing is employed if sinus rhythm cannot be achieved)</td> </tr> <tr> <td><strong>R</strong>ate (heart rate between 80 to 90 beats/minute)</td> </tr> <tr> <td><strong>R</strong>esistance (hypotension with normal or elevated bypass flow rate or cardiac output indicates low systemic vascular resistance and a need for vasopressors)</td> </tr> <tr> <td><strong>R</strong>espiration (adequate ventilation and oxygenation)</td> </tr> <tr> <td><strong>M</strong>etabolism (calcium [1.09 to 1.3 mmol/L], potassium [4 to 5.5 mmol/L], hemoglobin [&#8805;7 mg/dL], acid<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span>base status normalized)</td> </tr> <tr> <td><strong>M</strong>onitoring (all monitors functioning and volume on pulse oximeter audible)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96370 Version 5.0</div></div></div>"},"96371":{"type":"graphic_table","displayName":"NEOSPHERE","title":"Neoadjuvant pertuzumab, trastuzumab, and docetaxel followed by adjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) and trastuzumab for HER2-positive* breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neoadjuvant pertuzumab, trastuzumab, and docetaxel followed by adjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) and trastuzumab for HER2-positive* breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days.<br /> <strong>Duration of therapy:</strong> Prior to surgery (neoadjuvant portion of treatment), administer four cycles of docetaxel, trastuzumab, and pertuzumab.<sup>&#182;</sup> Following surgery, adjuvant treatment consists of three 21-day cycles of FEC plus trastuzumab followed by trastuzumab alone to complete a total of 51 weeks of trastuzumab. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td colspan=\"4\"><strong>Before surgery (neoadjuvant treatment)</strong></td> </tr> <tr> <td>Pertuzumab</td> <td>840 mg IV (loading dose)</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#916;</sup> and administer over 60 minutes. <strong>DO NOT</strong> mix with 5% dextrose in water (D5W) and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 1: Day 1</td> </tr> <tr> <td>Pertuzumab</td> <td>420 mg IV</td> <td>Dilute in 250 mL NS<sup>&#916;</sup> and administer over 30 to 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycles 2 to 4: Day 1</td> </tr> <tr> <td>Trastuzumab<sup>&#9674;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 1: Day 1</td> </tr> <tr> <td>Trastuzumab<sup>&#9674;</sup></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycles 2 to 4: Day 1</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Cycles 1 to 4: Day 1</td> </tr> <tr> <td colspan=\"4\"><strong>After surgery (adjuvant treatment)</strong><sup>&#167;</sup></td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Administer undiluted (50 mg/mL) as an intravenous push (IVP) bolus over five minutes.</td> <td>Cycles 5 to 7: Day 1</td> </tr> <tr> <td>Epirubicin</td> <td>90 mg/m<sup>2</sup> IV</td> <td>Administer into a free flowing IV infusion of NS over 3 to 20 minutes.</td> <td>Cycles 5 to 7: Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes.</td> <td>Cycles 5 to 7: Day 1</td> </tr> <tr> <td>Trastuzumab<sup>&#9674;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 8: Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Trastuzumab<sup>&#9674;</sup></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes for subsequent doses. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycles 9 to 20 to complete 51 weeks of trastuzumab:<sup>&#165;</sup> Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW (10 to 30%) during the neoadjuvant portion of treatment (Cycles 1 to 4);<br /> HIGH (&#62;90%) during the adjuvant portion with FEC (Cycles 5 to 7);<br /> MINIMAL (&#60;10%) during monotherapy with trastuzumab (Cycles 8 to 17). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[3]</sup> Premedication is not routinely indicated for pertuzumab or during FEC. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. </li> <li>Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is a vesicant; avoid extravasation. Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated for neither neoadjuvant nor adjuvant portions of this regimen (incidence of neutropenic fever during Cycles 1 to 4 of this regimen was 8%<sup>[1]</sup>). Although not noted in initial report of the NEOSPHERE trial<sup>[1]</sup>, the rate of febrile neutropenia associated with FEC is approximately 10%.<sup>[4,5]</sup> </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations &#62;1.5 times the ULN.<sup>[3]</sup> Dose modification of FU may be needed for patients with hepatic impairment.<sup>[6]</sup> A lower starting dose of cyclophosphamide and epirubicin may be needed for patients with renal or hepatic impairment.<sup>[2,7]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Trastuzumab and pertuzumab are associated with cardiotoxicity;<sup>[8,9]</sup> assess baseline left ventricular ejection fraction (LVEF) prior to therapy. Patients with a baseline LVEF &#60;55% were excluded from the study.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary issues</strong></td> <td colspan=\"3\"> <ul> <li>Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count every three weeks prior to each cycle during neoadjuvant and adjuvant treatment when chemotherapy is being administered (Cycles 1 to 7). These labs are not required during trastuzumab monotherapy (Cycles 8 to 20). </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests every three weeks prior to each cycle during neoadjuvant and adjuvant treatment when chemotherapy is being administered (Cycles 1 to 7). These labs are not required during trastuzumab monotherapy (Cycles 8 to 20). </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias) during FEC. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for infusion reactions, especially during the first two courses of trastuzumab and pertuzumab. </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each cycle of docetaxel. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>It is recommended to observe the patient for one hour after the initial dose of pertuzumab and for 30 minutes after all subsequent doses for signs of infusion reactions.<sup>[8]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>In the clinical trial, LVEF was assessed every second cycle<sup>[1]</sup>, but there are no standard guidelines for cardiac monitoring in routine clinical practice. A reasonable strategy is to assess cardiac function prior to initiation of both neoadjuvant chemotherapy (pre-Cycle 1), adjuvant chemotherapy (pre-Cycle 5), and adjuvant trastuzumab monotherapy (pre-Cycle 8). During adjuvant trastuzumab, consider repeating evaluation every 12 weeks (prior to Cycles 12 and 16) and if clinically indicated. </li> <li>Refer to UpToDate topics on \"Cardiotoxicity of anthracycline-like chemotherapy agents\" and \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li><strong>During the neoadjuvant portion:</strong> Docetaxel should only be administered if the absolute neutrophil count (ANC) is &#62;1500 cells/microL. Reduce docetaxel dose by 25% for subsequent cycles in patients who develop severe prolonged neutropenia (&#60;500 cells/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences).<sup>[3]</sup> </li> <li><strong>During the adjuvant portion of therapy with FEC:</strong> Based on the original FEC trial in metastatic breast cancer, if the ANC is &#60;1500 cells/microL and platelets are &#60;100,000/microL on day 1 of each cycle, therapy should be delayed until counts recover. For mid-cycle platelet count &#60;40,000/microL and ANC &#60;500 cells/microL, reduce epirubicin by 10 mg/m<sup>2</sup>.<sup>[1,4]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel dose reduction to 60 mg/m<sup>2</sup> may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold both trastuzumab and pertuzumab during the neoadjuvant portion of this protocol if the LVEF drops to &#60;45% or if the LVEF was 45 to 49% with a 10% or greater absolute decrease below baseline. Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\". </li> <li>Do not start adjuvant chemotherapy (FEC) if the patient has cardiac symptoms, or if the LVEF has fallen &#62;10% below the lower limit of normal, or if there has been &#62;15% drop in LVEF from the patient's baseline. During FEC treatment, if cardiac symptoms develop, or the LVEF falls to &#8805;10% below the lowest limit of normal, or there is a &#8805;15% drop below the patient's baseline, discontinue epirubicin.<sup>[4]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue trastuzumab for serious pulmonary toxicity. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>.<sup>[3]</sup> Discontinue if toxicity persists. During FEC portion or adjuvant therapy, hold FU for &#8805;grade 2 palmar-plantar erythrodysesthesia and reduce subsequent dose by 20%.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>During neoadjuvant treatment (Cycles 1 to 4), delay docetaxel for grade 2 or worse diarrhea and restart at a 20% lower dose after complete resolution; reduce docetaxel by 20% for the first episode of grade 3 diarrhea. During adjuvant treatment (Cycles 5 to 7), hold FU for grade 2 or worse diarrhea or mucositis and restart at a 20% lower dose after complete resolution. For the first episode of grade 3 to 4 diarrhea or grade 3 to 4 mucositis, reduce FU by 20%; subsequent episodes, reduce both FU and epirubicin by 20%<sup>[5]</sup> or discontinue treatment. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; G-CSF: granulocyte colony-stimulating factors.<br />* High levels of HER2-overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab and pertuzumab. Refer to UpToDate topic on \"HER2 and predicting response to therapy in breast cancer\".<br />Â¶ Administer pertuzumab, trastuzumab, and docetaxel sequentially, with either pertuzumab (followed by a 30- to 60-minute observation period) or trastuzumab administered first; administer docetaxel after pertuzumab and trastuzumab.<SUP>[8]</SUP><br />Î Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge>â</FONT> A repeat loading dose of trastuzumab is required if subsequent scheduled treatment has been delayed for over one week, which is the case for patients resuming trastuzumab after definitive surgery.<br />Â§ This regimen is consistent with the approved indication for neoadjuvant pertuzumab in the United States (in combination with trastuzumab and docetaxel).<SUP>[8]</SUP> However, alternative regimens may be used following surgery (adjuvant treatment). Refer to UpToDate topic on \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\".<br />Â¥ In the original protocol, trastuzumab was administered concomitantly with FEC and then continued to complete one year of treatment.<SUP>[1]</SUP> However, we would advise sequential treatment (FEC followed by trastuzumab) as indicated.<br />â¡ If adverse reactions occur for which discontinuation of trastuzumab or pertuzumab is indicated, both drugs should be discontinued. Dose modifications of trastuzumab and pertuzumab were not allowed in the original protocol.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gianni L, et al. Lancet Oncol 2012; 13:25.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at: www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</LI>&#xD;&#xA;<LI>Brufman G, et al. Ann Oncol 1997; 8:155.</LI>&#xD;&#xA;<LI>Wildiers H, et al. Breast Cancer Res Treat 2009; 114:103.</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</LI>&#xD;&#xA;<LI>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</LI>&#xD;&#xA;<LI>Pertuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</LI>&#xD;&#xA;<LI>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at: www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 96371 Version 6.0</div></div></div>"},"96372":{"type":"graphic_table","displayName":"TRYPHAENA","title":"Neoadjuvant trastuzumab, pertuzumab, carboplatin, and docetaxel followed by adjuvant trastuzumab for HER2-positive* breast cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neoadjuvant trastuzumab, pertuzumab, carboplatin, and docetaxel followed by adjuvant trastuzumab for HER2-positive* breast cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: Every 21 days.<br /> Duration of therapy: Prior to surgery, carboplatin, docetaxel, trastuzumab, and pertuzumab<sup>&#916;</sup> are administered every 21 days for six cycles (neoadjuvant therapy). Following surgery, adjuvant treatment consists of 11 cycles of trastuzumab alone to complete one year of trastuzumab.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">BEFORE SURGERY (neoadjuvant treatment)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#167;</sup> and administer over 90 minutes. <strong>DO NOT</strong> mix with dextrose in water (D5W) and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 1)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>6 mg/kg</td> <td>Dilute in 250 mL NS and administer over 30 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycles 2 to 6)</td> </tr> <tr> <td class=\"indent1\"><strong>Pertuzumab</strong><sup>&#9674;</sup></td> <td>840 mg IV (loading dose)</td> <td>Dilute in 250 mL NS and administer over 60 minutes for the loading dose. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 1)</td> </tr> <tr> <td class=\"indent1\"><strong>Pertuzumab</strong><sup>&#9674;</sup></td> <td>420 mg IV</td> <td>Dilute in 250 mL NS and administer over 30 to 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycles 2 to 6)</td> </tr> <tr> <td class=\"indent1\"><strong>Carboplatin</strong></td> <td>AUC<sup>&#165;</sup> = 6 mg/mL x min IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes.</td> <td>Day 1<br /> (Cycles 1 to 6 only)</td> </tr> <tr> <td class=\"indent1\"><strong>Docetaxel</strong></td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1<br /> (Cycles 1 to 6 only)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AFTER SURGERY (adjuvant treatment)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS<sup>&#167;</sup> and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycle 7)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>6 mg/kg</td> <td>Dilute in 250 mL NS and administer over 30 minutes for subsequent doses. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Day 1<br /> (Cycles 8 to 17 to complete one year of trastuzumab)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE (30 to 90 percent) during Cycles 1 to 6. Emesis risk MINIMAL (&#60;10 percent) during trastuzumab monotherapy. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with dexamethasone prior to docetaxel administration<sup>[2]</sup>. Premedication is not required for pertuzumab or carboplatin. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Carboplatin is an irritant. Docetaxel is also an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> In the original study, the risk of febrile neutropenia was 17 percent<sup>[1]</sup>. The decision to use primary prophylaxis with hematopoietic growth factors should be individualized and considered for patients who may be at risk for increased complications from prolonged neutropenia. Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations &#62;1.5 x ULN in conjunction with alkaline phosphatase &#62;2.5 x ULN. Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiopulmonary issues:</strong> Trastuzumab and pertuzumab are associated with cardiotoxicity<sup>[3,4]</sup>; assess baseline left ventricular ejection fraction (LVEF) prior to therapy. Patients with a baseline LVEF &#60;55 percent were excluded from the trial<sup>[1]</sup>. Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for known drug interactions:</strong> Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided<sup>[2]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count prior to each cycle during neoadjuvant treatment. They do not need to be checked during adjuvant trastuzumab monotherapy.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each cycle during neoadjuvant treatment. They do not need to be checked during adjuvant trastuzumab monotherapy.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; It is recommended to observe the patient for one hour after the initial dose of pertuzumab and for 30 minutes after all subsequent doses for signs of infusion reactions<sup>[4]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess cardiac function prior to initiation of neoadjuvant chemotherapy and HER2-directed therapies (pre-Cycle 1). In the absence of symptoms, routine cardiac monitoring may not be necessary. However, a reasonable strategy is to reassess cardiac function midway through adjuvant trastuzumab (prior to Cycle 7 and Cycle 13). In the protocol, LVEF was assessed at baseline and during Cycles 2, 4, 6, before Cycle 7, during Cycle 10, 12, 15, and 18, and at final visit after completion of combination therapy<sup>[1]</sup>. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Periodic neurologic examination is advised to detect sensory neuropathy.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Docetaxel should only be administered if the absolute neutrophil count is greater than 1500 cells/microL<sup>[2]</sup>. Reduce docetaxel dose by 25 percent for subsequent cycles in patients who develop severe prolonged neutropenia (less than 500 cells/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences)<sup>[2]</sup>. Carboplatin should only be administered if the platelet count is greater than 100,000/microL. Reduce carboplatin dose by 25 percent for subsequent cycles in patients who develop severe neutropenia (less than 500 cells/microL) or thrombocytopenia (less than 50,000 cells/microL), or in patients who require a greater than one week delay in treatment due to thrombocytopenia<sup>[5]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatotoxicity:</strong> Docetaxel dose reduction to 60 mg/m<sup>2</sup> may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> Hold both trastuzumab and pertuzumab during the neoadjuvant portion of this protocol if the LVEF drops to less than 45 percent or if the LVEF was 45 to 49 percent with a 10 percent or greater absolute decrease below baseline<sup>[4]</sup>. Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Discontinue trastuzumab for serious pulmonary toxicity. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infusion reactions:</strong> Respond as clinically indicated with supportive care and possible discontinuation of therapy for severe reactions. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous, mucosal, and neurologic toxicity:</strong> For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup><sup>[2]</sup>. Discontinue if toxicity persists. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* High levels of HER2-overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab and pertuzumab. Refer to UpToDate topic on \"HER2 and predicting response to therapy in breast cancer\".<br />&Delta; Administer trastuzumab, pertuzumab, carboplatin, and docetaxel sequentially, with carboplatin and docetaxel administered after trastuzumab and pertuzumab. During neoadjuvant treatment, wait 30 to 60 minutes following pertuzumab to begin carboplatin<sup>[1]</sup>.<br /><span class=\"lozenge\">&loz;</span> A repeat loading dose of trastuzumab is required if scheduled treatment has been delayed for over one week, which is the case for patients resuming trastuzumab after definitive surgery. If adverse reactions occur for which discontinuation of trastuzumab or pertuzumab is indicated, both drugs should be discontinued. Dose modifications of trastuzumab and pertuzumab were not allowed in the original protocol<sup>[1]</sup>.<br />&sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />&yen; AUC (area under the concentration x time curve) is converted to a patient-specific carboplatin dose (in mg) according to the renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schneeweiss A, et al. Annals of Oncology 2013; 24:2278.</li>&#xD;&#xA;    <li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on November 30, 2013).</li>&#xD;&#xA;    <li>Trastuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2013).</li>&#xD;&#xA;    <li>Pertuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</li>&#xD;&#xA;    <li>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96372 Version 5.0</div></div></div>"},"96373":{"type":"graphic_algorithm","displayName":"Diagnosis cholangiocarcinoma with PSC","title":"Approach to the diagnosis of cholangiocarcinoma in a patient with primary sclerosing cholangitis (PSC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of cholangiocarcinoma in a patient with primary sclerosing cholangitis (PSC)</div><div class=\"cntnt\"><img style=\"width:302px; height:459px;\" src=\"images/ONC/96373_Diag_cholangiocarcinoma_PSC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; CA 19-9: carbohydrate antigen 19-9; CCA: cholangiocarcinoma; CEA: carcinoembryonic antigen; CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; IDUS: intraductal ultrasound; MRCP: magnetic resonance cholangiopancreatography; PET: positron emission tomography; PSC: primary sclerosing cholangitis; PTC: percutaneous transhepatic cholangiography.<br />* In patients with PSC, cholangiocarcinoma should be considered if there is rapid clinical deterioration with jaundice, weight loss, and abdominal pain. The presence of progressive biliary dilatation in the setting of a dominant stricture or thickening of the bile duct wall should also raise a strong suspicion of cholangiocarcinoma. Cholangiocarcinoma should also be considered if suggested by screening test results (ie, CA 19-9, and/or MRCP).<br /><FONT class=bullet>â¢</FONT> All patients suspected of having cholangiocarcinoma should have tumor markers (CA 19-9, CEA, and for patients with intrahepatic lesions, AFP) checked. Elevated tumor markers may support a diagnosis of cholangiocarcinoma, or in the case of an elevated AFP, suggest an alternative diagnosis (hepatocellular carcinoma). In patients with PSC, the optimal CA 19-9 cutoff (providing optimal balance between sensitivity and specificity) is approximately 100 to 129 U/mL.<br />Î If at any point during the evaluation, an alternative diagnosis is made, treatment should be instituted as appropriate for that diagnosis.<br /><FONT class=lozenge>â</FONT> With brushings/biopsies of any intraductal lesions or strictures. Obstructing lesions can be stented if needed. If ERCP is nondiagnostic, consider cholangioscopy (if available) for direct visualization of the bile duct and biopsies. IDUS (if available) can be used to further define the extent of the tumor. If the lesion is not accessible endoscopically, consider PTC.<br />Â§ If the diagnosis of cholangiocarcinoma is strongly suspected but imaging has been nondiagnostic. Preoperative PET/CT scan may also help guide surgery by identifying areas more likely to harbor malignancy.<br />Â¥ If the patient is a surgical candidate.</div><div id=\"graphicVersion\">Graphic 96373 Version 3.0</div></div></div>"},"96374":{"type":"graphic_algorithm","displayName":"Diagnosis cholangiocarcinoma without PSC","title":"Approach to the diagnosis of cholangiocarcinoma in a patient who does not have primary sclerosing cholangitis (PSC)","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of cholangiocarcinoma in a patient who does not have primary sclerosing cholangitis (PSC)</div><div class=\"cntnt\"><img style=\"width:810px; height:741px;\" src=\"images/ONC/96374_Diag_cholangiocarcin_wo_PSC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; CA 19-9: carbohydrate antigen 19-9; CCA: cholangiocarcinoma; CEA: carcinoembryonic antigen; CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; IDUS: intraductal ultrasound; FNA: fine needle aspiration; MDCT: contrast-enhanced multiphasic multidetector row CT; MRCP: magnetic resonance cholangiopancreatography; MRI: magnetic resonance imaging; PET: positron emission tomography; PTC: percutaneous transhepatic cholangiography; US: ultrasound.<br />* A diagnosis of cholangiocarcinoma should be considered if there are signs of biliary obstruction (eg, jaundice, abnormal liver tests in a cholestatic pattern, bile duct dilation on imaging studies) without an alternative explanation (eg, choledocholithiasis, a pancreatic head lesion). The diagnosis should also be considered in patients with an isolated intrahepatic mass on imaging and a normal serum level of AFP.<br /><FONT class=bullet>â¢</FONT> All patients with suspected cholangiocarcinoma should have tumor markers (CA 19-9, CEA, and for patients with intrahepatic lesions, AFP) checked. Elevated tumor markers may support a diagnosis of cholangiocarcinoma, or in the case of an elevated AFP, suggest an alternative diagnosis (hepatocellular carcinoma). CA 19-9 is elevated if it is &gt;37 U/mL.<br />Î If at any point during the evaluation an alternative diagnosis is made, treatment should be instituted as appropriate for that diagnosis.<br /><FONT class=lozenge>â</FONT> If the patient is a surgical candidate. Preoperative PET/CT scan is of utility primarily for identifying occult metastases.<br />Â§ EUS preferred in many centers for patients with extrahepatic bile duct dilation unless drainage is required or tissue cannot be obtained with FNA. For patients with a perihilar mass or isolated intrahepatic bile duct dilation, ERCP is the next test obtained since the lesion may not be visualized on EUS.<br />Â¥ With brushings/biopsies of any intraductal lesions or strictures. Obstructing lesions can be stented if needed. If ERCP is nondiagnostic, consider cholangioscopy (if available) for direct visualization of the bile duct and biopsies. IDUS (if available) can be used to further define the extent of the tumor. If the lesion is not accessible endoscopically, consider PTC.</div><div id=\"graphicVersion\">Graphic 96374 Version 3.0</div></div></div>"},"96376":{"type":"graphic_picture","displayName":"Dermoscopy pigmented Bowen disease face","title":"Dermoscopic features of facial pigmented squamous cell carcinoma in situ (Bowen disease)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of facial pigmented squamous cell carcinoma in situ (Bowen disease)</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/96376_Pigment_Bowen_disease_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented Bowen disease is sometimes characterized by small, brown dots arranged in radial lines at the periphery of the lesion.</div><div id=\"graphicVersion\">Graphic 96376 Version 1.0</div></div></div>"},"96380":{"type":"graphic_algorithm","displayName":"Screening and diagnosis of aluminum toxicity","title":"Screening and diagnosis of aluminum toxicity","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">Screening and diagnosis of aluminum toxicity</div><div class=\"cntnt\"><img style=\"width:659px; height:431px;\" src=\"images/NEPH/96380_Screen_diag_alumin_toxicity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For treatment recommendations, refer to separate algorithms on treatment of aluminum toxicity in symptomatic and asymptomatic patients.</div><div class=\"graphic_footnotes\">* Serum aluminum measured before deferoxamine infusion and two days later.<br />&para; Includes diabetes mellitus, secondary hyperparathyroidism, vitamin D status, high citrate intake.</div><div class=\"graphic_reference\">Courtesy of Dr. Wajeh Y Qunibi, MD.</div><div id=\"graphicVersion\">Graphic 96380 Version 2.0</div></div></div>"},"96383":{"type":"graphic_picture","displayName":"Keloids on ear","title":"Keloids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keloids</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/96383_Keloids_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keloids presenting as firm, smooth nodules on the ear.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96383 Version 1.0</div></div></div>"},"96384":{"type":"graphic_picture","displayName":"Keloids secondary to pseudofolliculitis barbae","title":"Keloids","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Keloids</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96384_Keloids_scndry_psdfl_brbae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keloid formation in a patient with pseudofolliculitis barbae.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96384 Version 1.0</div></div></div>"},"96385":{"type":"graphic_table","displayName":"Initial assessment for urgent-start PD","title":"Initial assessment for urgent-start peritoneal dialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial assessment for urgent-start peritoneal dialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evaluation for uremia</td> </tr> <tr> <td class=\"indent1\">Intractable nausea/vomiting with inability to take medications or liquids by mouth</td> </tr> <tr> <td class=\"indent1\">Intractable itching</td> </tr> <tr> <td class=\"indent1\">Bleeding from gums or other mucosal surfaces</td> </tr> <tr> <td class=\"indent1\">Confusion not attributable to other known causes</td> </tr> <tr> <td class=\"indent1\">Other symptoms of uremia</td> </tr> <tr> <td class=\"subtitle1_single\">Evaluation for volume overload</td> </tr> <tr> <td class=\"indent1\">Edema of legs above the level of the knee</td> </tr> <tr> <td class=\"indent1\">Shortness of breath at rest or dyspnea on minimal exertion (without another readily identifiable cause [ie, COPD, asthma, severe anemia, angina])</td> </tr> <tr> <td class=\"subtitle1_single\">Evaluation of laboratory parameters</td> </tr> <tr> <td class=\"indent1\">BUN &#62;100 mg/dL</td> </tr> <tr> <td class=\"indent1\">Potassium &#62;6.5 mEq/L</td> </tr> <tr> <td class=\"indent1\">Bicarbonate &#60;15 mEq/L</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; BUN: blood urea nitrogen.</div><div class=\"graphic_reference\">Original figure modified for this publication. Ghaffari A. Urgent-start peritoneal dialysis: A quality improvement report. Am J Kidney Dis 2012; 59:400. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96385 Version 1.0</div></div></div>"},"96386":{"type":"graphic_picture","displayName":"Dermatofibrosarcoma protuberans","title":"Dermatofibrosarcoma protuberans","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermatofibrosarcoma protuberans</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96386_Dermatofibrosarcoma_prtbrns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermatofibrosarcoma protuberans on the trunk presenting as a red-brown plaque with nodules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96386 Version 1.0</div></div></div>"},"96387":{"type":"graphic_table","displayName":"Vasoactive infusions used in the operating room: Adult dosing","title":"Vasoactive infusions used in the operating room: Adult dosing*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vasoactive infusions used in the operating room: Adult dosing*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Functional class</td> <td class=\"subtitle1\">Predominant receptor or&nbsp;mechanism of action</td> <td class=\"subtitle1\">Infusion dose</td> </tr> <tr class=\"divider_bottom\"> <td>Vasopressin</td> <td>Vasoconstrictor</td> <td>Vasopressin<sub>1</sub> and vasopressin<sub>2</sub> receptor agonist</td> <td> <p>1 to 6 units/<strong>hour</strong></p> <p class=\"indent1\">or</p> 0.01 to 0.1 units/minute<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Phenylephrine</td> <td>Vasoconstrictor</td> <td>Alpha adrenergic receptor agonist</td> <td> <p>10 to 200 mcg/minute</p> <p class=\"indent1\">or</p> 0.1 to 2 mcg/kg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Norepinephrine</td> <td>Inotrope/vasoconstrictor</td> <td>Alpha and beta<sub>1</sub> adrenergic receptor agonist</td> <td> <p>1 to 30 mcg/minute</p> <p class=\"indent1\">or</p> 0.01 to 0.3 mcg/kg/minute</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Dopamine</td> <td class=\"divider_bottom\" rowspan=\"3\">Inotrope/vasoconstrictor</td> <td>Dopaminergic receptor agonist</td> <td>&#60;3 mcg/kg/minute (D)</td> </tr> <tr> <td>Beta<sub>1</sub> and beta<sub>2</sub> adrenergic receptor agonist</td> <td><span style=\"color: black;\">3 to 10 mcg/kg/minute (beta<sub>1</sub> adrenergic&nbsp;and beta adrenergic)</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Alpha adrenergic receptor agonist</span></td> <td><span style=\"color: black;\">&#62;10 mcg/kg/minute (alpha adrenergic)</span></td> </tr> <tr class=\"divider_bottom\"> <td>Dobutamine</td> <td>Inotrope/vasodilator</td> <td>Beta<sub>1</sub> and beta<sub>2</sub> adrenergic receptor agonist</td> <td>1 to 20 mcg/kg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Epinephrine</td> <td>Inotrope/vasoconstrictor</td> <td> <p>Alpha adrenergic receptor agonist</p> Beta<sub>1</sub> and beta<sub>2</sub> adrenergic receptor agonist</td> <td> <p><span style=\"color: black;\">1 to 100 mcg/minute</span></p> <p class=\"indent1\"><span style=\"color: black;\">or</span></p> <p><span style=\"color: black;\">0.01 to 1 mcg/kg/minute</span></p> <p><span style=\"color: black;\">1 to 2 mcg/minute (beta<sub>2</sub> adrenergic)<sup>&#916;</sup></span></p> <p><span style=\"color: black;\">2 to 10 mcg/minute (beta<sub>1</sub> adrenergic, beta adrenergic)</span></p> <span style=\"color: black;\">10 to 100 mcg/minute (alpha adrenergic)</span></td> </tr> <tr class=\"divider_bottom\"> <td>Milrinone</td> <td>Inotrope/vasodilator</td> <td>Phosphodiesterase inhibitor (decreases rate of cyclic adenosine monophosphate [cAMP] degradation)</td> <td>Loading dose 50 mcg/kg over &#8805;10 minutes (usually omitted), then 0.375 to 0.75 mcg/kg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Isoproterenol</td> <td>Inotrope/vasodilator</td> <td>Beta<sub>1</sub> and beta<sub>2</sub> adrenergic receptor agonist</td> <td> <p>5 to 20 mcg/minute</p> <p class=\"indent1\">or</p> 0.05 to 0.2 mcg/kg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Clevidipine</td> <td>Vasodilator</td> <td>Inhibits calcium ion influx; selective arteriolar smooth muscle relaxation</td> <td> <p>1 to 16 mg/<strong>hour</strong></p> <p class=\"indent1\">or</p> 0.02 to 0.27 mg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Nicardipine</td> <td>Vasodilator</td> <td>Inhibits calcium ion influx; selective arteriolar smooth muscle relaxation</td> <td> <p>5 to 15 mg/<strong>hour</strong></p> <p class=\"indent1\">or</p> 0.08 to 0.25 mg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Nitroglycerin</td> <td>Vasodilator</td> <td>Increase in cyclic GMP (cGMP)</td> <td> <p>10 to 400 mcg/minute</p> <p class=\"indent1\">or</p> 0.1 to 4 mcg/kg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Nitroprusside</td> <td>Vasodilator</td> <td>Smooth muscle relaxation</td> <td> <p>10 to 400 mcg/minute<sup>&#9674;</sup></p> <p class=\"indent1\">or</p> 0.1 to 4 mcg/kg/minute</td> </tr> <tr class=\"divider_bottom\"> <td>Esmolol</td> <td>Adrenergic antagonist and anti-arrhythmic</td> <td>Beta<sub>1</sub> adrenergic receptor antagonist</td> <td>10 to 50 mg boluses, then 25 to 300 mcg/kg/minute</td> </tr> <tr> <td>Labetalol</td> <td>Adrenergic antagonist</td> <td>Beta<sub>1</sub>, beta<sub>2</sub>, and alpha<sub>1</sub> adrenergic receptor antagonist</td> <td>5 to 20 mg IV boluses, then 0.5 to 2 mg/minute</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">V: vasopressin; D: dopaminergic.<br />* Dose ranges are based on adult patients of normal size.<br />Â¶ Vasopressin doses &gt;0.04 units/minute are reserved for salvage therapy (ie, failure to achieve adequate mean arterial pressure goal with other vasopressor agents).<br />Î At low doses, epinephrine infusion has beneficial bronchodilatory effects and may cause arterial vasodilation and decreased blood pressure. Dose-related effect ranges vary somewhat in clinical practice.<br /><FONT class=lozenge>â</FONT> Nitroprusside doses &gt;400 mcg/minute are not recommended due to minimal added benefit and increased risk for thiocyanate or cyanide toxicity.</div><div id=\"graphicVersion\">Graphic 96387 Version 14.0</div></div></div>"},"96388":{"type":"graphic_picture","displayName":"Hanarostent","title":"Hanarostent","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Hanarostent</div><div class=\"cntnt\"><img style=\"width:531px; height:288px;\" src=\"images/PULM/96388_Hanarostent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endobronchial non-small cell cancer showing almost complete occlusion of the bronchus.<br />(B) Hanarostent inserted with improved patency of the endobronchial lumen.</div><div class=\"graphic_reference\">Courtesy of G Stratakos.</div><div id=\"graphicVersion\">Graphic 96388 Version 1.0</div></div></div>"},"96392":{"type":"graphic_table","displayName":"Substances with capacity to induce psychosis","title":"Substances and medications with capacity to induce psychosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Substances and medications with capacity to induce psychosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Substance or medication</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Alcohol and sedatives/hypnotics</td> <td>Alcohol (intoxication or withdrawal), barbiturates and benzodiazepines (particularly withdrawal)</td> </tr> <tr> <td>Anabolic steroids</td> <td>Testosterone, methyltestosterone</td> </tr> <tr> <td>Analgesics</td> <td>Meperidine, pentazocine, indomethacin</td> </tr> <tr> <td>Anticholinergics</td> <td>Atropine, scopolamine</td> </tr> <tr> <td>Antidepressants</td> <td>Bupropion, others if triggering a manic switch</td> </tr> <tr> <td>Antiepileptics</td> <td>Zonisamide, other anticonvulsants at high doses</td> </tr> <tr> <td>Antimalarial</td> <td>Mefloquine, chloroquine</td> </tr> <tr> <td>Anti-parkinsonian</td> <td>Levodopa, selegiline, amantadine, pramipexole, bromocriptine</td> </tr> <tr> <td>Antivirals</td> <td>Abacavir, efavirenz, nevirapine, acyclovir</td> </tr> <tr> <td>Cannabinoids</td> <td>Marijuana, synthetic cannabinoids (ie, \"spice\"), dronabinol</td> </tr> <tr> <td>Cardiovascular</td> <td>Digoxin, disopyramide, propafenone, quinidine</td> </tr> <tr> <td>Corticosteroids</td> <td>Prednisone, dexamethasone, etc</td> </tr> <tr> <td>Hallucinogens</td> <td>LSD, PCP (phencyclidine), ketamine, psilocybin-containing mushrooms, mescaline, synthetic \"designer drugs\" (eg, 2-CB, \"N-Bomb\" [25I-NBOMe]) , salvia divinorum</td> </tr> <tr> <td>Inhalants</td> <td>Toluene, butane, gasoline</td> </tr> <tr> <td>Interferons</td> <td>Interferon alfa-2a/2b</td> </tr> <tr> <td>Over-the-counter (OTC)</td> <td>Dextromethorphan (DXM), diphenhydramine, some decongestants</td> </tr> <tr> <td>Stimulants</td> <td>Cocaine, amphetamine/methamphetamine, methylphenidate, certain diet pills, \"bath salts\" (MDPV, mephedrone), MDMA/ecstasy</td> </tr> <tr> <td>Toxins</td> <td>Carbon monoxide, organophosphates, heavy metals (eg, arsenic, manganese, mercury, thallium)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96392 Version 1.0</div></div></div>"},"96394":{"type":"graphic_picture","displayName":"Leufen stent","title":"Leufen stent","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Leufen stent</div><div class=\"cntnt\"><img style=\"width:596px; height:242px;\" src=\"images/PULM/96394_Leufen_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fluoroscopic image of Leufen stent.<br />(B) Bronchoscopic image of Leufen stent at the level of the carina. The stent extends down both the right and left main stem bronchi.</div><div class=\"graphic_reference\">Courtesy of T Rosell and M Salamonsen.</div><div id=\"graphicVersion\">Graphic 96394 Version 1.0</div></div></div>"},"96395":{"type":"graphic_picture","displayName":"Alveolus aero stent","title":"Alveolus aero stent","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Alveolus aero stent</div><div class=\"cntnt\"><img style=\"width:542px; height:290px;\" src=\"images/PULM/96395_Alveolus_aero_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endobronchial alveolus aero stent with clear evidence of stent material on the endobronchial lumen wall.<br />(B) Granulation tissue obscuring the stent weeks after insertion.</div><div class=\"graphic_reference\">Courtesy of G Stratakos.</div><div id=\"graphicVersion\">Graphic 96395 Version 1.0</div></div></div>"},"96396":{"type":"graphic_picture","displayName":"Dermoscopy superficial nonpigmented BCC","title":"Dermoscopic features of superficial nonpigmented basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of superficial nonpigmented basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:390px;\" src=\"images/DERM/96396_Dermosc_superfic_nonpig_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial nonpigmented basal cell carcinoma is characterized by structureless white to red areas and multiple small erosions. Fine telangiectasias are also present.</div><div id=\"graphicVersion\">Graphic 96396 Version 1.0</div></div></div>"},"96398":{"type":"graphic_picture","displayName":"Dermoscopy superficial pigmented BCC 2","title":"Dermoscopic features of superficial pigmented basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of superficial pigmented basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96398_Dermo_superfic_pigmen_BCC2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short, light brown finger-like projections (leaf-like structures) can be seen at the periphery of this superficial pigmented basal cell carcinoma.</div><div id=\"graphicVersion\">Graphic 96398 Version 1.0</div></div></div>"},"96401":{"type":"graphic_table","displayName":"Risk factors for breast cancer in men","title":"Risk factors for breast cancer in men","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for breast cancer in men</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Age</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic factors</td> </tr> <tr> <td class=\"subtitle2_single indent1\">Well-established</td> </tr> <tr> <td class=\"indent2\">Family history</td> </tr> <tr> <td class=\"indent2\">BRCA2 &#62;&#62; BRCA1</td> </tr> <tr> <td class=\"subtitle2_single indent1\">Possible</td> </tr> <tr> <td class=\"indent2\">PALB2</td> </tr> <tr> <td class=\"indent2\">Androgen receptor</td> </tr> <tr> <td class=\"indent2\">CYP17</td> </tr> <tr> <td class=\"indent2\">CHEK2</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions associated with an abnormal estrogen-to-androgen ratio</td> </tr> <tr> <td class=\"indent1\">Klinefelter syndrome</td> </tr> <tr> <td class=\"indent1\">Exogenous estrogen or testosterone use</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Orchitis/epididymitis</td> </tr> <tr> <td class=\"indent1\">Finasteride</td> </tr> <tr> <td class=\"subtitle1_single\">Lifestyle</td> </tr> <tr> <td class=\"indent1\">Lack of exercise</td> </tr> <tr> <td class=\"subtitle1_single\">Exposures</td> </tr> <tr> <td class=\"subtitle2_single indent1\">Well-established</td> </tr> <tr> <td class=\"indent2\">Radiation</td> </tr> <tr> <td class=\"subtitle2_single indent1\">Possible</td> </tr> <tr> <td class=\"indent2\">Electromagnetic fields</td> </tr> <tr> <td class=\"indent2\">Heat</td> </tr> <tr> <td class=\"indent2\">Volatile organic compounds (eg, tetrachloroethylene, perchloroethylene, trichloroethylene, dichloroethylene, and benzene) or chemicals</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous possible risk factors</td> </tr> <tr> <td class=\"indent1\">Birth order (possible higher risk in first borns)</td> </tr> <tr> <td class=\"indent1\">Bone fracture after age 45</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Ruddy KJ, Winer EP. Male breast cancer: Risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 2013; 24(6):1434-43, by permission of Oxford University Press on behalf of the European Society for Medical Oncology. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 96401 Version 7.0</div></div></div>"},"96403":{"type":"graphic_picture","displayName":"Dermoscopy molluscum","title":"Clinical and dermoscopic image of molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic image of molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:597px; height:226px;\" src=\"images/DERM/96403_Dermoscopy_molluscum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Skin-colored papular lesions on the penis of a 17-year-old boy.<br />(B) Dermoscopy shows white clods with structureless areas at the periphery of the lesion.</div><div id=\"graphicVersion\">Graphic 96403 Version 1.0</div></div></div>"},"96411":{"type":"graphic_diagnosticimage","displayName":"Radiographs of CMC joint dislocation and reduction of thumb","title":"Dislocation and reduction of the first carpometacarpal joint of the thumb on radiograph","html":"<div class=\"graphic\"><div style=\"width: 701px\" class=\"figure\"><div class=\"ttl\">Dislocation and reduction of the first carpometacarpal joint of the thumb on radiograph</div><div class=\"cntnt\"><img style=\"width:681px; height:426px;\" src=\"images/RADIOL/96411_Radiogr_CMC_jt_disloc_reduc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a oblique view of the left hand and shows a dislocation (arrow) between the trapezium (T) and first metacarpal (MC). Image B is a lateral view confirming an anterior dislocation (arrow). Image C is a lateral radiograph following reduction (arrow).</div><div class=\"graphic_footnotes\">CMC: carpometacarpal.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 96411 Version 1.0</div></div></div>"},"96412":{"type":"graphic_diagnosticimage","displayName":"Imaging pyloric stenosis","title":"Pyloric stenosis on radiograph and ultrasound","html":"<div class=\"graphic\"><div style=\"width: 872px\" class=\"figure\"><div class=\"ttl\">Pyloric stenosis on radiograph and ultrasound</div><div class=\"cntnt\"><img style=\"width:852px; height:506px;\" src=\"images/RADIOL/96412_Imaging_pyloric_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This four-week-old male infant presented with projectile non-bilious emesis and failure to thrive. Image A is a supine radiograph and image B a lateral decubitus radiograph of the abdomen, revealing a dilated stomach with a single air fluid level (arrowhead) and peristaltic waves (arrows), which constitute&nbsp;the \"caterpillar sign\" of pyloric stenosis. Image C is a sonographic image of the distal stomach and pylorus and shows a dilated stomach (asterisk) with peristaltic waves (arrow) and pyloric wall thickening (arrowheads). Image D is a sonographic image of the epigastrium and shows wall thickening (arrows) and lengthening. The pyloric muscle thickness (PMT) measures 5 mm, and pyloric muscle length (PML) measures&nbsp;18 mm, consistent with pyloric stenosis.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 96412 Version 1.0</div></div></div>"},"96413":{"type":"graphic_diagnosticimage","displayName":"Barium enema of amebic colitis","title":"Amebic colitis on barium enema","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Amebic colitis on barium enema</div><div class=\"cntnt\"><img style=\"width:656px; height:421px;\" src=\"images/RADIOL/96413_BE_amebic_colitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A barium enema (A) shows a cone-shaped spastic cecum (between arrows), a deep ulcer (arrowhead) with surrounding halo of edema, and an incompetent ileocecal valve allowing for opacification of a normal appearing terminal ileum (asterisks). Image B shows a punctate ulcer (arrowhead) with surrounding halo of edema, spasm and narrowing of the proximal transverse colon (asterisk), and thumb printing (arrows)&nbsp;indicating submucosal edema. Image C shows spiculation (arrows) indicating fine ulceration of the mucosa.</div><div id=\"graphicVersion\">Graphic 96413 Version 1.0</div></div></div>"},"96418":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 1 bilaterally","title":"Sacroiliitis grade 1 bilaterally","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 1 bilaterally</div><div class=\"cntnt\"><img style=\"width:590px; height:513px;\" src=\"images/RHEUM/96418_Sacroiliitis_grade_1_bilat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral suspicion of sacroiliitis in a female patient (grade 1 bilaterally). Intrauterine device is present.</div><div class=\"graphic_footnotes\">L: left.</div><div class=\"graphic_reference\">Courtesy of Astrid van Tubergen, MD.</div><div id=\"graphicVersion\">Graphic 96418 Version 1.0</div></div></div>"},"96419":{"type":"graphic_table","displayName":"Overview of classification criteria sets for AS and SpA","title":"Overview of features included in the different classification criteria sets for AS and SpA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of features included in the different classification criteria sets for AS and SpA</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Features of criteria</td> <td class=\"subtitle1\">Modified New York criteria</td> <td class=\"subtitle1\">Amor criteria</td> <td class=\"subtitle1\">ESSG criteria</td> <td class=\"subtitle1\">ASAS axial SpA criteria</td> <td class=\"subtitle1\">ASAS peripheral SpA criteria</td> </tr> <tr> <td class=\"subtitle2\">Year of publication</td> <td class=\"subtitle2\">1984</td> <td class=\"subtitle2\">1990</td> <td class=\"subtitle2\">1991</td> <td class=\"subtitle2\">2009</td> <td class=\"subtitle2\">2011</td> </tr> <tr class=\"divider_bottom\"> <td>Inclusion or entry criteria</td> <td>Sacroiliitis on radiograph* plus &#8805;1 clinical criterion</td> <td>None, fulfillment of criteria requires a score of &#8805;6 points, assigned on the basis of clinical features that are considered from the list below; weightings for each feature are shown in parentheses</td> <td>Either IBP or synovitis (asymmetric or predominantly of the lower limbs), plus at least one other SpA feature</td> <td>&#8805;3 months' back pain before age 45 years and either sacroiliitis on imaging (radiographs or MRI) plus &#8805;1 other SpA feature (imaging arm) or HLA-B27<em>-</em>positive plus &#8805;2 other SpA features (clinical arm)</td> <td>Arthritis, enthesitis or dactylitis plus &#8805;1 SpA feature marked with<sup>a</sup> or &#8805;2 other SpA features marked with<sup>b</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">SpA features to be considered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IBP<sup>&#182;</sup></td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730; (ever)<sup>b</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternating buttock pain</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; or gluteal pain (1 point)</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pain at night or morning stiffness</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (1 point)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arthritis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; asymmetrical oligoarthritis (2 points)</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>b</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dactylitis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>b</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Enthesitis (heel)</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>b</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Good response to NSAIDs</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Psoriasis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)<sup>&#916;</sup></td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>a</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inflammatory bowel disease</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)<sup>&#916;</sup></td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>a</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Balanitis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)<sup>&#916;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Uveitis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>a</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diarrhea &#60;1 month before onset arthritis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (1 point)</td> <td class=\"centered\">&#8730;<sup>&#9674;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Urethritis/cervicitis &#60;1 month before onset arthritis</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (1 point)</td> <td class=\"centered\">&#8730;<sup>&#9674;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Preceding infection</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;<sup>a</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Positive family history for SpA<sup>&#167;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)<sup>&#165;</sup></td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>b</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HLA-B27</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730; (2 points)<sup>&#165;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&#8730;<sup>a</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Elevated CRP</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sacroiliitis</td> <td class=\"centered\">Not applicable (see: 'Inclusion or entry criteria' above)</td> <td class=\"centered\">&#8730; (radiographic*; 3 points)</td> <td class=\"centered\">&#8730; (radiographic*)</td> <td class=\"centered\">Not applicable (see: 'Inclusion or entry criteria' above)</td> <td class=\"centered\">&#8730;<sup>a</sup> (radiographic* or MRI-detected)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Limitation in mobility of lumbar spine</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Limitation in chest expansion</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AS: ankylosing spondylitis; SpA:&nbsp;spondyloarthritis; ESSG: European Spondyloarthropathy Study Group;&nbsp;ASAS: Assessment of SpondyloArthritis International Society; IBP: inflammatory back pain;&nbsp;MRI: magnetic resonance imaging; HLA-B27: human leukocyte antigen-B27; NSAIDs: nonsteroidal antiinflammatory drugs; CRP: C-reactive protein.<br />ââââ* Radiographic sacroiliitis is considered present when at least grade 2 bilaterally or grade 3 to 4 unilaterally.<br />Â¶ Different definitions for IBP exist for the different criteria sets.<br />Î Presence of psoriasis, balanitis, or inflammatory bowel disease is considered as one item, and 2 points are given in total if at least one is present.<br /><FONT class=lozenge>â</FONT> Presence of either urethritis/cervicitis or acute diarrhea within one month before onset of arthritis is sufficient to fulfill this SpA feature in the ESSG criteria.<br />Â§ Different definitions for a positive family history exist for the different criteria sets.<br />Â¥ Presence of either HLA-B27 positivity or a positive family history is sufficient to obtain the score of 2 points.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology. van Tubergen A, Weber U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. Nat Rev Rheumatol 2012; 8:253. Copyright &copy; 2012. <a href=\"http://www.nature.com/nrrheum\" spellcheck=\"true\" target=\"_blank\">www.nature.com/nrrheum</a>.</div><div id=\"graphicVersion\">Graphic 96419 Version 5.0</div></div></div>"},"96420":{"type":"graphic_figure","displayName":"CLL survival curves Rai and Binet stage","title":"Survival curves of chronic lymphocytic leukemia (CLL) by Rai and Binet stage","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Survival curves of chronic lymphocytic leukemia (CLL) by Rai and Binet stage</div><div class=\"cntnt\"><img style=\"width:561px; height:673px;\" src=\"images/HEME/96420_CLL_surviv_curv_Rai_Binet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival by Binet (A) and Rai (B) stage of 1863 patients with previously untreated chronic lymphocytic leukemia.</div><div class=\"graphic_reference\">This research was originally published in Blood. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124:49-62. Copyright &copy; 2014 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 96420 Version 1.0</div></div></div>"},"96421":{"type":"graphic_figure","displayName":"Survival curves German CLL Study Group","title":"Survival curves by German CLL Study Group prognostic score","html":"<div class=\"graphic\"><div style=\"width: 685px\" class=\"figure\"><div class=\"ttl\">Survival curves by German CLL Study Group prognostic score</div><div class=\"cntnt\"><img style=\"width:665px; height:915px;\" src=\"images/HEME/96421_Surv_crvs_Grmn_CLL_Stdy_Grp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival (A) and progression-free survival (B) by German CLL Study Group prognostic score.</div><div class=\"graphic_footnotes\">CLL: chronic lymphocytic leukemia.</div><div class=\"graphic_reference\">This research was originally published in Blood. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124:49-62. Copyright &copy; 2014 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 96421 Version 1.0</div></div></div>"},"96430":{"type":"graphic_picture","displayName":"Heel enthesitis","title":"Heel enthesitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Heel enthesitis</div><div class=\"cntnt\"><img style=\"width:590px; height:475px;\" src=\"images/RHEUM/96430_Heel_enthesitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right heel shows swelling at the insertion of the Achilles tendon to the calcaneus (arrow). This type of swelling is best examined from the back.</div><div class=\"graphic_reference\">Courtesy of James Wei, MD.</div><div id=\"graphicVersion\">Graphic 96430 Version 1.0</div></div></div>"},"96431":{"type":"graphic_picture","displayName":"Dermoscopy melanoma lip","title":"Melanoma of the lip","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">Melanoma of the lip</div><div class=\"cntnt\"><img style=\"width:731px; height:276px;\" src=\"images/DERM/96431_Dermoscopy_melanoma_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Invasive melanoma of the upper lip in a 37-year-old woman with Laugier-Hunziker syndrome.<br />(B) Dermoscopic examination shows lines, dots, clods, and structureless areas with brown, blue, and gray colors.</div><div class=\"graphic_reference\">Reproduced from: Simionescu O, Dumitrescu D, Costache M, Blum A. Dermatoscopy of an invasive melanoma on the upper lip shows possible association with Laugier-Hunziker syndrome. J Am Acad Dermatol 2008; 59:S105. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96431 Version 1.0</div></div></div>"},"96432":{"type":"graphic_waveform","displayName":"Late decelerations 2","title":"Late decelerations 2","html":"<div class=\"graphic\"><div style=\"width: 1020px\" class=\"figure\"><div class=\"ttl\">Late decelerations 2</div><div class=\"cntnt\"><img style=\"width:1000px; height:558px;\" src=\"images/OBGYN/96432_Late_decelerations_2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Late decelerations are characterized by gradual decrease and return to baseline of the fetal heart rate associated with a uterine contraction. The deceleration is delayed in timing, with the nadir of the deceleration occurring after the peak of the contraction. The onset, nadir, and recovery usually occur after the onset, peak, and termination of a contraction. In this tracing, late decelerations have occurred after the first two contractions.</div><div id=\"graphicVersion\">Graphic 96432 Version 1.0</div></div></div>"},"96436":{"type":"graphic_table","displayName":"Common wrist injuries and associated sports","title":"Common wrist injuries and associated sports","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common wrist injuries and associated sports</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Wrist injury</td> <td class=\"subtitle1\">Sport</td> </tr> <tr> <td>Distal radius fracture</td> <td>Skating, American football, basketball, snowboarding</td> </tr> <tr> <td>Hook of the hamate fracture</td> <td>Baseball, golf, tennis</td> </tr> <tr> <td>Intersection syndrome</td> <td>Rowing and racket sports</td> </tr> <tr> <td>Ulnar neuropathy</td> <td>Cycling</td> </tr> <tr> <td>TFCC tear</td> <td>Tennis</td> </tr> <tr> <td>Scaphoid stress fracture</td> <td>Golf and gymnastics</td> </tr> <tr> <td>Ulnar styloid impaction</td> <td>Gymnastics</td> </tr> <tr> <td>ECU subluxation</td> <td>Tennis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECU: extensor carpi ulnaris; TFCC: triangular fibrocartilage complex.</div><div id=\"graphicVersion\">Graphic 96436 Version 2.0</div></div></div>"},"96438":{"type":"graphic_waveform","displayName":"ECG APBs normally conducted and aberrantly conducted","title":"Electrocardiogram (ECG) showing atrial premature beats (APBs) which are normally conducted and aberrantly conducted","html":"<div class=\"graphic\"><div style=\"width: 824px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing atrial premature beats (APBs) which are normally conducted and aberrantly conducted</div><div class=\"cntnt\"><img style=\"width:804px; height:539px;\" src=\"images/CARD/96438_ECG_APBs_norm_cond_aberrant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">APBs may be normally (asterisk) or aberrantly conducted (double asterisk; usually RBBB aberrancy), and may have different P wave morphology and axis and variable PR intervals.</div><div class=\"graphic_footnotes\">APBs: atrial premature beats; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 96438 Version 1.0</div></div></div>"},"96448":{"type":"graphic_table","displayName":"Comparison of VFSS and FEES","title":"Comparison of videofluoroscopic swallow study (VFSS) and fiberoptic endoscopic evaluation of swallowing (FEES)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of videofluoroscopic swallow study (VFSS) and fiberoptic endoscopic evaluation of swallowing (FEES)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Videofluoroscopic swallow study (VFSS)*</td> <td class=\"subtitle1\">Fiberoptic endoscopic evaluation of swallowing (FEES)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Location</strong></td> <td> <ul> <li>Radiology department with fluoroscopy equipment </li> </ul> </td> <td> <ul> <li>Exam room or bedside </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Personnel</strong></td> <td> <ul> <li>Radiologist&nbsp;and speech therapist </li> <li>With or without occupational therapist </li> </ul> </td> <td> <ul> <li>Endoscopist&nbsp;and speech therapist </li> <li>With or without occupational therapist </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration</strong></td> <td> <ul> <li>Few minutes, to limit radiation </li> </ul> </td> <td> <ul> <li>As long as needed to gather information </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Media</strong></td> <td> <ul> <li>Contrast material is mixed with liquids and solids, as&nbsp;appropriate for the patient's age </li> </ul> </td> <td> <ul> <li>Colored foods, different consistencies </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Advantages</strong></td> <td> <ul> <li>Permits real-time assessment of all four swallow phases </li> <li>Immediate recommendation for safe swallowing practice </li> </ul> </td> <td> <ul> <li>Excellent evaluation of anatomy and swallowing function </li> <li>Immediate recommendation for safe swallowing practice </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Disadvantages</strong></td> <td> <ul> <li>Requires fluoroscopy suite </li> <li>Radiation exposure </li> <li>Limited study time </li> <li>Limited anatomic assessment </li> <li>Limited evaluation of esophageal phase </li> <li>Variable inter-observer reliability </li> </ul> </td> <td> <ul> <li>Requires patient cooperation (FEES usually is not possible in infants or toddlers).&nbsp; </li> <li>Availability of experienced providers </li> <li>Actual swallow is obscured briefly </li> <li>Misses oral preparatory and esophageal phases </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sensitivity and specificity (mostly adult data)</strong></td> <td> <ul> <li>Very good sensitivity with barium in airway </li> <li>Moderate&nbsp;specificity </li> </ul> </td> <td> <ul> <li>Good sensitivity </li> <li>Very good specificity if colored food is seen in airway </li> </ul> </td> </tr> <tr> <td><strong>Comment</strong></td> <td> <ul> <li>Most common initial evaluations </li> </ul> </td> <td> <ul> <li>Greatest experience with adults and older children </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The videofluoroscopic swallow study (VFSS) is also known as a modified barium swallow (MBS).</div><div class=\"graphic_reference\">Modified from the following sources:<br /><ol>&#xD;&#xA;    <li>Tutor JD and Gosa MM. Dysphagia and aspiration in children. Pediatr Pulmonol 2012; 47:321.</li>&#xD;&#xA;    <li>Boesch RP, Daines C, Willging JP, et al. Advances in the diagnosis and management of chronic pulmonary aspiration in children. Eur Resp J 2006; 28:847.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96448 Version 2.0</div></div></div>"},"96451":{"type":"graphic_table","displayName":"Formulas to estimate body surface area","title":"Formulas to estimate body surface area (BSA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formulas to estimate body surface area (BSA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td>Boyd*<sup>[1]</sup></td> <td>BSA (m<sup>2</sup>) = 0.0003207 x Ht (cm)<sup>0.3</sup> x Wt (g)<sup>(0.7285 &ndash; ( 0.0188 x LOG(Wt (g))))</sup></td> </tr> <tr> <td>DuBois and DuBois*<sup>[2]</sup></td> <td>BSA (m<sup>2</sup>) = Wt (kg)<sup>0.425</sup> x Ht (cm)<sup>0.725</sup> x 0.007184</td> </tr> <tr> <td>Gehan and George*<sup>[3]</sup></td> <td>BSA (m<sup>2</sup>) = Wt (kg)<sup>0.51456</sup> x Ht (cm)<sup>0.42246</sup> x 0.0235</td> </tr> <tr> <td>Haycock*<sup>[4]</sup></td> <td>BSA (m<sup>2</sup>) = Wt (kg)<sup>0.5378</sup> x Ht (cm)<sup>0.3964</sup> x 0.024265</td> </tr> <tr> <td>Mosteller*<sup>[5]</sup></td> <td>BSA (m<sup>2</sup>) = Square root&nbsp;((Ht (cm) x Wt (kg))/3600)</td> </tr> <tr> <td>Yu<sup>[6]</sup></td> <td>BSA (cm<sup>2</sup>)<sup>&#182;</sup> = 71.3989 x Ht (cm)<sup>0.7437</sup> x Wt (kg)<sup>0.4040</sup></td> </tr> <tr> <td>Livingston<sup>&#916;[7]</sup></td> <td>BSA (m<sup>2</sup>) = 0.1173 x Wt (kg)<sup>0.6466</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ht: height; SQRT: square root; Wt: weight.<br />* Recommended by American Society of Clinical Oncology guidelines.<br />Â¶ Original formula estimated BSA in cm<SUP>2</SUP>; to convert to m<SUP>2</SUP>, divide result by 10,000.<br />Î Only formula derived from a cohort containing significant numbers of obese persons.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Boyd E. The growth of the surface area of the human body, University of Minnesota Press, Minneapolis 1935.</li>&#xD;&#xA;    <li>DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17:863.</li>&#xD;&#xA;    <li>Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970; 54:225.</li>&#xD;&#xA;    <li>Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: A height weight formula validated in infants, children and adults. J Pediatr 1978; 93:62.</li>&#xD;&#xA;    <li>Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317:1098.</li>&#xD;&#xA;    <li>Yu CY, Lin CH, Yang YH. Human body surface area database and estimation formula. Burns 2010; 36:616.</li>&#xD;&#xA;    <li>Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 2001; 28:E586.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96451 Version 5.0</div></div></div>"},"96452":{"type":"graphic_figure","displayName":"Comparison of BSA estimates according to various formulas","title":"Comparison of body surface area estimates according to various formulas","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Comparison of body surface area estimates according to various formulas</div><div class=\"cntnt\"><img style=\"width:638px; height:436px;\" src=\"images/ONC/96452_Compar_BSA_various_formulas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calculated body surface areas (BSAs) using different formulae as a function of weight for a 175 cm tall subject. For normal and overweight weight individuals, these formulae do not differ significantly. For obese patients, several of the predicted BSAs diverge from each other.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 2001; 28:E586.</li>&#xD;&#xA;    <li>Boyd E. The growth of the surface area of the human body, University of Minnesota Press, Minneapolis 1935.</li>&#xD;&#xA;    <li>Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: A height weight formula validated in infants, children and adults. J Pediatr 1978; 93:62.</li>&#xD;&#xA;    <li>Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970; 54:225.</li>&#xD;&#xA;    <li>Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317:1098.</li>&#xD;&#xA;    <li>DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17:863.</li>&#xD;&#xA;    <li>Yu CY, Lin CH, Yang YH. Human body surface area database and estimation formula. Burns 2010; 36:616.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96452 Version 1.0</div></div></div>"},"96453":{"type":"graphic_table","displayName":"Intestinal parasite presumptive rx","title":"Medication regimen and dosing for presumptive treatment of parasitic infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medication regimen and dosing for presumptive treatment of parasitic infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Refugee population</td> <td class=\"subtitle1\" colspan=\"3\">Regimens by pathogen</td> </tr> <tr> <td class=\"subtitle2\">Soil-transmitted helminths: Albendazole*</td> <td class=\"subtitle2\">Strongyloidiasis: Ivermectin*</td> <td class=\"subtitle2\">Schistosomiasis<sup>&#182;</sup>: Praziquantel<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Adults</td> </tr> <tr> <td class=\"indent1\">Asia, Middle East, North Africa, Latin American, and Caribbean</td> <td>Albendazole 400 mg orally (single dose)</td> <td>Ivermectin 200 mcg/kg/day orally once a day for two days</td> <td>Not recommended</td> </tr> <tr> <td class=\"indent1\">Sub-Saharan Africa, non-<em>Loa loa</em>-endemic area</td> <td>Albendazole 400 mg orally (single dose)</td> <td>Ivermectin 200 mcg/kg/day orally once a day for two days</td> <td>Praziquantel 40 mg/kg orally (single dose; may be divided and given in two doses for better tolerance)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sub-Saharan Africa, <em>Loa loa</em>-endemic area</td> <td>Albendazole 400 mg orally (single dose)</td> <td> <p>If <em>Loa loa</em> cannot be excluded, treatment may be deferred until after arrival in the United States</p> <p>OR</p> Albendazole 400 mg orally twice a day for seven days</td> <td>Praziquantel 40 mg/kg orally (single dose; may be divided and given in two doses for better tolerance)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Pregnant women</td> </tr> <tr> <td class=\"indent1\">Asia, Middle East, North Africa, Latin America, and Caribbean</td> <td>Not recommended</td> <td>Not recommended</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sub-Saharan Africa</td> <td>Not recommended</td> <td>Not recommended</td> <td>Praziquantel 40 mg/kg orally (single dose; may be divided and given in two doses for better tolerance)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Children</td> </tr> <tr> <td class=\"indent1\">Asia, Middle East, North Africa, Latin America, and Carribean</td> <td> <p>12 to 23 months of age: Albendazole 200 mg orally (single dose)</p> Presumptive therapy is not recommended for any infant less than 12 months of age</td> <td> <p>Ivermectin 200 mcg/kg/day orally once a day for two days</p> Should not be used presumptively if less than or equal to 15 kg</td> <td>Not applicable</td> </tr> <tr> <td class=\"indent1\">Sub-Saharan Africa</td> <td> <p>12 to 23 months of age: Albendazole 200 mg orally for one day</p> Presumptive therapy is not recommended for any infant less than 12 months of age</td> <td> <p>Ivermectin 200 mcg/kg/day orally once a day for two days</p> Should not be used presumptively if less than or equal to 15 kg or from <em>Loa loa</em>-endemic country</td> <td>Children &#8804;4 years of age should not receive presumptive treatment with praziquantel. Only for children from sub-Saharan Africa.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Although the World Health Organization (WHO) states ivermectin and albendazole may be given concurrently, it is recommended that ivermectin be taken on an empty stomach and albendazole with fatty foods.<br />Â¶ All sub-Saharan African countries except Lesotho are considered endemic for schistosomiasis.<br />Î Praziquantel, if not coadministered, should be administered at least one day prior to either ivermectin or albendazole. Praziquantel should be taken with liquids during a meal.</div><div class=\"graphic_reference\">Reproduced from: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases. Guidelines for Overseas Presumptive Treatment of Strongyloidiasis, Schistosomiasis, and Soil-Transmitted Helminth Infections For Refugees Resettling to the United States. Centers for Disease Control and Prevention, Division of Global Migration and Quarantine 2013. Available at: <a href=\"http://www.cdc.gov/immigrantrefugeehealth/pdf/intestinal-parasites-overseas.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/immigrantrefugeehealth/pdf/intestinal-parasites-overseas.pdf</a>.</div><div id=\"graphicVersion\">Graphic 96453 Version 3.0</div></div></div>"},"96454":{"type":"graphic_table","displayName":"Loa loa endemic areas","title":"Endemicity of <em>Loa loa</em> in African countries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endemicity of <em>Loa loa</em> in African countries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">African countries NOT considered endemic for <em>Loa loa</em><br /> (may use presumptive ivermectin for <em>Strongyloides</em>)</td> <td class=\"subtitle1\">African countries considered endemic for <em>Loa loa</em><br /> (presumptive ivermectin should <em>not</em> be used for <em>Strongyloides</em>)</td> </tr> <tr> <td> <p>Algeria</p> <p>Botswana</p> <p>Burkina Faso</p> <p>Burundi</p> <p>C&#244;te d'Ivoire</p> <p>Egypt</p> <p>Ethiopia</p> <p>Eritrea</p> <p>Gambia</p> <p>Ghana</p> <p>Guinea</p> <p>Guinea-Bissau</p> <p>Kenya</p> <p>Liberia</p> <p>Libya</p> <p>Madagascar</p> <p>Malawi</p> <p>Mali</p> <p>Mauritania</p> <p>Mauritius</p> <p>Morocco</p> <p>Mozambique</p> <p>Namibia</p> <p>Niger</p> <p>Rwanda</p> <p>Senegal</p> <p>Sierra Leone</p> <p>Somalia</p> <p>South Africa</p> <p>Sudan</p> <p>Swaziland</p> <p>Tanzania</p> <p>Togo</p> <p>Uganda</p> <p>Zambia</p> Zimbabwe</td> <td> <p>Angola</p> <p>Cameroon</p> <p>Central Africa Republic</p> <p>Chad</p> <p>Republic of Congo</p> <p>Democratic Republic of the Congo</p> <p>Equatorial Guinea</p> <p>Gabon</p> <p>Nigeria</p> South Sudan</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases. Guidelines for Overseas Presumptive Treatment of Strongyloidiasis, Schistosomiasis, and Soil-Transmitted Helminth Infections For Refugees Resettling to the United States. Centers for Disease Control and Prevention, Division of Global Migration and Quarantine 2013. Available at: <a href=\"http://www.cdc.gov/immigrantrefugeehealth/pdf/intestinal-parasites-overseas.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/immigrantrefugeehealth/pdf/intestinal-parasites-overseas.pdf</a>.</div><div id=\"graphicVersion\">Graphic 96454 Version 1.0</div></div></div>"},"96455":{"type":"graphic_table","displayName":"Malaria immigrant presumptive rx","title":"Dosing of anti-malarials that may be considered for presumptive or directed* treatment of <em>Plasmodium falciparum</em> malaria in sub-Saharan refugees after arrival in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of anti-malarials that may be considered for presumptive or directed* treatment of <em>Plasmodium falciparum</em> malaria in sub-Saharan refugees after arrival in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Child dosing<br /> <em>children weighing 5 kg to &#60;35 kg</em></td> <td class=\"subtitle1\">Adult dosing<br /> <em>adults and children weighing &#62;35 kg</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Presumptive therapy</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Atovaquine-proguanil</strong></p> (adult tab = 250 mg atovaquone/100 mg proguanil; pediatric tab = 62.5 mg atovaquone/25 mg proquanil)</td> <td> <p><strong>5 to 8 kg:</strong> 2 pediatric tablets once a day for three days</p> <p><strong>9 to 10 kg:</strong> 3 pediatric tablets once a day for three days</p> <p><strong>11 to 20 kg:</strong> 1 adult tablets once a day<sup>&#182;</sup> for three days</p> <p><strong>21 to 30 kg:</strong> 2 adult tablets once a day<sup>&#182;</sup> for three days</p> <p><strong>31 to 40 kg:</strong> 3 adult tablets once a day<sup>&#182;</sup> for three days</p> <strong>&#62;40 kg:</strong> 4 adult tablets once a day<sup>&#182;</sup> three days</td> <td>4 adult tablets once a day<sup>&#182;</sup> for three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine)</strong></td> <td> <p>A six-dose regimen is recommended with 1 to 3 tablets per dose, depending on body weight:</p> <p><strong>5 to &#60;15 kg:</strong> 1 tablet, then 1 tablet after eight hours, then 1 tablet twice daily (morning and evening) on each of the following two days (total course: 12 tablets)</p> <p><strong>15 to &#60;25 kg:</strong> 2 tablets as a single dose, then 2 tablets after eight hours, then 2 tablets twice daily (morning and evening) on each of the following two days (total course: 18 tablets)</p> <strong>25 to &#60;35 kg:</strong> 3 tablets as a single dose, then 3 tablets after eight hours, then 3 tablets twice daily (morning and evening) on each of the following two days (total course: 18 tablets)<sup>&#916;</sup></td> <td> <p>A standard three-day treatment schedule with a total of six doses</p> 4 tablets as a single dose, then 4 tablets after eight hours, then 4 tablets twice daily (morning and evening) on each of the following two days (total course: 24 tablets)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternatives that may be used as directed therapy*</td> </tr> <tr> <td class=\"indent1\">Quinine sulfate</td> <td>30 mg/kg/day divided in three doses for 3 days</td> <td>650 mg every eight hours for 3 days<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>plus</strong> clindamycin</td> <td>20 to 40 mg/kg/day in three doses for 7 days</td> <td>900 mg three times a day for 7 days<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>or</strong> doxycycline<sup>&#167;</sup></td> <td>2 mg/kg/day for 7 days</td> <td>100 mg twice a day for 7 days<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other alternatives</td> </tr> <tr> <td class=\"indent1\">Mefloquine<sup>&#165;</sup></td> <td><strong>&#60;45 kg:</strong> 15 mg/kg then 10 mg/kg 12 hours later</td> <td>750 mg then 500 mg 12 hours later<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Directed therapy refers to treating after <em>P. falciparum</em> malaria has been detected by diagnostic examination in an asymptomatic individual. NOTE: more specific guidance can be found at: http://www.cdc.gov/malaria/diagnosis_treatment/index.html.<br />&para; May divide the dose and give one-half the dose in the morning and one-half in the evening for better gastrointestinal tolerance.<br />&Delta; Should be taken with foods rich in fat such as milk. If vomiting occurs within one hour after taking the medicine, another dose should be taken.<br /><span class=\"lozenge\">&loz;</span> Do not exceed adult dosing.<br />&sect; Not approved for use in children less than eight years.<br />&yen; Should not be given together with quinine or quinidine. Common adverse effects include nausea, vomiting, diarrhea, dizziness, toxic psychosis, and seizures.</div><div class=\"graphic_reference\">Reproduced from: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases. Domestic refugee health guidelines: Malaria. Centers for Disease Control and Prevention, Division of Global Migration and Quarantine 2012. Available at: <a href=\"http://www.cdc.gov/immigrantrefugeehealth/pdf/malaria-domestic.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/immigrantrefugeehealth/pdf/malaria-domestic.pdf</a>.</div><div id=\"graphicVersion\">Graphic 96455 Version 2.0</div></div></div>"},"96458":{"type":"graphic_picture","displayName":"Dactylitis (sausage toe)","title":"Dactylitis (sausage toe)","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Dactylitis (sausage toe)</div><div class=\"cntnt\"><img style=\"width:502px; height:342px;\" src=\"images/RHEUM/96458_Dactylitis_sausage_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dactylitis of the fourth toe of the left foot. The fourth toe is diffusely swollen and is described as a \"sausage toe.\"</div><div class=\"graphic_reference\">Courtesy of James Wei, MD.</div><div id=\"graphicVersion\">Graphic 96458 Version 1.0</div></div></div>"},"96459":{"type":"graphic_diagnosticimage","displayName":"Ganglion cyst ultrasound","title":"Ultrasound image of ganglion cyst","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of ganglion cyst</div><div class=\"cntnt\"><img style=\"width:725px; height:312px;\" src=\"images/EM/96459_Ganglion_cyst_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rectangle on the superimposed photograph indicates where the ultrasound probe was placed to obtain this image. Note the dark (anechoic) pocket created by the cyst.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, MD.</div><div id=\"graphicVersion\">Graphic 96459 Version 1.0</div></div></div>"},"96460":{"type":"graphic_diagnosticimage","displayName":"Scapholunate ligament ultrasound","title":"Scapholunate ligament ultrasound","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Scapholunate ligament ultrasound</div><div class=\"cntnt\"><img style=\"width:595px; height:312px;\" src=\"images/EM/96460_Scapholunate_ligame_ultraso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the images above, the asterisk (*) indicates the scapholunate ligament and the rectangle indicates the position of the probe when the ultrasound image was obtained.</div><div class=\"graphic_footnotes\">ECRB: extensor carpi radialis brevis.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, MD.</div><div id=\"graphicVersion\">Graphic 96460 Version 1.0</div></div></div>"},"96464":{"type":"graphic_table","displayName":"TRYPHAENA - FEC then DHP","title":"Neoadjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, trastuzumab, and pertuzumab (DHP) for HER2-positive* breast cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neoadjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, trastuzumab, and pertuzumab (DHP) for HER2-positive* breast cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: Every 21 days (for both neoadjuvant and adjuvant components).<br /> Duration of therapy: Prior to surgery, administer three cycles of FEC followed by three cycles of docetaxel, trastuzumab, and pertuzumab<sup>&#916;</sup>. Following surgery, adjuvant treatment consists of trastuzumab alone to complete one year of therapy.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">BEFORE SURGERY (neoadjuvant treatment)</td> </tr> <tr> <td class=\"indent1\"><strong>Fluorouracil (FU)</strong></td> <td>500 mg/m<sup>2</sup> IV</td> <td>Administer undiluted (50 mg/mL) as an intravenous push (IVP) bolus over five minutes.</td> <td>Day 1<br /> (Cycles 1 to 3)</td> </tr> <tr> <td class=\"indent1\"><strong>Epirubicin</strong></td> <td>100 mg/m<sup>2</sup> IV</td> <td>Administer into a free flowing IV infusion of normal saline (NS) over 3 to 20 minutes.</td> <td>Day 1<br /> (Cycles 1 to 3)</td> </tr> <tr> <td class=\"indent1\"><strong>Cyclophosphamide</strong></td> <td>600 mg/m<sup>2</sup></td> <td>Dilute with 250 to 500 mL NS or 5 percent dextrose in water (D5W) and administer over 30 to 60 minutes.</td> <td>Day 1<br /> (Cycles 1 to 3)</td> </tr> <tr> <td class=\"indent1\"><strong>Pertuzumab</strong><sup>&#9674;</sup></td> <td>840 mg IV (loading dose)</td> <td>Dilute in 250 mL NS<sup>&#167;</sup> and administer over 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IVP or bolus.</td> <td>Day 1<br /> (Cycle 4 only)</td> </tr> <tr> <td class=\"indent1\"><strong>Pertuzumab</strong><sup>&#9674;</sup></td> <td>420 mg IV</td> <td>Dilute in 250 mL NS<sup>&#167;</sup> and administer over 30 to 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IVP or bolus.</td> <td>Day 1<br /> (Cycles 5 to 6)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IVP or bolus.</td> <td>Day 1<br /> (Cycle 4)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IVP or bolus.</td> <td>Day 1<br /> (Cycles 5 to 6)</td> </tr> <tr> <td class=\"indent1\"><strong>Docetaxel</strong><sup>&#165;</sup></td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1<br /> (Cycles 4 to 6)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AFTER SURGERY (adjuvant treatment)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>8 mg/kg IV (loading dose)</td> <td>Dilute in 250 mL NS and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IVP or bolus.</td> <td>Day 1<br /> (Cycle 7)</td> </tr> <tr> <td class=\"indent1\"><strong>Trastuzumab</strong><sup>&#9674;</sup></td> <td>6 mg/kg</td> <td>Dilute in 250 mL NS and administer over 30 minutes for subsequent doses. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IVP or bolus.</td> <td>Day 1<br /> (Cycle 8 and then to complete one year of therapy or a maximum of 15 total cycles)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis<sup>[2]</sup>. Refer to UpToDate topic on \"Cystitis in patients with cancer\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> Emesis risk is HIGH (&#62;90 percent) during treatment with FEC (Cycles 1 to 3), LOW (10 to 30 percent) during the treatment with docetaxel, trastuzumab, and pertuzumab (Cycles 4 to 6), and MINIMAL (&#60;10 percent) during monotherapy with trastuzumab (Cycle 7 until completion of treatment). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with dexamethasone prior to docetaxel administration<sup>[3]</sup>. Premedication is not routinely indicated for pertuzumab or during FEC. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Epirubicin is a vesicant; avoid extravasation. Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated. The rate of febrile neutropenia associated with FEC is approximately 10 percent<sup>[4,5]</sup>. In the NEOSPHERE trial, the incidence of neutropenic fever during treatment with docetaxel with trastuzumab and pertuzumab was 9 percent<sup>[6]</sup>. Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Dose modification of FU may be needed for patients with hepatic impairment<sup>[7]</sup>. A lower starting dose of cyclophosphamide and epirubicin may be needed for patients with renal or hepatic impairment<sup>[2,8]</sup>. Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations &#62;1.5 times ULN<sup>[3]</sup>. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac issues:</strong> Epirubicin, trastuzumab, and pertuzumab are associated with cardiotoxicity; assess baseline left ventricular ejection fraction (LVEF) prior to therapy. Patients with a baseline LVEF &#60;55 percent were excluded from the study<sup>[1]</sup>. Refer to UpToDate topics on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\" and \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary issues:</strong> Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for known drug interactions:</strong> Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided<sup>[3]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count every three weeks prior to each cycle during neoadjuvant and adjuvant chemotherapy (Cycles 1 to 6). They need not be checked during adjuvant trastuzumab.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Serum electrolytes and liver and renal function tests every three weeks prior to each cycle of neoadjuvant and adjuvant chemotherapy (Cycles 1 to 6). These labs need not be checked during adjuvant trastuzumab.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias) during FEC.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess changes in neurologic function prior to each cycle of docetaxel.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; It is recommended to observe the patient for one hour after the initial dose of pertuzumab and for 30 minutes after all subsequent doses for signs of infusion reactions<sup>[9]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; In the clinical trial, LVEF was assessed every second cycle<sup>[1]</sup>, but there is no standard guidelines for cardiac monitoring in routine clinical practice. A reasonable strategy is to assess cardiac function prior to initiation of both neoadjuvant FEC (pre-Cycle 1), neoadjuvant DHP (pre-Cycle 4), and adjuvant trastuzumab monotherapy (pre-Cycle 7). During adjuvant trastuzumab, consider repeating evaluation every 12 weeks (prior to Cycles 12 and 16) and if clinically indicated. Refer to UpToDate topics on \"Cardiotoxicity of anthracycline-like chemotherapy agents\" and \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Myelotoxicity:</strong></p> <p class=\"indent2\"><strong>During the neoadjuvant portion of therapy with FEC:</strong> The published report did not include specific recommendations for dose modification during FEC or DHP<sup>[1]</sup>. Based on the original FEC trial in metastatic breast cancer, if the absolute neutrophil count (ANC) is less than 1500 cells/microL or platelets are less than 100,000/microL on day 1 of each cycle, therapy should be delayed until counts recover<sup>[4]</sup>. Reduce epirubicin by 10 mg/m<sup>2</sup> for subsequent cycles in patients who develop severe prolonged neutropenia (less than 500 cells/microL lasting seven days or more), severe thrombocytopenia (platelet count less than 50,000/microL), or febrile neutropenia<sup>[1,4]</sup>.</p> <p class=\"indent2\"><strong>During the neoadjuvant portion of therapy with docetaxel:</strong> Docetaxel should only be administered if the ANC is greater than 1500 cells/microL. For patients who develop severe prolonged neutropenia (less than 500 cells/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences) at the docetaxel dose of 75 mg/m<sup>2</sup>, reduce subsequent doses to 60 mg/m<sup>2</sup><sup>[3]</sup>. For patients who developed severe symptoms at a docetaxel dose of 100 mg/m<sup>2</sup>, reduce dose to 75 mg/m<sup>2</sup>. If symptoms recur, a second dose reduction to 60 mg/m<sup>2</sup> was performed in the protocol<sup>[1]</sup>.</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatotoxicity:</strong> Docetaxel dose reduction (as outlined above) may also be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy<sup>[3]</sup>. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> During neoadjuvant FEC treatment, if cardiac symptoms develop or the LVEF falls to &#8805;10 percent below the lower limit of normal or there is a &#8805;15 percent drop below the patient's baseline, discontinue epirubicin<sup>[4]</sup>. Hold both trastuzumab and pertuzumab during the neoadjuvant portion of this protocol if the LVEF drops to less than 45 percent, or if the LVEF was 45 to 49 percent with a 10 percent or greater absolute decrease below baseline. Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available<sup>[1]</sup>. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Discontinue trastuzumab for serious pulmonary toxicity. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous, mucosal, and neurologic toxicity:</strong> During FEC, hold FU for &#8805;grade 2 palmar plantar erythrodysesthesia and reduce subsequent dose by 20 percent<sup>[7]</sup>. During docetaxel, for severe or cumulative cutaneous reactions (erythema and desquamation), grade 2 or worse mucositis, grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup><sup>[3]</sup>. Discontinue if toxicity persists. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Gastrointestinal toxicity:</strong> During FEC (cycles 1 to 3), hold FU for grade 2 or worse diarrhea or mucositis and restart at a 20 percent lower dose after complete resolution. For the first episode of grade 3 to 4 diarrhea or grade 3 to 4 mucositis, reduce FU by 20 percent; subsequent episodes, reduce both FU and epirubicin by 20 percent<sup>[4-6]</sup> or discontinue treatment. During docetaxel (Cycles 3 to 6), delay docetaxel for grade 2 or worse diarrhea and restart at a 20 percent lower dose after complete resolution; reduce docetaxel by 20 percent for the first episode of grade 3 diarrhea. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infusion reactions:</strong> Respond as clinically indicated with supportive care and possible discontinuation of therapy for severe reactions. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">CBC: complete blood count; IV: intravenous; G-CSF: granulocyte colony-stimulating factor.<br />* High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab and pertuzumab. Refer to UpToDate topic on \"HER2 and predicting response to therapy in breast cancer\".<br />&Delta; During Cycles 3 to 6, administer pertuzumab, trastuzumab, and docetaxel sequentially, with either pertuzumab (followed by a 30- to 60-minute observation period) or trastuzumab administered first; administer docetaxel after both pertuzumab and trastuzumab<sup>[9]</sup>.<br /><span class=\"lozenge\">&loz;</span> A repeat loading dose of trastuzumab is required if scheduled treatment has been delayed for over one week, which is the case for patients resuming trastuzumab after definitive surgery. If adverse reactions occur for which discontinuation of trastuzumab or pertuzumab is indicated, both drugs should be discontinued. Dose modifications of trastuzumab and pertuzumab were not allowed in the original protocol<sup>[1]</sup>.<br />&sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />&yen; If tolerated during Cycle 4, the dose of docetaxel was increased to 100 mg/m<sup>2</sup> for Cycles 5 and 6 in the protocol<sup>[1]</sup>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schneeweiss A, et al. Ann Oncol 2013; 24:2278.</li>&#xD;&#xA;    <li>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</li>&#xD;&#xA;    <li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</li>&#xD;&#xA;    <li>Brufman G, et al. Ann Oncol 1997; 8:155.</li>&#xD;&#xA;    <li>Wildiers H, et al. Breast Cancer Res Treat 2009; 114:103.</li>&#xD;&#xA;    <li>Gianni L, et al. Lancet Oncol 2012; 13:25.</li>&#xD;&#xA;    <li>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 16, 2013).</li>&#xD;&#xA;    <li>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</li>&#xD;&#xA;    <li>Pertuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 16, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96464 Version 5.0</div></div></div>"},"96467":{"type":"graphic_table","displayName":"Differential diagnosis of osteolytic bone metastases","title":"Differential diagnosis of osteolytic bone metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of osteolytic bone metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Radiographic features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Primary malignant tumors</td> </tr> <tr> <td class=\"indent1\">Conventional osteosarcomas</td> <td>Destruction of the normal trabecular bone pattern, indistinct margins, and lack of endosteal bone response. There is usually a mixture of both radiodense and radiolucent areas, with periosteal new bone formation, and sometimes formation of a Codman's triangle.</td> </tr> <tr> <td class=\"indent1\">Chondrosarcoma</td> <td>Cartilage can be recognized on imaging because it tends to grow in nodules, has a very high water content (making it bright on T2-weighted MRI and dark on CT scan), and deposits mineral in dense \"rings and arcs\" whose density can focally exceed cortical bone.</td> </tr> <tr> <td class=\"indent1\">Fibrosarcoma</td> <td>Can present as a solitary lytic lesion and tends to resemble osteosarcoma, but without ossification.</td> </tr> <tr> <td class=\"indent1\">Ewing sarcoma of bone</td> <td>Has a characteristic \"permeative\" or \"moth-eaten\" pattern on imaging, with very poorly defined margins. The tumors can be large and frequently involve the diaphysis. The characteristic periosteal reaction produces layers of reactive bone, deposited in an \"onion peel\" appearance. The cortex is often permeated by tumor, which extends into the soft tissues.</td> </tr> <tr> <td class=\"indent1\">Solitary plasmacytoma of bone/POEMS syndrome</td> <td>The presence of a lytic bone lesion with or without a sclerotic rim or a single osteosclerotic bone lesion in a patient with a monoclonal gammopathy suggests the possibility of solitary plasmacytoma of bone; a small subset for these patients have POEMS syndrome (osteosclerotic myeloma: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes). However, a subset of patients may have bone&nbsp;metastases from&nbsp;kidney, breast, non-small cell lung cancer, and other primary lesions with an associated, unrelated monoclonal gammopathy (eg, MGUS). Typically, patients with metastatic carcinoma have multiple lytic bone lesions rather than a single lesion such as that seen with solitary plasmacytoma of bone.</td> </tr> <tr> <td class=\"indent1\">Primary lymphoma of bone</td> <td>Generally associated with less bone destruction than Ewing sarcoma. The earliest radiographic sign is diffuse medullary mottling. Plain films may demonstrate lytic or radiolucent lesions associated with a noncalcified soft tissue mass.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Benign bone tumors</td> </tr> <tr> <td class=\"indent1\">Hemangioma of bone (unicameral)</td> <td>Coarse vertical striations within bone give a typical&nbsp;\"polka dot\" or honeycomb appearance on CT.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Bone cysts</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Unicameral </li> </ul> </td> <td>Typically appear as well-marginated cystic lesions of the metaphysis or metadiaphysis without reactive sclerosis. Usually involves the full diameter of bone with expansion of the cortex.</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Aneurysmal </li> </ul> </td> <td>Sharply circumscribed, aggressive, expansile, lytic metaphysical lesions with an \"eggshell\" sclerotic rim. Maybe have a \"soap bubble\" appearance secondary to trabecular reinforcement. Cortex usually intact.</td> </tr> <tr> <td class=\"indent1\">Osseous lipoma</td> <td>Well-circumscribed radiolucency with a central calcification and sclerotic rim; occasional cortical expansion.</td> </tr> <tr> <td class=\"indent1\">Eosinophilic granuloma</td> <td>Typically a medullary-based lytic lesion with geographic destruction, lobular contour, and well-defined edges. Destructive eosinophilic granulomas are usually not associated with a sizable soft tissue mass.</td> </tr> <tr> <td class=\"indent1\">Enchondroma</td> <td>Usually a central metaphyseal oval well-circumscribed central lucent lesion with or without matrix calcification.</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> <td>Small, round lucency with a sclerotic margin with or without central ossification.</td> </tr> <tr> <td class=\"indent1\">Non-ossifying fibroma</td> <td>Small, well-defined eccentric expansile lytic lesion located in the metaphysis with scalloped sclerotic borders (may be multiple).</td> </tr> <tr> <td class=\"indent1\">Giant cell tumor of bone</td> <td>Expansile, eccentrically placed lytic area on plain radiographs (the result of intratumoral hemorrhage), typically involving the epiphysis and adjacent diaphysis. Absent matrix calcification and reactive periosteal new bone formation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MGUS: monoclonal gammopathy of unknown significance; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 96467 Version 1.0</div></div></div>"},"96468":{"type":"graphic_table","displayName":"Grading of postoperative pancreatic fistula","title":"Grading of postoperative pancreatic fistula (POPF) ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of postoperative pancreatic fistula (POPF) </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">A</td> <td class=\"subtitle1\">B</td> <td class=\"subtitle1\">C</td> </tr> <tr> <td>Clinical conditions</td> <td>Well</td> <td>Often well</td> <td>Ill appearing/bad</td> </tr> <tr> <td>Specific treatment*</td> <td>No</td> <td>Yes/no</td> <td>Yes</td> </tr> <tr> <td>US/CT (if obtained)</td> <td>Negative</td> <td>Negative/positive</td> <td>Positive</td> </tr> <tr> <td>Persistent drainage (after three weeks)<sup>&#182;</sup></td> <td>No</td> <td>Usually yes</td> <td>Yes</td> </tr> <tr> <td>Reoperation</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Death related to POPF</td> <td>No</td> <td>No</td> <td>Possibly yes</td> </tr> <tr> <td>Signs of infections</td> <td>No</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Sepsis</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Readmission</td> <td>No</td> <td>Yes/no</td> <td>Yes/no</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: ultrasonography; CT: computed tomographic scan.<br />* Partial (peripheral) or total parenteral nutrition, antibiotics, enteral nutrition, somatostatin analog and/or minimal invasive drainage.<br />Â¶&nbsp;With or without a drain in situ.</div><div class=\"graphic_reference\">Reproduced from: Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 2005; 138:8. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96468 Version 1.0</div></div></div>"},"96469":{"type":"graphic_table","displayName":"Examples of blood biomarkers studied in stroke","title":"Examples of blood biomarkers studied in stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of blood biomarkers studied in stroke</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Markers of cardiac function</td> </tr> <tr> <td class=\"indent1\">Brain natriuretic peptide</td> </tr> <tr> <td class=\"indent1\">Troponin</td> </tr> <tr> <td class=\"subtitle1_single\">Markers of coagulation function</td> </tr> <tr> <td class=\"indent1\">Activated protein C resistance</td> </tr> <tr> <td class=\"indent1\">Alpha-2 antiplasmin</td> </tr> <tr> <td class=\"indent1\">Antithrombin III</td> </tr> <tr> <td class=\"indent1\">Beta-thromboglobulin</td> </tr> <tr> <td class=\"indent1\">D-dimer</td> </tr> <tr> <td class=\"indent1\">Fibrinogen</td> </tr> <tr> <td class=\"indent1\">Fibrinopeptide A</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator</td> </tr> <tr> <td class=\"indent1\">Prothrombin fragment 1.2</td> </tr> <tr> <td class=\"indent1\">Thrombin/antithrombin complexes</td> </tr> <tr> <td class=\"indent1\">Thrombomodulin</td> </tr> <tr> <td class=\"indent1\">Von Willebrand factor</td> </tr> <tr> <td class=\"subtitle1_single\">Markers of endothelial function/atherosclerotic plaque</td> </tr> <tr> <td class=\"indent1\">Endothelin-1</td> </tr> <tr> <td class=\"indent1\">Homocysteine</td> </tr> <tr> <td class=\"indent1\">Lipoprotein associated phospholipase A2</td> </tr> <tr> <td class=\"indent1\">Pregnancy associated plasma protein A</td> </tr> <tr> <td class=\"subtitle1_single\">Markers of inflammation</td> </tr> <tr> <td class=\"indent1\">Adiponectin</td> </tr> <tr> <td class=\"indent1\">Cellular fibronectin</td> </tr> <tr> <td class=\"indent1\">C-reactive protein</td> </tr> <tr> <td class=\"indent1\">Ferritin</td> </tr> <tr> <td class=\"indent1\">Interleukins</td> </tr> <tr> <td class=\"indent1\">Matrix metalloproteinases</td> </tr> <tr> <td class=\"indent1\">Monocyte chemoattractant protein</td> </tr> <tr> <td class=\"indent1\">Procalcitonin</td> </tr> <tr> <td class=\"indent1\">Receptor for advanced glycation end-product (RAGE)</td> </tr> <tr> <td class=\"indent1\">Serum amyloid A</td> </tr> <tr> <td class=\"indent1\">Tumor necrosis factor alpha</td> </tr> <tr> <td class=\"indent1\">Vascular cell adhesion molecule</td> </tr> <tr> <td class=\"subtitle1_single\">Markers of neuronal/glial injury</td> </tr> <tr> <td class=\"indent1\">B-type neurotrophic growth factor</td> </tr> <tr> <td class=\"indent1\">Glial fibrillary acidic protein</td> </tr> <tr> <td class=\"indent1\">Myelin basic protein</td> </tr> <tr> <td class=\"indent1\">Neuron specific enolase</td> </tr> <tr> <td class=\"indent1\">N-methyl-D-aspartate receptor subunit</td> </tr> <tr> <td class=\"indent1\">PARK7</td> </tr> <tr> <td class=\"indent1\">S100 calcium binding protein B</td> </tr> <tr> <td class=\"indent1\">Tau</td> </tr> <tr> <td class=\"indent1\">Visinin-like protein 1</td> </tr> <tr> <td class=\"subtitle1_single\">Markers of physiologic stress</td> </tr> <tr> <td class=\"indent1\">Copeptin</td> </tr> <tr> <td class=\"indent1\">Cortisol</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96469 Version 3.0</div></div></div>"},"96470":{"type":"graphic_table","displayName":"Examples of potential uses of blood biomarkers in stroke","title":"Examples of potential uses of blood biomarkers in stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of potential uses of blood biomarkers in stroke</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Potential use</td> <td class=\"subtitle1\">Biomarkers</td> </tr> <tr> <td>Prediction of stroke risk</td> <td>BNP, Lp-PLA2, fibrinogen</td> </tr> <tr> <td>Determination of stroke mechanism</td> <td>BNP, d-dimer</td> </tr> <tr> <td>Diagnosis of cerebral vein thrombosis</td> <td>D-dimer</td> </tr> <tr> <td>Prediction of infarct volume</td> <td>NSE, S100B</td> </tr> <tr> <td>Prediction of stroke outcome</td> <td>BNP, copeptin, fibrinogen, MMP9</td> </tr> <tr> <td>Estimating risk of in-hospital complications</td> <td>Copeptin</td> </tr> <tr> <td>Determining response to therapy</td> <td>BNP, c-Fn, fibrinogen, MMP9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BNP: brain natriuretic protein; c-Fn: cellular fibronectin; Lp-PLA2: lipoprotein-associated phospholipase A2; NSE: neuron-specific enolase; MMP9: matrix metalloproteinase 9; S100B: S100 calcium binding protein B.</div><div id=\"graphicVersion\">Graphic 96470 Version 1.0</div></div></div>"},"96471":{"type":"graphic_figure","displayName":"Time course of neurologic recovery after stroke","title":"Time course of neurologic recovery after stroke","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Time course of neurologic recovery after stroke</div><div class=\"cntnt\"><img style=\"width:694px; height:474px;\" src=\"images/NEURO/96471_Weeks_from_stroke_onset.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The time course of recovery in survivors shown as the cumulated rate of patients having reached their best neurological outcome. Rates are given for all patients, <strong>&sect;</strong>; for patients with initial mild stroke severity, <strong>&loz;</strong>; for patients with initial moderate stroke severity, <strong>&Delta;</strong>; for patients with initial severe stroke severity, <strong>*</strong>; for patients with initial very severe stroke severity, <strong>&bull;</strong>. The ANOVA test showed an overall difference in the time course of recovery between the groups, p&lt;0.0001. Further analyses showed that the time course of recovery differed significantly between patients with initially mild strokes versus moderate strokes, p&lt;0.0001, and between patients with moderate strokes versus severe strokes, p&lt;0.03. No difference was found between patients with severe versus very severe strokes, p = 0.19.</div><div class=\"graphic_reference\">Reproduced from: J&oslash;rgensen HS1, Nakayama H, Raaschou HO, et al. Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil 1995; 76:406. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96471 Version 3.0</div></div></div>"},"96472":{"type":"graphic_table","displayName":"Causes of straining in infants","title":"Differential diagnosis of straining in infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of straining in infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody></table><table cellspacing=\"0\"> <colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause of straining</td> <td class=\"subtitle1\">Clinical characteristics</td> </tr> <tr class=\"divider_bottom\"> <td>Infant dyschezia</td> <td> <ul> <li>Healthy infant zero to&nbsp;nine months of age </li> <li>Soft stool passed after straining </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Constipation</td> <td> <ul> <li>Healthy infant </li> <li>Stools are hard or pellet-like </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Anal fissure</td> <td> <ul> <li>Healthy infant </li> <li>May or may not have history of constipation </li> <li>Fissure identified on inspection of anus </li> <li>Straining may be caused by voluntary stool withholding </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cow's milk intolerance</td> <td> <ul> <li>Healthy infant </li> <li>Diet contains cow&rsquo;s milk protein (breast- or formula-fed) </li> <li>Normal or loose stools with gross or occult blood and/or mucus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hirschsprung disease</td> <td> <ul> <li>Newborn or infant </li> <li>History of delayed passage of meconium (after 48 hours of life) </li> <li>Well- or ill-appearing </li> <li>Constipation or abdominal distension; occasionally diarrhea </li> <li>Rectal examination may reveal tight sphincter, empty ampulla, and/or explosive squirt of stool on withdrawal of finger </li> <li>Anorectal manometry demonstrates absence of rectosphincteric reflex </li> <li>Ganglion cells absent on rectal biopsy </li> </ul> </td> </tr> <tr> <td>Internal anal sphincter achalasia</td> <td> <ul> <li>Presentation and anorectal manometry similar to Hirschsprung disease as described above </li> <li>Ganglion cells present on rectal biopsy </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Manu Sood.</div><div id=\"graphicVersion\">Graphic 96472 Version 2.0</div></div></div>"},"96475":{"type":"graphic_picture","displayName":"Lichen striatus histo high power","title":"Histopathogic features of lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histopathogic features of lichen striatus</div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/DERM/96475_Lichen_striat_histo_hgh_pow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphocytes are present in a band-like, lichenoid pattern with vacuolar alteration of the dermal-epidermal junction and scattered dyskeratotic keratinocytes (H&amp;E 200x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey North, MD<br />Assistant Clinical Professor<br />Department of Dermatology, University of California, San Francisco.</div><div id=\"graphicVersion\">Graphic 96475 Version 1.0</div></div></div>"},"96476":{"type":"graphic_picture","displayName":"Lichen striatus histo low power","title":"Histopathologic features of lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of lichen striatus</div><div class=\"cntnt\"><img style=\"width:497px; height:507px;\" src=\"images/DERM/96476_Lichen_striat_histo_low_pow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A superficial, band-like lymphocytic infiltrate fills dermal papillae and obscures the dermal-epidermal junction. The inflammatory infiltrate is also present in the deeper reticular dermis around adnexal epithelium (H&amp;E 20x).</div><div class=\"graphic_reference\">Courtesy of Jeffrey North, MD<br />Assistant Clinical Professor<br />Department of Dermatology, University of California, San Francisco.</div><div id=\"graphicVersion\">Graphic 96476 Version 1.0</div></div></div>"},"96486":{"type":"graphic_figure","displayName":"Valves involved in the process of swallowing","title":"Valves involved in the process of swallowing","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Valves involved in the process of swallowing</div><div class=\"cntnt\"><img style=\"width:527px; height:595px;\" src=\"images/PALC/96486_Valves_involved_in_the_process_of_swallowing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Valves of the upper aerodigestive tract involved in swallowing.</div><div class=\"graphic_reference\">Courtesy of Tessa Goldsmith, MA, CCC-SLP and Audrey Kurash Cohen, MS, CCC-SLP. Modified from: Dahlin CM, Cohen AK, Goldsmith T. Dysphagia, Xerostomia, and Hiccups. In: Oxford Textbook of Palliative Nursing, 3rd ed, Ferrell BR, Coyle N (Eds), Oxford University Press 2010.</div><div id=\"graphicVersion\">Graphic 96486 Version 2.0</div></div></div>"},"96487":{"type":"graphic_figure","displayName":"Group A Streptococcus","title":"GAS virulence factors","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">GAS virulence factors</div><div class=\"cntnt\"><img style=\"width:720px; height:434px;\" src=\"images/ID/96487_Group_A_Streptococcus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arsenal of virulence factors expressed by GAS to thwart the host innate immune response. The secreted proteases SpyCEP/ScpC and ScpA degrade the chemokines IL-8 and C5a, respectively, hindering phagocyte recruitment to the site of infection. Surface-associated M protein binds Fc domains of Ig and the complement-regulatory proteins C4BP and factor H to interfere with complement deposition. Mac-1/2 degrades Ig and binds phagocyte Fc receptors to block phagocytosis. Antimicrobial peptide resistance is mediated by hyaluronic acid capsule, D-alanylation of surface lipoteichoic acid by DltABCD, inactivation though SIC binding, and degradation by the cysteine protease SpeB. Ig and antimicrobial peptides are degraded by SpeB to facilitate the establishment of GAS infection in vivo. Secreted Sda1 DNase activity degrades NETs to promote neutrophil survival. The cytolysins SLS and SLO mediate lysis and apoptosis of neutrophils and macrophages.</div><div class=\"graphic_footnotes\">GAS: group A <em>Streptococcus</em>; IL: interleukin; Fc: fragment crystallizable; Ig: immunoglobulin; SIC: streptococcal inhibitor of complement; NETs: neutrophil extracellular traps; SLS: streptolysin S; SLO: streptolysin O.</div><div class=\"graphic_reference\">From: Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev 2014; 27:264. Copyright &copy; 2014. Reproduced with permission from the American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 96487 Version 1.0</div></div></div>"},"96488":{"type":"graphic_table","displayName":"Benefits of guideline recommended HF therapies","title":"Demonstrated benefits of guideline-recommended heart failure therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Demonstrated benefits of guideline-recommended heart failure therapies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Guideline-recommended therapy</td> <td class=\"subtitle1\"> <p>Relative risk reductions in pivotal randomized clinical trial(s) (%)</p> </td> <td class=\"subtitle1\">Number needed to treat for mortality benefit&nbsp;(standardized to 12 m)</td> <td class=\"subtitle1\">Relative risk reduction in meta-analysis</td> </tr> <tr> <td>Angiotensin converting enzyme inhibitor OR angiotensin II receptor blocker</td> <td class=\"centered\">17</td> <td class=\"centered\">77</td> <td class=\"centered\">20%</td> </tr> <tr> <td>Beta-blocker therapy (carvedilol, bisoprolol, extended release metoprolol succinate)</td> <td class=\"centered\">34</td> <td class=\"centered\">28</td> <td class=\"centered\">31%</td> </tr> <tr> <td>Aldosterone antagonist</td> <td class=\"centered\">30</td> <td class=\"centered\">18</td> <td class=\"centered\">25%</td> </tr> <tr> <td>Hydralazine plus nitrate</td> <td class=\"centered\">43</td> <td class=\"centered\">21</td> <td class=\"centered\">Not available</td> </tr> <tr> <td>Cardiac resynchronization therapy</td> <td class=\"centered\">36</td> <td class=\"centered\">24</td> <td class=\"centered\">29/22%</td> </tr> <tr> <td>Implantable cardioverter-defibrillator</td> <td class=\"centered\">23</td> <td class=\"centered\">70</td> <td class=\"centered\">26%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011; 161:1024. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96488 Version 3.0</div></div></div>"},"96492":{"type":"graphic_figure","displayName":"Ectopic pregnancy vasopressin injection","title":"Ectopic pregnancy: Vasopressin injection prior to surgical treatment","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Ectopic pregnancy: Vasopressin injection prior to surgical treatment</div><div class=\"cntnt\"><img style=\"width:456px; height:659px;\" src=\"images/OBGYN/96492_Ectopicpregvasopressininject.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A&nbsp;22-gauge needle is inserted through a 5 mm portal and used to inject a solution of vasopressin into the wall of the tube at the area of maximal distention; this helps to minimize bleeding at the salpingostomy site. <br />(B) A 10 mm longitudinal incision is made along the tube overlying the ectopic gestation. The incision is made along the border of the tube that is not on the side to which the mesosalpinx attaches.</div><div id=\"graphicVersion\">Graphic 96492 Version 4.0</div></div></div>"},"96493":{"type":"graphic_figure","displayName":"Fallopian tube salpingectomy","title":"Fallopian tube: Salpingectomy","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Fallopian tube: Salpingectomy</div><div class=\"cntnt\"><img style=\"width:466px; height:498px;\" src=\"images/OBGYN/96493_Fallopiantubesalpingectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96493 Version 3.0</div></div></div>"},"96495":{"type":"graphic_figure","displayName":"ILO description of radiographic features B","title":"ILO description of radiographic features of pneumoconioses B","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">ILO description of radiographic features of pneumoconioses B</div><div class=\"cntnt\"><img style=\"width:469px; height:735px;\" src=\"images/PULM/96495_ILO_descript_radiograph_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synopsis of parameters and additional symbols that are noted and graded on the International Labour Organization (ILO) pneumoconiosis form.</div><div class=\"graphic_footnotes\">* Extent refers to the longitudinal dimension of the pleural abnormality relative to the chest wall. The box in the image shows that the pleural plaque is up to Â¼ the length of the lateral chest wall, which is designated by \"1.\" In contrast, the pleural thickening on the left side of the same image is between Â¼ and Â½ of the lateral chest wall on that side, which is designated by a \"2.\"<br /><FONT class=bullet>â¢</FONT> Width refers to the thickness of the pleural abnormality. The measurement of width is made from the innermost margin of the rib to the innermost sharp margin of the plaque at the pleural-parenchymal boundary.&nbsp;Thus, in a given patient, if&nbsp;the thickness is 4 mm, it would be designated by \"a,\" but if 7 mm, by \"b.\"</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 96495 Version 1.0</div></div></div>"},"96496":{"type":"graphic_figure","displayName":"ILO description of radiographic features C","title":"ILO description of radiographic features of pneumoconioses C","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">ILO description of radiographic features of pneumoconioses C</div><div class=\"cntnt\"><img style=\"width:470px; height:729px;\" src=\"images/PULM/96496_ILO_descript_radiograph_C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synopsis of parameters and additional symbols that are noted and graded on the International Labour Organization (ILO) pneumoconiosis form.</div><div class=\"graphic_footnotes\">The definition of each symbol should be understood as being preceded by an introductory qualifying word or phrase such as \"changes indicative of,\" \"opacities suggestive of,\" or \"suspect.\"<br />aa: atherosclerotic aorta; at: significant apical pleural thickening; ax: coalescence of small opacities; bu: bulla(e); ca: cancer, thoracic malignancies excluding mesothelioma; cg: calcified non-pneumoconiotic nodules (eg, granuloma) or nodes; cn: calcification in small pneumoconiotic opacities; co: abnormality of cardiac size or shape; cp: cor pulmonale; cv: cavity; di: marked distortion of an intrathoracic structure; ef: pleural effusion; em: emphysema; es: eggshell calcification of hilar or mediastinal lymph nodes; fr: fractured rib(s) (acute or healed); hi: enlargement of non-calcified hilar or mediastinal lymph nodes; ho: honeycomb lung; id: ill-defined diaphragm border; ih: ill-defined heart border; kl: septal (Kerley) lines; me: mesothelioma; pa: plate atelectasis; pb: parenchymal bands; pi: pleural thickening of an interlobar fissure; px: pneumothorax; ra: rounded atelectasis; rp: rheumatoid pneumoconiosis; tb: tuberculosis; od: other disease or significant abnormality.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 96496 Version 1.0</div></div></div>"},"96498":{"type":"graphic_picture","displayName":"CLL peripheral smear","title":"Chronic lymphocytic leukemia peripheral blood smear","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chronic lymphocytic leukemia peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:590px; height:455px;\" src=\"images/HEME/96498_CLL_peripheral_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear reveals five CLL cells with prominent chromatin clumping (snickerdoodle-like) and two smudge (basket) cells. Wright-Giemsa, 150x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinical application: Chronic lymphocytic leukemia of B-cell lineage. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 96498 Version 4.0</div></div></div>"},"96506":{"type":"graphic_table","displayName":"Fiebig stages of early HIV infection","title":"Fiebig stages of early HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fiebig stages of early HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Fiebig stage</td> <td class=\"subtitle1\">Cumulative duration (days)</td> <td class=\"subtitle1\">HIV RNA</td> <td class=\"subtitle1\">p24 antigen</td> <td class=\"subtitle1\">Immunoassay</td> <td class=\"subtitle1\">Western blot</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">5</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">10</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">14</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">19</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">Indeterminate</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">88</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+ (p31 band negative)</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">Open-ended</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+ (p31 band positive)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Fiebig stages describe the emergence of virologic and immunologic markers following infection with HIV. Immunoassays and Western blot testing detect antibodies against HIV antigens.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Adapted from: Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871.</div><div id=\"graphicVersion\">Graphic 96506 Version 3.0</div></div></div>"},"96510":{"type":"graphic_table","displayName":"Clues etiology osteomyelitis children","title":"Clinical features associated with bacterial pathogens that cause acute hematogenous osteomyelitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features associated with bacterial pathogens that cause acute hematogenous osteomyelitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gram-positive bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>All ages; possible associated skin or soft tissue infection; MRSA may be associated with venous thromboembolism and pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Coagulase-negative staphylococci</td> <td>Neonates in intensive care unit; children with indwelling vascular catheters (eg, for chronic hemodialysis)</td> </tr> <tr> <td class=\"indent1\">Group A <em>Streptococcus</em></td> <td>More common in children younger than four years; may occur as a complication of concurrent varicella-zoster virus infection; associated with higher fever</td> </tr> <tr> <td class=\"indent1\">Group B <em>Streptococcus</em></td> <td>Infants younger than three months (usually two to four weeks)</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em></td> <td>Children younger than two years who are incompletely immunized; children older than two years with underlying medical condition (eg, sickle cell disease, asplenia, splenic dysfunction, immunodeficiency, chronic heart disease, chronic lung disease, diabetes mellitus)</td> </tr> <tr> <td class=\"indent1\">Actinomyces</td> <td>May affect the facial bones, the pelvis,&nbsp;or vertebral bodies</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gram-negative bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Kingella kingae</em></td> <td>Children 6 to 36 months; indolent onset; oral ulcers preceding musculoskeletal findings; may affect nontubular bones</td> </tr> <tr> <td class=\"indent1\">Nonsalmonella gram-negative bacilli (eg, <em>Escherichia coli</em>, <em>Serratia</em>)</td> <td>Birth to three months; children with sickle cell disease; instrumentation of the gastrointestinal or urinary tract; immunocompromised host (eg, chronic granulomatous disease)</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em> type b</td> <td>Incompletely immunized children in areas with low Hib immunization rates</td> </tr> <tr> <td class=\"indent1\"><em>Bartonella henselae</em></td> <td>Children with cat exposure; may affect the vertebral column and pelvic girdle</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>Injectable drug use</td> </tr> <tr> <td class=\"indent1\"><em>Brucella</em></td> <td>Travel to or living in an endemic area; ingestion of unpasteurized dairy products</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em></td> <td>Birth in, travel to, or contact with a visitor from a region endemic for <em>M. tuberculosis</em></td> </tr> <tr> <td class=\"indent1\">Nontuberculous mycobacteria</td> <td>Surgery or penetrating injury; chronic granulomatous disease; other underlying immunodeficiency; HIV infection</td> </tr> <tr> <td class=\"indent1\"><em>Salmonella</em> species</td> <td>Children with sickle cell disease or related hemoglobinopathies; children in developing countries</td> </tr> <tr> <td><strong>Polymicrobial infection</strong></td> <td>More likely with direct inoculation (eg, penetrating trauma) or contiguous spread (eg, from skull, face, hands, feet)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>S. aureus</EM>; Hib: <EM>H. influenzae</EM> type b; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 96510 Version 5.0</div></div></div>"},"96511":{"type":"graphic_diagnosticimage","displayName":"Hip disease and grade 4 sacroiliitis in AS","title":"Hip involvement and grade 4 sacroiliitis in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hip involvement and grade 4 sacroiliitis in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:590px; height:474px;\" src=\"images/RHEUM/96511_Hip_grade_4_sacroiliitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Destructive disease in both right and left hips in a patient with sacroiliitis. In addition, both sacroiliac joints show grade 4 sacroiliitis.</div><div class=\"graphic_reference\">Courtesy of Dr. Sheng Guang Li, The First Affiliated Hospital of PLA General Hospital, China.</div><div id=\"graphicVersion\">Graphic 96511 Version 1.0</div></div></div>"},"96512":{"type":"graphic_picture","displayName":"Traditional CO2 laser for acne scars, intraoperative","title":"Traditional multi-pass full-face CO<sub>2</sub> laser resurfacing for facial acne scars, intraoperative","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Traditional multi-pass full-face CO<sub>2</sub> laser resurfacing for facial acne scars, intraoperative</div><div class=\"cntnt\"><img style=\"width:590px; height:384px;\" src=\"images/DERM/96512_Clas_multipass_laser_resurf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative photograph. Notice the prominent individual acne scars are \"etched\" with the CO<SUB>2</SUB> or erbium:yttrium aluminum garnet (Er:YAG) laser and wiped to a very specific endpoint. This procedure is very effective yet highly operator-dependent and results in 10 days of \"downtime\" with potential for&nbsp;six or more weeks of persistent dyschromia.</div><div id=\"graphicVersion\">Graphic 96512 Version 2.0</div></div></div>"},"96513":{"type":"graphic_picture","displayName":"Traditional CO2 laser for acne scars, preoperative","title":"Traditional full-face CO<sub>2</sub> laser resurfacing for facial acne scars, preoperative","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traditional full-face CO<sub>2</sub> laser resurfacing for facial acne scars, preoperative</div><div class=\"cntnt\"><img style=\"width:327px; height:401px;\" src=\"images/DERM/96513_Classic_laser_resurf_preop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative photograph demonstrating multiple acne scars on the cheek.</div><div id=\"graphicVersion\">Graphic 96513 Version 2.0</div></div></div>"},"96514":{"type":"graphic_picture","displayName":"Traditional CO2 laser for acne scars, postoperative","title":"Traditional full-face CO<sub>2</sub> laser resurfacing for facial acne scars, postoperative","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traditional full-face CO<sub>2</sub> laser resurfacing for facial acne scars, postoperative</div><div class=\"cntnt\"><img style=\"width:330px; height:383px;\" src=\"images/DERM/96514_Classic_laser_resurf_CO2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Six months following CO<SUB>2</SUB> laser resurfacing. This case demonstrates the effectiveness of full-face laser resurfacing as the single most consistently effective laser procedure for severe acne scars. Although the optimal approach to acne scars involves multiple modalities, an excellent result can be achieved with one full-face multiple-pass CO<SUB>2</SUB> or erbium laser treatment session.</div><div id=\"graphicVersion\">Graphic 96514 Version 2.0</div></div></div>"},"96515":{"type":"graphic_picture","displayName":"Microdroplet silicone injection, preoperative","title":"Microdroplet silicone injection of facial acne scars, preoperative","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Microdroplet silicone injection of facial acne scars, preoperative</div><div class=\"cntnt\"><img style=\"width:551px; height:590px;\" src=\"images/DERM/96515_Microdrop_silic_injec_preop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative photo demonstrating acne scars on the cheek.</div><div class=\"graphic_reference\">Courtesy of J. Barnett, MD.</div><div id=\"graphicVersion\">Graphic 96515 Version 1.0</div></div></div>"},"96516":{"type":"graphic_picture","displayName":"Microdroplet silicone injection, postoperative","title":"Microdroplet silicone injection of facial acne scars, postoperative","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Microdroplet silicone injection of facial acne scars, postoperative</div><div class=\"cntnt\"><img style=\"width:486px; height:590px;\" src=\"images/DERM/96516_Microdrop_sili_injec_postop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One-year postoperative photo. As a monotherapy, the results and risks of microdroplet silicone injection far outperform any other single procedure. However, it remains controversial as it requires the operator to be technically proficient. Following the strict use of the microdroplet \"stimulation of collagen\" protocol and avoiding classic filling techniques, the results are typically dramatic and persistent for many years.</div><div id=\"graphicVersion\">Graphic 96516 Version 1.0</div></div></div>"},"96517":{"type":"graphic_picture","displayName":"CO2 laser resurfacing for acne scars, preoperative","title":"Combination CO<sub>2</sub> laser resurfacing for facial acne scars, preoperative","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combination CO<sub>2</sub> laser resurfacing for facial acne scars, preoperative</div><div class=\"cntnt\"><img style=\"width:301px; height:488px;\" src=\"images/DERM/96517_Combin_CO2_resurf_preop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative photograph demonstrating multiple acne scars on the lateral cheek and chin.</div><div class=\"graphic_reference\">Courtesy of E.V. Ross, MD.</div><div id=\"graphicVersion\">Graphic 96517 Version 2.0</div></div></div>"},"96518":{"type":"graphic_picture","displayName":"CO2 laser resurfacing for acne scars, postoperative","title":"Combination CO<sub>2</sub> laser resurfacing for facial acne scars, postoperative","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combination CO<sub>2</sub> laser resurfacing for facial acne scars, postoperative</div><div class=\"cntnt\"><img style=\"width:285px; height:563px;\" src=\"images/DERM/96518_Combin_CO2_resurf_postop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combination CO<SUB>2</SUB> fractional and non-fractional laser&nbsp;resurfacing. Three-months postoperative photo demonstrating reduced prominence of acne scarring. Notice the typical result of using two-pass fractional CO<SUB>2</SUB>&nbsp;laser&nbsp;resurfacing followed by single-pass&nbsp;traditional CO<SUB>2</SUB> laser resurfacing (no wiping). This procedure is predictably effective, but is associated with more intraoperative pain and postoperative downtime when compared with nonablative laser options.</div><div class=\"graphic_reference\">Courtesy of E.V. Ross, MD.</div><div id=\"graphicVersion\">Graphic 96518 Version 2.0</div></div></div>"},"96519":{"type":"graphic_table","displayName":"Etiology osteomyelitis by age","title":"Most common causes of bacterial osteomyelitis in children according to age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common causes of bacterial osteomyelitis in children according to age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Most common bacterial etiologies</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&#60;3 months</td> <td><em>Staphylococcus aureus</em> (MSSA and MRSA)</td> </tr> <tr> <td>Group B <em>Streptococcus</em> (<em>Streptococcus agalactiae</em>)</td> </tr> <tr class=\"divider_bottom\"> <td>Gram negative bacilli</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">3 months to early childhood</td> <td><em>S. aureus</em> (MSSA and MRSA)</td> </tr> <tr> <td>Group A <em>Streptococcus</em> (<em>S. pyogenes</em>)</td> </tr> <tr> <td><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td><em>Kingella kingae</em>*</td> </tr> <tr class=\"divider_bottom\"> <td><em>Haemophilus influenzae</em> type b (Hib)<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"3\">Older children and adolescents</td> <td><em>S. aureus</em> (MSSA and MRSA)</td> </tr> <tr> <td>Group A <em>Streptococcus</em> (<em>S. pyogenes</em>)</td> </tr> <tr> <td><em>S. pneumoniae</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <EM>S. aureus</EM>; MRSA: methicillin-resistant <EM>S. aureus</EM>.<br />* 36 months of age or less.<br />Â¶&nbsp;In children incompletely immunized against Hib.</div><div id=\"graphicVersion\">Graphic 96519 Version 1.0</div></div></div>"},"96520":{"type":"graphic_table","displayName":"DDx osteomyelitis children","title":"Differential diagnosis of osteomyelitis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of osteomyelitis in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Features that distinguish from osteomyelitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other infections</td> </tr> <tr> <td class=\"indent1\"> <p>Septicemia</p> <p>Cellulitis</p> <p>Septic arthritis</p> <p>Deep abscess</p> Pyomyositis</td> <td> <ul> <li>MRI or scintigraphy studies lack abnormalities characteristic of osteomyelitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Noninfectious conditions</td> </tr> <tr> <td class=\"indent1\">Chronic nonbacterial osteomyelitis (eg, CRMO)</td> <td> <ul> <li>Multifocal lesions demonstrated by scintigraphy </li> <li>Lack of response to antimicrobial therapy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malignancy (eg, primary bone tumor, leukemia)</td> <td> <ul> <li>Intermittent symptoms </li> <li>Lack of response to antimicrobial therapy </li> <li>Characteristic histopathology </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bone infarction in patients with hemoglobinopathy</td> <td> <ul> <li>Improvement with hydration and other supportive measures </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Vitamin C deficiency (scurvy)</td> <td> <ul> <li>Dietary history of limited vitamin C intake</li> <li>Petechiae, ecchymoses, bleeding gums, coiled hair, hyperkeratosis</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gaucher disease</td> <td> <ul> <li>Characteristic radiographic features </li> <li>Dysmorphic features on examination </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Complex regional pain syndrome</td> <td> <ul> <li>Autonomic dysfunction </li> <li>Normal erythrocyte sedimentation rate, C-reactive protein </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Caffey disease (infantile cortical hyperostosis)</td> <td> <ul> <li>Characteristic histopathology </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Radiographic mimics*</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Benign bone tumors:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Fibrous dysplasia </li> <li>Osteoid osteoma </li> <li>Osteoblastoma </li> <li>Chondroblastoma </li> <li>Chondromyxoid fibroma </li> </ul> </td> <td> <ul> <li>Absence of acute symptoms </li> <li>Lack of response to antimicrobial therapy </li> <li>Characteristic histopathology </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> <td> <ul> <li>Characteristic histopathology </li> </ul> </td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Malignant bone tumors:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Osteosarcoma </li> </ul> </td> <td> <ul> <li>Intermittent symptoms </li> <li>Lack of response to antimicrobial therapy </li> <li>Characteristic histopathology </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRMO: chronic recurrent multifocal osteomyelitis.<br />* Refer to UpToDate topics on benign bone tumors, Langerhans cell histiocytosis, and malignant bone tumors for additional information about the radiographic appearance of these conditions.</div><div id=\"graphicVersion\">Graphic 96520 Version 1.0</div></div></div>"},"96521":{"type":"graphic_table","displayName":"Osteomyelitis imaging modalities","title":"Comparison of imaging modalities in children with osteomyelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of imaging modalities in children with osteomyelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Comments*</td> </tr> <tr class=\"divider_bottom\"> <td>Plain radiographs</td> <td> <p>Baseline</p> <p>Excluding other conditions in differential diagnosis</p> Monitoring disease progression</td> <td> <p>Inexpensive</p> Easy to obtain</td> <td>Abnormal findings usually not present at onset of symptoms, except in newborns</td> <td> <p>Sensitivity 16 to 20 percent</p> <p>Specificity 80 to 100 percent</p> Normal radiograph at onset does not exclude osteomyelitis</td> </tr> <tr class=\"divider_bottom\"> <td>Magnetic resonance imaging (MRI)<sup>&#182;</sup></td> <td> <p>Identify location and extent of disease</p> <p>Evaluation of adjacent structures for extension of infection (soft tissues, growth plate, epiphysis, joint)</p> <p>Evaluation of difficult sites (eg, pelvis, vertebral bodies, intervertebral discs)</p> Planning surgical intervention</td> <td> <p>No radiation risk</p> <p>Demonstrates early changes in the marrow cavity</p> <p>Improved demonstration of subperiosteal abscess</p> <p>Demonstration of concomitant septic arthritis, venous thrombosis, or pyomyositis</p> <p>&nbsp;</p> </td> <td> <p>Costly</p> <p>Less useful in multifocal or poorly localized disease</p> <p>Requires more time than computed tomography</p> <p>Young children may require sedation or anesthesia</p> <p>Not always available</p> <p>&nbsp;</p> </td> <td> <p>Sensitivity: 80 to 100 percent</p> <p>Specificity: 70 to 100 percent</p> <p>Osteomyelitis unlikely if MRI is normal</p> <p>&nbsp;</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Scintigraphy</td> <td> <p>Poorly localized symptoms (eg, young children who cannot verbalize)</p> Multifocal disease</td> <td> <p>More useful than MRI in multifocal or poorly localized disease</p> <p>Demonstrates early changes</p> <p>Readily available</p> May require less sedation than MRI</td> <td> <p>Radiation exposure</p> Does not provide information about extent of purulent collections that may require drainage</td> <td> <p>Sensitivity: 53 to 100 percent</p> <p>Specificity: 50 to 100 percent</p> <p>Osteomyelitis unlikely if scintigraphy is normal</p> May be falsely negative if blood supply to periosteum is interrupted (eg, subperiosteal abscess)</td> </tr> <tr class=\"divider_bottom\"> <td>Computed tomography (CT)</td> <td> <p>Evaluation of cortical destruction, bone gas, and sequestrum</p> <p>Delineating extent of bone injury in subacute/chronic osteomyelitis</p> <p>Planning surgical interventions</p> Evaluation of complications if MRI not available or contraindicated</td> <td> <p>Less time consuming than MRI</p> Does not require sedation</td> <td> <p>Expensive</p> <p>Increased radiation exposure</p> Poor soft tissue contrast</td> <td> <p>Sensitivity: 67 percent</p> <p>Specificity: 50 percent</p> Generally used only if other studies are not possible or inconclusive</td> </tr> <tr> <td>Ultrasonography</td> <td> <p>Evaluate fluid collections in adjacent structures (eg, joint, periosteum)</p> Monitor abscess resolution or progression</td> <td> <p>Inexpensive</p> <p>No radiation burden</p> <p>Noninvasive</p> Portable</td> <td>Does not penetrate bone cortex</td> <td> <p>Sensitivity: 55 percent</p> Specificity: 47 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Values for sensitivity and specificity are from: Dartnell J, Ramachandran M, Katchburian M. Haematogenous acute and subacute paediatric osteomyelitis: a systematic review of the literature. J Bone Joint Surg Br 2012; 94:584.<br />Â¶&nbsp;Preferred imaging study when imaging other than plain radiographs are necessary to establish the diagnosis of osteomyelitis.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Dartnell J, Ramachandran M, Katchburian M. Haematogenous acute and subacute paediatric osteomyelitis: a systematic review of the literature. J Bone Joint Surg Br 2012; 94:584.</li>&#xD;&#xA;    <li>Faust SN, Clark J, Pallett A, Clarke NM. Managing bone and joint infection in children. Arch Dis Child 2012; 97:545.</li>&#xD;&#xA;    <li>Peltola H, P&auml;&auml;kk&ouml;nen M. Acute osteomyelitis in children. N Engl J Med 2014; 370:352.</li>&#xD;&#xA;    <li>Yeo A, Ramachandran M. Acute haematogenous osteomyelitis in children. BMJ 2014; 348:g66.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96521 Version 3.0</div></div></div>"},"96524":{"type":"graphic_diagnosticimage","displayName":"Bilateral hip disease in AS","title":"Bilateral hip involvement in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Bilateral hip involvement in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:590px; height:527px;\" src=\"images/RHEUM/96524_Left_right_hip_ankylosing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Destructive disease in both right and left hips in a patient with ankylosing spondylitis.</div><div class=\"graphic_reference\">Courtesy of Dr. Sheng Guang Li, The First Affiliated Hospital of PLA General Hospital, China.</div><div id=\"graphicVersion\">Graphic 96524 Version 1.0</div></div></div>"},"96527":{"type":"graphic_table","displayName":"Causes of hemoptysis","title":"Causes of hemoptysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hemoptysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Airway diseases</td> </tr> <tr> <td class=\"indent1\">Airway trauma</td> </tr> <tr> <td class=\"indent1\">Bronchitis: Acute or chronic</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis*, including cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Bullous emphysema</td> </tr> <tr> <td class=\"indent1\">Bronchovascular fistula (eg, aortic aneurysm with erosion into airway)</td> </tr> <tr> <td class=\"indent1\">Bronchial adenoma</td> </tr> <tr> <td class=\"indent1\">Bronchogenic carcinoma*</td> </tr> <tr> <td class=\"indent1\">Dieulafoy disease (subepithelial bronchial artery)</td> </tr> <tr> <td class=\"indent1\">Metastatic cancer to bronchus or trachea</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Foreign body in airway</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary parenchymal diseases</td> </tr> <tr> <td class=\"indent1\"><strong>Infection</strong></td> </tr> <tr> <td class=\"indent2\">Anthrax</td> </tr> <tr> <td class=\"indent2\">Lung abscess</td> </tr> <tr> <td class=\"indent2\">Mycetoma and other fungal infections</td> </tr> <tr> <td class=\"indent2\">Necrotizing pneumonia</td> </tr> <tr> <td class=\"indent2\">Parasitic (eg, <em>Paragonimus westermani</em>*)</td> </tr> <tr> <td class=\"indent2\">Tuberculous* and nontuberculous mycobacterial disease</td> </tr> <tr> <td class=\"indent2\">Tuleremia</td> </tr> <tr> <td class=\"indent2\">Viral (eg, Herpes simplex)</td> </tr> <tr> <td class=\"indent2\"><em>Yersinia pestis</em> (plague)</td> </tr> <tr> <td class=\"indent1\"><strong>Rheumatic disease</strong></td> </tr> <tr> <td class=\"indent2\">Amyloid</td> </tr> <tr> <td class=\"indent2\">Anti-glomerular basement membrane disease (Goodpasture disease)</td> </tr> <tr> <td class=\"indent2\">Beh&#231;et's disease</td> </tr> <tr> <td class=\"indent2\">Genetic defect of collagen (eg, Ehlers-Danlos vascular type)</td> </tr> <tr> <td class=\"indent2\">Granulomatosis with polyangiitis (Wegener's) and other vasculitides</td> </tr> <tr> <td class=\"indent2\">Primary antiphospholipid antibody syndrome</td> </tr> <tr> <td class=\"indent2\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\"><strong>Other</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Idiopathic pulmonary hemosiderosis</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary vascular diseases</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Mitral stenosis</td> </tr> <tr> <td class=\"indent1\">Tricuspid endocarditis</td> </tr> <tr> <td class=\"indent1\">Pulmonary arteriovenous malformation</td> </tr> <tr> <td class=\"indent1\">Pulmonary artery pseudoaneurysm </td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism (eg, fat, septic, thrombotic)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pulmonary veno-occlusive disease</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of coagulation</td> </tr> <tr> <td class=\"indent1\">Anticoagulant and antiplatelet medications</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation (DIC)</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Platelet dysfunction</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia (ITP, TTP, HUS)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">von Willebrand disease</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic injuries</td> </tr> <tr> <td class=\"indent1\">Airway stent</td> </tr> <tr> <td class=\"indent1\">Aortobronchial fistula due to aortic graft or stent</td> </tr> <tr> <td class=\"indent1\">Bronchoscopy with endobronchial or transbronchial biopsy or needle aspiration</td> </tr> <tr> <td class=\"indent1\">Erosion of tracheal tube into innominate artery</td> </tr> <tr> <td class=\"indent1\">Transthoracic needle aspiration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vascular injury from pulmonary artery catheter</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\"><strong>Drugs and toxins</strong></td> </tr> <tr> <td class=\"indent2\">Argemone alkaloid-contaminated cooking oil (epidemic dropsy)</td> </tr> <tr> <td class=\"indent2\">Bevacizumab treatment</td> </tr> <tr> <td class=\"indent2\">Catamenial hemoptysis due to thoracic endometriosis</td> </tr> <tr> <td class=\"indent2\">Cocaine use</td> </tr> <tr> <td class=\"indent2\">Nitrogen dioxide toxicity (eg, silo fillers, indoor ice arenas with faulty propane powered equipment and poor ventilation)</td> </tr> <tr> <td class=\"indent1\"><strong>Trauma</strong></td> </tr> <tr> <td class=\"indent2\">Blunt chest trauma (eg, bronchial rupture, lung contusion)</td> </tr> <tr> <td class=\"indent2\">Penetrating lung injury</td> </tr> <tr> <td class=\"indent1\"><strong>Idiopathic</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The most common causes of massive hemoptysis are marked with an asterisk. Massive hemoptysis is variably defined. One definition is: &ge;500 mL of expectorated blood over a 24 hour period or bleeding at a rate &ge;100 mL/hour.</div><div class=\"graphic_footnotes\">ITP: immune thrombocytopenia; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome.</div><div id=\"graphicVersion\">Graphic 96527 Version 4.0</div></div></div>"},"96529":{"type":"graphic_table","displayName":"Useful questions for the evaluation of hemoptysis","title":"Useful questions for the evaluation of hemoptysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Useful questions for the evaluation of hemoptysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Present illness</td> </tr> <tr> <td class=\"indent1\">How much blood has been coughed up in the past 24 to 48 hours?</td> </tr> <tr> <td class=\"indent1\">Is the blood mixed with phlegm? Is the phlegm clear, white, or purulent?</td> </tr> <tr> <td class=\"indent1\">When was the first time the hemoptysis occurred?</td> </tr> <tr> <td class=\"indent1\">Is hemoptysis a new or recurrent symptom?</td> </tr> <tr> <td class=\"indent1\">Is there any bleeding from the nose, gums, stomach, or rectum?</td> </tr> <tr> <td class=\"indent1\">Is the patient dyspneic?</td> </tr> <tr> <td class=\"indent1\">Does the patient raise phlegm (without hemoptysis) daily or frequently?</td> </tr> <tr> <td class=\"indent1\">Are there other symptoms to suggest infection (eg, fever, chills, night sweats, purulent sputum)?</td> </tr> <tr> <td class=\"indent1\">Has the patient had a skin rash?</td> </tr> <tr> <td class=\"indent1\">Has the patient lost weight? Any headache or bone pain?</td> </tr> <tr> <td class=\"subtitle1_single\">Comorbidities or risk factors</td> </tr> <tr> <td class=\"indent1\">Does the patient currently smoke? How much?</td> </tr> <tr> <td class=\"indent1\">Has the patient previously smoked? How many pack years?</td> </tr> <tr> <td class=\"indent1\">Does the patient use cocaine?</td> </tr> <tr> <td class=\"indent1\">Does the patient have known or suspected pulmonary, cardiac, or renal disease?</td> </tr> <tr> <td class=\"indent1\">Has the patient had a thoracic procedure (eg, stent placement, pulmonary artery catheter, aortic graft) or surgery?</td> </tr> <tr> <td class=\"indent1\">Does the patient have a known or suspected bleeding disorder?</td> </tr> <tr> <td class=\"indent1\">Does the patient take aspirin, nonsteroidal anti-inflammatory drugs, anti-platelet drugs, or an anticoagulant?</td> </tr> <tr> <td class=\"indent1\">Are there any recent risk factors for deep vein thrombosis (DVT), such as surgery, hospitalization, travel, or immobility?</td> </tr> <tr> <td class=\"indent1\">Does the patient have a history of upper airway or upper gastrointestinal disease or symptoms?</td> </tr> <tr> <td class=\"indent1\">Where has the patient travelled, either recently or in the past?</td> </tr> <tr> <td class=\"indent1\">Has the patient had tuberculosis (TB) or been exposed to TB?</td> </tr> <tr> <td class=\"indent1\">Is the patient at high risk for TB or unusual parasitic disorders based upon travel history?</td> </tr> <tr> <td class=\"indent1\">Has the patient been exposed to trimellitic anhydride or other organic chemicals?</td> </tr> <tr> <td class=\"indent1\">Has the patient been exposed to asbestos?</td> </tr> <tr> <td class=\"subtitle1_single\">Family history</td> </tr> <tr> <td class=\"indent1\">Have family members had problems with blood clots?</td> </tr> <tr> <td class=\"indent1\">Have family members had problems with hemoptysis, brain aneurysms, epistaxis, or gastrointestinal bleeding (suggesting possible hereditary hemorrhagic telangiectasia)?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96529 Version 1.0</div></div></div>"},"96530":{"type":"graphic_table","displayName":"The directed physical examination for evaluation of hemoptysis","title":"The directed physical examination for evaluation of hemoptysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The directed physical examination for evaluation of hemoptysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Is the patient in respiratory distress (eg, tachypneic, cyanotic, not able to speak in full sentences, using accessory muscles of respiration)?</td> </tr> <tr> <td>Are there telangiectasias on the lips, tongue, or buccal mucosa to suggest that the patient may have hereditary hemorrhagic telangiectasia?</td> </tr> <tr> <td>Is there blood in the anterior nose?</td> </tr> <tr> <td>Does the patient have clubbing of the digits that might suggest lung cancer?</td> </tr> <tr> <td>Is there a skin rash that may indicate vasculitis, systemic lupus erythematosus (SLE), fat embolism, or infective endocarditis?</td> </tr> <tr> <td>Are there conjunctival hemorrhages or splinter hemorrhages under the fingernails to suggest endocarditis or vasculitis?</td> </tr> <tr> <td>Are there needle tracks to suggest right-sided endocarditis?</td> </tr> <tr> <td>Are there any abnormalities on chest examination (eg, adventitial sounds or a bruit)?</td> </tr> <tr> <td>Is there an audible chest bruit or murmur that increases with inspiration? These findings may indicate a large pulmonary arteriovenous malformation.</td> </tr> <tr> <td>Is the pulmonic heart sound (P2) augmented, or are there murmurs of tricuspid regurgitation or pulmonic insufficiency? These findings with or without a right ventricular lift may suggest pulmonary hypertension.</td> </tr> <tr> <td>Is there a heart murmur that might signal pulmonary vascular congestion (eg, mitral stenosis, mitral regurgitation) or endocarditis, a potential source of septic emboli?</td> </tr> <tr> <td>Does the patient have asymmetric peripheral edema or a posterior calf palpable cord to indicate deep venous thrombosis?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96530 Version 1.0</div></div></div>"},"96534":{"type":"graphic_figure","displayName":"Daily mood chart","title":"Daily mood chart","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Daily mood chart</div><div class=\"cntnt\"><img style=\"width:808px; height:693px;\" src=\"images/PSYCH/96534_Daily_mood_chart.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Long-term monitoring is valuable in bipolar disorder to facilitate recognition of the variability in the mood swings associated with the condition, including identification of symptom-free intervals. Ongoing monitoring also provides an \"early warning\" system and a method to recognize any patterns of stressful life events that may act as triggers.</LI>&#xD;&#xA;<LI>Various approaches that provide graphic representations of mood variability have been developed that include 2, 3, or 4 levels of depressive or mania-related severity. The levels are operationalized by indicating functionality in everyday life or its impairment due to mood symptoms.</LI>&#xD;&#xA;<LI>Detailed documentation of medication provides information about adherence and the relationship of the medication type and schedule to the mood swings.</LI>&#xD;&#xA;<LI>The National Institute of Mental Health's prospective Life Chart Method (NIMH-LCM) uses daily ratings by the person with bipolar disorder. The ratings specify the polarity an severity of manic and depressive episodes and their course; also recording the concomitant use/impact of medication and life events that may precipitate episodes.</LI>&#xD;&#xA;<LI>In a study to validate the NIMH-LCM instrument, researchers found that depression rates correlated highly with the Inventory of Depressive Symptomatology-clinician rated scale (IDS-C) (r = â0.785) and manic rates correlated highly with the Young Mania Rating Scale (YMRS) (r = 0.656)<SUP>[1]</SUP>.</LI>&#xD;&#xA;<LI>Mood Charting is a simplified patient self-report technique derived from the more extensive Life Chart approach. The participation of the patient in providing input to the daily documentation has been found to promote a more involved and collaborative therapeutic alliance with the clinician.</LI>&#xD;&#xA;<LI>Patient participation serves to reinforce education and information about the condition and how to manage lifestyle (sleep habits, etc) and promotes active involvement win the management of the disorder.</LI></UL></div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Denicoff KD, Leverich GS, Nolen WA, et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM&trade;-p) for longitudinal assessment of bipolar illness. Psychol Med 2000; 30:1391.</li>&#xD;&#xA;</ol>&#xD;&#xA;Leverich GS, Post RM. The NIMH Life Chart Manual&trade; for Recurrent Affective Illness: The LCM&trade; - S/P (Self-Version/Prospective). National Institute of Mental Health, 2002. Reproduced with permission from Robert M. Post, MD.</div><div id=\"graphicVersion\">Graphic 96534 Version 1.0</div></div></div>"},"96535":{"type":"graphic_figure","displayName":"PBGD splice variants","title":"PBGD gene alternative splicing: Housekeeping and erythroid-specific variants","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">PBGD gene alternative splicing: Housekeeping and erythroid-specific variants</div><div class=\"cntnt\"><img style=\"width:509px; height:247px;\" src=\"images/HEME/96535_PBGD_splice_variants.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Organization of the PBGD gene and alternative splicing to produce housekeeping and erythroid-specific transcripts. Exons are shown as solid rectangles; Alu repeat elements are shown by pentagons. The promotor for the housekeeping transcript is upstream of exon 1, and the promotor for the erythroid transcript is immediately upstream of exon 2. ATG-H and ATG-E&nbsp;represent the translation initiation codons for the housekeeping and erythroid forms, respectively.</div><div class=\"graphic_footnotes\">PBGD: porphobilinogen deaminase, also called hydroxymethylbilane synthase (HMBS).</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: The Metabolic and Molecular Basis of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al (Eds), McGraw-Hill, New York 2001. Copyright &copy; 2001 McGraw-Hill Education.</div><div id=\"graphicVersion\">Graphic 96535 Version 2.0</div></div></div>"},"96540":{"type":"graphic_table","displayName":"STIC studies","title":"Serous tubal intraepithelial neoplasm (STIC): Follow-up of cases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serous tubal intraepithelial neoplasm (STIC): Follow-up of cases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">No. of patients with STIC</td> <td class=\"subtitle1\">Positive washings</td> <td class=\"subtitle1\">Chemotherapy</td> <td class=\"subtitle1\">Recurrence</td> <td class=\"subtitle1\">Follow-up<br /> (in months)</td> </tr> <tr> <td>Paley et al. 2001<sup>[1]</sup></td> <td class=\"centered\">2</td> <td class=\"centered\">2 of 2</td> <td class=\"centered\">1</td> <td class=\"centered\">0</td> <td class=\"centered\">36 to 48</td> </tr> <tr> <td>Agoff et al. 2002/2004<sup>[2,3]</sup></td> <td class=\"centered\">3</td> <td class=\"centered\">1 of 3</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> <td class=\"centered\">36</td> </tr> <tr> <td>Leeper et al. 2002<sup>[4]</sup></td> <td class=\"centered\">2</td> <td class=\"centered\">1 of 2</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> <td class=\"centered\">8 to 17</td> </tr> <tr> <td>Manchanda et al. 2011/2012<sup>[5,6]</sup></td> <td class=\"centered\">7</td> <td class=\"centered\">3 of 7</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">7 to 48</td> </tr> <tr> <td>Powell et al. 2013<sup>[7]</sup></td> <td class=\"centered\">17</td> <td class=\"centered\">3 of 17</td> <td class=\"centered\">4</td> <td class=\"centered\">1 (43 months)</td> <td class=\"centered\">40 to 150</td> </tr> <tr> <td>Wethington et al. 2013<sup>[8]</sup></td> <td class=\"centered\">12</td> <td class=\"centered\">1 of 12</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">16 to 44</td> </tr> <tr> <td>Conner et al. 2014<sup>[9]</sup></td> <td class=\"centered\">11</td> <td class=\"centered\">5 of 11</td> <td class=\"centered\">3</td> <td class=\"centered\">1 (48 months)</td> <td class=\"centered\">12 to 96</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STIC: serous tubal intraepithelial carcinoma.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Paley PJ, Swisher EM, Garcia RL, et al. Gynecol Oncol 2001; 80:176.</li>&#xD;&#xA;    <li>Agoff SN, Mendelin JE, Grieco VS, Garcia RL. Am J Surg Pathol 2002; 26:171.</li>&#xD;&#xA;    <li>Agoff SN, Garcia RL, Goff B, Swisher E. Am J Surg Pathol 2004; 28:1112.</li>&#xD;&#xA;    <li>Leeper K, Garcia R, Swisher E, et al. Gynecol Oncol 2002; 87:52.</li>&#xD;&#xA;    <li>Manchanda R, Abdelraheim A, Johnson M, et al. BJOG 2011; 118:814.</li>&#xD;&#xA;    <li>Manchanda R, Drapkin R, Jacobs I, Menon U. Gynecol Oncol 2012; 124:185.</li>&#xD;&#xA;    <li>Powell CB, Swisher EM, Cass I, et al. Gynecol Oncol 2013; 129:364.</li>&#xD;&#xA;    <li>Wethington SL, Park KJ, Soslow RA, et al. Int J Gynecol Cancer 2013; 23:1603.</li>&#xD;&#xA;    <li>Conner JR, Meserve E, Pizer E, et al. Gynecol Oncol 2014; 132:280.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96540 Version 1.0</div></div></div>"},"96548":{"type":"graphic_table","displayName":"Causes of swallowing dysfunction in children","title":"Causes of swallowing dysfunction in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of swallowing dysfunction in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Anatomic abnormalities</td> </tr> <tr> <td class=\"subtitle2_single\">Location</td> <td class=\"subtitle2_single\">Disorder</td> </tr> <tr> <td class=\"indent1\">Nasopharynx</td> <td> <ul> <li>Choanal atresia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Oropharynx</td> <td> <ul> <li>Cleft lip/palate </li> <li>Micrognathia (eg, Pierre Robin syndrome or craniofacial dysostosis) </li> <li>Macroglossia (eg, in Beckwith-Wiedemann syndrome or hypothyroidism) </li> <li>Pharyngeal tumors and cysts </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Larynx</td> <td> <ul> <li>Laryngeal cleft </li> <li>Laryngeal web </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Esophagus and mediastinum</td> <td> <ul> <li>Tracheoesophageal fistula, with or without esophageal atresia </li> <li>Vascular rings </li> <li>Esophageal inflammation (eg, due to gastroesophageal reflux disease or eosinophilic esophagitis, causing dysphagia) </li> <li>Esophageal stricture (eg, due to severe esophagitis or caustic ingestion) </li> <li>Achalasia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Functional disorders </td> </tr> <tr> <td class=\"subtitle2_single\">Category</td> <td class=\"subtitle2_single\">Examples</td> </tr> <tr> <td class=\"indent1\">Delayed maturation</td> <td class=\"indent1\"> <ul> <li>Prematurity </li> <li>Down syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Static encephalopathy</td> <td class=\"indent1\"> <ul> <li>Cerebral palsy </li> <li>Intrauterine infections </li> <li>Birth trauma/asphyxia </li> <li>Intracranial hemorrhage </li> <li>Encephalitis/meningitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CNS malformation, mass or tumor</td> <td class=\"indent1\"> <ul> <li>Chiari malformations </li> <li>CNS tumor </li> <li>Traumatic brain injury </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cranial nerve palsy (especially CN IX or X)</td> <td class=\"indent1\"> <ul> <li>CNS process (meningitis, CNS tumor) </li> <li>Guillain Barr&#233; syndrome </li> <li>Multiple sclerosis </li> <li>Enterovirus 68, poliomyelitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Vocal cord paralysis</td> <td class=\"indent1\"> <ul> <li>Idiopathic </li> <li>Injury to the recurrent laryngeal nerve (eg, during delivery, or cardiothoracic surgery) </li> <li>CNS process </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Neuromuscular diseases</td> <td class=\"indent1\"> <ul> <li>Spinal muscular atrophy </li> <li>Muscular dystrophy </li> <li>Familial dysautonomia </li> <li>Myotonic dystrophy </li> <li>Myasthenia gravis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Other causes</td> </tr> <tr> <td class=\"subtitle2_single\">Category</td> <td class=\"subtitle2_single\">Examples</td> </tr> <tr> <td class=\"indent1\">Transient loss of consciousness</td> <td class=\"indent1\"> <ul> <li>Seizures </li> <li>Intoxication with alcohol or other drugs </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Medications that alter alertness</td> <td class=\"indent1\"> <ul> <li>Narcotics </li> <li>Anticonvulsants </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tachypnea with upper respiratory tract obstruction</td> <td class=\"indent1\"> <ul> <li>Bronchiolitis (especially RSV) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Iatrogenic</td> <td class=\"indent1\"> <ul> <li>Orogastric or nasogastric tubes </li> <li>Tracheostomy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Idiopathic&nbsp;</td> <td class=\"indent1\"> <ul> <li>Neurologically normal infant with aspiration </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; CN: cranial nerves; RSV: respiratory syncytial virus.</div><div id=\"graphicVersion\">Graphic 96548 Version 2.0</div></div></div>"},"96558":{"type":"graphic_table","displayName":"Differential diagnosis of fetal abdominal wall defects","title":"Differential diagnosis of fetal abdominal wall defects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fetal abdominal wall defects</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Covering membrane</td> <td class=\"subtitle1\">Site of defect</td> <td class=\"subtitle1\">Findings</td> </tr> <tr class=\"divider_bottom\"> <td>Omphalocele</td> <td class=\"centered\">Yes</td> <td>Cord inserts into the apex of omphalocele membrane.</td> <td>Full thickness abdominal wall defect with covering membrane and herniation of viscera; liver is often herniated, stomach and spleen may also herniate. Associated abnormalities are common and include additional gastrointestinal abnormalities, cardiac defects, genitourinary anomalies, orofacial clefts, neural tube defects, defects of the diaphragm, polyhydramnios, and growth restriction.</td> </tr> <tr class=\"divider_bottom\"> <td>Gastroschisis</td> <td class=\"centered\">No</td> <td>Cord inserts adjacent to the abdominal wall defect. The defect is usually to the right of the umbilicus.</td> <td>Full thickness and usually small abdominal wall defect with herniation of bowel, which floats in the amniotic fluid. Liver not usually herniated. Associated anatomic defects uncommon.</td> </tr> <tr class=\"divider_bottom\"> <td>Umbilical hernia</td> <td class=\"centered\">No</td> <td>Defect in linea alba. Cord inserts into the hernia sac.</td> <td>Loops of bowel may be seen within the umbilical cord or bulge into otherwise intact abdominal wall.</td> </tr> <tr class=\"divider_bottom\"> <td>Pentalogy of Cantrell</td> <td class=\"centered\">Yes</td> <td>Cord inserts into omphalocele membrane. The associated abnormalities are cephalad to the umbilical insertion.</td> <td>Pentalogy consists of <ol class=\"decimal_heading\"> <li>lower sternum defect, </li> <li>anterior diaphragm defect, </li> <li>parietal pericardium defect, </li> <li>omphalocele, </li> <li>congenital heart anomalies. </li> </ol> Ectopia cordis may be present.</td> </tr> <tr class=\"divider_bottom\"> <td>Body stalk anomaly</td> <td class=\"centered\">Yes</td> <td>Variable</td> <td>Large body wall defects of the thorax and/or abdomen and limb defects. The intrathoracic and abdominal organs lie outside the cavity and are contained within a sac. The umbilical cord may be extremely short. Severe kyphoscoliosis is often present. Large complex cranial defects and facial clefts may also be present. The combination of scoliosis, omphalocele, short cord, and bizarre appearance of the fetal body suggests this diagnosis. Two key features that distinguish this anomaly from omphalocele are that the fetus appears adherent to the placenta and there is no freely floating umbilical cord.</td> </tr> <tr class=\"divider_bottom\"> <td>Bladder exstrophy</td> <td class=\"centered\">No</td> <td>Cord insertion lower than normal on fetal abdomen. Abdominal wall defect is below umbilicus.</td> <td>Nonvisualization of the bladder is a key finding. Visualization of a normal urinary bladder excludes the diagnosis. Classic bladder exstrophy is not associated with cranial, thoracic, umbilical, spinal, or limb defects.</td> </tr> <tr class=\"divider_bottom\"> <td>Cloacal exstrophy (also called OEIS complex: omphalocele, exstrophy of the bladder, imperforate anus, spinal defects)</td> <td class=\"centered\">Yes</td> <td>Cord insertion lower than normal on fetal abdomen. Abdominal wall defect is below umbilicus.</td> <td>Full thickness ventral abdominal wall defect with an omphalocele at the superior margin of the defect and exposed bowel and bladder at the inferior margin. The lower abdominal wall defect helps to distinguish cloacal exstrophy from simple omphalocele. The major findings are: nonvisualization of the bladder, omphalocele, meningomyelocele, midline infraumbilical anterior wall defect. Lower extremity defects, renal anomalies, widened pubic arches, narrow thorax, hydrocephalus, single umbilical artery may be observed.</td> </tr> <tr> <td>Amniotic band sequence</td> <td class=\"centered\">No</td> <td>Variable</td> <td>Constriction rings and limb and digital amputation are common findings but the clinical spectrum is highly variable. Craniofacial abnormalities and nonmidline body wall defects may be present.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: If the omphalocele sac ruptures, bowel may be seen floating in the amniotic fluid, as in gastroschisis. In cloacal exstrophy, hydrocolpos can be mistaken for a bladder containing urine.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Prefumo F, Izzi C. Fetal abdominal wall defects. Best Pract Res Clin Obstet Gynaecol 2014; 28:391.</li>&#xD;&#xA;    <li>Nakagawa M, Hara M, Shibamoto Y. MRI findings in fetuses with an abdominal wall defect: Gastroschisis, omphalocele, and cloacal exstrophy. Jpn J Radiol 2013; 31:153.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96558 Version 2.0</div></div></div>"},"96559":{"type":"graphic_figure","displayName":"GPI anchor on RBC","title":"Structure of the glycosylphosphatidylinositol anchor on a RBC","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Structure of the glycosylphosphatidylinositol anchor on a RBC</div><div class=\"cntnt\"><img style=\"width:472px; height:643px;\" src=\"images/HEME/96559_GPI_anchor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of GPI-linked protein on red blood cell surface; the GPI linkage is deficient&nbsp;in paroxysmal nocturnal hemoglobinuria (PNH).</div><div class=\"graphic_footnotes\">GPI: Glycosylphosphatidylinositol; RBC: red blood cell.</div><div class=\"graphic_reference\">Courtesy of Robert&nbsp;A Brodsky, MD.</div><div id=\"graphicVersion\">Graphic 96559 Version 2.0</div></div></div>"},"96560":{"type":"graphic_figure","displayName":"Hemolysis in PNH","title":"Mechanisms of hemolysis in paroxysmal nocturnal hemoglobinuria","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Mechanisms of hemolysis in paroxysmal nocturnal hemoglobinuria</div><div class=\"cntnt\"><img style=\"width:527px; height:703px;\" src=\"images/HEME/96560_Hemolysis_in_PNH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanisms of red blood cell hemolysis in PNH.<br />(A) Normal red blood cells have GPI-linked complement inhibitors CD59 and CD55, which prevent intravascular and extravascular hemolysis, respectively.<br />(B) In PNH, CD59 and CD55 are deficient due to lack of the GPI anchor. Intravascular hemolysis caused by the complement membrane attack complex (MAC) predominates.<br />(C) Eculizumab is a humanized monoclonal antibody to complement component C5 that blocks C5 conversion to C5a and C5b and prevents intravascular hemolysis. Eculizumab does not block extravascular hemolysis due to lack of CD55.<br />Refer to UpToDate topics on PNH pathogenesis and treatment for further details.</div><div class=\"graphic_footnotes\">PNH: paroxysmal nocturnal hemoglobinuria; GPI: glycosylphosphatidylinositol; MAC: membrane attack complex.</div><div class=\"graphic_reference\">Courtesy of Robert A Brodsky, MD.</div><div id=\"graphicVersion\">Graphic 96560 Version 2.0</div></div></div>"},"96561":{"type":"graphic_picture","displayName":"Perianal streptococcal infection","title":"Perianal streptococcal infection","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Perianal streptococcal infection</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96561_Perianal_streptococ_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal streptococcal infection in a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96561 Version 1.0</div></div></div>"},"96562":{"type":"graphic_picture","displayName":"Extramammary Paget disease","title":"Extramammary Paget disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Extramammary Paget disease</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96562_Extramammary_Paget_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Localized red plaque with erosions.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96562 Version 1.0</div></div></div>"},"96563":{"type":"graphic_algorithm","displayName":"Stepwise approach to perioperative cardiac assessment for CAD","title":"Stepwise approach to perioperative cardiac assessment for CAD","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Stepwise approach to perioperative cardiac assessment for CAD</div><div class=\"cntnt\"><img style=\"width:549px; height:770px;\" src=\"images/CARD/96563_Step_app_peri_card_ases_CAD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; CABG: coronary artery bypass graft surgery; CAD: coronary artery disease; CPG: clinical practice guideline; DASI: Duke Activity Status Index; GDMT: guideline-directed therapy; HF: heart failure; MACE: major adverse cardiac event; MET: metabolic equivalent; NB: no benefit; NSQIP: National Surgical Quality Improvement Program; PCI: percutaneous coronary intervention; RCRI: Revised Cardiac Risk Index; STEMI: ST elevation myocardial infarction; UA/NSTEMI: unstable angina/non-ST elevation myocardial infarction; VHD: valvular heart disease.</div><div class=\"graphic_reference\">Reproduced from: Fleisher LA, Fleischmann KE, Auerbach AD. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014. [Epub ahead of print]. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96563 Version 3.0</div></div></div>"},"96564":{"type":"graphic_picture","displayName":"Tools for removal of magnetic intranasal foreign bodies","title":"Tools for removal of magnetic intranasal foreign bodies","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Tools for removal of magnetic intranasal foreign bodies</div><div class=\"cntnt\"><img style=\"width:588px; height:440px;\" src=\"images/EM/96564_Tool_rmov_mag_nas_forgn_bod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnets in the nose can be retrieved using a rare-earth magnet that is clamped in a hemostat or a pocket magnet.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson MD.</div><div id=\"graphicVersion\">Graphic 96564 Version 1.0</div></div></div>"},"96565":{"type":"graphic_picture","displayName":"Magnet intranasal foreign body removal","title":"Magnetic intranasal foreign body removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic intranasal foreign body removal</div><div class=\"cntnt\"><img style=\"width:217px; height:598px;\" src=\"images/EM/96565_Mag_intran_forgn_bod_remov.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Intranasal magnet.<br />(B) Magnetic foreign body attached to a clamped rare-earth magnet (larger and darker round disk) after removal.<br />(C) Mucosal injury and cartilage exposure from the pressure effects of the paired magnets.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson MD.</div><div id=\"graphicVersion\">Graphic 96565 Version 1.0</div></div></div>"},"96566":{"type":"graphic_table","displayName":"Intrapartum management of glucose and insulin","title":"Intrapartum glycemic management of women with type 1 and type 2 diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intrapartum glycemic management of women with type 1 and type 2 diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Maternal plasma glucose mg/dL (mmol/L)</td> <td class=\"subtitle1\">Glucose management using subcutaneous rapid-acting insulin (units)*</td> <td class=\"subtitle1\" colspan=\"2\">Intravenous solution and comments</td> <td class=\"subtitle1\">Alternative approach to glucose management using intravenous insulin(units/hour)<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#8804;120 (6.6)</td> <td>0</td> <td rowspan=\"2\">5% dextrose in 0.45% NS<sup>&#916;</sup></td> <td>&nbsp;</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td>121 to 140 (6.7 to 7.7)</td> <td>1</td> <td>&nbsp;</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>141 to 160 (7.8 to 8.8)</td> <td>2</td> <td rowspan=\"4\">0.45% NS<sup>&#916;</sup></td> <td>&nbsp;</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td>161 to 180 (8.9 to 9.9)</td> <td>3</td> <td rowspan=\"2\">Check ketones</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td>181 to 200* (10 to 11.1)</td> <td>4</td> <td>4</td> </tr> <tr> <td>&#8805;200 (11.1)</td> <td>4 units subcutaneously plus a short acting or regular insulin by intravenous push starting at 2 units</td> <td>Check ketones and intensive monitoring </td> <td>4 units/hour intravenously plus a short acting or regular insulin intravenous push starting at 2 units</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In pregnant women with type 1 or type 2 diabetes managed prepartum with multiple daily insulin injections, intrapartum glucose control can be achieved using&nbsp;either intermittent subcutaneous insulin&nbsp;or continuous intravenous insulin infusion. <br /><br />If induction is scheduled, the night before induction the patient should take her usual evening/bedtime dose of intermediate-acting insulin, short- or rapid-acting insulin, oral anti-hyperglycemic medication, or continuous insulin infusion. Patients using long-acting insulins should decrease their evening/bedtime dose by 50%. The morning of induction, the patient should take 50% of her morning intermediate-or long-acting insulin dose to decrease the amount of insulin infusion needed during induction. Women who are not eating or drinking are given 5% dextrose&nbsp;with 0.45%NS intravenous infusion&nbsp;for glucose levels &lt;140 mg/dL (7.7 mmol/L).</div><div class=\"graphic_footnotes\">CBG: capillary blood glucose; NS: normal saline.<br />* Check glucose every two hours in patients receiving insulin subcutaneously.<br />Â¶ Check glucose every&nbsp;hour during insulin infusion.&nbsp;For the intravenous insulin infusion, mix regular insulin with saline to yield a concentration of 1 unit insulin/10 mL saline in the bag and prime the line with 10 mL of the insulin mixture. After the line connected to the bag has been primed, it can be connected to the patientâs main intravenous infusion line.<br />Î Consider limiting daily total sodium to 140 mEq/day by changing to 5% dextrose after 2 liters of 5% dextrose with 0.45% NS.</div><div class=\"graphic_reference\">Modified from: Kitzmiller JL, Gavin L. Preexisting diabetes and pregnancy. In: Manual of Endocrinology and Metabolism, 3rd ed, Lavin N (Ed), Lippincott Williams &amp; Wilkins, 2002.</div><div id=\"graphicVersion\">Graphic 96566 Version 4.0</div></div></div>"},"96567":{"type":"graphic_table","displayName":"Sliding scale insulin postpartum","title":"Sliding insulin scale for postpartum management of glucose levels*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sliding insulin scale for postpartum management of glucose levels*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Glucose<br /> (mg/dL)</td> <td class=\"subtitle1\" colspan=\"6\">All women with diabetes regardless of classification</td> </tr> <tr> <td>&#60;50 (2.8 mmol/L)</td> <td colspan=\"6\"> <ol> <li>Give 25 mL (12.5 gm) of D50% IV push&nbsp;x 1 </li> <li>Recheck BG in 15 minutes: <p class=\"indent1\">a. If repeat BG &#60;50 mg/dL (2.8 mmol/L) repeat step 1 &#38; 2</p> <p class=\"indent1\">b. If repeat BG is 50 to 69 mg/dL (2.8 to 3.8 mmol/L)&nbsp;go to next level below</p> </li> </ol> </td> </tr> <tr> <td>50 to 69 (2.8 to 3.8 mmol/L)</td> <td colspan=\"6\"> <ol> <li>No insulin; if alert and tolerating&nbsp;oral fluids, give 4 oz juice; if unable to tolerate fluids, give 25 mL (12.5 gm) of D50% IV push&nbsp;x 1 </li> <li>Recheck BG in 15 minutes: <p class=\"indent1\">a. If repeat BG is &#60;50 mg/dL (2.8 mmol/L): Follow step above for BG &#60;50 mg/dL (2.8 mmol/L)</p> <p class=\"indent1\">b. If repeat BG is 50 to 69 mg/dL (2.8 to 3.8 mmol/L): Repeat 1 above </p> <p class=\"indent1\">c. If repeat BG is 70 to 100 mg/dL (3.9 to 5.5 mmol/L), follow step below for 70 to 100 mg/dL (3.9 to 5.5 mmol/L)&nbsp;</p> </li> <li>Reevaluate insulin dosage </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>70 to 100 (3.9 to 5.5 mmol/L)</td> <td colspan=\"6\"> <ol> <li>No insulin; if this was bedtime BG, recheck CBG at 3:00 AM </li> <li>Give snack if eating (half of a sandwich, three graham crackers, or 4 oz milk) </li> <li>If NPO, increase rate of D5 solution, recheck BG in two hours </li> <li>Reevaluate insulin dosage </li> </ol> </td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Glucose<br /> (mg/dL)</td> <td class=\"subtitle1\" colspan=\"2\">Low dose<br /> (pre-pregnancy BMI &#60;25; T1DM)</td> <td class=\"subtitle1\" colspan=\"2\">Intermediate dose<br /> (pre-pregnancy BMI 25 to 35, T2DM)</td> <td class=\"subtitle1\" colspan=\"2\">High dose<br /> (pre-pregnancy BMI &#62;35, T2DM)</td> </tr> <tr> <td class=\"subtitle2\">AC or NPO</td> <td class=\"subtitle2\">HS</td> <td class=\"subtitle2\">AC or NPO</td> <td class=\"subtitle2\">HS</td> <td class=\"subtitle2\">AC or NPO</td> <td class=\"subtitle2\">HS</td> </tr> <tr> <td>100 to 150 (5.5 to 8.3 mmol/L)</td> <td>No insulin</td> <td>No insulin</td> <td>No insulin</td> <td>No insulin</td> <td>No insulin</td> <td>No insulin</td> </tr> <tr> <td>151 to 200 (8.4 to 11.1 mmol/L)</td> <td>1 unit</td> <td>No insulin</td> <td>2 units</td> <td>No insulin</td> <td>4 units</td> <td>2 units</td> </tr> <tr> <td>201 to 250 (11.2 to 13.8 mmol/L)</td> <td>2 units</td> <td>No insulin</td> <td>4 units</td> <td>1 unit</td> <td>8 units</td> <td>4 units</td> </tr> <tr> <td>251 to 300 (13.9 to 16.6 mmol/L)</td> <td>3 units</td> <td>1 unit</td> <td>6 units</td> <td>2 units</td> <td>12 units</td> <td>6 units</td> </tr> <tr> <td>301 to 350 (16.7 to 19.4 mmol/L)</td> <td>4 units</td> <td>2 units</td> <td>8 units</td> <td>4 units</td> <td>16 units</td> <td>8 units</td> </tr> <tr> <td>351 to 400 (19.5 to 21.2 mmol/L)</td> <td>5 units</td> <td>3 units</td> <td>10 units</td> <td>6 units</td> <td>20 units</td> <td>10 units</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Do not give insulin supplemental sliding scale alone for more than 24 hours unless blood glucose goals meet or there is reason for not adding maintenance insulin. If goals are not met, add daily maintenance dose.</LI>&#xD;&#xA;<LI>Do not give sliding scale more frequently than every four hours.</LI>&#xD;&#xA;<LI>Obtain nutrition consult to recalculate ADA diet (based on ideal body weight, 500 additional calories if breast feeding, and adjustments for post-surgery recovery).</LI>&#xD;&#xA;<LI>Postpartum insulin total daily dose for subcutaneous, multiple daily injections when resumed normal activity and appropriate diet are calculated at approximately 50% of pre-delivery dose or 0.6 units per kg true body weight.</LI></UL></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; BG: blood glucose; AC: before meal; NPO: nothing by mouth; BMI: body mass index; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; HS: hour of sleep; ADA: American Diabetes Association; CBG: capillary blood glucose; oz: ounces; %: percent; IV: intravenous.<br />* Not for DKA or hyperosmolar non-ketotic state.</div><div id=\"graphicVersion\">Graphic 96567 Version 1.0</div></div></div>"},"96568":{"type":"graphic_picture","displayName":"RA boutonniere and Z-deformities of hand","title":"Rheumatoid arthritis hand deformities: Boutonniere deformity and Z-deformity of the thumb","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis hand deformities: Boutonniere deformity and Z-deformity of the thumb</div><div class=\"cntnt\"><img style=\"width:582px; height:447px;\" src=\"images/RHEUM/96568_Boutonnie_defor_Zdefor_thmb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A woman with longstanding rheumatoid arthritis has soft tissue swelling and subluxation of the metacarpophalangeal joints. The right thumb shows hyperextension of the interphalangeal joint (a Z deformity). Both ring fingers have boutonniere deformities with flexion of the proximal and hyperextension of the distal interphalangeal joints. </div><div class=\"graphic_reference\">Copyright Â© 2014 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 96568 Version 2.0</div></div></div>"},"96569":{"type":"graphic_picture","displayName":"Rheumatoid arthritis metatarsal head subluxation","title":"Rheumatoid arthritis in the feet: Metatarsal head subluxation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis in the feet: Metatarsal head subluxation</div><div class=\"cntnt\"><img style=\"width:306px; height:464px;\" src=\"images/RHEUM/96569_Lat_drift_plantar_subluxati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic inflammation at the metatarsophalangeal (MTP) joints causes damage resulting in subluxation of the toes upwards. With the MTP joints displaced, weightbearing is not shared through the toes, but falls directly on the prominent metatarsal heads. This painful condition results in pain on weightbearing and difficulty in walking, and can cause the metatarsal to erode through the skin on the sole of the foot. Treatment in the early stages includes appropriate shoes and fitting of an orthotic that will support weight away from the painful metatarsal heads. Late-stage treatment may involve surgical excision of the prominent metatarsal heads. </div><div class=\"graphic_reference\">Copyright Â© 2014 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 96569 Version 3.0</div></div></div>"},"96570":{"type":"graphic_picture","displayName":"Erosive vulvar lichen planus","title":"Erosive vulvar lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosive vulvar lichen planus</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/96570_Erosive_vulvar_lichen_planu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vulvar lichen planus demonstrating loss of architecture, muddy white macules, and formation of vulvar synechiae causing superior and inferior restriction of the introitus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96570 Version 1.0</div></div></div>"},"96571":{"type":"graphic_picture","displayName":"Vulvar lichen planus with erosions","title":"Erosive vulvar lichen planus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Erosive vulvar lichen planus</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/96571_Vulvar_lichen_planu_erosion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions, muddy white macules, and streaks bilaterally on the medial labia majora and interlabial folds.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96571 Version 1.0</div></div></div>"},"96606":{"type":"graphic_figure","displayName":"Crowing rooster maneuver in a pediatric patient","title":"Crowing rooster maneuver in a pediatric patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crowing rooster maneuver in a pediatric patient</div><div class=\"cntnt\"><img style=\"width:427px; height:406px;\" src=\"images/EM/96606_Crowing_rooster_maneuver_in_a_pediatric_patient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The physician asks the patient to clasp his or her hands behind the head. While standing behind the patient, the physician grasps the elbows and exerts backward and superiorly directed traction as pictured. &nbsp;</div><div id=\"graphicVersion\">Graphic 96606 Version 1.0</div></div></div>"},"96607":{"type":"graphic_figure","displayName":"Horizontal arm traction maneuver in a pediatric patient","title":"Horizontal arm traction maneuver in a pediatric patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Horizontal arm traction maneuver in a pediatric patient</div><div class=\"cntnt\"><img style=\"width:427px; height:406px;\" src=\"images/EM/96607_Horizontal_arm_traction_maneuver_in_a_pediatric_patient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The physician pulls the flexed arm across the anterior chest with steady, prolonged traction while providing pushing against the opposite shoulder. </div><div id=\"graphicVersion\">Graphic 96607 Version 1.0</div></div></div>"},"96608":{"type":"graphic_figure","displayName":"Hooking maneuver in a child","title":"Hooking maneuver in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hooking maneuver in a child</div><div class=\"cntnt\"><img style=\"width:427px; height:406px;\" src=\"images/EM/96608_Hooking_maneuver_in_a_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clinician performs the hooking maneuver by hooking the curled fingers under the anterior costal margins and gently pulling the rib cage anteriorly. </div><div id=\"graphicVersion\">Graphic 96608 Version 1.0</div></div></div>"},"96611":{"type":"graphic_picture","displayName":"Suture and scissors for performing vulvar biopsy","title":"Use of a suture and scissors to perform a vulvar biopsy","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Use of a suture and scissors to perform a vulvar biopsy</div><div class=\"cntnt\"><img style=\"width:537px; height:590px;\" src=\"images/OBGYN/96611_Suture_scissors_vulvar_biop.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96611 Version 1.0</div></div></div>"},"96617":{"type":"graphic_diagnosticimage","displayName":"Normal ACL and avulsion injuries on MRI","title":"MRI of normal ACL and with avulsion injuries","html":"<div class=\"graphic\"><div style=\"width: 703px\" class=\"figure\"><div class=\"ttl\">MRI of normal ACL and with avulsion injuries</div><div class=\"cntnt\"><img style=\"width:683px; height:255px;\" src=\"images/RADIOL/96617_Normal_ACL_avulsion_inj_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A and B are sagittal projections of the knee using proton density fat saturated sequences. Image A shows a normal ACL (arrowheads). Image B shows a full thickness tear (arrow) and fraying of the proximal and distal components (arrowheads). Image C is a sagittal image of the knee using T2 weighted, fast spin echo technique and shows complete avulsion of the ACL at its insertion on to the tibia (arrow), and normal proximal ligament (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; ACL: anterior cruciate ligament.</div><div id=\"graphicVersion\">Graphic 96617 Version 1.0</div></div></div>"},"96620":{"type":"graphic_figure","displayName":"Time to appearance of ipilimumab-related adverse events","title":"Time to appearance of ipilimumab-related adverse events","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Time to appearance of ipilimumab-related adverse events</div><div class=\"cntnt\"><img style=\"width:528px; height:304px;\" src=\"images/ONC/96620_Kntcapprimnrltadvrsevn.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with Ipilimumab. J Clin Oncol 2012; 30:2691-7. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96620 Version 3.0</div></div></div>"},"96622":{"type":"graphic_picture","displayName":"Rash associated with checkpoint inhibition","title":"Rash associated with checkpoint inhibition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash associated with checkpoint inhibition</div><div class=\"cntnt\"><img style=\"width:295px; height:720px;\" src=\"images/ONC/96622_Rash_assoc_chckpnt_inhibit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rash due to ipilimumab in patients with metastatic melanoma.<br />(A) Generalized erythema, erythematous macules and papules.<br />(B) Generalized erythema, erythematous macules, erythematous and some heme-crusted papules, and exfoliative scale on upper extremities in patient with high-grade rash.<br />(C) Maculopapular exanthema.</div><div class=\"graphic_reference\">Reproduced from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69:e121. Illustration used with the permission of Elsevier Inc. All rights reserved.</li>&#xD;&#xA;    <li>Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161. Illustration used with the permission of Elsevier Inc. All rights reserved.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96622 Version 2.0</div></div></div>"},"96623":{"type":"graphic_picture","displayName":"Colitis associated with checkpoint inhibition","title":"Colitis associated with checkpoint inhibition","html":"<div class=\"graphic\"><div style=\"width: 955px\" class=\"figure\"><div class=\"ttl\">Colitis associated with checkpoint inhibition</div><div class=\"cntnt\"><img style=\"width:935px; height:708px;\" src=\"images/ONC/96623_Colitis_assct_chckpnt_inhbt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Colonoscopic view of bowel edema and ulceration in the descending colon of patient 29, who experienced autoimmune colitis.<br />(B) Histopathologic analyses revealed focal active colitis (left panel) with crypt destruction, loss of goblet cells, and neutrophilic infiltrates in the crypt epithelium (right panel) (original magnification: left panel, Ã20; right panel, Ã60).</div><div class=\"graphic_reference\">Annals of Surgical Oncology, Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study, Vol. 12, 2005, p. 1005, Maker AV, Phan GQ, Attia P, et al, &copy; The Society of Surgical Oncology, Inc. 2005. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 96623 Version 2.0</div></div></div>"},"96625":{"type":"graphic_diagnosticimage","displayName":"Hypophysitis associated with checkpoint inhibition","title":"Hypophysitis associated with checkpoint inhibition","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Hypophysitis associated with checkpoint inhibition</div><div class=\"cntnt\"><img style=\"width:783px; height:388px;\" src=\"images/ONC/96625_Hypphystasctchckpntinhbt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal MRI section from patient 7 before anti-CTLA-4 antibody treatment and after onset of clinical symptoms. Pituitary height is in parentheses.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96625 Version 2.0</div></div></div>"},"96627":{"type":"graphic_picture","displayName":"Lobomycosis with verrucous features","title":"Lobomycosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lobomycosis</div><div class=\"cntnt\"><img style=\"width:590px; height:387px;\" src=\"images/DERM/96627_Lobomycosis_verrucous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large plaque with peripheral nodules, verrucous changes, hypopigmentation, and an erosion in a patient with lobomycosis.</div><div class=\"graphic_reference\">Courtesy of Ted Rosen, MD.</div><div id=\"graphicVersion\">Graphic 96627 Version 1.0</div></div></div>"},"96646":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for body dysmorphic disorder","title":"DSM-5 diagnostic criteria for body dysmorphic disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for body dysmorphic disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Preoccupation with one or more perceived defects or flaws in physical appearance that are not observable or appear slight to others.</td> </tr> <tr> <td><strong>B.</strong> At some point during the course of the disorder, the individual has performed repetitive behaviors (eg, mirror checking, excessive grooming, skin picking, reassurance seeking) or mental acts (eg, comparing his or her appearance with that of others) in response to the appearance concerns.</td> </tr> <tr> <td><strong>C.</strong> The preoccupation causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>D.</strong> The appearance preoccupation is not better explained by concerns with body fat or weight in an individual whose symptoms meet diagnostic criteria for an eating disorder.</td> </tr> <tr> <td><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\"><strong>With muscle dysmorphia:</strong> The individual is preoccupied with the idea that his or her body build is too small or insufficiently muscular. This specifier is used even if the individual is preoccupied with other body areas, which is often the case.</td> </tr> <tr> <td><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\">Indicate degree of insight regarding body dysmorphic disorder beliefs (eg, \"I look ugly\" or \"I look deformed\").</td> </tr> <tr> <td class=\"indent2\"><strong>With good or fair insight:</strong> The individual recognizes that the body dysmorphic disorder beliefs are definitely or probably not true or that they may or may not be true.</td> </tr> <tr> <td class=\"indent2\"><strong>With poor insight:</strong> The individual thinks that the body dysmorphic disorder beliefs are probably true.</td> </tr> <tr> <td class=\"indent2\"><strong>With absent insight/delusional beliefs:</strong> The individual is completely convinced that the body dysmorphic disorder beliefs are true.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright &copy; 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 96646 Version 5.0</div></div></div>"},"96647":{"type":"graphic_table","displayName":"Questions to diagnose body dysmorphic disorder","title":"Questions to diagnose body dysmorphic disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to diagnose body dysmorphic disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Questions to diagnose body dysmorphic disorder</td> </tr> <tr> <td class=\"indent1\">1. \"Are you very worried about your appearance in any way?\" or \"Are you unhappy with how you look?\"</td> </tr> <tr> <td class=\"indent1\">2. Ask the patient to describe their concern by asking a question like \"What don't you like about how you look?\" or \"Can you tell me about your concern?\"</td> </tr> <tr> <td class=\"indent1\">3. Ask if there are other disliked body areas;&nbsp;for example, \"Are you unhappy with any other aspects of your appearance, such as your face, skin, hair, nose, or the shape or size of any other body area?\"</td> </tr> <tr> <td class=\"indent1\">4. Ascertain that the patient is preoccupied with these perceived flaws by asking \"How much time would you estimate that you spend each day thinking about your appearance if you add up all the time you spend?\" or \"Do these concerns preoccupy you?\"</td> </tr> <tr> <td class=\"indent1\">5. \"How much distress do these concerns cause you?\" Ask specifically about resulting anxiety, social anxiety, depression, and suicidal thinking.</td> </tr> <tr> <td class=\"indent1\">6. Ask about effects of the appearance preoccupations on the patient's life; for example, \"Do these concerns interfere with your life or cause problems for you?\" Ask specifically about effects on school, work, other aspects of role functioning (eg, managing a household), relationships, intimacy, family and social activities, household tasks, and other activities and responsibilities.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96647 Version 2.0</div></div></div>"},"96649":{"type":"graphic_table","displayName":"Styles of yoga","title":"Styles of yoga: Theory, features, and level of exertion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Styles of yoga: Theory, features, and level of exertion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Style</td> <td class=\"subtitle1\">Theory and key features</td> <td class=\"subtitle1\">Level of exertion</td> </tr> <tr class=\"divider_bottom\"> <td>Anusara</td> <td> <ul> <li>Lighthearted style of yoga </li> <li>Derived from Iyengar yoga with elements of Hindu spirituality </li> </ul> </td> <td> <ul> <li>Gentle to moderate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ashtanga</td> <td> <ul> <li>Synchronizes breathing with progressive and continuous series of postures </li> <li>Less emphasis on alignment of specific postures than other styles </li> </ul> </td> <td> <ul> <li>Vigorous, fast-paced, demanding </li> <li>Practitioners should be healthy and comfortable with athletic difficulty </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Bikram</td> <td> <ul> <li>26-posture series that begins and ends with controlled breathing </li> <li>Each floor posture followed by brief relaxation period </li> <li>Classroom heated to 100 to 110&#176;F with 30 to 40% humidity </li> <li>Taught exactly the same way in every studio, making acquisition easier </li> </ul> </td> <td> <ul> <li>Vigorous </li> <li>Practitioners should be healthy, able to tolerate heat, humidity, and high level of athletic difficulty </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hatha or Integrated</td> <td> <ul> <li>Generic terms for a combination of different styles of yoga, including postures, controlled breathing, meditation, relaxation techniques, and sometimes chanting and devotional practices </li> </ul> </td> <td> <ul> <li>Depends on the instructor's choice of components </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Iyengar<br /> <a href=\"https://iynaus.org/\" target=\"_blank\">(www.iynaus.org)</a></td> <td> <ul> <li>Analytical with constant attention to correct alignment </li> <li>Anatomically sophisticated and therapeutically oriented </li> <li>Props (belts, blocks, and pillow-like bolsters) to guide beginners into correct postures </li> </ul> </td> <td> <ul> <li>Gentle to moderate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Kirtan Kriya</td> <td> <ul> <li>A form of chanting meditation from Kundalini yoga </li> <li>Chanting accompanied by performing ritual finger movements (mudras) </li> </ul> </td> <td> <ul> <li>Gentle </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Kripalu<br /> (<a href=\"http://www.kripalu.org/\" target=\"_blank\">www.kripalu.org</a>)</td> <td> <ul> <li>Posture sequences not standardized, so every class is different </li> <li>Less strict emphasis on physical alignment </li> </ul> </td> <td> <ul> <li>Gentle to moderate </li> <li>Beginning practitioners, healthy adults, and those with chronic conditions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Kundalini<br /> (<a href=\"http://www.kundaliniresearchinstitute.org/\" target=\"_blank\">www.kundalinresearchinstitute.org</a>)</td> <td> <ul> <li>Combines meditation, mantra, physical exercises, and breath control </li> <li>More emphasis on spiritual and philosophical aspects, but includes postures </li> </ul> </td> <td> <ul> <li>Gentle to moderate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Therapeutic yoga</td> <td> <ul> <li>For those recovering from, or living with, injury or illness </li> <li>Blends restorative yoga (supported postures), gentle yoga, regulated breathing, hands-on healing, and guided meditation techniques </li> </ul> </td> <td> <ul> <li>Gentle </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Silver yoga</td> <td> <ul> <li>Created so seniors could safely practice yoga, by combining the principles of hatha yoga and gerontology </li> <li>Distinct in that it takes into consideration the limitations of the participants </li> </ul> </td> <td> <ul> <li>Gentle </li> <li>Seniors </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Sudarshan Kriya (SKY)<br /> (<a href=\"http://www.artofliving.org/sudarshan-kriya\"><span style=\"color: #3966bf;\">www.artofliving.org/sudarshan-kriya</span></a>)</td> <td> <ul> <li>Breathing and chanting with minimal attention to posture </li> <li>Four breathing techniques used together believed to change emotional states <ul> <li>Victorious or Ujjayi breath -&nbsp;Slow controlled breathing technique accomplished by partially closing the glottis leading to increased airway resistance </li> <li>Bellows breath -&nbsp;Rapid inhalation and forceful exhalation (30 breaths per minute) </li> <li>Chanting - \"Om\" chanted three times with very prolonged expiration </li> <li>Sudarshan Kriya -&nbsp;Rhythmic, cyclical breathing with slow, medium, and fast cycles </li> </ul> </li> </ul> </td> <td> <ul> <li>Gentle </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Viniyoga</td> <td> <ul> <li>How breathing affects postures, rather than precise execution of posture </li> <li>Individualized approach to each practitioner's unique stage of life, health, goals, and limitations </li> </ul> </td> <td> <ul> <li>Gentle </li> <li>Beginners, and those who want to focus on flexibility, injury recovery, body awareness, and relaxation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Vital&#64;Work</td> <td> <ul> <li>Worksite lifestyle program designed to improve mental and physical functioning </li> <li>Includes weekly yoga classes, workout sessions, unsupervised aerobic exercise, and visits to a trained personal coach </li> </ul> </td> <td> <ul> <li>Moderate </li> <li>All practitioners free of serious underlying disease </li> </ul> </td> </tr> <tr> <td>Yoga Nidra</td> <td> <ul> <li>Awareness and relaxation of each part of the body </li> <li>Focus on positive statements </li> </ul> </td> <td> <ul> <li>Gentle </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Broad WJ. Styles of yoga. In: The Science of Yoga: The Risks and the Rewards. Simon &amp; Schuster, New York 2012. p.xxii.</li>&#xD;&#xA;    <li>Strijk JE, Proper KI, van der Beek AJ, van MW. The Vital@Work Study. The systematic development of a lifestyle intervention to improve older workers' vitality and the design of a randomised controlled trial evaluating this intervention. BMC Public Health 2009; 9:408.</li>&#xD;&#xA;    <li>Cook, J. Not all yoga is created equal. <a href=\"http://www.yogajournal.com/basics/165\" target=\"_blank\">http://www.yogajournal.com/basics/165</a> (Accessed on August 14, 2013).</li>&#xD;&#xA;    <li>Yoga disciplines - different types of yoga. <a href=\"http://www.matsmatsmats.com/yoga/yoga-disciplines.html\" target=\"_blank\">http://www.matsmatsmats.com/yoga/yoga-disciplines.html</a> (Accessed on August 14, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96649 Version 5.0</div></div></div>"},"96650":{"type":"graphic_figure","displayName":"Pancreaticoduodenectomy with Roux-en-Y reconstruction","title":"Pancreaticoduodenectomy with Roux-en-Y reconstruction","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Pancreaticoduodenectomy with Roux-en-Y reconstruction</div><div class=\"cntnt\"><img style=\"width:455px; height:608px;\" src=\"images/SURG/96650_Pancreaticoduodenectomy_with_Roux-en-Y_reconstruction.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96650 Version 1.0</div></div></div>"},"96665":{"type":"graphic_figure","displayName":"Relationship between BSA and drug clearance for six chemo agents","title":"Relationship between body surface area (BSA) and drug clearance for six conventional chemotherapy agents","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Relationship between body surface area (BSA) and drug clearance for six conventional chemotherapy agents</div><div class=\"cntnt\"><img style=\"width:471px; height:717px;\" src=\"images/ONC/96665_Rltnshp_btwn_BSA_drg_chmo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For irinotecan, apparent clearance corresponding to SN-38 was considered. R<SUP>2</SUP> values indicate the contribution of BSA to the inter-individual variability in clearance.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: British Journal of Cancer. Chatelut E, White-Koning ML, Mathijssen RH, et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 2012; 107:1100. Copyright Â© 2012. <A spellcheck=true href=\"http://www.nature.com/bjc\" target=_blank>www.nature.com/bjc</A>.</div><div id=\"graphicVersion\">Graphic 96665 Version 1.0</div></div></div>"},"96667":{"type":"graphic_figure","displayName":"Interindividual pharmacokinetic variability of anticancer agents","title":"Inter-individual pharmacokinetic variability of selected cytotoxic and molecularly targeted anticancer agents","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Inter-individual pharmacokinetic variability of selected cytotoxic and molecularly targeted anticancer agents</div><div class=\"cntnt\"><img style=\"width:481px; height:419px;\" src=\"images/ONC/96667_Intr_phrmc_vria_atcncr_agnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inter-individual pharmacokinetic variability of select cytotoxic agents (white bars) and molecularly targeted agents (black bars), expressed as percentage coefficient of variation in apparent clearance. Coefficient of variation is defined as the standard deviation in measurement divided by the mean.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Clinical Pharmacology &amp; Therapeutics. Sparreboom A, Verweij J. Advances in cancer therapeutics. Clin Pharmacol Ther 2009; 85:113. Copyright Â© 2009. <A spellcheck=true href=\"http://www.nature.com/clpt\" target=_blank>www.nature.com/clpt</A>.</div><div id=\"graphicVersion\">Graphic 96667 Version 1.0</div></div></div>"},"96668":{"type":"graphic_picture","displayName":"SCC progression model","title":"Progression model of keratinocyte skin cancer","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Progression model of keratinocyte skin cancer</div><div class=\"cntnt\"><img style=\"width:742px; height:464px;\" src=\"images/DERM/96668_SCC_progression_model.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96668 Version 1.0</div></div></div>"},"96669":{"type":"graphic_picture","displayName":"Nodular BCC","title":"Nodular basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nodular basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:358px;\" src=\"images/DERM/96669_Nodular_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two nodular basal cell carcinomas are present on the nose and nasolabial fold of this patient.</div><div id=\"graphicVersion\">Graphic 96669 Version 1.0</div></div></div>"},"96670":{"type":"graphic_picture","displayName":"Superficial BCC","title":"Superficial basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:588px; height:461px;\" src=\"images/DERM/96670_Superficial_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This erythematous, slightly scaly patch on the neck is representative of a superficial basal cell carcinoma.</div><div id=\"graphicVersion\">Graphic 96670 Version 1.0</div></div></div>"},"96671":{"type":"graphic_picture","displayName":"Intradermal nevus nose","title":"Intradermal nevus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Intradermal nevus</div><div class=\"cntnt\"><img style=\"width:590px; height:559px;\" src=\"images/DERM/96671_Intradermal_nevus_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical skin-colored intradermal nevus is present on the nose.</div><div id=\"graphicVersion\">Graphic 96671 Version 1.0</div></div></div>"},"96672":{"type":"graphic_picture","displayName":"Blue nevus cheek","title":"Blue nevus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Blue nevus</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96672_Blue_nevus_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue nevus on the face presenting as a small bluish papule.</div><div id=\"graphicVersion\">Graphic 96672 Version 1.0</div></div></div>"},"96673":{"type":"graphic_picture","displayName":"Spitz nevus pigmented child","title":"Pigmented Spitz nevus (Reed nevus)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pigmented Spitz nevus (Reed nevus)</div><div class=\"cntnt\"><img style=\"width:590px; height:439px;\" src=\"images/DERM/96673_Spitz_nevus_pigmen_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented Spitz nevus on the face of a four-year-old child.</div><div id=\"graphicVersion\">Graphic 96673 Version 1.0</div></div></div>"},"96674":{"type":"graphic_picture","displayName":"Solar lentigines forehead","title":"Solar lentigines","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Solar lentigines</div><div class=\"cntnt\"><img style=\"width:590px; height:233px;\" src=\"images/DERM/96674_Solar_lentigines_forehead.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical image of multiple solar lentigines on the forehead.</div><div id=\"graphicVersion\">Graphic 96674 Version 1.0</div></div></div>"},"96675":{"type":"graphic_picture","displayName":"Sebaceous hyperplasia forehead","title":"Sebaceous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sebaceous hyperplasia</div><div class=\"cntnt\"><img style=\"width:338px; height:471px;\" src=\"images/DRUG/96675_Sebaceous_hyperplasia_frhd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A yellowish papule is present on the forehead of this patient.</div><div id=\"graphicVersion\">Graphic 96675 Version 1.0</div></div></div>"},"96676":{"type":"graphic_picture","displayName":"Dermoscopy moth-eaten borders","title":"Dermoscopic image of seborrheic keratosis: Moth-eaten borders","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Moth-eaten borders</div><div class=\"cntnt\"><img style=\"width:582px; height:435px;\" src=\"images/DERM/96676_Dermoscopy_moth_eaten_bord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of invaginations in the lesion edges gives it a moth-eaten appearance.</div><div id=\"graphicVersion\">Graphic 96676 Version 1.0</div></div></div>"},"96677":{"type":"graphic_picture","displayName":"Dermoscopy milia-like cysts","title":"Dermoscopic image of seborrheic keratosis: Milia-like cysts","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Milia-like cysts</div><div class=\"cntnt\"><img style=\"width:580px; height:427px;\" src=\"images/DERM/96677_Dermoscopy_milia_like_cysts.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96677 Version 1.0</div></div></div>"},"96678":{"type":"graphic_picture","displayName":"Dermoscopy comedo-like openings","title":"Dermoscopic image of seborrheic keratosis: Comedo-like openings","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Comedo-like openings</div><div class=\"cntnt\"><img style=\"width:581px; height:433px;\" src=\"images/DERM/96678_Dermoscop_comedo_like_open.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96678 Version 1.0</div></div></div>"},"96680":{"type":"graphic_table","displayName":"ASCO guideline appropriate chemo dosing for obese adults","title":"American Society of Clinical Oncology (ASCO) guideline on appropriate dosing for cytotoxic chemotherapy in obese adults with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Clinical Oncology (ASCO) guideline on appropriate dosing for cytotoxic chemotherapy in obese adults with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intervention</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recommendations for appropriate chemotherapy dosing for obese adult patients with cancer.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Target audience</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Medical oncologists, pharmacists, oncology nurses.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Key recommendations</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Panel recommends that full weight-based chemotherapy doses be used in the treatment of the obese patient with cancer, particularly when the goal of treatment is cure.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Clinicians should respond to all treatment-related toxicities in obese patients with cancer in the same ways they do for non-obese patients.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If a dose reduction is employed in response to toxicity, consideration should be given to the resumption of full weight-based doses for subsequent cycles, especially if a possible cause of toxicity (eg, impaired renal, hepatic function) has been resolved; there is no evidence to support the need for greater dose reductions for obese patients compared with non-obese patients.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The use of fixed-dose cytotoxic chemotherapy is rarely justified (except for a few select agents).</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Methods</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Systematic review of the medical literature and analysis of the medical literature by the update committee of an expert panel.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Additional information</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recommendations and a brief summary of the literature and analysis are provided in the executive summary of the full-text article.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The full guideline with methodology, comprehensive discussions of the literature, full reference list, data supplements, evidence tables, and clinical tool and resources can be found at www.asco.org/guidelines/wbd. Patient information is available at www.cancer.net.</div><div class=\"graphic_reference\">From: Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2012; 30(13):1553-61. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96680 Version 1.0</div></div></div>"},"96681":{"type":"graphic_picture","displayName":"Dermoscopy sharp demarcation","title":"Dermoscopic image of seborrheic keratosis: Sharp demarcation","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Sharp demarcation</div><div class=\"cntnt\"><img style=\"width:580px; height:433px;\" src=\"images/DERM/96681_Dermoscop_sharp_demarcation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96681 Version 1.0</div></div></div>"},"96682":{"type":"graphic_picture","displayName":"Dermoscopy fissures and ridges","title":"Dermoscopic image of seborrheic keratosis: Fissures and ridges","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Fissures and ridges</div><div class=\"cntnt\"><img style=\"width:581px; height:426px;\" src=\"images/DERM/96682_Dermoscopy_fissures_ridges.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 96682 Version 1.0</div></div></div>"},"96683":{"type":"graphic_picture","displayName":"Dermoscopy fat fingers","title":"Dermoscopic image of seborrheic keratosis: Fat fingers","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Fat fingers</div><div class=\"cntnt\"><img style=\"width:582px; height:433px;\" src=\"images/DERM/96683_Dermoscopy_fat_fingers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elongated brown circles closely aligned to one another are called \"fat fingers.\"</div><div id=\"graphicVersion\">Graphic 96683 Version 1.0</div></div></div>"},"96685":{"type":"graphic_picture","displayName":"Dermoscopy fingerprinting","title":"Dermoscopic image of seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:585px; height:438px;\" src=\"images/DERM/96685_Dermoscopy_fingerprinting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A delicate, network-like structure resembling a fingerprint is visible in this dermoscopic image of a seborrheic keratosis.</div><div id=\"graphicVersion\">Graphic 96685 Version 1.0</div></div></div>"},"96686":{"type":"graphic_picture","displayName":"Dermoscopy hairpin vessels","title":"Dermoscopic image of seborrheic keratosis: Hairpin blood vessels","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of seborrheic keratosis: Hairpin blood vessels</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96686_Dermoscopy_hairpin_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In seborrheic keratoses, hairpin vessels appear as red, U-shaped structures on a whitish or light-pink background.</div><div id=\"graphicVersion\">Graphic 96686 Version 1.0</div></div></div>"},"96693":{"type":"graphic_table","displayName":"Oral antibiotic therapy for impetigo","title":"Oral antibiotic therapy for impetigo*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antibiotic therapy for impetigo*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Child dose<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preferred</td> </tr> <tr> <td class=\"indent1\">Dicloxacillin <strong>or</strong></td> <td>250 to 500 mg four times per day</td> <td>25 to 50 mg/kg per day in four divided doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cephalexin</td> <td>250 to 500 mg four times per day</td> <td>25 to 50 mg/kg per day in three to four divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternate for penicillin and cephalosporin hypersensitivity</td> </tr> <tr> <td class=\"indent1\">Erythromycin (base)<sup>&#916;</sup> <strong>or</strong></td> <td>250 mg four times per day</td> <td>40 mg/kg per day in three to four divided doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Clarithromycin<sup>&#916;</sup></td> <td>250 mg twice per day</td> <td>15 mg/kg per day in two divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">If MRSA is suspected or confirmed</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#9674;</sup> <strong>or</strong></td> <td>300 to 450 mg four times per day</td> <td>20 mg/kg per day in three divided doses</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole <strong>or</strong></td> <td>1 to 2 double strength tablets twice per day</td> <td>8 to 12 mg/kg (trimethoprim) per day in two divided doses</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td>100 mg twice per day</td> <td> <p>&#62;8 years: 2 to 4 mg/kg per day in two divided doses<sup>&#167;</sup></p> &#8804;8 years: not recommended</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Oral antibiotic therapy is indicated for ecthyma, impetigo with numerous lesions, or to control transmission during outbreaks. A seven-day course of oral antibiotic treatment is recommended.</div><div class=\"graphic_footnotes\">MRSA: methicillin resistant <EM>Staphylococcus aureus</EM>.<br />* Doses listed in table are for patients with normal renal function; the doses of some agents must be adjusted in patients with renal insufficiency.<br />Â¶Maximum single dose should not exceed dose for adults.<br />Î Some strains of <EM>Staphylococcus aureus</EM> and <EM>Streptococcus pyogenes</EM> may be resistant to macrolides.<br /><FONT class=lozenge>â</FONT> Potential cross resistance in erythromycin resistant isolates; inducible resistance in MRSA.<br />Â§ A seven day course of doxycycline in a child older than 8 years is unlikely to cause tooth staining.</div><div class=\"graphic_reference\">Courtesy of authors with additional data from Stevens DL et al. IDSA Practice Guidelines for SSTIs. CID 2014; 59:147.</div><div id=\"graphicVersion\">Graphic 96693 Version 2.0</div></div></div>"},"96694":{"type":"graphic_algorithm","displayName":"Rx algorithm non-vertebral bone metastases","title":"Suggested algorithmic approach to local management for non-vertebral bone metastases from solid tumors","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Suggested algorithmic approach to local management for non-vertebral bone metastases from solid tumors</div><div class=\"cntnt\"><img style=\"width:715px; height:375px;\" src=\"images/ONC/96694_Algnonvertebralbonemetas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assumes optimization of systemic therapy. First-line therapies for bone pain include adequate analgesia with nonsteroidal antiinflammatory drugs with or without opioids. Osteoclast inhibitors are recommended for most patients with bone metastases to enhance analgesia and prevent skeletal-related events. Algorithm not applicable to patients with multiple myeloma.</div><div class=\"graphic_footnotes\">PS: performance status; EBRT: external beam radiation therapy; SBRT: stereotactic body radiotherapy; CRPC: castration-resistant prostate cancer.<br />* Assess fracture risk using a validated classification system, such as Mirels scoring system. Refer to UpToDate text.<br />&para; If observation is chosen, consider periodic repeat imaging and treat with EBRT if the lesion progresses or there is impending fracture.</div><div id=\"graphicVersion\">Graphic 96694 Version 5.0</div></div></div>"},"96711":{"type":"graphic_picture","displayName":"Lip and tongue telangiectasias in HHT","title":"Mucosal telangiectasias in hereditary hemorrhagic telangiectasia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Mucosal telangiectasias in hereditary hemorrhagic telangiectasia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/96711_Lip_tngue_telangiectasi_HHT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple telangiectasias on the lips and tongue of a patient with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96711 Version 1.0</div></div></div>"},"96712":{"type":"graphic_picture","displayName":"Oral telangiectasias in HHT","title":"Oral telangiectasias in hereditary hemorrhagic telangiectasia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Oral telangiectasias in hereditary hemorrhagic telangiectasia</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/96712_Oral_telangiectasias_HHT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple telangiectasias are visible on the hard palate of a patient with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Â© 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96712 Version 1.0</div></div></div>"},"96715":{"type":"graphic_algorithm","displayName":"Lynch syndrome testing strategy","title":"Traditional testing strategy when family mutation known","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traditional testing strategy when family mutation known</div><div class=\"cntnt\"><img style=\"width:407px; height:272px;\" src=\"images/GAST/96715_Lynchsyndrometststrtgy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LS: Lynch syndrome; CRC: colorectal cancer.</div><div class=\"graphic_reference\">From: Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum 2014; 57:1025. DOI: <a href=\"http://journals.lww.com/dcrjournal/pages/articleviewer.aspx?year=2014&amp;issue=08000&amp;article=00016&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/DCR.000000000000000</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 by the American Society of Colon and Rectal Surgeons, American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96715 Version 3.0</div></div></div>"},"96718":{"type":"graphic_figure","displayName":"Trends IPD young children 2006-2013","title":"Annual trends in invasive pneumococcal disease among children <5 years old, United States, 2006-2013","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Annual trends in invasive pneumococcal disease among children &lt;5 years old, United States, 2006-2013</div><div class=\"cntnt\"><img style=\"width:636px; height:356px;\" src=\"images/PEDS/96718_Trnd_IPD_yng_chld_2006-2013.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NVT: non-vaccine serotypes; PCV<sub>5</sub>: serotypes included in the 13-valent pneumococcal conjugate vaccine that are not included in the 7-valent pneumococcal vaccine, excluding serotype 6A (1, 5, 3, 7F, 19A); PCV<sub>7</sub>+6A: serotypes in the 7-valent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, 23F) plus serotype 6A (for which serotype 6B antigen provides cross-protection); IPD: invasive pneumococcal disease.</div><div class=\"graphic_reference\">Reproduced from: Moore MR. Update on effectiveness and impact of PCV13 use among US children. ACIP presentation slides, February 2014. Available at www.cdc.gov/vaccines/acip/meetings/slides-2014-02.html (Accessed on August 21, 2014).</div><div id=\"graphicVersion\">Graphic 96718 Version 3.0</div></div></div>"},"96735":{"type":"graphic_diagnosticimage","displayName":"Scheuermann kyphosis anterior wedging","title":"Scheuermann kyphosis lateral radiograph","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Scheuermann kyphosis lateral radiograph</div><div class=\"cntnt\"><img style=\"width:457px; height:596px;\" src=\"images/PEDS/96735_Scheuerma_kyphosis_ant_wedg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lateral radiograph of Scheuermann kyphosis.<br />(B) This close up demonstrates the characteristic anterior wedging of vertebral bodies (arrows).</div><div id=\"graphicVersion\">Graphic 96735 Version 1.0</div></div></div>"},"96738":{"type":"graphic_table","displayName":"Indications for HCT for PID","title":"Indications for hematopoietic cell transplantation (HCT) for primary immunodeficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for hematopoietic cell transplantation (HCT) for primary immunodeficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of primary immunodeficiency</td> <td class=\"subtitle1\">Indications</td> </tr> <tr class=\"divider_bottom\"> <td>Severe combined immunodeficiency (SCID)</td> <td>Indicated for all patients meeting criteria</td> </tr> <tr class=\"divider_bottom\"> <td>Leaky SCID or combined immunodeficiency</td> <td> <p>Potentially indicated, depending upon the severity of the phenotype</p> <p class=\"indent1\">Examples:</p> <ul class=\"decimal_heading\"> <li>T cell receptor complex defects </li> <li>Cytokine receptor defects</li> <li>DNA recombination/repair defects</li> <li>Enzyme deficiencies (adenosine deaminase, nucleoside phosphorylase)</li> <li>Ca/Mg channel defects </li> <li>MHC defects </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Immunodeficiency syndromes</td> <td> <p>Potentially indicated for some patients, based upon the specific defects and severity of the phenotype</p> <p class=\"indent1\">Examples:</p> <ul class=\"decimal_heading\"> <li>Cartilage-hair hypoplasia </li> <li>Dyskeratosis congenita </li> <li>DOCK8 deficiency </li> <li>Wiskott-Aldrich syndrome </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Predominantly antibody deficiencies</td> <td>HCT is generally NOT indicated for patients in this category. One exception is patients with a very severe phenotype of common variable immunodeficiency.</td> </tr> <tr class=\"divider_bottom\"> <td>Diseases of immune dysregulation</td> <td> <p>HCT is indicated for most patients</p> <p class=\"indent1\">Examples:</p> <ul class=\"decimal_heading\"> <li>Familial hemophagocytic lymphohistiocytosis </li> <li>X-linked lymphoproliferative disease </li> <li>Autoimmune lymphoproliferative syndrome </li> <li>Immune dysregulation, polyendocrinopathy, enteropathy, X-linked </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Phagocytic cell defects</td> <td> <p>HCT is indicated for most patients</p> <p class=\"indent1\">Examples:</p> <ul class=\"decimal_heading\"> <li>Chronic granulomatous disease </li> <li>Leukocyte-adhesion deficiency </li> <li>Severe congenital neutropenia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Defects of innate immunity</td> <td>Experience with HCT is limited, but is potentially indicated, especially for NEMO syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>Autoinflammatory disorders</td> <td> <p>HCT is generally NOT indicated for patients in this category, but there is limited experience for some disorders</p> <p class=\"indent1\">Examples:</p> <ul class=\"decimal_heading\"> <li>Familial Mediterranean fever </li> <li>Hyperimmunoglobulin D syndrome </li> </ul> </td> </tr> <tr> <td>Complement deficiencies</td> <td>HCT is NOT indicated for any form of complement defect</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ca: calcium; Mg: magnesium; MHC: major histocompatibility complex; DOCK8: dedicator of cytokinesis 8; NEMO: nuclear factor (NF)-kappa-B essential modulator.</div><div id=\"graphicVersion\">Graphic 96738 Version 2.0</div></div></div>"},"96739":{"type":"graphic_table","displayName":"Causes of nontraumatic chest pain in children and adolescents","title":"Causes of nontraumatic chest pain in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of nontraumatic chest pain in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Life-threatening conditions (1 to 6% of patients)</td> </tr> <tr> <td class=\"indent1\">Cardiac conditions <ul class=\"decimal_heading\"> <li>Hypertrophic cardiomyopathy </li> <li>Aortic stenosis </li> <li>Coarctation of the aorta </li> <li>Coronary artery abnormalities (eg, Kawasaki disease, anomalous coronary arteries) </li> <li>Variant angina after recreational drug use (eg, cocaine, amphetamines, bath salts [methcanthinones], marijuana, and synthetic cannabinoids) </li> <li>Classic angina (early atherosclerotic disease from hyperlipidemias or diabetes mellitus) </li> <li>Pericarditis </li> <li>Myocarditis </li> <li>Dilated cardiomyopathy </li> <li>Tachyarrhythmias </li> <li>Aortic aneurysm or dissection </li> <li>Ruptured sinus of Valsalva aneurysm </li> </ul> <p>Airway foreign body</p> <p>Spontaneous pneumothorax</p> <p>Pulmonary embolism</p> <p>Pulmonary hypertension</p> <p>Sickle cell disease with acute chest syndrome</p> <p>Tumor (chest wall, pulmonary, or mediastinum)</p> <p>Nontraumatic esophageal rupture (Boerhaave syndrome)</p> Spinal cord compression (tumor, vertebral collapse, or epidural abscess)</td> </tr> <tr> <td class=\"subtitle1_single\">Common conditions (94 to 99% of patients)</td> </tr> <tr> <td class=\"indent1\">Musculoskeletal conditions <ul class=\"decimal_heading\"> <li>Muscle strain </li> <li>Costochondritis </li> <li>Slipping rib syndrome </li> <li>Precordial catch (Texidor's twinge) </li> <li>Fibromyalgia </li> <li>Pectus excavatum or carinatum </li> </ul> Psychiatric <ul class=\"decimal_heading\"> <li>Anxiety </li> <li>Panic disorder with or without hyperventilation syndrome </li> <li>Depression </li> <li>Hypochondriasis </li> <li>Somatization </li> </ul> Respiratory <ul class=\"decimal_heading\"> <li>Pneumonia (can be life-threatening) </li> <li>Asthma (can be life-threatening) </li> <li>Chronic cough with muscle strain or, if severe, fractured rib </li> <li>Spontaneous pneumomediastinum </li> </ul> Gastrointestinal <ul class=\"decimal_heading\"> <li>Gastroesophageal reflux disease </li> <li>Medication-induced (\"pill\") esophagitis </li> <li>Esophageal foreign body </li> <li>Esophageal spasm and achalasia </li> <li>Gastritis </li> <li>Peptic ulcer </li> <li>Irritable bowel disease </li> <li>Cholecystitis </li> <li>Pancreatitis </li> </ul> Breast <ul class=\"decimal_heading\"> <li>Male adolescents: Gynecomastia </li> <li>Female adolescents: Pregnancy, thelarche, mastitis, or fibrocystic disease </li> </ul> Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td class=\"indent1\"> <p>Tietze syndrome</p> <p>Pleurodynia</p> Herpes zoster</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96739 Version 3.0</div></div></div>"},"96743":{"type":"graphic_figure","displayName":"SICCA ocular staining score form","title":"SjÃ¶gren's International Collaborative Clinical Alliance (SICCA) ocular staining score form","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">SjÃ¶gren's International Collaborative Clinical Alliance (SICCA) ocular staining score form</div><div class=\"cntnt\"><img style=\"width:711px; height:451px;\" src=\"images/RHEUM/96743_SICCA_ocular_stain_scr_frm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ocular surface staining is assessed using fluorescein dye for the cornea and lissamine green dye for the conjunctiva. A sequential examination is required. First, fluorescein is instilled in each eye and corneal staining is assessed in a period of less than four minutes using a slit lamp outfitted with a cobalt blue filter. Second, a drop of 1 percent lissamine green dye is instilled in each unanesthetized eye. The number of discrete \"dots\" of staining in the cornea and in the nasal and temporal portions of the conjunctiva is counted for each eye and graded according to the schema shown here. A summation of the fluorescein score for the cornea and the lissamine green scores for the nasal and temporal bulbar conjunctiva yields the total ocular staining score for each eye. The maximum possible score for each eye is 12. Based on an analysis of the SjÃ¶gren's International Collaborative Clinical Alliance (SICCA) registry, an ocular surface score of 3 or more in either eye was considered to be abnormal and supportive of the ocular component of SjÃ¶gren's syndrome.</div><div class=\"graphic_reference\">Reproduced from: Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol 2010; 149:405. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96743 Version 1.0</div></div></div>"},"96745":{"type":"graphic_table","displayName":"Chagas cardioembolism risk score","title":"Chagas cardioembolism risk score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chagas cardioembolism risk score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><span class=\"subtitle1\"></span>Clinical characteristic</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td>Any degree of left ventricular systolic dysfunction</td> <td class=\"centered\">2</td> </tr> <tr> <td>Left ventricular apical aneurysm</td> <td class=\"centered\">1</td> </tr> <tr> <td>Primary ST-T wave changes on 12-lead electrocardiogram</td> <td class=\"centered\">1</td> </tr> <tr> <td>Age greater than 48 years old</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle1\">Risk score</td> <td class=\"subtitle1\">Recommended therapy</td> </tr> <tr> <td>4-5 points</td> <td class=\"centered\"> <p>warfarin</p> </td> </tr> <tr> <td>3 points</td> <td class=\"centered\">warfarin*</td> </tr> <tr> <td>2 points</td> <td class=\"centered\">aspirin<sup>&#182;</sup></td> </tr> <tr> <td>0-1 points</td> <td class=\"centered\">no need for prophylaxis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The cardioembolic risk score for each patient is obtained by summing points for the above clinical characteristics.</div><div class=\"graphic_footnotes\">* In the source document, warfarin or aspirin was recommended in these patients with risk score of 3 points (for whom the risk of cardioembolic stroke is similar to the risk of bleeding).<br />&para; In the source document, aspirin or no prophylaxis was recommended for a risk score of 2 points.</div><div class=\"graphic_reference\">Data from: de Sousa AS, Xavier SS, de Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic Stroke in Chagas' disease. Arq Bras Cardiol 2008; 91:280.</div><div id=\"graphicVersion\">Graphic 96745 Version 2.0</div></div></div>"},"96746":{"type":"graphic_figure","displayName":"Digital ulcerations in SSc","title":"Digital ulcerations and ischemia in systemic sclerosis","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Digital ulcerations and ischemia in systemic sclerosis</div><div class=\"cntnt\"><img style=\"width:592px; height:436px;\" src=\"images/RHEUM/96746_Digital_ulcerations_SSc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scleroderma and Raynaud's phenomenon can be associated with ischemic and traumatic digital ulcerations and digital ischemia.<br />(A) Traumatic ulcers over the proximal interphalangeal joints.<br />(B, C) Ischemic digital tip ulcerations secondary to small arterial disease.<br />(D) Digital gangrene secondary to vascular disease.</div><div class=\"graphic_reference\">Reproduced from: Firestein GS, Budd RC, Gabriel SE, et al. Kelley's Textbook of Rheumatology, 9th ed, Saunders, Philadelphia 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96746 Version 2.0</div></div></div>"},"96747":{"type":"graphic_figure","displayName":"Modified Rodnan skin score for SSc","title":"Modified Rodnan skin score for systemic sclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Rodnan skin score for systemic sclerosis</div><div class=\"cntnt\"><img style=\"width:393px; height:307px;\" src=\"images/RHEUM/96747_Modified_Rodnan_skn_scr_SSc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Method used to semi-quantify skin thickness in scleroderma. The modified Rodnan skin score is obtained by clinical palpation of 17 different body areas (fingers, hands, forearms, upper arms, face, chest, abdomen, thighs, lower legs, and feet) and subjective averaging of the thickness of each specific site: 0 = normal (A); 1 = mild (B); 2 = moderate (C); and 3 = severe (D). The maximum total&nbsp;score is 51.</div><div class=\"graphic_reference\">Reproduced from: Firestein GS, Budd RC, Gabriel SE, et al. Kelley's Textbook of Rheumatology, 9th ed, Saunders, Philadelphia 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96747 Version 2.0</div></div></div>"},"96748":{"type":"graphic_figure","displayName":"Oral manifestations of SSc","title":"Oral manifestations of systemic sclerosis","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Oral manifestations of systemic sclerosis</div><div class=\"cntnt\"><img style=\"width:635px; height:549px;\" src=\"images/RHEUM/96748_Oral_manifestations_SSc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral manifestations.<br />(A) Perioral skin tightening with decreased oral aperature, furrowing around the lips, and dry mucous membranes.<br />(B) Periodontal disease with regression of gum and loosening of teeth.<br />(C, D) Telangiectasias on lips and tongue.</div><div class=\"graphic_reference\">Reproduced from: Firestein GS, Budd RC, Gabriel SE, et al. Kelley's Textbook of Rheumatology, 9th ed, Saunders, Philadelphia 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96748 Version 2.0</div></div></div>"},"96749":{"type":"graphic_figure","displayName":"Puffy hands and shiny skin in early SSc","title":"Puffy hands and shiny skin in early systemic sclerosis","html":"<div class=\"graphic\"><div style=\"width: 689px\" class=\"figure\"><div class=\"ttl\">Puffy hands and shiny skin in early systemic sclerosis</div><div class=\"cntnt\"><img style=\"width:669px; height:235px;\" src=\"images/RHEUM/96749_Pffy_hnd_shny_skn_early_SSc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diffusely puffy&nbsp;fingers are a common initial presentation.<br />(B) Shiny skin suggests impending skin thickening.</div><div class=\"graphic_reference\">Reprinted with permission from Systemic Sclerosis/Scleroderma: A Treatable Multisystem Disease, October 15, 2008, Vol 78, No 8, American Family Physician. Copyright Â© 2008 American Academy of Family Physicians. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 96749 Version 2.0</div></div></div>"},"96750":{"type":"graphic_figure","displayName":"Vessel involvement of the vasculitides","title":"Distribution of vessel involvement by large-, medium-, and small-vessel vasculitis","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Distribution of vessel involvement by large-, medium-, and small-vessel vasculitis</div><div class=\"cntnt\"><img style=\"width:634px; height:444px;\" src=\"images/RHEUM/96750_Vessel_involv_vasculitides.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of vessel involvement by large-vessel vasculitis, medium-vessel vasculitis, and small-vessel vasculitis. Note that there is substantial overlap with respect to arterial involvement, and an important concept is that all three major categories of vasculitis can affect any size artery. Large-vessel vasculitis affects large arteries more often than other vasculitides. Medium-vessel vasculitis predominantly affects medium arteries. Small-vessel vasculitis predominantly affects small vessels, but medium arteries and veins may be affected, although immune-complex small-vessel vasculitis rarely affects arteries. Not shown is variable-vessel vasculitis, which can affect any type of vessel, from aorta to veins. The diagram depicts (from left to right) aorta, large artery, medium artery, small artery/arteriole, capillary, venule, and vein.</div><div class=\"graphic_footnotes\">Anti-GBM: anti-glomerular basement membrane; ANCA: antineutrophil cytoplasmic antibody.</div><div class=\"graphic_reference\">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1. Reproduced with permission from John Wiley &amp; Sons, Inc. Copyright &copy; 2013 by the American College of Rheumatology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96750 Version 3.0</div></div></div>"},"96752":{"type":"graphic_table","displayName":"Approach to a positive SCD result newborn","title":"Approach to a positive result from newborn/infant screening for sickle cell disease (SCD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to a positive result from newborn/infant screening for sickle cell disease (SCD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"3\" width=\"29%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Newborn screen</td> <td class=\"subtitle1\">FS pattern</td> <td class=\"subtitle1\">FSA pattern</td> <td class=\"subtitle1\">FAS pattern</td> </tr> <tr class=\"divider_bottom\"> <td>Implications</td> <td>Suggests SCD (ie, HbSS or HbS/B<sup>0</sup> thalassemia)</td> <td>Suggests a compound SCD state (HbSC or HbS/B<sup>+</sup> thalassemia)</td> <td>Suggests sickle cell trait</td> </tr> <tr class=\"divider_bottom\"> <td>Action</td> <td>Refer to an SCD specialist</td> <td>Refer to an SCD specialist</td> <td>Reassurance and counseling</td> </tr> <tr class=\"divider_bottom\"> <td>Communication of the diagnosis</td> <td>Inform the family of the diagnosis of a sickle disease</td> <td>Inform the family of the diagnosis of a sickle disorder</td> <td>Provide education regarding the inheritance of sickle cell disorders, and reassurance that the infant does not have a chronic blood disorder</td> </tr> <tr class=\"divider_bottom\"> <td>Safety measures</td> <td> <p>Initiate prophylactic penicillin (125 mg orally twice daily)</p> Inform the family that they should seek immediate medical attention if the infant has a fever of 101&#176;F (38.3&#176;C) and inform the treating clinician of the sickle cell disease diagnosis</td> <td> <p>Follow measures for FS pattern until a definitive diagnosis is established</p> Repeat hemoglobin electrophoresis in three to six months to further characterize the hemoglobinopathy</td> <td>Explain that under settings of significant hypoxia (eg, high altitude unpressurized aircraft, very strenuous exercise with dehydration), sickling can occur and there is a risk of hematuria, worsening of traumatic hyphema, and a very rare type of renal cancer</td> </tr> <tr> <td>Preliminary genetic counseling</td> <td> <p>Provide information regarding the genetic inheritance of the disorder</p> Offer hemoglobinopathy screening to other family members who may carry a sickle cell mutation and are unaware of their status, and referral for genetic counseling or hematologic consultation if further information is desired</td> <td> <p>Provide information regarding the genetic inheritance of the disorder</p> Offer hemoglobinopathy screening to other family members who may carry a sickle cell mutation and are unaware of their status, and referral for genetic counseling or hematologic consultation if further information is desired </td> <td> <p>Counsel patients on the reproductive consequences of sickle cell carrier status (eg, potential for a&nbsp;child with&nbsp;SCD if the other parent is also a carrier)</p> Offer hemoglobinopathy screening to other family members who may carry a sickle cell mutation and are unaware of their status, and referral for genetic counseling or hematologic consultation if further information is desired</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table shows potential results from newborn screening, implications for diagnosis, and immediate management issues. Refer to UpToDate topics on diagnosis and management of sickle cell disorders for further details.</div><div class=\"graphic_footnotes\">SCD: sickle cell disease; Hb: hemoglobin.</div><div id=\"graphicVersion\">Graphic 96752 Version 1.0</div></div></div>"},"96753":{"type":"graphic_table","displayName":"Berlin questionnaire scoring","title":"Berlin questionnaire scoring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Berlin questionnaire scoring</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Patients can be classified into high risk or low risk based on their responses to the individual items and their overall scores in the symptom categories:</td> </tr> <tr> <td class=\"indent1\"><strong>High risk:</strong> if there are&nbsp;two or more categories where the score is positive</td> </tr> <tr> <td class=\"indent1\"><strong>Low risk:</strong> if there is only&nbsp;one or no categories where the score is positive</td> </tr> <tr> <td class=\"indent1\">Additional question: item 9 should be noted separately</td> </tr> <tr> <td class=\"indent1\"><strong>Categories and scoring:</strong></td> </tr> <tr> <td> <p class=\"indent2\"><strong>Category 1:</strong> items 1, 2, 3, 4, 5</p> <p class=\"indent3\">Item 1: if '<strong>Yes</strong>', assign <strong>1 point</strong></p> <p class=\"indent3\">Item 2: if '<strong>c</strong>' or '<strong>d</strong>' is the response, assign <strong>1 point</strong></p> <p class=\"indent3\">Item 3: if '<strong>a</strong>' or '<strong>b</strong>' is the response, assign <strong>1 point</strong></p> <p class=\"indent3\">Item 4: if '<strong>a</strong>' is the response, assign <strong>1 point</strong></p> <p class=\"indent3\">Item 5: if '<strong>a</strong>' or '<strong>b</strong>' is the response, assign <strong>2 points</strong></p> <p class=\"indent3\"><strong>Add points. Category 1 is positive if the total score is 2 or more points.</strong></p> &nbsp; <p class=\"indent2\"><strong>Category 2:</strong> items 6, 7, 8 (item 9 should be noted separately)</p> <p class=\"indent3\">Item 6: if '<strong>a</strong>' or '<strong>b</strong>' is the response, assign <strong>1 point</strong></p> <p class=\"indent3\">Item 7: if '<strong>a</strong>' or '<strong>b</strong>' is the response, assign <strong>1 point</strong></p> <p class=\"indent3\">Item 8: if '<strong>a</strong>' is the response, assign <strong>1 point</strong></p> <p class=\"indent3\"><strong>Add points. Category 2 is positive if the total score is 2 or more points.</strong></p> &nbsp; <p class=\"indent2\"><strong>Category 3 is positive if the answer to item 10 is 'Yes' OR if the BMI of the patient is greater than 30 kg/m<sup>2</sup>.</strong><br /> (BMI must be calculated. BMI is defined as weight (kg) divided by height (m) squared, ie, kg/m<sup>2</sup>).</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">From<EM> Annals of Internal Medicine</EM>, Netzer NC, Stoohs RA, Netzer CM, et al, Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome, vol. 131, p. 485. Copyright Â© 1999 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 96753 Version 7.0</div></div></div>"},"96762":{"type":"graphic_table","displayName":"Androgen levels in pregnancy","title":"Androgen levels in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Androgen levels in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Compartment</td> <td class=\"subtitle1\">Change</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Maternal</td> </tr> <tr> <td class=\"indent1\">Free testosterone</td> <td>Modest increase until the third trimester when the level doubles</td> </tr> <tr> <td class=\"indent1\">Total testosterone</td> <td>Increases progressively throughout pregnancy</td> </tr> <tr> <td class=\"indent1\">Androstenedione</td> <td>Increases primarily in late pregnancy</td> </tr> <tr> <td class=\"indent1\">Dihydrotestosterone</td> <td>Increases progressively throughout pregnancy</td> </tr> <tr> <td class=\"indent1\">Sex hormone-binding globulin (SHBG)</td> <td>Increases markedly by the second trimester and remains elevated through term</td> </tr> <tr> <td class=\"indent1\">Dehydroepiandrosterone</td> <td>Modest increase in early pregnancy and then remains stable through term</td> </tr> <tr> <td class=\"indent1\">Dehydroepiandrosterone sulfate</td> <td>Marked decrease in second trimester and continues to fall until delivery</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3-alpha-17-beta-androstanediol glucuronide</td> <td>Increased in pregnancy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Amniotic fluid</td> </tr> <tr> <td class=\"indent1\">Total testosterone</td> <td>Two to three times higher in male compared with female fetuses</td> </tr> <tr> <td class=\"indent1\">Androstenedione</td> <td>Two to three times higher in male compared with female fetuses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dehydroepiandrosterone</td> <td>Similar level in male and female fetuses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fetal</td> </tr> <tr> <td class=\"indent1\">Testosterone</td> <td> <p>Male fetus: Level rises to a peak of approximately one-half the lower limit of normal in adult men at the end of the first trimester and then gradually declines by approximately 60 to 70%</p> Female fetus: Level is low throughout most of gestation and declines near term</td> </tr> <tr> <td class=\"indent1\">Dehydroepiandrosterone</td> <td>Similar level in male and female fetuses</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96762 Version 2.0</div></div></div>"},"96766":{"type":"graphic_table","displayName":"G8 geriatric assessment to determine baseline characteristics","title":"G8 geriatric assessment instrument to determine baseline characteristics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">G8 geriatric assessment instrument to determine baseline characteristics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Items</td> <td class=\"subtitle1\">Possible responses (score)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>A</strong></td> <td>Has food intake declined over the past&nbsp;three months due to loss of appetite, digestive problems, chewing, or swallowing difficulties</td> <td> <p>0 = severe decrease in food intake</p> <p>1 = moderate decrease in food intake</p> 2 = no decrease in food intake</td> </tr> <tr class=\"divider_bottom\"> <td><strong>B</strong></td> <td>Weight loss during the last&nbsp;three months</td> <td> <p>0 = weight loss &#62;3 kg</p> <p>1 = does not know</p> <p>2 = weight loss between 1 and 3 kg</p> 3 = no weight loss</td> </tr> <tr class=\"divider_bottom\"> <td><strong>C</strong></td> <td>Mobility</td> <td> <p>0 = bed or chair bound</p> <p>1 = able to get out of bed/chair but does not go out</p> 2 = goes out</td> </tr> <tr class=\"divider_bottom\"> <td><strong>E</strong></td> <td>Neuropsychological problems</td> <td> <p>0 = severe dementia or depression</p> <p>1 = mild dementia</p> 2 = no psychological problems</td> </tr> <tr class=\"divider_bottom\"> <td><strong>F</strong></td> <td>BMI (weight in kg)/(height in m)<sup>2</sup></td> <td> <p>0 = BMI &#60;19</p> <p>1 = BMI 19 to &#60;21</p> <p>2 = BMI 21 to &#60;23</p> 3 = BMI &#8805;23</td> </tr> <tr class=\"divider_bottom\"> <td><strong>G</strong></td> <td>Takes more than three prescription drugs per day</td> <td> <p>0 = yes</p> 1 = no</td> </tr> <tr class=\"divider_bottom\"> <td><strong>H</strong></td> <td>In comparison with other people of the same age, how does the patient consider his/her health status</td> <td> <p>0 = not as good</p> <p>0.5 = does not know</p> <p>1 = as good</p> 2 = better</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&nbsp;I</strong></td> <td>Age</td> <td> <p>0: &#62;85</p> <p>1: 80 to 85</p> 2: &#60;80</td> </tr> <tr> <td>&nbsp;</td> <td>Total score</td> <td>0 to 17</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Reproduced from: Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012; 23:2166, by permission of Oxford University Press on behalf of the European Society for Medical Oncology. Copyright Â© 2012 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 96766 Version 5.0</div></div></div>"},"96767":{"type":"graphic_table","displayName":"Osteomyelitis imaging abnormalities","title":"Imaging abnormalities in osteomyelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imaging abnormalities in osteomyelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Imaging modality</td> <td class=\"subtitle1\">Abnormal findings</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Plain radiograph*</td> <td>Deep soft tissue swelling (3 days after onset)</td> </tr> <tr> <td>Periosteal reaction or elevation (10 to 21 days after onset)</td> </tr> <tr class=\"divider_bottom\"> <td>Lytic sclerosis (&#8805;1 month after onset)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Magnetic resonance imaging</td> <td>Bone marrow inflammation (decreased signal in T1-weighted images; increased signal in T2-weighted images)</td> </tr> <tr> <td>Edema in marrow and soft tissues</td> </tr> <tr> <td>Penumbra sign (high-intensity-signal transition zone between abscess and sclerotic bone marrow in T1-weighted images)</td> </tr> <tr class=\"divider_bottom\"> <td>With&nbsp;gadolinium enhancement: absent blood flow, suggestive of necrosis or abscess</td> </tr> <tr class=\"divider_bottom\"> <td>Three-phase bone scan</td> <td>Focal uptake of tracer in the third phase (delayed phase)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Computed tomography</td> <td>Increased density of bone marrow</td> </tr> <tr> <td>Cortex destruction</td> </tr> <tr> <td>Periosteal reaction (new bone formation) formation</td> </tr> <tr> <td>Periosteal purulence</td> </tr> <tr class=\"divider_bottom\"> <td>Sequestra (devitalized, sclerotic bone)</td> </tr> <tr> <td rowspan=\"3\">Ultrasonography</td> <td>Fluid collection adjacent to bone without intervening soft tissue</td> </tr> <tr> <td>Thickening of periosteum</td> </tr> <tr> <td>Periosteal elevation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The timing and typical sequence of radiographic changes may vary with the site of infection and age of the patient.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Browne LP, Mason EO, Kaplan SL, et al. Optimal imaging strategy for community-acquired Staphylococcus aureus musculoskeletal infections in children. Pediatr Radiol 2008; 38:841.</li>&#xD;&#xA;    <li>Jaramillo D, Treves ST, Kasser JR, et al. Osteomyelitis and septic arthritis in children: appropriate use of imaging to guide treatment. AJR Am J Roentgenol 1995; 165:399.</li>&#xD;&#xA;    <li>Saigal G, Azouz EM, Abdenour G. Imaging of osteomyelitis with special reference to children. Semin Musculoskelet Radiol 2004; 8:255.</li>&#xD;&#xA;    <li>Schmit P, Glorion C. Osteomyelitis in infants and children. Eur Radiol 2004; 14 Suppl 4:L44.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96767 Version 2.0</div></div></div>"},"96769":{"type":"graphic_picture","displayName":"Hyperacute rejection of lung transplant","title":"Histopathology of hyperacute lung transplant rejection: Low power","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of hyperacute lung transplant rejection: Low power</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/PULM/96769_Hyperacute_reject_lung_tr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology from a patient with hyperacute lung transplant rejection demonstrating intense inflammatory infiltration with hemorrhage and necrosis. Additionally, thrombosis of multiple vessels is seen (4x magnification).</div><div id=\"graphicVersion\">Graphic 96769 Version 1.0</div></div></div>"},"96770":{"type":"graphic_picture","displayName":"Hyperacute rejection of lung transplant 2","title":"Histopathology of hyperacute lung transplant rejection: High power","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of hyperacute lung transplant rejection: High power</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/PULM/96770_Hyperacute_reject_lung_tr2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this high power magnification of lung histopathology from a patient with hyperacute lung transplant rejection, thrombosis of vessels and inflammatory cell infiltration in vessel walls are present (10x magnification).</div><div id=\"graphicVersion\">Graphic 96770 Version 1.0</div></div></div>"},"96771":{"type":"graphic_picture","displayName":"Acute antibody-mediated rejection lung","title":"Lung histopathology of acute antibody-mediated rejection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lung histopathology of acute antibody-mediated rejection</div><div class=\"cntnt\"><img style=\"width:504px; height:352px;\" src=\"images/PULM/96771_Acute_antibody_reject_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology from a patient with acute antibody-mediated rejection of lung transplant illustrating acute pneumonitis with neutrophils infiltrating alveolar septae, suggesting alveolar capillary injury (10x magnification).</div><div id=\"graphicVersion\">Graphic 96771 Version 1.0</div></div></div>"},"96772":{"type":"graphic_picture","displayName":"Antibody-mediated lung transplant rejection Cd4 deposition","title":"Complement C4d deposition in acute antibody-mediated lung transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Complement C4d deposition in acute antibody-mediated lung transplant rejection</div><div class=\"cntnt\"><img style=\"width:590px; height:437px;\" src=\"images/PULM/96772_Lung_trans_reject_Cd4_depos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunohistochemistry stain for C4d showing deposition (arrows) in alveolar capillaries in a patient with acute antibody-mediated rejection (10x magnification).</div><div id=\"graphicVersion\">Graphic 96772 Version 1.0</div></div></div>"},"96774":{"type":"graphic_figure","displayName":"Lymph node stations pancreatic cancer","title":"Lymph node stations pancreatic cancer","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Lymph node stations pancreatic cancer</div><div class=\"cntnt\"><img style=\"width:540px; height:465px;\" src=\"images/SURG/96774_Lymph_node_stations_pancreatic_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymph node drainage of the pancreas is depicted in the figure. The labels correspond to the lymph node stations as classified by the Japanese Pancreas Society.</div><div class=\"graphic_reference\">Adapted from: Japan Pancreas Society. Classification of pancreatic carcinoma, 2nd English Edition. Tokyo: Kanehara &amp; Co. Ltd, 2003.</div><div id=\"graphicVersion\">Graphic 96774 Version 2.0</div></div></div>"},"96775":{"type":"graphic_table","displayName":"Potential interventions to reduce risk of percutaneous injuries","title":"Potential interventions to reduce the risk of percutaneous injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential interventions to reduce the risk of percutaneous injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General measures</td> </tr> <tr> <td class=\"indent1\">Puncture-resistant sharps disposal containers</td> </tr> <tr> <td class=\"indent1\">Use of safer needles (eg, needles that can be resheathed without placing the operator at increased exposure, needles with blunted tips)</td> </tr> <tr> <td class=\"indent1\">Needleless connectors for infusion sets</td> </tr> <tr> <td class=\"indent1\">Improved education</td> </tr> <tr> <td class=\"subtitle1_single\">Measures to prevent sharp injuries during surgery</td> </tr> <tr> <td class=\"indent1\">Double gloves for high risk surgical or obstetrical procedures (ie, when glove puncture may occur)</td> </tr> <tr> <td class=\"indent1\">Use of \"no-touch\" techniques that emphasize the use of instruments, rather than hands, for retracting and exploring tissue</td> </tr> <tr> <td class=\"indent1\">Avoiding hands of two or more operators in the operative field simultaneously</td> </tr> <tr> <td class=\"indent1\">Prohibition of hand-to-hand passage of sharp instruments</td> </tr> <tr> <td class=\"indent1\">Blunted suture needles</td> </tr> <tr> <td class=\"indent1\">Use of alternatives to needles and other sharp instruments (eg, tape skin closure, staples, tissue glue, electrocautery)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">David Weber, MD, MPH.</div><div id=\"graphicVersion\">Graphic 96775 Version 1.0</div></div></div>"},"96776":{"type":"graphic_table","displayName":"Evaluation and monitoring of HIV-infected patients","title":"Evaluation and monitoring of HIV-infected patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and monitoring of HIV-infected patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Interval</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>HIV-related testing</strong></td> <td>HIV serology</td> <td>At baseline if there is no laboratory documentation of infection</td> </tr> <tr> <td>CD4 cell count</td> <td> <p>At baseline</p> Every&nbsp;three to six&nbsp;months (may be extended to every 12 months in clinically stable patients*)</td> </tr> <tr> <td>HIV viral load</td> <td> <p>At baseline</p> After ART initiation: <ul class=\"decimal_heading\"> <li>At&nbsp;two to four&nbsp;weeks </li> <li>Every&nbsp;four to eight&nbsp;weeks until the viral load is suppressed </li> <li>Every&nbsp;three to four&nbsp;months thereafter (may be extended to every&nbsp;six months in patients who have suppressed viral loads for &#8805;2 years) </li> </ul> </td> </tr> <tr> <td>Genotypic resistance testing</td> <td> <p>At baseline</p> Prior to initiation of ART (recommended in pregnant women; optional for others if performed at baseline visit)</td> </tr> <tr> <td>HLA-B5701 testing</td> <td>If considering use of abacavir</td> </tr> <tr class=\"divider_bottom\"> <td>Tropism testing</td> <td>If considering use of maraviroc</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Cardiovascular risk factors</strong></td> <td>Blood pressure check</td> <td>At baseline and annually</td> </tr> <tr> <td>Fasting glucose and/or hemoglobin A1c</td> <td> <p>At baseline and every 6 to 12 months</p> One to three&nbsp;months following ART initiation or modification</td> </tr> <tr> <td>Fasting lipid profile</td> <td> <p>At baseline and every 6 to 12 months</p> One to three&nbsp;months following ART initiation or modification</td> </tr> <tr> <td>Weight assessment</td> <td>At baseline and follow-up visits</td> </tr> <tr class=\"divider_bottom\"> <td>Tobacco use assessment</td> <td>At baseline and annually</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Other metabolic complications</strong></td> <td>Bone densitometry</td> <td> <p>At baseline in postmenopausal women and men &#8805;50 years old</p> Subsequent testing frequency depends on findings on baseline exam</td> </tr> <tr class=\"divider_bottom\"> <td>Aortic aneurysm screening (abdominal ultrasonography)</td> <td>Once in men 65 to 75 years old who have ever smoked</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Neuropsychiatric disorders</strong></td> <td>Depression screening</td> <td>At baseline and annually</td> </tr> <tr class=\"divider_bottom\"> <td>Screening for cognitive deficits</td> <td>At baseline and annually</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Cancers</strong></td> <td>Colonoscopy</td> <td> <p>At 50 years old in asymptomatic patients at average risk</p> <p>Earlier screening may be warranted for those with strong family history of colon cancer</p> Subsequent testing frequency depends on findings on baseline exam</td> </tr> <tr> <td>Mammography</td> <td>Annually in all women 50 to 74 years old</td> </tr> <tr> <td>Cervical Pap smear<br /> (with or without HPV testing in women &#8805;30 years)</td> <td> <p>At baseline; interval for repeat testing depends on results and whether HPV co-testing was performed<sup>&#167;</sup></p> <p>Additional testing may be warranted for those with abnormal results</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Anal Pap smear</td> <td> <p>Consider at baseline and annually</p> More frequent or additional testing may be warranted for those with abnormal results</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Other infections</strong></td> <td>Syphilis serology</td> <td> <p>At baseline</p> Annually for sexually active&nbsp;persons (or more frequently if at high risk)</td> </tr> <tr> <td>Chlamydia and gonorrhea testing (at all sites of potential exposure)</td> <td> <p>At baseline</p> Annually for sexually active persons (or more frequently if at high risk)</td> </tr> <tr> <td>Trichomonas</td> <td> <p>At baseline for women</p> Annually for sexually active women</td> </tr> <tr> <td>TB&nbsp;testing (TST or IGRA)</td> <td> <p>At baseline unless there is a history of a prior positive test</p> Annually in patients at ongoing risk for TB unless there is a history of a prior positive test</td> </tr> <tr> <td>HAV and&nbsp;HBV serologies</td> <td>At baseline, with vaccination(s) in persons&nbsp;not immune</td> </tr> <tr class=\"divider_bottom\"> <td>HCV serology, with reflex viral level for positive result</td> <td> <p>At baseline</p> Annually in patients at risk (ie, injection drug users, men who have sex with men)</td> </tr> <tr> <td rowspan=\"5\"><strong>Medication toxicity</strong></td> <td>Complete blood count with differential</td> <td>At baseline and every&nbsp;three to six&nbsp;months</td> </tr> <tr> <td>BUN and creatinine<sup>&#182;</sup><sup>&#916;</sup></td> <td> <p>At baseline and every 6 to 12 months prior to ART initiation</p> Two to eight weeks after ART initiation and every&nbsp;three to six&nbsp;months thereafter</td> </tr> <tr> <td>ALT, AST, and total bilirubin</td> <td> <p>At baseline and every 6 to 12 months prior to ART initiation</p> Two to eight&nbsp;weeks after ART initiation and every&nbsp;three to six&nbsp;months thereafter</td> </tr> <tr> <td>Urinalysis</td> <td> <p>At baseline</p> <p>After ART initiation or change</p> Every 12 months on ART (every&nbsp;six months while on tenofovir-containing regimens)</td> </tr> <tr> <td>Dilated fundoscopic exam</td> <td>Consider every 6 to 12 months in patients with CD4 cell count &#60;50 cells/microL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists intervals for routine testing. Testing is also performed when clinically indicated.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; ART: antiretroviral therapy; HLA: human leukocyte antigen; HPV: human papillomavirus; TST: tuberculin skin test; IGRA: interferon-gamma release assay; TB: tuberculosis&nbsp;HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; BUN: blood urea nitrogen; ALT: alanine aminotransferase; AST: aspartate aminotransferase.<br />* Less frequent measurements of the CD4 cell count&nbsp;are appropriate in patients who have been on ART for at least two years, have a stable CD4 cell count at a level well above the threshold for opportunistic infection risk (eg, 300 cells/microL), and have a consistently undetectable viral load. In such patients, CD4 cell count monitoring can be done every 12 months if the CD4 cell count is between 300 and 500 cells/microL and is optional if the CD4 cell count is &gt;500 cells/microL.<br />Â§ Refer to the UpToDate topic on HIV and women for additional details. <br />Â¶ Determination of renal function should include estimation of CrCl using Cockcroft-Gault equation or estimation of glomerular filtration rate based on MDRD equation. More frequent monitoring may be indicated for patients with evidence of kidney disease (eg, proteinuria, decreased glomerular dysfunction) or increased risk of renal insufficiency (eg, patients with diabetes, hypertension).<br />Î Some experts also suggest monitoring the phosphorus levels of patients on tenofovir.<br /></div><div class=\"graphic_reference\">Adapted from: Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:e1; Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available at: <A href=\"http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf\" target=_blank>http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf</A> (accessed on August 29, 2017); and Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <A href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</A>&nbsp;(accessed on&nbsp;August 29, 2017).</div><div id=\"graphicVersion\">Graphic 96776 Version 5.0</div></div></div>"},"96779":{"type":"graphic_diagnosticimage","displayName":"Urinary schistosomiasis","title":"Urinary schistosomiasis â calcified bladder wall","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Urinary schistosomiasis â calcified bladder wall</div><div class=\"cntnt\"><img style=\"width:484px; height:371px;\" src=\"images/ID/96779_Urinary_schistosomiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Joannes Clerinx, MD, DTM,&nbsp;and Patrick Soentjens, MD.</div><div id=\"graphicVersion\">Graphic 96779 Version 2.0</div></div></div>"},"96780":{"type":"graphic_diagnosticimage","displayName":"Spinal schistosomiasis","title":"41-year-old woman with spinal schistosomiasis","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">41-year-old woman with spinal schistosomiasis</div><div class=\"cntnt\"><img style=\"width:706px; height:720px;\" src=\"images/ID/96780_Spinal_schistosomiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal T2-weighted magnetic resonance image (MRI) shows diffuse signal prolongation and expansion of distal spinal cord and conus (arrow).<br />(B) Sagittal contrast-enhanced T1-weighted MRI shows central linear enhancement surrounded by multiple punctate enhancing nodules (arrows) that form masslike structure.</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Sanelli PC, Lev MH, Gonzalez RG, Schaefer PW. Unique Linear and Nodular MR Enhancement Pattern in Schistosomiasis of the Central Nervous System: Report of Three Patients. AJR Am J Roentgenol 2001; 177:1471. Copyright &copy; 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 96780 Version 1.0</div></div></div>"},"96781":{"type":"graphic_diagnosticimage","displayName":"Cerebral schistosomiasis","title":"30-year-old man with cerebral schistosomiasis","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">30-year-old man with cerebral schistosomiasis</div><div class=\"cntnt\"><img style=\"width:723px; height:283px;\" src=\"images/ID/96781_Cerebral_schistosomiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T2-weighted magnetic resonance image (MRI) shows vasogenic edema and mass effect involving left temporal lobe.<br />(B) Axial contrast-enhanced T1-weighted MRI shows multiple areas of central linear enhancement surrounded by enhancing punctate nodules (arrows).<br />(C) Coronal contrast-enhanced T1-weighted MRI confirms linear and nodular enhancement pattern in different imaging plane.</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Sanelli PC, Lev MH, Gonzalez RG, Schaefer PW. Unique Linear and Nodular MR Enhancement Pattern in Schistosomiasis of the Central Nervous System: Report of Three Patients. AJR Am J Roentgenol 2001; 177:1471. Copyright &copy; 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 96781 Version 1.0</div></div></div>"},"96782":{"type":"graphic_picture","displayName":"Schistosomiasis histopathology","title":"Schistosomiasis histopathology","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Schistosomiasis histopathology</div><div class=\"cntnt\"><img style=\"width:545px; height:710px;\" src=\"images/ID/96782_Schistosomiasis_histopathol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of histopathologic section shows granuloma formation (arrows) with surrounding inflammation (Hematoxylin and eosin stain, x250).</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Sanelli PC, Lev MH, Gonzalez RG, Schaefer PW. Unique Linear and Nodular MR Enhancement Pattern in Schistosomiasis of the Central Nervous System: Report of Three Patients. AJR Am J Roentgenol 2001; 177:1471. Copyright &copy; 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 96782 Version 1.0</div></div></div>"},"96785":{"type":"graphic_table","displayName":"Virology HFMD and herpangina","title":"VirologyÂ of hand, foot, and mouth disease and herpangina","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Virology&nbsp;of hand, foot, and mouth disease and herpangina</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hand, foot, and mouth disease</td> <td class=\"subtitle1\">Herpangina</td> </tr> <tr> <td>Coxsackievirus A2, A4 to A10, <span style=\"color: black;\"><strong>A16</strong></span>, B2, B3, B5</td> <td>Coxsackievirus <span style=\"color: black;\"><strong>A1 to A6</strong></span>, A7, <span style=\"color: black;\"><strong>A8</strong></span>, A9,&nbsp;<span style=\"color: black;\"><strong>A10</strong></span>, A16*, A22, B1 to B5</td> </tr> <tr> <td>Echovirus 1, 4, 7, 19</td> <td>Echovirus 6, 9, 16, 19</td> </tr> <tr> <td><span style=\"color: black;\"><strong>Enterovirus A71</strong></span></td> <td>Enterovirus A71*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\"><STRONG>Bold</STRONG></SPAN>: most common causes.<br />* A common cause in the Asia Pacific region.</div><div id=\"graphicVersion\">Graphic 96785 Version 2.0</div></div></div>"},"96786":{"type":"graphic_picture","displayName":"Atypical HFMD caused by CVA6","title":"Clinical manifestations of hand, foot, and mouth disease associated with coxsackievirus A6 in Shizuoka, Japan, June-July 2011","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Clinical manifestations of hand, foot, and mouth disease associated with coxsackievirus A6 in Shizuoka, Japan, June-July 2011</div><div class=\"cntnt\"><img style=\"width:583px; height:318px;\" src=\"images/PEDS/96786_Atypical_HFMD_caused_CVA6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hand and arm of a 2.5-year-old boy.<br />(B) Foot and (C) Buttocks of a 6-year-old boy.<br />(D) Nail matrix of a 20-month-old boy.</div><div class=\"graphic_reference\">Reproduced from: Fujimoto T, Iizuka S, Enomoto M, et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011. Emerg Infect Dis 2012; 18:337.</div><div id=\"graphicVersion\">Graphic 96786 Version 1.0</div></div></div>"},"96787":{"type":"graphic_picture","displayName":"Infantile hemangioma - biker glove","title":"Infantile hemangioma with \"biker glove\" distribution","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Infantile hemangioma with \"biker glove\" distribution</div><div class=\"cntnt\"><img style=\"width:651px; height:247px;\" src=\"images/DERM/96787_Infnt_hemangiom_biker_glove.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental hemangioma extending over the right extremity in a classic \"biker glove\" distribution.<br />(A) Dorsal view.<br />(B) Ventral view.</div><div id=\"graphicVersion\">Graphic 96787 Version 1.0</div></div></div>"},"96788":{"type":"graphic_picture","displayName":"Bunion (hallux valgus) appearance","title":"Bunion (hallux valgus) appearance","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Bunion (hallux valgus) appearance</div><div class=\"cntnt\"><img style=\"width:648px; height:485px;\" src=\"images/EM/96788_Bunion_hallux_valgus_appear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows a bunion and valgus shift with redness and mild swelling over medial first metatarsophalangeal&nbsp;joint of the left foot.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96788 Version 1.0</div></div></div>"},"96789":{"type":"graphic_picture","displayName":"Bilateral Morton foot with bunion","title":"Bilateral Morton foot with bunion","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Bilateral Morton foot with bunion</div><div class=\"cntnt\"><img style=\"width:720px; height:336px;\" src=\"images/EM/96789_Bilater_Mortons_foot_bunion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show the feet of a&nbsp;38-year-old female runner with bilateral Morton foot who has developed a bunion&nbsp;in her left&nbsp;left and splaying between rays&nbsp;one and two&nbsp;in the&nbsp;right foot (note the enlarged space between the great and second toes).</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96789 Version 2.0</div></div></div>"},"96791":{"type":"graphic_diagnosticimage","displayName":"CEUS of a malignant liver lesion","title":"Contrast-enhanced ultrasound of a malignant liver lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound of a malignant liver lesion</div><div class=\"cntnt\"><img style=\"width:310px; height:625px;\" src=\"images/GAST/96791_CEUS_malignant_liver_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arterial enhancement pattern is initially heterogenous displaying neoplastic vascularity (A). A few seconds later, the enhancement is homogenously hyperenhancing (B). Portal-venous and late phase enhancement provides important information regarding the character of a lesion, since malignant lesions are hypoenhancing (C).</div><div id=\"graphicVersion\">Graphic 96791 Version 2.0</div></div></div>"},"96792":{"type":"graphic_diagnosticimage","displayName":"CEUS of hepatic hemangioma","title":"Contrast-enhanced ultrasound of a hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound of a hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:609px; height:622px;\" src=\"images/GAST/96792_CEUS_hepatic_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical contrast-enhanced ultrasound findings in hepatic hemangiomas include peripheral nodular contrast enhancement (A-E) with centripetal fill-in (iris diaphragm phenomenon).</div><div id=\"graphicVersion\">Graphic 96792 Version 2.0</div></div></div>"},"96793":{"type":"graphic_table","displayName":"CEUS findings in hemangioma","title":"Contrast-enhanced ultrasound findings in 400 patients with hepatic hemangioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound findings in 400 patients with hepatic hemangioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td><strong>Number</strong></td> <td class=\"centered\">400</td> </tr> <tr> <td><strong>Mean size (cm)</strong></td> <td class=\"centered\">2.6 &#177; 3.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">B-mode, echogenicity</td> </tr> <tr> <td class=\"indent1\">Hyperechoic</td> <td class=\"centered\">363 (91%)</td> </tr> <tr> <td class=\"indent1\">Isoechoic or hypoechoic</td> <td class=\"centered\">37 (9%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vascularity assessed by color Doppler imaging</td> </tr> <tr> <td class=\"indent1\">No intralesional vessels</td> <td class=\"centered\">379 (95%)</td> </tr> <tr> <td class=\"indent1\">Intralesional vessels (hypervascular)</td> <td class=\"centered\">21 (5%)</td> </tr> <tr> <td class=\"indent1\">Peripheral nodular contrast enhancement</td> <td class=\"centered\">328 (82%)</td> </tr> <tr> <td class=\"indent1\">Strong homogenous arterial enhancement</td> <td class=\"centered\">31 (8%)</td> </tr> <tr> <td class=\"indent1\">No specific enhancement pattern or not determinable (eg, due to size of the lesion, solitary fibrotic nodule)</td> <td class=\"centered\">41 (10%)</td> </tr> <tr> <td class=\"indent1\">Complete iris diaphragm phenomenon</td> <td class=\"centered\">320 (80%)</td> </tr> <tr> <td class=\"indent1\">Incomplete iris diaphragm phenomenon</td> <td class=\"centered\">80 (20%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dietrich CF, Maddalena ME, Cui XW, et al. Liver tumor characterization - review of the literature. Ultraschall Med 2012; 33 Suppl 1:S3.</li>&#xD;&#xA;    <li>Dietrich CF, Mertens JC, Braden B, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45:1139.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96793 Version 3.0</div></div></div>"},"96795":{"type":"graphic_diagnosticimage","displayName":"CEUS of FNH","title":"Contrast-enhanced ultrasound of focal nodular hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 674px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound of focal nodular hyperplasia</div><div class=\"cntnt\"><img style=\"width:654px; height:206px;\" src=\"images/GAST/96795_CEUS_of_FNH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focal nodular hyperplasia (FNH) is characterized by a central or eccentric arterial vascular supply (A). In the portal-venous and delayed phases, FNH is most often hyperenhancing (B).</div><div id=\"graphicVersion\">Graphic 96795 Version 2.0</div></div></div>"},"96796":{"type":"graphic_table","displayName":"CEUS findings in FNH and HA","title":"Contrast-enhanced ultrasound findings in 424 patients with focal nodular hyperplasia and 36 patients with hepatic adenoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound findings in 424 patients with focal nodular hyperplasia and 36 patients with hepatic adenoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">FNH</td> <td class=\"subtitle1\">HA</td> </tr> <tr> <td><strong>Number</strong></td> <td class=\"centered\">424</td> <td class=\"centered\">36</td> </tr> <tr> <td><strong>Size of lesion (mm; range)</strong></td> <td class=\"centered\">49 &#177; 24 (12 to 110)</td> <td class=\"centered\">34 &#177; 22 (20 to 120)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Conventional B-mode ultrasound</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Echo texture</td> </tr> <tr> <td class=\"indent2\">Hypoechoic</td> <td class=\"centered\">36*</td> <td class=\"centered\">8*</td> </tr> <tr> <td class=\"indent2\">Isoechoic</td> <td class=\"centered\">382</td> <td class=\"centered\">20</td> </tr> <tr> <td class=\"indent2\">Hyperechoic</td> <td class=\"centered\">6</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\">Central scar</td> <td class=\"centered\">241</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Color/power Doppler imaging</td> </tr> <tr> <td class=\"indent1\">Hypervacsular</td> <td class=\"centered\">369</td> <td class=\"centered\">33</td> </tr> <tr> <td class=\"indent1\">Radial vascular architecture</td> <td class=\"centered\">234</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Contrast-enhanced ultrasound</td> </tr> <tr> <td class=\"indent1\">Arterial phase enhancement</td> <td class=\"centered\">424</td> <td class=\"centered\">36</td> </tr> <tr> <td class=\"indent1\">(Early) portal-venous phase enhancement</td> <td class=\"centered\">406</td> <td class=\"centered\">6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FNH: focal nodular hyperplasia; HA: hepatic adenoma.<br />* Depending on the technique and ultrasound machine used.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dietrich CF, Maddalena ME, Cui XW, et al. Liver tumor characterization - review of the literature. Ultraschall Med 2012; 33 Suppl 1:S3.</li>&#xD;&#xA;    <li>Dietrich CF, Schuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78:704.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 96796 Version 3.0</div></div></div>"},"96797":{"type":"graphic_table","displayName":"CCS grading of angina pectoris","title":"Canadian Cardiovascular Society grading of angina pectoris","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian Cardiovascular Society grading of angina pectoris</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td><strong>Class I</strong></td> <td>Angina only during strenuous or prolonged physical activity</td> </tr> <tr> <td><strong>Class II</strong></td> <td>Slight limitation, with angina only during vigorous physical activity</td> </tr> <tr> <td><strong>Class III</strong></td> <td>Symptoms with everyday living activities, ie, moderate limitation</td> </tr> <tr> <td><strong>Class IV</strong></td> <td>Inability to perform any activity without angina or angina at rest, ie, severe limitation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Canadian Cardiovascular Society grading of angina pectoris. Available at: <a href=\"http://www.ccs.ca/index.php/en/\" spellcheck=\"true\" target=\"_blank\">http://www.ccs.ca/index.php/en/</a> (Accessed on September 3, 2014).</div><div id=\"graphicVersion\">Graphic 96797 Version 1.0</div></div></div>"},"96801":{"type":"graphic_picture","displayName":"Bunionette appearance","title":"Bunionette appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bunionette appearance</div><div class=\"cntnt\"><img style=\"width:417px; height:640px;\" src=\"images/SM/96801_Bunionette_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The foot pictured above belongs to a patient with a supinated gait that placed excess stress on fifth metatarsophalangeal (MTP) joint and led to the development of a bunionette - a lateral fifth toe MTP joint subluxation with varus deviation and rotation (arrow). Note how the small toe angles medially towards the other toes.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96801 Version 4.0</div></div></div>"},"96802":{"type":"graphic_diagnosticimage","displayName":"CEUS of HA","title":"Contrast-enhanced ultrasound of a hepatic adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound of a hepatic adenoma</div><div class=\"cntnt\"><img style=\"width:342px; height:595px;\" src=\"images/GAST/96802_CEUS_HA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatic adenomas are characterized by an arterial vascular supply, with contrast enhancement in the arterial phase progressing from the edge of the lesion (A) to the center (B). In the portal-venous and delayed phases, hepatic adenomas are iso- or slightly hypoenhancing.</div><div id=\"graphicVersion\">Graphic 96802 Version 2.0</div></div></div>"},"96803":{"type":"graphic_diagnosticimage","displayName":"CEUS of HCC after RFA","title":"Contrast-enhanced ultrasound of hepatocellular carcinoma following radiofrequency ablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced ultrasound of hepatocellular carcinoma following radiofrequency ablation</div><div class=\"cntnt\"><img style=\"width:310px; height:408px;\" src=\"images/GAST/96803_CEUS_HCC_after_RFA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatocellular carcinoma (HCC) after radiofrequency thermoablation (A). Contrast-enhanced ultrasound is helpful for detecting viable tumor persistence following locoregional treatment (B).</div><div id=\"graphicVersion\">Graphic 96803 Version 2.0</div></div></div>"},"96819":{"type":"graphic_picture","displayName":"Intermetatarsal ligament breakdown causing splayed toes","title":"Intermetatarsal ligament breakdown causing splayed toes","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Intermetatarsal ligament breakdown causing splayed toes</div><div class=\"cntnt\"><img style=\"width:477px; height:317px;\" src=\"images/SM/96819_Intrligbrkdncausplytoe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excessive pressure over the metatarsal heads and transverse arch leads to breakdown of intermetatarsal ligaments. In the case pictured above, the ligament between the second and third&nbsp;metatarsals has stretched and&nbsp;the third&nbsp;metatarsal head has subluxed and protrudes&nbsp;through the plantar capsule leading to a \"splayed toe sign.\"</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96819 Version 2.0</div></div></div>"},"96821":{"type":"graphic_picture","displayName":"Bilateral splayed toes","title":"Bilateral splayed toes","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Bilateral splayed toes</div><div class=\"cntnt\"><img style=\"width:584px; height:334px;\" src=\"images/SM/96821_Bilateral_splayed_toes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above displays bilateral splayed toes found&nbsp;between the second and third toes&nbsp;in the&nbsp;right foot&nbsp;and the third and fourth toes in the left foot.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96821 Version 2.0</div></div></div>"},"96824":{"type":"graphic_picture","displayName":"Metatarsal pad placement","title":"Metatarsal pad placement","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Metatarsal pad placement</div><div class=\"cntnt\"><img style=\"width:596px; height:468px;\" src=\"images/SM/96824_Metatarsalpadplacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sequence of photographs outlines the steps for making a metatarsal pad. The lipstick mark on the foot in photograph A outlines the proximal arch at the&nbsp;metatarsal head. The patient then stands on a soft insole (photograph B), leaving a mark that designates where the additional padding is placed (photograph C).</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96824 Version 2.0</div></div></div>"},"96825":{"type":"graphic_table","displayName":"Application of a metatarsal pad","title":"Application of a metatarsal pad","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Application of a metatarsal pad</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Palpate the distal diaphysis of the metatarsal where it meets the proximal metatarsal head.</td> </tr> <tr> <td>2. Using lipstick (or a comparable marker), outline the proximal arch at the metatarsal head.</td> </tr> <tr> <td>3. Have the patient step onto and apply full weight to a shoe insert, thereby marking the insole.</td> </tr> <tr> <td>4. Place metatarsal pad at the proximal edge of the lipstick mark.</td> </tr> <tr> <td>5. Place the insert into the patient's shoe and observe their gait. The patient may feel pressure from the pad but should not feel pain.</td> </tr> <tr> <td>6. Repeat on opposite foot only if needed for pain relief.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96825 Version 2.0</div></div></div>"},"96826":{"type":"graphic_picture","displayName":"Athletic shoe insole and posting materials","title":"Athletic shoe insole and posting materials","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Athletic shoe insole and posting materials</div><div class=\"cntnt\"><img style=\"width:593px; height:259px;\" src=\"images/SM/96826_Athlshoeinsolepostmater.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show sports insoles and posting materials made of foam rubber, felt,&nbsp;and mole skin.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96826 Version 2.0</div></div></div>"},"96827":{"type":"graphic_picture","displayName":"Insole with lateral post to treat bunionette","title":"Insole with lateral post to treat bunionette","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Insole with lateral post to treat bunionette</div><div class=\"cntnt\"><img style=\"width:714px; height:532px;\" src=\"images/SM/96827_Insolelatpsttreatbunion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows&nbsp;a lateral post attached to the undersurface of a sports insole to take pressure off a bunionette.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96827 Version 2.0</div></div></div>"},"96830":{"type":"graphic_picture","displayName":"Mortons foot with early pathologic changes","title":"Morton's foot with early pathologic changes","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Morton's foot with early pathologic changes</div><div class=\"cntnt\"><img style=\"width:586px; height:428px;\" src=\"images/SM/96830_Mrtnsfootearlypathochng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows a classic Morton foot with a short first metatarsal and early pathologic changes consisting of foot pronation and hallux valgus. Flattening of the transverse arch is suggested by loss of the normal appearance of the extensor tendons, which is also seen in the photograph above.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96830 Version 4.0</div></div></div>"},"96831":{"type":"graphic_picture","displayName":"Morton foot variant with long second ray","title":"Morton foot variant with long second ray","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Morton foot variant with long second ray</div><div class=\"cntnt\"><img style=\"width:596px; height:240px;\" src=\"images/SM/96831_Mrtnfootvarilngscndray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show feet with an isolated long second ray. Note how the second toe extends beyond the end of the great toe.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96831 Version 2.0</div></div></div>"},"96837":{"type":"graphic_diagnosticimage","displayName":"3D echo with TR vena contracta","title":"Three-dimensional echocardiogram showing tricuspid regurgitation with vena contracta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiogram showing tricuspid regurgitation with vena contracta</div><div class=\"cntnt\"><img style=\"width:366px; height:485px;\" src=\"images/CARD/96837_TR_vena_contracta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional transthoracic echocardiogram with color Doppler showing tricuspid regurgitation. Two-dimensional images (A) show the tricuspid valve with tricuspid regurgitation (as a blue jet in the upper image). A three-dimensional image (B) shows the vena contracta en faceâ in a view&nbsp;orthogonal to the modified four-chamber three-dimensional&nbsp;view (C) showing the vena contracta and remainder of the tricuspid regurgitation jet.</div><div class=\"graphic_reference\">Courtesy of Xiushui Ren, MD.</div><div id=\"graphicVersion\">Graphic 96837 Version 2.0</div></div></div>"},"96838":{"type":"graphic_picture","displayName":"Aircast A60 ankle brace","title":"Aircast A60 ankle brace","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aircast A60 ankle brace</div><div class=\"cntnt\"><img style=\"width:433px; height:714px;\" src=\"images/EM/96838_Aircast_A60_ankle_brace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph shows a type of elastic semi-rigid brace suitable for wearing during sport to reduce the risk of recurrent ankle sprain.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 DJO Global. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96838 Version 3.0</div></div></div>"},"96839":{"type":"graphic_diagnosticimage","displayName":"Tibial metaphyseal-diaphyseal angle","title":"Tibial metaphyseal-diaphyseal angle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tibial metaphyseal-diaphyseal angle</div><div class=\"cntnt\"><img style=\"width:272px; height:583px;\" src=\"images/PEDS/96839_Tibial_metaphys_diaphy_angl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tibial metaphyseal-diaphyseal angle is measured on an anteroposterior standing radiograph of the knee as follows: 1) draw a line along the longitudinal axis of the tibia (line 1); 2) draw a line through the lateral peaks of the proximal tibial metaphysis (line 2); 3) draw a line perpendicular to line 1 at the intersection of lines 1 and 2 (line 3); 3) measure the angle between lines 2 and 3 (the tibial metaphyseal-diaphyseal angle). A tibial metaphyseal-diaphyseal angle &le;11&deg; suggests physiologic rather than pathologic bowing. In this patient with Blount disease, the tibial metaphyseal-diaphyseal angle is approximately 18&deg;.</div><div id=\"graphicVersion\">Graphic 96839 Version 1.0</div></div></div>"},"96845":{"type":"graphic_picture","displayName":"Histoplasma endocarditis","title":"<em>Histoplasma</em> endocarditis","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\"><em>Histoplasma</em> endocarditis</div><div class=\"cntnt\"><img style=\"width:612px; height:456px;\" src=\"images/ID/96845_Histoplasmaendocarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prosthetic aortic valve stained with methenamine silver stain showing a mixture of yeast and hyphal forms in a patient with <em>Histoplasma capsulatum</em> endocarditis.</div><div class=\"graphic_reference\">Reproduced with permission from: Riddell J 4th, Kauffman CA, Smith JA, et al. Histoplasma capsulatum endocarditis: Multicenter case series with review of current diagnostic techniques and treatment. Medicine 2014; 93:186. DOI: <a href=\"http://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2014&amp;issue=07020&amp;article=00002&amp;type=abstract\" target=\"_blank\">10.1097/MD.0000000000000034</a>. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 96845 Version 3.0</div></div></div>"},"96849":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of plantar fascia thickening","title":"Ultrasound of plantar fascia thickening","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Ultrasound of plantar fascia thickening</div><div class=\"cntnt\"><img style=\"width:594px; height:306px;\" src=\"images/EM/96849_Ultrasnd_plntr_fascia_thick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vertical lines in the images&nbsp;above&nbsp;correspond to&nbsp;the thickness of the plantar fascia. Note&nbsp;how the fascia&nbsp;in the&nbsp;ultrasound image on the left,&nbsp;taken from a patient diagnosed with plantar fasciitis,&nbsp;is twice as thick as the normal fascia pictured on the right.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 96849 Version 1.0</div></div></div>"},"96868":{"type":"graphic_table","displayName":"Staging and treatment of MRONJ","title":"Staging and treatment of medication-related osteonecrosis of the jaw (MRONJ)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging and treatment of medication-related osteonecrosis of the jaw (MRONJ)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">MRONJ* staging</td> <td class=\"subtitle1\">Treatment strategies<sup>&#182;</sup></td> </tr> <tr> <td><strong>At risk category</strong> No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates</td> <td> <ul> <li>No treatment indicated </li> <li>Patient education </li> </ul> </td> </tr> <tr> <td><strong>Stage 0</strong> No clinical evidence of necrotic bone, but non-specific clinical findings, radiographic changes and symptoms</td> <td> <ul> <li>Systemic management, including the use of pain medication and antibiotics </li> </ul> </td> </tr> <tr> <td><strong>Stage 1</strong> Exposed and necrotic bone, or a fistula that probes to bone, in a patient who is asymptomatic and has no evidence of infection</td> <td> <ul> <li>Antibacterial mouth rinse </li> <li>Clinical follow-up on a quarterly basis </li> <li>Patient education and review of indications for continued bisphosphonate therapy </li> </ul> </td> </tr> <tr> <td><strong>Stage 2</strong> Exposed and necrotic bone, or a&nbsp;fistula that probes to bone, associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage</td> <td> <ul> <li>Symptomatic treatment with oral antibiotics </li> <li>Oral antibacterial mouth rinse </li> <li>Pain control </li> <li>Debridement to relieve soft tissue irritation and infection control </li> </ul> </td> </tr> <tr> <td><strong>Stage 3</strong> Exposed and necrotic bone or a fistula that probes to bone in a&nbsp;patient with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone (ie, inferior border and ramus of the mandible, maxillary sinus, and zygoma in the maxilla), resulting in pathologic fracture, extra-oral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible or sinus floor</td> <td> <ul> <li>Antibacterial mouth rinse </li> <li>Antibiotic therapy and pain control </li> <li>Surgical debridement/resection for longer term palliation of infection and pain </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Exposed or probable exposed&nbsp;bone in the maxillofacial region without resolution for greater than&nbsp;eight weeks in patients treated with an antiresorptive and/or an antiangiogenic agent who have not received radiation therapy to the jaws.<br />Â¶ Regardless of the disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone. The extraction of symptomatic teeth within exposed, necrotic bone should be considered since it is unlikely that the extraction will exacerbate the established necrotic process.</div><div class=\"graphic_reference\">Reproduced from: Ruggiero et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jawâ2014 Update. J Oral Maxillofac Surg 2014; 72(10):1949. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96868 Version 7.0</div></div></div>"},"96876":{"type":"graphic_algorithm","displayName":"ALPS diagnostic algorithm","title":"Autoimmune lymphoproliferative syndrome (ALPS) diagnostic algorithm","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Autoimmune lymphoproliferative syndrome (ALPS) diagnostic algorithm</div><div class=\"cntnt\"><img style=\"width:507px; height:612px;\" src=\"images/ALLRG/96876_ALPS_diagnostic_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DNT: double-negative T; IL-10: interleukin-10; FasL: Fas ligand; IL-18: interleukin-18; ALPS-FAS: ALPS due to germline mutations in FAS gene; ALPS-sFAS: ALPS due to somatic mutations in FAS gene; CASP10: caspase 10 gene; ALPS-CASP10: ALPS due to mutations in CASP10; FASLG: gene for Fas ligand; ALPS-FASLG: ALPS due to mutations in FASGL; ALPS-U:ALPS due to unknown genetic defect.</div><div id=\"graphicVersion\">Graphic 96876 Version 1.0</div></div></div>"},"96899":{"type":"graphic_diagnosticimage","displayName":"Uterine leiomyoma calcifications","title":"Ultrasound of uterine leiomyoma with calcifications","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ultrasound of uterine leiomyoma with calcifications</div><div class=\"cntnt\"><img style=\"width:590px; height:425px;\" src=\"images/OBGYN/96899_Uterine_leiomyoma_calcifica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal image of a postmenopausal woman with calcified fibroids. The dense calcifications (arrows) have shadowing behind them. The borders of the fibroids and uterus are not well seen due to the dense calcifications.</div><div id=\"graphicVersion\">Graphic 96899 Version 1.0</div></div></div>"},"96903":{"type":"graphic_picture","displayName":"Trichotillomania scalp","title":"Trichotillomania scalp","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichotillomania scalp</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PSYCH/96903_Trichotillomania_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregular areas of alopecia secondary to trichotillomania.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96903 Version 1.0</div></div></div>"},"96905":{"type":"graphic_picture","displayName":"Trichotillomania eyebrows","title":"Trichotillomania eyebrows","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichotillomania eyebrows</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PSYCH/96905_Trichotillomania_eyebrows.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of eyebrows and eyelashes due to trichotillomania.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96905 Version 1.0</div></div></div>"},"96906":{"type":"graphic_picture","displayName":"Trichotillomania eyebrow","title":"Trichotillomania eyebrow","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Trichotillomania eyebrow</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PSYCH/96906_Trichotillomania_eyebrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bizarre pattern of eyebrow pattern hair loss.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 96906 Version 1.0</div></div></div>"},"96926":{"type":"graphic_table","displayName":"Stages of TR","title":"Stages of tricuspid regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of tricuspid regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Valve anatomy</td> <td class=\"subtitle1\">Valve hemodynamics*</td> <td class=\"subtitle1\">Hemodynamic consequences</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td class=\"centered\"><strong>A</strong></td> <td>At risk of TR</td> <td><strong>Primary</strong> <ul class=\"decimal_heading\"> <li>Mild rheumatic change </li> <li>Mild prolapse </li> <li>Other (eg, IE with vegetation, early carcinoid deposition, radiation) </li> <li>Intra-annular RV pacemaker or ICD lead </li> <li>Postcardiac transplant (biopsy related) </li> </ul> <strong>Functional</strong> <ul class=\"decimal_heading\"> <li>Normal </li> <li>Early annular dilation </li> </ul> </td> <td> <ul> <li>No or trace TR </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>None or in relation to other left heart or pulmonary/pulmonary vascular disease </li> </ul> </td> </tr> <tr class=\"divider_bottom highlight_green_text\"> <td class=\"centered\"><strong>B</strong></td> <td>Progressive TR</td> <td><strong>Primary</strong> <ul class=\"decimal_heading\"> <li>Progressive leaflet deterioration/destruction </li> <li>Moderate-to-severe prolapse, limited chordal rupture </li> </ul> <strong>Functional</strong> <ul class=\"decimal_heading\"> <li>Early annular dilation </li> <li>Moderate leaflet tethering </li> </ul> </td> <td><strong>Mild TR</strong> <ul class=\"decimal_heading\"> <li>Central jet area &#60;5.0 cm<sup>2</sup> </li> <li>Vena contracta width not defined </li> <li>CW jet density and contour: soft and parabolic </li> <li>Hepatic vein flow: systolic dominance </li> </ul> <strong>Moderate TR</strong> <ul class=\"decimal_heading\"> <li>Central jet area 5 to 10 cm<sup>2</sup> </li> <li>Vena contracta width not defined but &#60;0.70 cm </li> <li>CW jet density and contour: dense, variable contour </li> <li>Hepatic vein flow: systolic blunting </li> </ul> </td> <td><strong>Mild TR</strong> <ul class=\"decimal_heading\"> <li>RV/RA/IVC size normal </li> </ul> <strong>Moderate TR</strong> <ul class=\"decimal_heading\"> <li>No RV enlargement </li> <li>No or mild RA enlargement </li> <li>No or mild IVC enlargement with normal respirophasic variation </li> <li>Normal RA pressure </li> </ul> </td> <td> <ul> <li>None or in relation to other left heart or pulmonary/pulmonary vascular disease </li> </ul> </td> </tr> <tr class=\"divider_bottom highlight_red_text\"> <td class=\"centered\"><strong>C</strong></td> <td>Asymptomatic, severe TR</td> <td><strong>Primary</strong> <ul class=\"decimal_heading\"> <li>Flail or grossly distorted leaflets </li> </ul> <strong>Functional</strong> <ul class=\"decimal_heading\"> <li>Severe annular dilation (&#62;40 mm or 21 mm/m<sup>2</sup>) </li> <li>Marked leaflet tethering </li> </ul> </td> <td> <ul> <li>Central jet area &#62;10.0 cm<sup>2</sup> </li> <li>Vena contracta width &#62;0.7 cm </li> <li>CW jet density and contour: dense, triangular with early peak </li> <li>Hepatic vein flow: systolic reversal </li> </ul> </td> <td> <ul> <li>RV/RA/IVC dilated with decreased IVC respirophasic variation </li> <li>Elevated RA pressure with \"c-V\" wave </li> <li>Diastolic interventricular septal flattening may be present </li> </ul> </td> <td> <ul> <li>None, or in relation to other left heart or pulmonary/pulmonary vascular disease </li> </ul> </td> </tr> <tr class=\"highlight_yellow_text\"> <td class=\"centered\"><strong>D</strong></td> <td>Symptomatic severe TR</td> <td><strong>Primary</strong> <ul class=\"decimal_heading\"> <li>Flail or grossly distorted leaflets </li> </ul> <strong>Functional</strong> <ul class=\"decimal_heading\"> <li>Severe annular dilation (&#62;40 mm or &#62;21 mm/m<sup>2</sup>) </li> <li>Marked leaflet tethering </li> </ul> </td> <td> <ul> <li>Central jet area &#62;10.0 cm<sup>2</sup> </li> <li>Vena contracta width &#62;0.70 cm </li> <li>CW jet density and contour: dense, triangular with early peak </li> <li>Hepatic vein flow: systolic reversal </li> </ul> </td> <td> <ul> <li>RV/RA/IVC dilated with decreased IVC respirophasic variation </li> <li>Elevated RA pressure with \"c-V\" wave </li> <li>Diastolic interventricular septal flattening </li> <li>Reduced RV systolic function in late phase </li> </ul> </td> <td> <ul> <li>Fatigue, palpitations, dyspnea, abdominal bloating, anorexia, edema </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CW: continuous wave; ICD: implantable cardioverter-defibrillator; IE: infective endocarditis; IVC: inferior vena cava; RA: right atrium; RV: right ventricle; TR: tricuspid regurgitation.<br />â* Several valve hemodynamic criteria are provided for assessment of severity of TR, but not all criteria for each category will necessarily be present in every patient. Categorization of severity of TR as mild, moderate, or severe also depends on image quality and integration of these parameters with clinical findings.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96926 Version 3.0</div></div></div>"},"96927":{"type":"graphic_figure","displayName":"Female genital tract anomalies ESHRE ESGE classification table","title":"Female genital tract anomalies: ESHRE ESGE classification system","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Female genital tract anomalies: ESHRE ESGE classification system</div><div class=\"cntnt\"><img style=\"width:602px; height:867px;\" src=\"images/OBGYN/96927_Fm_trct_anm_ESHRE_ESGE_tbl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scheme for the classification of female genital tract anomalies according to the new ESHRE/ESGE classification system.</div><div class=\"graphic_footnotes\">ESHRE: European Society of Human Reproduction and Embryology; ESGE: European Society for Gynaecological Endoscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Grimbizis GF, Gordts S, Di Spiezio, et al. The ESHRE/ESGE consensus on the classification of female genital tract congenital anomalies. Hum Reprod 2013; 28(8):2032. Copyright &copy; The Author 2013. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.</div><div id=\"graphicVersion\">Graphic 96927 Version 1.0</div></div></div>"},"96937":{"type":"graphic_table","displayName":"Likelihood of drugs triggering microscopic colitis","title":"Assessment of the level of likelihood that a specific drug can trigger MC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of the level of likelihood that a specific drug can trigger MC</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">High likelihood</td> <td class=\"subtitle1\">Intermediate likelihood</td> <td class=\"subtitle1\">Low likelihood</td> </tr> <tr> <td class=\"centered\">Acarbose</td> <td class=\"centered\">Carbamazepine</td> <td class=\"centered\">Cimetidine</td> </tr> <tr> <td class=\"centered\">Aspirin and NSAIDs</td> <td class=\"centered\">Celecoxib</td> <td class=\"centered\">Gold salts</td> </tr> <tr> <td class=\"centered\">Clozapine</td> <td class=\"centered\">Duloxetine</td> <td class=\"centered\">Piascledine</td> </tr> <tr> <td class=\"centered\">Entocapone</td> <td class=\"centered\">Fluvastatin</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">Flavonoid*</td> <td class=\"centered\">Flutamide</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">Proton pump inhibitors</td> <td class=\"centered\">Oxetorone</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">Ranitidine</td> <td class=\"centered\">Madopar</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">Sertraline</td> <td class=\"centered\">Paroxetine</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">Ticlopidine</td> <td class=\"centered\">Simvastatin</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Stalevo<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Venotonic drugs containing flavonoids (diosmin, rutin, or hesperidin).<br />Â¶ Anti-parkinsonian drugs, containing levodopa and benserazide (Madopar) and carbidopa, levodopa and entocapone (Stalevo).</div><div class=\"graphic_reference\">Reproduced from: M&uuml;nch A, Aust D, Bohr J, et al. Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis 2012; 6:932. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96937 Version 3.0</div></div></div>"},"96938":{"type":"graphic_table","displayName":"Histologic key features of microscopic colitis","title":"Histologic key features of different forms of microscopic colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic key features of different forms of microscopic colitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">LC</td> <td class=\"subtitle1\">CC</td> <td class=\"subtitle1\">MCi or MCnos</td> </tr> <tr> <td><strong>IELs</strong></td> <td class=\"centered\">&#62;20 IELs</td> <td class=\"centered\">Normal to slightly increased</td> <td class=\"centered\">5-20 IELs</td> </tr> <tr> <td><strong>Subepithelial collagen layer</strong></td> <td class=\"centered\">Normal to slightly thickened</td> <td class=\"centered\">&#62;10 micrometers</td> <td class=\"centered\">5-10 micrometers</td> </tr> <tr> <td><strong>Surface epithelium damage</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">(+)</td> </tr> <tr> <td><strong>Lamina propria inflammation</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+/++</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LC: lymphocytic colitis; CC: collagenous colitis; MCi: microscopic colitis incomplete; MCnos: microscopic colitis not otherwise specified; IELs: intraepithelial lymphocytes.</div><div class=\"graphic_reference\">Reproduced from: MÃ¼nch A, Langner C. Microscopic colitis: Clinical and pathologic perspectives. Clin Gastroenterol Hepatol 2014 (in press). Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96938 Version 2.0</div></div></div>"},"96940":{"type":"graphic_table","displayName":"International birth weight centiles","title":"International birth weight centiles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International birth weight centiles</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"7\">Boys</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle2\" rowspan=\"2\">Number of observations</td> <td class=\"subtitle2\" colspan=\"5\">Centiles for birth weight (kg)</td> </tr> <tr> <td class=\"subtitle3\">3rd</td> <td class=\"subtitle3\">10th</td> <td class=\"subtitle3\">50th</td> <td class=\"subtitle3\">90th</td> <td class=\"subtitle3\">97th</td> </tr> <tr> <td class=\"centered\">33 weeks</td> <td class=\"centered\">34</td> <td class=\"centered\">1.18</td> <td class=\"centered\">1.43</td> <td class=\"centered\">1.95</td> <td class=\"centered\">2.52</td> <td class=\"centered\">2.82</td> </tr> <tr> <td class=\"centered\">34 weeks</td> <td class=\"centered\">48</td> <td class=\"centered\">1.45</td> <td class=\"centered\">1.71</td> <td class=\"centered\">2.22</td> <td class=\"centered\">2.79</td> <td class=\"centered\">3.08</td> </tr> <tr> <td class=\"centered\">35 weeks</td> <td class=\"centered\">128</td> <td class=\"centered\">1.70</td> <td class=\"centered\">1.95</td> <td class=\"centered\">2.47</td> <td class=\"centered\">3.03</td> <td class=\"centered\">3.32</td> </tr> <tr> <td class=\"centered\">36 weeks</td> <td class=\"centered\">323</td> <td class=\"centered\">1.93</td> <td class=\"centered\">2.18</td> <td class=\"centered\">2.69</td> <td class=\"centered\">3.25</td> <td class=\"centered\">3.54</td> </tr> <tr> <td class=\"centered\">37 weeks</td> <td class=\"centered\">857</td> <td class=\"centered\">2.13</td> <td class=\"centered\">2.38</td> <td class=\"centered\">2.89</td> <td class=\"centered\">3.45</td> <td class=\"centered\">3.74</td> </tr> <tr> <td class=\"centered\">38 weeks</td> <td class=\"centered\">2045</td> <td class=\"centered\">2.32</td> <td class=\"centered\">2.57</td> <td class=\"centered\">3.07</td> <td class=\"centered\">3.63</td> <td class=\"centered\">3.92</td> </tr> <tr> <td class=\"centered\">39 weeks</td> <td class=\"centered\">3009</td> <td class=\"centered\">2.49</td> <td class=\"centered\">2.73</td> <td class=\"centered\">3.24</td> <td class=\"centered\">3.79</td> <td class=\"centered\">4.08</td> </tr> <tr> <td class=\"centered\">40 weeks</td> <td class=\"centered\">2568</td> <td class=\"centered\">2.63</td> <td class=\"centered\">2.88</td> <td class=\"centered\">3.38</td> <td class=\"centered\">3.94</td> <td class=\"centered\">4.22</td> </tr> <tr> <td class=\"centered\">41 weeks</td> <td class=\"centered\">1179</td> <td class=\"centered\">2.76</td> <td class=\"centered\">3.01</td> <td class=\"centered\">3.51</td> <td class=\"centered\">4.06</td> <td class=\"centered\">4.35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">42 weeks</td> <td class=\"centered\">206</td> <td class=\"centered\">2.88</td> <td class=\"centered\">3.12</td> <td class=\"centered\">3.62</td> <td class=\"centered\">4.17</td> <td class=\"centered\">4.46</td> </tr> <tr> <td class=\"centered\">Total</td> <td class=\"centered\">10397</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"7\">Girls</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle2\" rowspan=\"2\">Number of observations</td> <td class=\"subtitle2\" colspan=\"5\">Centiles for birth weight (kg)</td> </tr> <tr> <td class=\"subtitle3\">3rd</td> <td class=\"subtitle3\">10th</td> <td class=\"subtitle3\">50th</td> <td class=\"subtitle3\">90th</td> <td class=\"subtitle3\">97th</td> </tr> <tr> <td class=\"centered\">33 weeks</td> <td class=\"centered\">17</td> <td class=\"centered\">1.20</td> <td class=\"centered\">1.41</td> <td class=\"centered\">1.86</td> <td class=\"centered\">2.35</td> <td class=\"centered\">2.61</td> </tr> <tr> <td class=\"centered\">34 weeks</td> <td class=\"centered\">65</td> <td class=\"centered\">1.47</td> <td class=\"centered\">1.68</td> <td class=\"centered\">2.13</td> <td class=\"centered\">2.64</td> <td class=\"centered\">2.90</td> </tr> <tr> <td class=\"centered\">35 weeks</td> <td class=\"centered\">114</td> <td class=\"centered\">1.71</td> <td class=\"centered\">1.92</td> <td class=\"centered\">2.38</td> <td class=\"centered\">2.89</td> <td class=\"centered\">3.16</td> </tr> <tr> <td class=\"centered\">36 weeks</td> <td class=\"centered\">293</td> <td class=\"centered\">1.92</td> <td class=\"centered\">2.14</td> <td class=\"centered\">2.60</td> <td class=\"centered\">3.12</td> <td class=\"centered\">3.39</td> </tr> <tr> <td class=\"centered\">37 weeks</td> <td class=\"centered\">803</td> <td class=\"centered\">2.11</td> <td class=\"centered\">2.33</td> <td class=\"centered\">2.80</td> <td class=\"centered\">3.32</td> <td class=\"centered\">3.60</td> </tr> <tr> <td class=\"centered\">38 weeks</td> <td class=\"centered\">1802</td> <td class=\"centered\">2.28</td> <td class=\"centered\">2.50</td> <td class=\"centered\">2.97</td> <td class=\"centered\">3.51</td> <td class=\"centered\">3.78</td> </tr> <tr> <td class=\"centered\">39 weeks</td> <td class=\"centered\">2869</td> <td class=\"centered\">2.42</td> <td class=\"centered\">2.65</td> <td class=\"centered\">3.13</td> <td class=\"centered\">3.66</td> <td class=\"centered\">3.94</td> </tr> <tr> <td class=\"centered\">40 weeks</td> <td class=\"centered\">2523</td> <td class=\"centered\">2.55</td> <td class=\"centered\">2.78</td> <td class=\"centered\">3.26</td> <td class=\"centered\">3.80</td> <td class=\"centered\">4.08</td> </tr> <tr class=\"centered\"> <td class=\"centered\">41 weeks</td> <td class=\"centered\">1195</td> <td class=\"centered\">2.65</td> <td class=\"centered\">2.89</td> <td class=\"centered\">3.37</td> <td class=\"centered\">3.92</td> <td class=\"centered\">4.20</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">42 weeks</td> <td class=\"centered\">224</td> <td class=\"centered\">2.74</td> <td class=\"centered\">2.98</td> <td class=\"centered\">3.46</td> <td class=\"centered\">4.01</td> <td class=\"centered\">4.30</td> </tr> <tr> <td class=\"centered\">Total</td> <td class=\"centered\">9905</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> <td class=\"centered\">..</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">International standards for newborn weight by gestational age and sex from&nbsp;the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Table shows smoothed centiles for birth weight of boys and girls according to gestational age.</div><div class=\"graphic_footnotes\">kg: kilogram.</div><div class=\"graphic_reference\">Reproduced from: Villar J, Cheikh Ismail L, Victoria CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 2014; 384:857. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 96940 Version 2.0</div></div></div>"},"96963":{"type":"graphic_picture","displayName":"Medium length Gram positive rod","title":"Medium-length gram-positive rod","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Medium-length gram-positive rod</div><div class=\"cntnt\"><img style=\"width:641px; height:250px;\" src=\"images/ID/96963_Medium_Gram_positive_rod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chain.<br />(B) Cluster.</div><div class=\"graphic_reference\">Reproduced with permission from: Marler LM, Siders JA, Allen SD. Direct Smear Atlas: A Monograph of Gram-Stained Preparations of Clinical Specimens. Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 96963 Version 5.0</div></div></div>"},"96964":{"type":"graphic_picture","displayName":"Medium to long, plump gram negative rod","title":"Medium-to-long, plump gram-negative rod","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Medium-to-long, plump gram-negative rod</div><div class=\"cntnt\"><img style=\"width:645px; height:251px;\" src=\"images/ID/96964_Med_long_plump_Gram_negativ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Single and pairs.<br />(B) Single, pair, and short chain.</div><div class=\"graphic_reference\">Reproduced with permission from: Marler LM, Siders JA, Allen SD. Direct Smear Atlas: A Monograph of Gram-Stained Preparations of Clinical Specimens. Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 96964 Version 5.0</div></div></div>"},"96965":{"type":"graphic_picture","displayName":"Medium to long, thin gram negative rod","title":"Medium-to-long, thin gram-negative rod","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Medium-to-long, thin gram-negative rod</div><div class=\"cntnt\"><img style=\"width:645px; height:250px;\" src=\"images/ID/96965_Med_long_thin_Gram_neg_rod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Singles and short chain.<br />(B) Long, thin.</div><div class=\"graphic_reference\">Reproduced with permission from: Marler LM, Siders JA, Allen SD. Direct Smear Atlas: A Monograph of Gram-Stained Preparations of Clinical Specimens. Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 96965 Version 5.0</div></div></div>"},"96966":{"type":"graphic_picture","displayName":"Short to long, pleomorphic gram negative rod","title":"Short-to-long, pleomorphic gram-negative rod","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Short-to-long, pleomorphic gram-negative rod</div><div class=\"cntnt\"><img style=\"width:656px; height:171px;\" src=\"images/ID/96966_Short_long_pleom_Gram_neg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Short, vacuolated.<br />(B) Small and medium sized, vacuolated.<br />(C) Short and medium length.</div><div class=\"graphic_reference\">Reproduced with permission from: Marler LM, Siders JA, Allen SD. Direct Smear Atlas: A Monograph of Gram-Stained Preparations of Clinical Specimens. Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 96966 Version 5.0</div></div></div>"},"96970":{"type":"graphic_table","displayName":"Paraneoplastic syndromes associated with thymic neoplasms","title":"Paraneoplastic syndromes associated with thymic neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paraneoplastic syndromes associated with thymic neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td><strong>Neurologic and neuromuscular</strong></td> <td>Myasthenia gravis, polymyositis, sensory neuropathy, stiff person syndrome, neuromyelitis optica, Isaac's syndrome (neuromyotonia), Eaton Lambert syndrome, hemichorea</td> </tr> <tr> <td><strong>Hematologic</strong></td> <td>Pure red cell aplasia, agranulocytosis, hemolytic anemia, pernicious anemia</td> </tr> <tr> <td><strong>Dermatologic</strong></td> <td>Alopecia areata, pemphigus, scleroderma, oral lichen planus, vitiligo</td> </tr> <tr> <td><strong>Endocrine</strong></td> <td>Addison's disease, Cushing syndrome, panhypopituitarism, thyroiditis</td> </tr> <tr> <td><strong>Miscellaneous</strong></td> <td>Acquired hypogammaglobulinemia, myocarditis, nephrotic syndrome, rheumatoid arthritis, sarcoidosis, hepatitis, gastrointestinal pseudoobstruction, ulcerative colitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 96970 Version 1.0</div></div></div>"},"96971":{"type":"graphic_picture","displayName":"Application of plastic bags to keep casts dry","title":"Application of plastic bags to keep casts dry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Application of plastic bags to keep casts dry</div><div class=\"cntnt\"><img style=\"width:433px; height:577px;\" src=\"images/EM/96971_App_plstc_bgs_keep_csts_dry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Casts can be kept dry by covering the affected limb with two plastic bags, one over the other, and then taping the bags to the skin, as pictured above.</div><div class=\"graphic_reference\">Reproduced with permission from John Schlechter, DO, FAOAO.</div><div id=\"graphicVersion\">Graphic 96971 Version 1.0</div></div></div>"},"96977":{"type":"graphic_waveform","displayName":"Late decelerations 3","title":"Late deceleration","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Late deceleration</div><div class=\"cntnt\"><img style=\"width:605px; height:280px;\" src=\"images/OBGYN/96977_Late_decelerations_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Christina Davidson.</div><div id=\"graphicVersion\">Graphic 96977 Version 1.0</div></div></div>"},"96978":{"type":"graphic_waveform","displayName":"Deep late deceleration","title":"Deep late deceleration","html":"<div class=\"graphic\"><div style=\"width: 651px\" class=\"figure\"><div class=\"ttl\">Deep late deceleration</div><div class=\"cntnt\"><img style=\"width:631px; height:308px;\" src=\"images/OBGYN/96978_Deep_late_decelerat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow tracing in the upper panel represents the fetal heart rate. Arrow points to the nadir of the late deceleration.</div><div class=\"graphic_reference\">Courtesy of Dr. Christina Davidson.</div><div id=\"graphicVersion\">Graphic 96978 Version 1.0</div></div></div>"},"96980":{"type":"graphic_waveform","displayName":"Late decelerations 4","title":"Recurrent late decelerations","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Recurrent late decelerations</div><div class=\"cntnt\"><img style=\"width:609px; height:293px;\" src=\"images/OBGYN/96980_Late_decelerations_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow tracing in the upper panel represents the fetal heart rate. Arrow points to the nadir of a late deceleration.</div><div class=\"graphic_reference\">Courtesy of Dr. Christina Davidson.</div><div id=\"graphicVersion\">Graphic 96980 Version 1.0</div></div></div>"},"96988":{"type":"graphic_diagnosticimage","displayName":"GTN lung metastases","title":"Gestational trophoblastic neoplasia: Lung metastases","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Gestational trophoblastic neoplasia: Lung metastases</div><div class=\"cntnt\"><img style=\"width:539px; height:590px;\" src=\"images/ONC/96988_GTN_lung_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing pulmonary infiltrates in patient with gestational trophoblastic neoplasia.</div><div id=\"graphicVersion\">Graphic 96988 Version 1.0</div></div></div>"},"96989":{"type":"graphic_picture","displayName":"GTN vaginal metastases","title":"Gestational trophoblastic neoplasia: Vaginal metastases","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Gestational trophoblastic neoplasia: Vaginal metastases</div><div class=\"cntnt\"><img style=\"width:595px; height:227px;\" src=\"images/ONC/96989_GTN_vaginal_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vaginal metastases in a patient with choriocarcinoma.</div><div id=\"graphicVersion\">Graphic 96989 Version 1.0</div></div></div>"},"96991":{"type":"graphic_diagnosticimage","displayName":"GTN brain metastasis MRI","title":"Gestational trophoblastic neoplasia: Brain metastasis on MRI","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Gestational trophoblastic neoplasia: Brain metastasis on MRI</div><div class=\"cntnt\"><img style=\"width:491px; height:356px;\" src=\"images/ONC/96991_GTN_brain_metastasis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 96991 Version 2.0</div></div></div>"},"96992":{"type":"graphic_picture","displayName":"Palpebral fissure measurement","title":"Measurement of palpebral fissure length","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measurement of palpebral fissure length</div><div class=\"cntnt\"><img style=\"width:216px; height:116px;\" src=\"images/PEDS/96992_Palpebral_fissure_measure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpebral fissure length is measured from the endocanthion (en) to the exocanthion (ex), as indicated above.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Susan Astley PhD, University of Washington.</div><div id=\"graphicVersion\">Graphic 96992 Version 1.0</div></div></div>"},"96993":{"type":"graphic_table","displayName":"Prevalence intimate partner violence","title":"Lifetime and 12-month prevalence of intimate partner violence victimization, by sex of victim and time period â National Intimate Partner and Sexual Violence Survey, United States, 2011","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifetime and 12-month prevalence of intimate partner violence victimization, by sex of victim and time period &mdash; National Intimate Partner and Sexual Violence Survey, United States, 2011</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Type of IPV</td> <td class=\"subtitle1\" colspan=\"2\">Women</td> <td class=\"subtitle1\" colspan=\"2\">Men</td> </tr> <tr> <td class=\"subtitle2\">Lifetime %* (95% CI)</td> <td class=\"subtitle2\">12-month %* (95% CI)</td> <td class=\"subtitle2\">Lifetime %* (95% CI)</td> <td class=\"subtitle2\">12-month %* (95% CI)</td> </tr> <tr> <td>Rape</td> <td>8.8 (7.8-9.8)</td> <td>0.8 (0.5-1.2)</td> <td>0.5 (0.3-0.8)</td> <td>Estimate not reported</td> </tr> <tr> <td>Other sexual violence</td> <td>15.8 (14.6-17.1)</td> <td>2.1 (1.6 to 2.6)</td> <td>9.5 (8.4-10.8)</td> <td>2.1 (1.7-2.7)</td> </tr> <tr> <td>Physical violence</td> <td>31.5 (29.9-33.2)</td> <td>4.0 (3.2-4.8)</td> <td>27.5 (25.8-29.3)</td> <td>4.8 (4.0-5.8)</td> </tr> <tr> <td>Stalking</td> <td>9.2 (8.2-103)</td> <td>2.4 (1.9-3.0)</td> <td>2.5 (1.9-3.3)</td> <td>0.8 (0.6-1.2)</td> </tr> <tr> <td>Psychological aggression<sup>&#182;</sup></td> <td>47.1 (45.3-48.8)</td> <td>14.2 (12.9-15.5)</td> <td>46.5 (44.6-48.4)</td> <td>18.0 (16.5-19.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IPV: intimate partner violence; CI: confidence interval.<br />* Percentages are weighted.<br />Â¶ Psychological aggression includes expressive aggression (such as name calling, or insulting or humiliating an intimate partner) and coercive control, which includes behaviors that are intended to monitor, control, or threaten an intimate partner.</div><div class=\"graphic_reference\">Data from: Breiding MJ, Smith SG, Basile KC, et al. Prevalence and characteristics of sexual violence, stalking, and intimate partner violence victimization - National Intimate Partner and Sexual Violence Survey, United States, 2011. MMWR Surveill Summ 2014; 63 Suppl 8:1.</div><div id=\"graphicVersion\">Graphic 96993 Version 3.0</div></div></div>"},"96994":{"type":"graphic_figure","displayName":"Age first episode intimate partner violence","title":"Age at occurrence of first intimate partner violence experience among males and females who experienced rape, physical violence, or stalking by an intimate partner â National Intimate Partner and Sexual Violence Survey, United States, 2010","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Age at occurrence of first intimate partner violence experience among males and females who experienced rape, physical violence, or stalking by an intimate partner â National Intimate Partner and Sexual Violence Survey, United States, 2010</div><div class=\"cntnt\"><img style=\"width:505px; height:317px;\" src=\"images/PEDS/96994_Agefrstepsintmprtvioln.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Spivak HR, Jenkins L, VanAudenhove K, et al. CDC Grand Rounds:&nbsp;A public health approach to prevention of intimate partner violence. MMWR Morb Mortal Wkly Rep 2014; 63:38.</div><div id=\"graphicVersion\">Graphic 96994 Version 3.0</div></div></div>"},"96995":{"type":"graphic_diagnosticimage","displayName":"Scapulothoracic bursitis","title":"Scapulothoracic bursitis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Scapulothoracic bursitis</div><div class=\"cntnt\"><img style=\"width:538px; height:256px;\" src=\"images/RHEUM/96995_Scapulothoracic_bursitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest computed tomography (CT)&nbsp;shows a heterogeneous cystic mass measuring approximately 8Ã2.5 cm on the right chest wall lateral aspect inferior latissimus muscle (arrow).<br />(B) A magnetic resonance axial T1-weighted image revealed a well-defined cystic mass located in the right subscapular region (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Son SA, Lee DH, Lee YO, et al. Operative management in a patient with scapulothoracic bursitis. Korean J Thorac Cardiovasc Surg 2013; 46:486. Copyright &copy; 2013. The originality of this figure belongs to the Korean Journal of Thoracic and Cardiovascular Surgery (KJTCVS).</div><div id=\"graphicVersion\">Graphic 96995 Version 1.0</div></div></div>"},"96996":{"type":"graphic_picture","displayName":"GTN bowel metastasis","title":"Gestational trophoblastic neoplasia: Bowel metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gestational trophoblastic neoplasia: Bowel metastasis</div><div class=\"cntnt\"><img style=\"width:424px; height:435px;\" src=\"images/ONC/96996_GTN_bowel_metastasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bowel metastasis in a patient with choriocarcinoma.</div><div id=\"graphicVersion\">Graphic 96996 Version 1.0</div></div></div>"},"96997":{"type":"graphic_diagnosticimage","displayName":"GTN liver metastasis CT","title":"Gestational trophoblastic neoplasia: Liver metastasis on CT","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Gestational trophoblastic neoplasia: Liver metastasis on CT</div><div class=\"cntnt\"><img style=\"width:476px; height:203px;\" src=\"images/ONC/96997_GTN_liver_metastasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 96997 Version 2.0</div></div></div>"}};